WO2015160842A1 - Methods and formulatiions of capsaicinoids and capsinoids - Google Patents
Methods and formulatiions of capsaicinoids and capsinoids Download PDFInfo
- Publication number
- WO2015160842A1 WO2015160842A1 PCT/US2015/025810 US2015025810W WO2015160842A1 WO 2015160842 A1 WO2015160842 A1 WO 2015160842A1 US 2015025810 W US2015025810 W US 2015025810W WO 2015160842 A1 WO2015160842 A1 WO 2015160842A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- muscle
- capsinoid
- capsaicinoid
- combination
- Prior art date
Links
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 title claims abstract description 352
- 238000000034 method Methods 0.000 title claims abstract description 126
- 239000000203 mixture Substances 0.000 claims abstract description 596
- 238000009472 formulation Methods 0.000 claims abstract description 66
- 208000007101 Muscle Cramp Diseases 0.000 claims description 172
- -1 fatty acid esters Chemical class 0.000 claims description 166
- 238000012360 testing method Methods 0.000 claims description 164
- 210000003205 muscle Anatomy 0.000 claims description 116
- 230000004118 muscle contraction Effects 0.000 claims description 116
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 88
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 71
- 239000007787 solid Substances 0.000 claims description 64
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 61
- 230000000638 stimulation Effects 0.000 claims description 58
- 230000000694 effects Effects 0.000 claims description 56
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 54
- 238000011282 treatment Methods 0.000 claims description 50
- 208000035475 disorder Diseases 0.000 claims description 47
- 208000010118 dystonia Diseases 0.000 claims description 47
- 239000007788 liquid Substances 0.000 claims description 47
- 235000020357 syrup Nutrition 0.000 claims description 47
- 239000006188 syrup Substances 0.000 claims description 47
- 239000003826 tablet Substances 0.000 claims description 46
- 208000005392 Spasm Diseases 0.000 claims description 45
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 claims description 45
- 239000012190 activator Substances 0.000 claims description 41
- 208000014094 Dystonic disease Diseases 0.000 claims description 37
- 239000002775 capsule Substances 0.000 claims description 35
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 31
- RBCYRZPENADQGZ-UHFFFAOYSA-N dihydrocapsaicin Natural products COC1=CC(COC(=O)CCCCCCC(C)C)=CC=C1O RBCYRZPENADQGZ-UHFFFAOYSA-N 0.000 claims description 31
- 239000003921 oil Substances 0.000 claims description 30
- 235000019198 oils Nutrition 0.000 claims description 30
- 239000007937 lozenge Substances 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 26
- 206010028293 Muscle contractions involuntary Diseases 0.000 claims description 25
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 25
- 210000003169 central nervous system Anatomy 0.000 claims description 24
- 239000000499 gel Substances 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 23
- AKDLSISGGARWFP-UHFFFAOYSA-N Homodihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCCCC(C)C)=CC=C1O AKDLSISGGARWFP-UHFFFAOYSA-N 0.000 claims description 22
- VQEONGKQWIFHMN-UHFFFAOYSA-N Nordihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCC(C)C)=CC=C1O VQEONGKQWIFHMN-UHFFFAOYSA-N 0.000 claims description 22
- BXBVPYSHEOQGHP-UHFFFAOYSA-N Nordihydrocapsiate Chemical compound COC1=CC(COC(=O)CCCCCC(C)C)=CC=C1O BXBVPYSHEOQGHP-UHFFFAOYSA-N 0.000 claims description 22
- 229960002504 capsaicin Drugs 0.000 claims description 22
- 235000017663 capsaicin Nutrition 0.000 claims description 22
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 22
- 229930195729 fatty acid Natural products 0.000 claims description 22
- 239000000194 fatty acid Substances 0.000 claims description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims description 22
- 239000000725 suspension Substances 0.000 claims description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 201000006417 multiple sclerosis Diseases 0.000 claims description 21
- 201000000306 sarcoidosis Diseases 0.000 claims description 21
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 20
- 239000000839 emulsion Substances 0.000 claims description 20
- SGEUEXJZQFSBNX-UHFFFAOYSA-N n-[(4-hydroxy-3-methoxyphenyl)methyl]hexadecanamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 SGEUEXJZQFSBNX-UHFFFAOYSA-N 0.000 claims description 20
- 239000006072 paste Substances 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 239000004530 micro-emulsion Substances 0.000 claims description 19
- 208000018360 neuromuscular disease Diseases 0.000 claims description 19
- 208000019901 Anxiety disease Diseases 0.000 claims description 17
- 239000000654 additive Substances 0.000 claims description 17
- 230000000996 additive effect Effects 0.000 claims description 17
- 235000009508 confectionery Nutrition 0.000 claims description 17
- 210000002784 stomach Anatomy 0.000 claims description 17
- 239000013078 crystal Substances 0.000 claims description 16
- 230000001939 inductive effect Effects 0.000 claims description 16
- 208000005264 motor neuron disease Diseases 0.000 claims description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims description 15
- 239000003963 antioxidant agent Substances 0.000 claims description 15
- 239000003086 colorant Substances 0.000 claims description 15
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 15
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 15
- 239000003755 preservative agent Substances 0.000 claims description 15
- 208000018198 spasticity Diseases 0.000 claims description 15
- 208000000209 Isaacs syndrome Diseases 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 14
- 235000003599 food sweetener Nutrition 0.000 claims description 14
- 230000000241 respiratory effect Effects 0.000 claims description 14
- 239000003765 sweetening agent Substances 0.000 claims description 14
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 13
- 230000002159 abnormal effect Effects 0.000 claims description 13
- 235000015111 chews Nutrition 0.000 claims description 13
- 150000004665 fatty acids Chemical class 0.000 claims description 13
- 239000000796 flavoring agent Substances 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- 210000000278 spinal cord Anatomy 0.000 claims description 13
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 13
- 206010011224 Cough Diseases 0.000 claims description 12
- QVLMCRFQGHWOPM-ZKWNWVNESA-N N-arachidonoyl vanillylamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCC1=CC=C(O)C(OC)=C1 QVLMCRFQGHWOPM-ZKWNWVNESA-N 0.000 claims description 12
- 239000007902 hard capsule Substances 0.000 claims description 12
- 239000007901 soft capsule Substances 0.000 claims description 12
- IFFDMDPMYLRJPN-JDPCYWKWSA-N (4z,7z,10z,13z,16z,19z)-n-[(4-hydroxy-3-methoxyphenyl)methyl]docosa-4,7,10,13,16,19-hexaenamide Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCC1=CC=C(O)C(OC)=C1 IFFDMDPMYLRJPN-JDPCYWKWSA-N 0.000 claims description 11
- HDRFKJZUJQBRMH-UHFFFAOYSA-N 1-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-3-[2-(4-chlorophenyl)ethyl]thiourea Chemical compound C1=C(OCCN)C(OC)=CC(CNC(=S)NCCC=2C=CC(Cl)=CC=2)=C1 HDRFKJZUJQBRMH-UHFFFAOYSA-N 0.000 claims description 11
- NSAIEKZGHYMYFD-UHFFFAOYSA-N 1-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-3-[2-(4-fluorophenyl)ethyl]thiourea Chemical compound C1=C(OCCN)C(OC)=CC(CNC(=S)NCCC=2C=CC(F)=CC=2)=C1 NSAIEKZGHYMYFD-UHFFFAOYSA-N 0.000 claims description 11
- OUEKLNJUMVZULZ-UHFFFAOYSA-N 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-n-[3-(3,4-dimethylphenyl)propyl]acetamide;hydron;chloride Chemical compound Cl.C1=C(OCCN)C(OC)=CC(CC(=O)NCCCC=2C=C(C)C(C)=CC=2)=C1 OUEKLNJUMVZULZ-UHFFFAOYSA-N 0.000 claims description 11
- OAOABCKPVCUNKO-UHFFFAOYSA-M 8-methylnonanoate Chemical compound CC(C)CCCCCCC([O-])=O OAOABCKPVCUNKO-UHFFFAOYSA-M 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 11
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 11
- ZEWSMOFWZCBFSU-UHFFFAOYSA-N Capsiconiate Natural products COC1=CC(C=CCOC(=O)CCCCC=CC(C)C)=CC=C1O ZEWSMOFWZCBFSU-UHFFFAOYSA-N 0.000 claims description 11
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 claims description 11
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 11
- 208000026072 Motor neurone disease Diseases 0.000 claims description 11
- UTNZMGHHFHHIAY-FNORWQNLSA-N Norcapsaicin Chemical compound COC1=CC(CNC(=O)CCC\C=C\C(C)C)=CC=C1O UTNZMGHHFHHIAY-FNORWQNLSA-N 0.000 claims description 11
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 11
- 206010067672 Spasmodic dysphonia Diseases 0.000 claims description 11
- STEQPJJDFVFRGX-UHFFFAOYSA-N Tinyatoxin Natural products CC1CC2(CC34OC(Cc5ccccc5)(O2)OC13C6C=C(C)C(=O)C6(O)CC(=C4)COC(=O)Cc7ccc(O)cc7)C(=C)C STEQPJJDFVFRGX-UHFFFAOYSA-N 0.000 claims description 11
- ZEWSMOFWZCBFSU-OAMUUVBCSA-N [(e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enyl] (e)-8-methylnon-6-enoate Chemical compound COC1=CC(\C=C\COC(=O)CCCC\C=C\C(C)C)=CC=C1O ZEWSMOFWZCBFSU-OAMUUVBCSA-N 0.000 claims description 11
- MPGLKHMQOVOUKA-CSKARUKUSA-N [(e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enyl] 8-methylnonanoate Chemical compound COC1=CC(\C=C\COC(=O)CCCCCCC(C)C)=CC=C1O MPGLKHMQOVOUKA-CSKARUKUSA-N 0.000 claims description 11
- ZICNYIDDNJYKCP-SOFGYWHQSA-N capsiate Chemical compound COC1=CC(COC(=O)CCCC\C=C\C(C)C)=CC=C1O ZICNYIDDNJYKCP-SOFGYWHQSA-N 0.000 claims description 11
- 230000003111 delayed effect Effects 0.000 claims description 11
- VWTINHYPRWEBQY-UHFFFAOYSA-N denatonium Chemical compound [O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C VWTINHYPRWEBQY-UHFFFAOYSA-N 0.000 claims description 11
- 229940006275 denatonium Drugs 0.000 claims description 11
- MPGLKHMQOVOUKA-UHFFFAOYSA-N dihydrocapsiconiate Natural products COC1=CC(C=CCOC(=O)CCCCCCC(C)C)=CC=C1O MPGLKHMQOVOUKA-UHFFFAOYSA-N 0.000 claims description 11
- 239000003792 electrolyte Substances 0.000 claims description 11
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- MLJGZARGNROKAC-VQHVLOKHSA-N homocapsaicin Chemical compound CCC(C)\C=C\CCCCC(=O)NCC1=CC=C(O)C(OC)=C1 MLJGZARGNROKAC-VQHVLOKHSA-N 0.000 claims description 11
- JKIHLSTUOQHAFF-UHFFFAOYSA-N homocapsaicin Natural products COC1=CC(CNC(=O)CCCCCC=CC(C)C)=CC=C1O JKIHLSTUOQHAFF-UHFFFAOYSA-N 0.000 claims description 11
- JZNZUOZRIWOBGG-UHFFFAOYSA-N homocapsaicin-II Natural products COC1=CC(CNC(=O)CCCCC=CCC(C)C)=CC=C1O JZNZUOZRIWOBGG-UHFFFAOYSA-N 0.000 claims description 11
- GOBFKCLUUUDTQE-UHFFFAOYSA-N homodihydrocapsaicin-II Natural products CCC(C)CCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 GOBFKCLUUUDTQE-UHFFFAOYSA-N 0.000 claims description 11
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 11
- QLNWXBAGRTUKKI-UHFFFAOYSA-N metacetamol Chemical compound CC(=O)NC1=CC=CC(O)=C1 QLNWXBAGRTUKKI-UHFFFAOYSA-N 0.000 claims description 11
- 239000011707 mineral Substances 0.000 claims description 11
- 229960004036 nonivamide Drugs 0.000 claims description 11
- UTNZMGHHFHHIAY-UHFFFAOYSA-N norcapsaicin Natural products COC1=CC(CNC(=O)CCCC=CC(C)C)=CC=C1O UTNZMGHHFHHIAY-UHFFFAOYSA-N 0.000 claims description 11
- QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 claims description 11
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 claims description 11
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 claims description 11
- 229940073454 resiniferatoxin Drugs 0.000 claims description 11
- 201000002849 spasmodic dystonia Diseases 0.000 claims description 11
- WWZMXEIBZCEIFB-ACAXUWNGSA-N tinyatoxin Chemical compound C([C@@]12O[C@]3(C[C@H]([C@@]4([C@H]5[C@](C(C(C)=C5)=O)(O)CC(COC(=O)CC=5C=CC(O)=CC=5)=C[C@H]4[C@H]3O2)O1)C)C(C)=C)C1=CC=CC=C1 WWZMXEIBZCEIFB-ACAXUWNGSA-N 0.000 claims description 11
- 229940088594 vitamin Drugs 0.000 claims description 11
- 229930003231 vitamin Natural products 0.000 claims description 11
- 235000013343 vitamin Nutrition 0.000 claims description 11
- 239000011782 vitamin Substances 0.000 claims description 11
- 239000001993 wax Substances 0.000 claims description 11
- YKPUWZUDDOIDPM-VURMDHGXSA-N zucapsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C/C(C)C)=CC=C1O YKPUWZUDDOIDPM-VURMDHGXSA-N 0.000 claims description 11
- 229960002860 zucapsaicin Drugs 0.000 claims description 11
- WQGCUFUTFWQLQG-UHFFFAOYSA-N 3-(4-hydroxy-3-methoxyphenyl)propyl 8-methylnonanoate Chemical compound COC1=CC(CCCOC(=O)CCCCCCC(C)C)=CC=C1O WQGCUFUTFWQLQG-UHFFFAOYSA-N 0.000 claims description 10
- OPZKBPQVWDSATI-KHPPLWFESA-N N-Vanillyloleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-KHPPLWFESA-N 0.000 claims description 10
- 235000021355 Stearic acid Nutrition 0.000 claims description 10
- 206010044074 Torticollis Diseases 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- 201000002866 cervical dystonia Diseases 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 10
- 208000018631 connective tissue disease Diseases 0.000 claims description 10
- 230000008602 contraction Effects 0.000 claims description 10
- 230000002496 gastric effect Effects 0.000 claims description 10
- DYQCYTHCHNSRBF-UHFFFAOYSA-N n-(2-methylpropyl)heptanamide Chemical compound CCCCCCC(=O)NCC(C)C DYQCYTHCHNSRBF-UHFFFAOYSA-N 0.000 claims description 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 10
- OPZKBPQVWDSATI-UHFFFAOYSA-N oleoyl vanillylamide Natural products CCCCCCCCC=CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-UHFFFAOYSA-N 0.000 claims description 10
- 229950010717 olvanil Drugs 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 10
- 230000035945 sensitivity Effects 0.000 claims description 10
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 10
- 239000008117 stearic acid Substances 0.000 claims description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 9
- 208000027747 Kennedy disease Diseases 0.000 claims description 9
- 208000000112 Myalgia Diseases 0.000 claims description 9
- 206010072359 Neuromyotonia Diseases 0.000 claims description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 9
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 9
- SESRAFXWYNELHQ-PKNBQFBNSA-N [2-methoxy-4-[[[(e)-8-methylnon-6-enoyl]amino]methyl]phenyl] 2,2-dimethylpropanoate Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1OC(=O)C(C)(C)C SESRAFXWYNELHQ-PKNBQFBNSA-N 0.000 claims description 9
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 9
- XJQPQKLURWNAAH-UHFFFAOYSA-N dihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCCC(C)C)=CC=C1O XJQPQKLURWNAAH-UHFFFAOYSA-N 0.000 claims description 9
- 235000013355 food flavoring agent Nutrition 0.000 claims description 9
- 229940057995 liquid paraffin Drugs 0.000 claims description 9
- HOXAPJDPLOCBKP-UHFFFAOYSA-N n-hexadecanoyl-4-hydroxy-3-methoxybenzamide Chemical compound CCCCCCCCCCCCCCCC(=O)NC(=O)C1=CC=C(O)C(OC)=C1 HOXAPJDPLOCBKP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002105 nanoparticle Substances 0.000 claims description 9
- 239000004006 olive oil Substances 0.000 claims description 9
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 9
- 208000005198 spinal stenosis Diseases 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- 235000021314 Palmitic acid Nutrition 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 206010005159 blepharospasm Diseases 0.000 claims description 8
- 230000000744 blepharospasm Effects 0.000 claims description 8
- 235000005687 corn oil Nutrition 0.000 claims description 8
- 239000002285 corn oil Substances 0.000 claims description 8
- 239000011859 microparticle Substances 0.000 claims description 8
- 208000013465 muscle pain Diseases 0.000 claims description 8
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 8
- 235000008390 olive oil Nutrition 0.000 claims description 8
- 201000008482 osteoarthritis Diseases 0.000 claims description 8
- 150000003626 triacylglycerols Chemical class 0.000 claims description 8
- 208000000412 Avitaminosis Diseases 0.000 claims description 7
- 235000021357 Behenic acid Nutrition 0.000 claims description 7
- 208000019505 Deglutition disease Diseases 0.000 claims description 7
- 206010014418 Electrolyte imbalance Diseases 0.000 claims description 7
- 206010021135 Hypovitaminosis Diseases 0.000 claims description 7
- 235000019486 Sunflower oil Nutrition 0.000 claims description 7
- 229940116226 behenic acid Drugs 0.000 claims description 7
- 239000004204 candelilla wax Substances 0.000 claims description 7
- 235000013868 candelilla wax Nutrition 0.000 claims description 7
- 229940073532 candelilla wax Drugs 0.000 claims description 7
- 239000004203 carnauba wax Substances 0.000 claims description 7
- 235000013869 carnauba wax Nutrition 0.000 claims description 7
- 238000009505 enteric coating Methods 0.000 claims description 7
- 239000002702 enteric coating Substances 0.000 claims description 7
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 claims description 7
- 239000002480 mineral oil Substances 0.000 claims description 7
- 235000019488 nut oil Nutrition 0.000 claims description 7
- 239000010466 nut oil Substances 0.000 claims description 7
- 239000012169 petroleum derived wax Substances 0.000 claims description 7
- 235000019381 petroleum wax Nutrition 0.000 claims description 7
- 210000002027 skeletal muscle Anatomy 0.000 claims description 7
- 235000012424 soybean oil Nutrition 0.000 claims description 7
- 239000002600 sunflower oil Substances 0.000 claims description 7
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 7
- 239000008158 vegetable oil Substances 0.000 claims description 7
- 208000030401 vitamin deficiency disease Diseases 0.000 claims description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 206010041250 Social phobia Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 6
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 235000010446 mineral oil Nutrition 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 230000036407 pain Effects 0.000 claims description 6
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 6
- 230000000750 progressive effect Effects 0.000 claims description 6
- 238000013268 sustained release Methods 0.000 claims description 6
- 239000012730 sustained-release form Substances 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 208000025436 Cramp-fasciculation syndrome Diseases 0.000 claims description 5
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 5
- 206010014561 Emphysema Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 206010022562 Intermittent claudication Diseases 0.000 claims description 5
- 208000001738 Nervous System Trauma Diseases 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 5
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 claims description 5
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 5
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 235000001465 calcium Nutrition 0.000 claims description 5
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 5
- 206010008129 cerebral palsy Diseases 0.000 claims description 5
- 208000024980 claudication Diseases 0.000 claims description 5
- 239000002934 diuretic Substances 0.000 claims description 5
- 229940030606 diuretics Drugs 0.000 claims description 5
- 229940125753 fibrate Drugs 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 206010022000 influenza Diseases 0.000 claims description 5
- 201000010901 lateral sclerosis Diseases 0.000 claims description 5
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 235000010981 methylcellulose Nutrition 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 208000019906 panic disease Diseases 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 201000002241 progressive bulbar palsy Diseases 0.000 claims description 5
- 201000008752 progressive muscular atrophy Diseases 0.000 claims description 5
- 201000000196 pseudobulbar palsy Diseases 0.000 claims description 5
- 210000002460 smooth muscle Anatomy 0.000 claims description 5
- 238000009495 sugar coating Methods 0.000 claims description 5
- 206010003805 Autism Diseases 0.000 claims description 4
- 208000020706 Autistic disease Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 206010033799 Paralysis Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 208000002894 beriberi Diseases 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 208000015114 central nervous system disease Diseases 0.000 claims description 4
- 201000002904 focal dystonia Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 208000028412 nervous system injury Diseases 0.000 claims description 4
- 208000030613 peripheral artery disease Diseases 0.000 claims description 4
- 210000003281 pleural cavity Anatomy 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 3
- 208000006888 Agnosia Diseases 0.000 claims description 3
- 206010003062 Apraxia Diseases 0.000 claims description 3
- 206010006956 Calcium deficiency Diseases 0.000 claims description 3
- 208000006561 Cluster Headache Diseases 0.000 claims description 3
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims description 3
- 206010013976 Dyspraxia Diseases 0.000 claims description 3
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 claims description 3
- 206010021036 Hyponatraemia Diseases 0.000 claims description 3
- 208000000038 Hypoparathyroidism Diseases 0.000 claims description 3
- 208000009612 Laryngismus Diseases 0.000 claims description 3
- 206010023891 Laryngospasm Diseases 0.000 claims description 3
- 208000008167 Magnesium Deficiency Diseases 0.000 claims description 3
- 208000001826 Marfan syndrome Diseases 0.000 claims description 3
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000020339 Spinal injury Diseases 0.000 claims description 3
- 206010043269 Tension headache Diseases 0.000 claims description 3
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 3
- 208000005428 Thiamine Deficiency Diseases 0.000 claims description 3
- 206010053509 Venomous bite Diseases 0.000 claims description 3
- 206010053510 Venomous sting Diseases 0.000 claims description 3
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 3
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 3
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 3
- 229940124604 anti-psychotic medication Drugs 0.000 claims description 3
- 239000002876 beta blocker Substances 0.000 claims description 3
- 229940097320 beta blocking agent Drugs 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 201000002648 nephronophthisis Diseases 0.000 claims description 3
- 230000011164 ossification Effects 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000007442 rickets Diseases 0.000 claims description 3
- 230000036262 stenosis Effects 0.000 claims description 3
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 2
- 206010007882 Cellulitis Diseases 0.000 claims description 2
- 208000018380 Chemical injury Diseases 0.000 claims description 2
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 2
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 2
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims description 2
- 206010051841 Exposure to allergen Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000013038 Hypocalcemia Diseases 0.000 claims description 2
- 206010021027 Hypomagnesaemia Diseases 0.000 claims description 2
- 208000032984 Intraoperative Complications Diseases 0.000 claims description 2
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 2
- 229960000794 baclofen Drugs 0.000 claims description 2
- 229940089093 botox Drugs 0.000 claims description 2
- 239000002561 chemical irritant Substances 0.000 claims description 2
- 230000000705 hypocalcaemia Effects 0.000 claims description 2
- 235000004764 magnesium deficiency Nutrition 0.000 claims description 2
- 229960003941 orphenadrine Drugs 0.000 claims description 2
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 230000009747 swallowing Effects 0.000 claims description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 3
- QNWOXYYMDJVEGG-UHFFFAOYSA-N 1-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-3-[2-(2,4-dichlorophenyl)ethyl]thiourea Chemical compound C1=C(OCCN)C(OC)=CC(C\N=C(/S)NCCC=2C(=CC(Cl)=CC=2)Cl)=C1 QNWOXYYMDJVEGG-UHFFFAOYSA-N 0.000 claims 1
- DLIQMAJTXGIWMG-UHFFFAOYSA-N 1-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-3-[2-(4-phenylmethoxyphenyl)ethyl]thiourea Chemical compound C1=C(OCCN)C(OC)=CC(CNC(=S)NCCC=2C=CC(OCC=3C=CC=CC=3)=CC=2)=C1 DLIQMAJTXGIWMG-UHFFFAOYSA-N 0.000 claims 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 229940124748 beta 2 agonist Drugs 0.000 claims 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 5
- 239000000556 agonist Substances 0.000 description 64
- 108091006146 Channels Proteins 0.000 description 57
- 239000012530 fluid Substances 0.000 description 50
- 239000012669 liquid formulation Substances 0.000 description 38
- 102000003566 TRPV1 Human genes 0.000 description 30
- 101150016206 Trpv1 gene Proteins 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- 229940079593 drug Drugs 0.000 description 25
- 239000003814 drug Substances 0.000 description 25
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 210000000214 mouth Anatomy 0.000 description 24
- 238000005538 encapsulation Methods 0.000 description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 22
- 235000008504 concentrate Nutrition 0.000 description 19
- 239000012141 concentrate Substances 0.000 description 19
- 239000000126 substance Substances 0.000 description 17
- 239000006196 drop Substances 0.000 description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 108010068806 Acid Sensing Ion Channels Proteins 0.000 description 13
- 235000021251 pulses Nutrition 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229920001661 Chitosan Polymers 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- 239000008187 granular material Substances 0.000 description 12
- 102000001671 Acid Sensing Ion Channels Human genes 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 235000013361 beverage Nutrition 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 238000003556 assay Methods 0.000 description 9
- 238000002567 electromyography Methods 0.000 description 9
- 230000005021 gait Effects 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 208000001640 Fibromyalgia Diseases 0.000 description 8
- 102000004310 Ion Channels Human genes 0.000 description 8
- 108090000862 Ion Channels Proteins 0.000 description 8
- 230000005856 abnormality Effects 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 235000015165 citric acid Nutrition 0.000 description 8
- 210000002161 motor neuron Anatomy 0.000 description 8
- 210000005036 nerve Anatomy 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000006835 compression Effects 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- 239000007903 gelatin capsule Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 208000020431 spinal cord injury Diseases 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- QVZVYMMFEPIZLC-UHFFFAOYSA-N 1-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-3-[(4-octoxyphenyl)methyl]thiourea Chemical compound C1=CC(OCCCCCCCC)=CC=C1CNC(=S)NCC1=CC=C(OCCN)C(OC)=C1 QVZVYMMFEPIZLC-UHFFFAOYSA-N 0.000 description 6
- VJCGNKXIJXJHND-UHFFFAOYSA-N 1-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-3-[2-(4-octoxyphenyl)ethyl]thiourea Chemical compound C1=CC(OCCCCCCCC)=CC=C1CCNC(=S)NCC1=CC=C(OCCN)C(OC)=C1 VJCGNKXIJXJHND-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 208000001308 Fasciculation Diseases 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 6
- 230000000422 nocturnal effect Effects 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 229960004793 sucrose Drugs 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 239000000227 bioadhesive Substances 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 229940105329 carboxymethylcellulose Drugs 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 229960004242 dronabinol Drugs 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 235000012907 honey Nutrition 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 235000021580 ready-to-drink beverage Nutrition 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000042565 transient receptor (TC 1.A.4) family Human genes 0.000 description 5
- 108091053409 transient receptor (TC 1.A.4) family Proteins 0.000 description 5
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 4
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241001315609 Pittosporum crassifolium Species 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000017803 cinnamon Nutrition 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- SNQFEECGHGUHBK-UHFFFAOYSA-N diphenylboranyloxy(diphenyl)borane Chemical compound C=1C=CC=CC=1B(C=1C=CC=CC=1)OB(C=1C=CC=CC=1)C1=CC=CC=C1 SNQFEECGHGUHBK-UHFFFAOYSA-N 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical group CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- 238000013265 extended release Methods 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 235000002780 gingerol Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000008297 liquid dosage form Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 206010028417 myasthenia gravis Diseases 0.000 description 4
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100022094 Acid-sensing ion channel 2 Human genes 0.000 description 3
- 206010000598 Acrodynia Diseases 0.000 description 3
- 231100000455 Acrodynia Toxicity 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 3
- 235000002566 Capsicum Nutrition 0.000 description 3
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000010428 Muscle Weakness Diseases 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 208000009905 Neurofibromatoses Diseases 0.000 description 3
- 206010034701 Peroneal nerve palsy Diseases 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000004373 Pullulan Substances 0.000 description 3
- 229920001218 Pullulan Polymers 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 102000003568 TRPV3 Human genes 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 101150043371 Trpv3 gene Proteins 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 3
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 230000009460 calcium influx Effects 0.000 description 3
- 239000001390 capsicum minimum Substances 0.000 description 3
- 229950008138 carmellose Drugs 0.000 description 3
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 3
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 3
- 235000007746 carvacrol Nutrition 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 3
- 229940117916 cinnamic aldehyde Drugs 0.000 description 3
- 239000010630 cinnamon oil Substances 0.000 description 3
- 239000010634 clove oil Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 235000015243 ice cream Nutrition 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 230000003232 mucoadhesive effect Effects 0.000 description 3
- 201000004931 neurofibromatosis Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002248 primary sensory neuron Anatomy 0.000 description 3
- 235000011962 puddings Nutrition 0.000 description 3
- 235000019423 pullulan Nutrition 0.000 description 3
- 238000001525 receptor binding assay Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 210000001044 sensory neuron Anatomy 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- ULDHMXUKGWMISQ-SECBINFHSA-N (-)-carvone Chemical compound CC(=C)[C@@H]1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-SECBINFHSA-N 0.000 description 2
- NFLGAXVYCFJBMK-BDAKNGLRSA-N (-)-menthone Chemical compound CC(C)[C@@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-BDAKNGLRSA-N 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
- CDOSHBSSFJOMGT-SNVBAGLBSA-N (S)-linalool Chemical compound CC(C)=CCC[C@](C)(O)C=C CDOSHBSSFJOMGT-SNVBAGLBSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- NKTOLZVEWDHZMU-UHFFFAOYSA-N 2,5-xylenol Chemical compound CC1=CC=C(C)C(O)=C1 NKTOLZVEWDHZMU-UHFFFAOYSA-N 0.000 description 2
- BLZVCIGGICSWIG-UHFFFAOYSA-N 2-aminoethoxydiphenylborane Chemical compound C=1C=CC=CC=1B(OCCN)C1=CC=CC=C1 BLZVCIGGICSWIG-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- XOUQAVYLRNOXDO-UHFFFAOYSA-N 2-tert-butyl-5-methylphenol Chemical compound CC1=CC=C(C(C)(C)C)C(O)=C1 XOUQAVYLRNOXDO-UHFFFAOYSA-N 0.000 description 2
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 2
- RCEFMOGVOYEGJN-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-1,4-dihydropyrimidin-2-one Chemical compound OC1=CC=CC=C1N1C(=O)NC(C=2C=C(C=CC=2)[N+]([O-])=O)=CC1 RCEFMOGVOYEGJN-UHFFFAOYSA-N 0.000 description 2
- JWMBOBQNPBCYER-UHFFFAOYSA-N 4-[(4,8-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl)oxy]-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound OC1C(CO)OC(O)C(O)C1OC1C(O)C(C2O)OCC2O1 JWMBOBQNPBCYER-UHFFFAOYSA-N 0.000 description 2
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 102100021624 Acid-sensing ion channel 1 Human genes 0.000 description 2
- 101710099904 Acid-sensing ion channel 1 Proteins 0.000 description 2
- 101710099902 Acid-sensing ion channel 2 Proteins 0.000 description 2
- 102100022097 Acid-sensing ion channel 3 Human genes 0.000 description 2
- 101710099898 Acid-sensing ion channel 3 Proteins 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 2
- 208000008811 Agoraphobia Diseases 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 102000007371 Ataxin-3 Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 244000017106 Bixa orellana Species 0.000 description 2
- 206010065417 Brachial plexopathy Diseases 0.000 description 2
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 235000005747 Carum carvi Nutrition 0.000 description 2
- 240000000467 Carum carvi Species 0.000 description 2
- BAVONGHXFVOKBV-UHFFFAOYSA-N Carveol Chemical compound CC(=C)C1CC=C(C)C(O)C1 BAVONGHXFVOKBV-UHFFFAOYSA-N 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 244000008991 Curcuma longa Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- UBJVUCKUDDKUJF-UHFFFAOYSA-N Diallyl sulfide Chemical compound C=CCSCC=C UBJVUCKUDDKUJF-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KRCZYMFUWVJCLI-UHFFFAOYSA-N Dihydrocarveol Chemical compound CC1CCC(C(C)=C)CC1O KRCZYMFUWVJCLI-UHFFFAOYSA-N 0.000 description 2
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 101000844519 Homo sapiens Transient receptor potential cation channel subfamily M member 6 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 229920001144 Hydroxy alpha sanshool Polymers 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 208000028226 Krabbe disease Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- 206010050219 Lumbar radiculopathy Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 2
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 206010027439 Metal poisoning Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 206010028424 Myasthenic syndrome Diseases 0.000 description 2
- 208000011644 Neurologic Gait disease Diseases 0.000 description 2
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010034912 Phobia Diseases 0.000 description 2
- 208000008713 Piriformis Muscle Syndrome Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 2
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 208000000810 Separation Anxiety Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 2
- 102000003623 TRPC6 Human genes 0.000 description 2
- 102000027545 TRPM Human genes 0.000 description 2
- 108091008847 TRPM Proteins 0.000 description 2
- 101150095096 TRPM2 gene Proteins 0.000 description 2
- 102000003608 TRPM6 Human genes 0.000 description 2
- 102000027544 TRPML Human genes 0.000 description 2
- 108091008846 TRPML Proteins 0.000 description 2
- 108010025083 TRPV1 receptor Proteins 0.000 description 2
- 102000003565 TRPV2 Human genes 0.000 description 2
- 102000003567 TRPV4 Human genes 0.000 description 2
- 101150098315 TRPV4 gene Proteins 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108050001421 Transient receptor potential channel, canonical 6 Proteins 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 101150077905 Trpv2 gene Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 241000234314 Zingiber Species 0.000 description 2
- 208000028752 abnormal posture Diseases 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 229960004998 acesulfame potassium Drugs 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 2
- 239000010362 annatto Substances 0.000 description 2
- 235000012665 annatto Nutrition 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 201000006431 brachial plexus neuropathy Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940107161 cholesterol Drugs 0.000 description 2
- 229960005233 cineole Drugs 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- PFRGXCVKLLPLIP-UHFFFAOYSA-N diallyl disulfide Chemical compound C=CCSSCC=C PFRGXCVKLLPLIP-UHFFFAOYSA-N 0.000 description 2
- UBAXRAHSPKWNCX-UHFFFAOYSA-N diallyl trisulfide Chemical compound C=CCSSSCC=C UBAXRAHSPKWNCX-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 229940073505 ethyl vanillin Drugs 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000010643 fennel seed oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960004369 flufenamic acid Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 2
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical class II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- KZMACGJDUUWFCH-UHFFFAOYSA-O malvidin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KZMACGJDUUWFCH-UHFFFAOYSA-O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 239000002539 nanocarrier Substances 0.000 description 2
- 229960002362 neostigmine Drugs 0.000 description 2
- 208000020469 nerve plexus disease Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 206010049433 piriformis syndrome Diseases 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 201000006380 plexopathy Diseases 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- WUILNKCFCLNXOK-CFBAGHHKSA-N salirasib Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1=CC=CC=C1C(O)=O WUILNKCFCLNXOK-CFBAGHHKSA-N 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 2
- 210000002105 tongue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 239000011701 zinc Chemical class 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- 229960003849 (+)- linalool Drugs 0.000 description 1
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- AZOCECCLWFDTAP-RKDXNWHRSA-N (+)-dihydrocarvone Chemical compound C[C@@H]1CC[C@@H](C(C)=C)CC1=O AZOCECCLWFDTAP-RKDXNWHRSA-N 0.000 description 1
- 229930007066 (+)-dihydrocarvone Natural products 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- ZYTMANIQRDEHIO-KXUCPTDWSA-N (-)-Isopulegol Natural products C[C@@H]1CC[C@@H](C(C)=C)[C@H](O)C1 ZYTMANIQRDEHIO-KXUCPTDWSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- BAVONGHXFVOKBV-ZJUUUORDSA-N (-)-trans-carveol Natural products CC(=C)[C@@H]1CC=C(C)[C@@H](O)C1 BAVONGHXFVOKBV-ZJUUUORDSA-N 0.000 description 1
- LCYXQUJDODZYIJ-DJLDLDEBSA-N (-)-trans-pinocarveol Chemical compound C1[C@H]2C(C)(C)[C@@H]1C[C@@H](O)C2=C LCYXQUJDODZYIJ-DJLDLDEBSA-N 0.000 description 1
- LMXFTMYMHGYJEI-IWSPIJDZSA-N (1R,2R,5R)-2-(1-hydroxy-1-methylethyl)-5-methylcyclohexanol Chemical compound C[C@@H]1CC[C@@H](C(C)(C)O)[C@H](O)C1 LMXFTMYMHGYJEI-IWSPIJDZSA-N 0.000 description 1
- VNQXSTWCDUXYEZ-QUBYGPBYSA-N (1S)-(+)-Bornanedione Chemical compound C1C[C@]2(C)C(=O)C(=O)[C@H]1C2(C)C VNQXSTWCDUXYEZ-QUBYGPBYSA-N 0.000 description 1
- SSBZLMMXFQMHDP-REDNKFHQSA-N (1r,2s,5e,9e,12s)-1,5,9-trimethyl-12-propan-2-yl-15-oxabicyclo[10.2.1]pentadeca-5,9-dien-2-ol Chemical compound O1[C@]2(C)CC[C@@]1(C(C)C)C/C=C(C)/CC/C=C(C)/CC[C@@H]2O SSBZLMMXFQMHDP-REDNKFHQSA-N 0.000 description 1
- REPVLJRCJUVQFA-BZNPZCIMSA-N (1s,3r,4r,5r)-4,6,6-trimethylbicyclo[3.1.1]heptan-3-ol Chemical compound C1[C@@H](O)[C@H](C)[C@@H]2C(C)(C)[C@H]1C2 REPVLJRCJUVQFA-BZNPZCIMSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- LJSBBBWQTLXQEN-UHFFFAOYSA-N (2-methyl-1-propyl-3-indolyl)-(1-naphthalenyl)methanone Chemical compound C12=CC=CC=C2N(CCC)C(C)=C1C(=O)C1=CC=CC2=CC=CC=C12 LJSBBBWQTLXQEN-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ZMYMOKYVEYEAEH-RQLXMFKESA-N (2e)-2-[3-[(1r,2s,4as,8as)-5,5,8a-trimethylspiro[3,4,4a,6,7,8-hexahydro-1h-naphthalene-2,2'-oxirane]-1-yl]propylidene]butanedial Chemical compound C([C@]12[C@H](CC\C=C(/CC=O)C=O)[C@@]3(C)CCCC([C@@H]3CC2)(C)C)O1 ZMYMOKYVEYEAEH-RQLXMFKESA-N 0.000 description 1
- AVTQSDUNQOANPK-MCJWARNPSA-N (2e)-2-[3-[(1s,2s,4as,8ar)-2-formyl-5,5,8a-trimethyl-1,2,3,4,4a,6,7,8-octahydronaphthalen-1-yl]propylidene]butanedial Chemical compound O=CC\C(C=O)=C/CC[C@H]1[C@@H](C=O)CC[C@H]2C(C)(C)CCC[C@@]21C AVTQSDUNQOANPK-MCJWARNPSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- GNSDEDOVXZDMKM-NRFANRHFSA-N (S)-1,2-didecanoylglycerol Chemical compound CCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCC GNSDEDOVXZDMKM-NRFANRHFSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- NBXZJPXDDBBXBL-KHPPLWFESA-N (Z)-N-[2-(4,5-dihydroxy-5-methylcyclohexa-1,3-dien-1-yl)ethyl]octadec-9-enamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCC1=CC=C(O)C(C)(O)C1 NBXZJPXDDBBXBL-KHPPLWFESA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- AIUJHENHBJHHMY-UHFFFAOYSA-N 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-(3-pyridin-4-ylpropyl)urea Chemical compound C1C(C2)CC(C3)CC2CC13CCN(CCCCC)C(=O)NCCCC1=CC=NC=C1 AIUJHENHBJHHMY-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- ZBONBGOYILUGCL-UHFFFAOYSA-N 2,2-dimethylpropanoate Chemical compound CC(C)([CH2+])C([O-])=O ZBONBGOYILUGCL-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- YNZFFALZMRAPHQ-SYYKKAFVSA-N 2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol Chemical compound OC1=CC(C(C)(C)CCCCCC)=CC=C1[C@H]1[C@H](CCCO)CC[C@@H](O)C1 YNZFFALZMRAPHQ-SYYKKAFVSA-N 0.000 description 1
- RCRCTBLIHCHWDZ-DOFZRALJSA-N 2-arachidonoylglycerol Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-DOFZRALJSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical class CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- WDXXEUARVHTWQF-DLBZAZTESA-N 3-hydroxy-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(CCCCC)=CC(=O)C([C@H]2[C@@H](CCC(C)=C2)C(C)=C)=C1O WDXXEUARVHTWQF-DLBZAZTESA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- LLJRXVHJOJRCSM-UHFFFAOYSA-N 3-pyridin-4-yl-1H-indole Chemical group C=1NC2=CC=CC=C2C=1C1=CC=NC=C1 LLJRXVHJOJRCSM-UHFFFAOYSA-N 0.000 description 1
- DGOSGFYDFDYMCW-OEFRVDPMSA-N 4alpha-phorbol 12,13-didecanoate Chemical compound C([C@@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CCCCCCCCC)C1(C)C DGOSGFYDFDYMCW-OEFRVDPMSA-N 0.000 description 1
- LZPKWQOLOCLSBO-UHFFFAOYSA-N 6-(trifluoromethyl)-1,3-dihydroindol-2-one Chemical compound FC(F)(F)C1=CC=C2CC(=O)NC2=C1 LZPKWQOLOCLSBO-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 102100022099 Acid-sensing ion channel 4 Human genes 0.000 description 1
- 101710099897 Acid-sensing ion channel 4 Proteins 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- ZAWCPGMKVKTLKI-FTOUISBVSA-N Aframodial Natural products O=C/C(=C\C[C@@H]1[C@@]2(C)[C@H](C(C)(C)CCC2)CC[C@@]21OC2)/CC=O ZAWCPGMKVKTLKI-FTOUISBVSA-N 0.000 description 1
- 240000004246 Agave americana Species 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 208000003808 Amyloid Neuropathies Diseases 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- MVVPIAAVGAWJNQ-DOFZRALJSA-N Arachidonoyl dopamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCC1=CC=C(O)C(O)=C1 MVVPIAAVGAWJNQ-DOFZRALJSA-N 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 208000022316 Arachnoid cyst Diseases 0.000 description 1
- 244000201691 Arctic bramble Species 0.000 description 1
- 235000010646 Arctic bramble Nutrition 0.000 description 1
- 241001444063 Aronia Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 235000021537 Beetroot Nutrition 0.000 description 1
- 206010004906 Biotin deficiency Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 244000178937 Brassica oleracea var. capitata Species 0.000 description 1
- KAWOEDMUUFFXAM-UHFFFAOYSA-N CC1(C)CCCC2(C)C(C)C(C=O)=CCC21 Polymers CC1(C)CCCC2(C)C(C)C(C=O)=CCC21 KAWOEDMUUFFXAM-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241000208293 Capsicum Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 201000003728 Centronuclear myopathy Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 206010011674 Cutaneous sarcoidosis Diseases 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N Dopamine Natural products NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000207934 Eriodictyon Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 235000000495 Erythronium japonicum Nutrition 0.000 description 1
- 240000000745 Erythronium japonicum Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- TXDUTHBFYKGSAH-SFHVURJKSA-N Evodiamine Chemical compound C1=CC=C2N(C)[C@@H]3C(NC=4C5=CC=CC=4)=C5CCN3C(=O)C2=C1 TXDUTHBFYKGSAH-SFHVURJKSA-N 0.000 description 1
- HMXRXBIGGYUEAX-SFHVURJKSA-N Evodiamine Natural products CN1[C@H]2N(CCc3[nH]c4ccccc4c23)C(=O)c5ccccc15 HMXRXBIGGYUEAX-SFHVURJKSA-N 0.000 description 1
- 208000001441 Familial Periodic Paralyses Diseases 0.000 description 1
- VWFJDQUYCIWHTN-FBXUGWQNSA-N Farnesyl diphosphate Natural products CC(C)=CCC\C(C)=C/CC\C(C)=C/COP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-FBXUGWQNSA-N 0.000 description 1
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102100031510 Fibrillin-2 Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- IVYQPSHHYIAUFO-VXKWHMMOSA-N GSK1016790A Chemical compound N([C@@H](CO)C(=O)N1CCN(CC1)C(=O)[C@@H](NC(=O)C=1SC2=CC=CC=C2C=1)CC(C)C)S(=O)(=O)C1=CC=C(Cl)C=C1Cl IVYQPSHHYIAUFO-VXKWHMMOSA-N 0.000 description 1
- 206010017585 Gait spastic Diseases 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 206010064140 Hand-arm vibration syndrome Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 235000005206 Hibiscus Nutrition 0.000 description 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000901079 Homo sapiens Acid-sensing ion channel 2 Proteins 0.000 description 1
- 101000846890 Homo sapiens Fibrillin-2 Proteins 0.000 description 1
- 101000605625 Homo sapiens Polycystic kidney disease 2-like 1 protein Proteins 0.000 description 1
- 101000605623 Homo sapiens Polycystic kidney disease 2-like 2 protein Proteins 0.000 description 1
- 101001074439 Homo sapiens Polycystin-2 Proteins 0.000 description 1
- 101000844510 Homo sapiens Transient receptor potential cation channel subfamily M member 1 Proteins 0.000 description 1
- 101000844504 Homo sapiens Transient receptor potential cation channel subfamily M member 4 Proteins 0.000 description 1
- 101000844521 Homo sapiens Transient receptor potential cation channel subfamily M member 5 Proteins 0.000 description 1
- 101000844518 Homo sapiens Transient receptor potential cation channel subfamily M member 7 Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020597 Hyperchloraemia Diseases 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010020669 Hypermagnesaemia Diseases 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010020955 Hypochloraemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000029663 Hypophosphatemia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 235000013740 Juglans nigra Nutrition 0.000 description 1
- 244000184861 Juglans nigra Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 201000000251 Locked-in syndrome Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001082241 Lythrum hyssopifolia Species 0.000 description 1
- 208000028656 Löfgren syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000010804 Maranta arundinacea Nutrition 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000078639 Mentha spicata Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- VOEKGBXENFNRQW-UHFFFAOYSA-N Miogatrial Natural products O=CCC(C=O)=CCC1C(C=O)CCC2C(C)(C)CCCC21C VOEKGBXENFNRQW-UHFFFAOYSA-N 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 102100030870 Mucolipin-2 Human genes 0.000 description 1
- 102100030868 Mucolipin-3 Human genes 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 241000498779 Myristica Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- QQBPLXNESPTPNU-KTKRTIGZSA-N N-oleoyldopamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCC1=CC=C(O)C(O)=C1 QQBPLXNESPTPNU-KTKRTIGZSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000034965 Nemaline Myopathies Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101100426589 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) trp-3 gene Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- HVBACKJYWZTKCA-XSLBTUIJSA-N O1[C@]2(C)CC[C@@]1(C(C)C)C/C=C(C)/CC/C=C(C)/CC[C@@H]2OC(C)=O Chemical compound O1[C@]2(C)CC[C@@]1(C(C)C)C/C=C(C)/CC/C=C(C)/CC[C@@H]2OC(C)=O HVBACKJYWZTKCA-XSLBTUIJSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000005546 Piper methysticum Species 0.000 description 1
- 235000016787 Piper methysticum Nutrition 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920000436 Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) Polymers 0.000 description 1
- 102100038330 Polycystic kidney disease 2-like 1 protein Human genes 0.000 description 1
- 102100038335 Polycystic kidney disease 2-like 2 protein Human genes 0.000 description 1
- 102100036142 Polycystin-2 Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- AZJUJOFIHHNCSV-KCQAQPDRSA-N Polygodial Polymers C[C@@]1([C@H](C(C=O)=CC2)C=O)[C@@H]2C(C)(C)CCC1 AZJUJOFIHHNCSV-KCQAQPDRSA-N 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000010401 Prunus avium Nutrition 0.000 description 1
- 240000008296 Prunus serotina Species 0.000 description 1
- 235000014441 Prunus serotina Nutrition 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000014370 Psychogenic movement disease Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000037323 Rare tumor Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N Rohrzucker Natural products OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- 101100100680 Schizosaccharomyces pombe (strain 972 / ATCC 24843) trp4 gene Proteins 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010048871 Sensory integrative dysfunction Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000008981 Smilax officinalis Nutrition 0.000 description 1
- 240000002493 Smilax officinalis Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 244000046109 Sorghum vulgare var. nervosum Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000027077 Stickler syndrome Diseases 0.000 description 1
- 208000032978 Structural Congenital Myopathies Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229940123416 TRP agonist Drugs 0.000 description 1
- 108060008646 TRPA Proteins 0.000 description 1
- 102000027549 TRPC Human genes 0.000 description 1
- 108060008648 TRPC Proteins 0.000 description 1
- 102000003627 TRPC1 Human genes 0.000 description 1
- 101150017559 TRPC1 gene Proteins 0.000 description 1
- 102000003629 TRPC3 Human genes 0.000 description 1
- 102000003622 TRPC4 Human genes 0.000 description 1
- 102000003621 TRPC5 Human genes 0.000 description 1
- 101150042815 TRPC5 gene Proteins 0.000 description 1
- 102000003564 TRPC7 Human genes 0.000 description 1
- 102000003617 TRPM1 Human genes 0.000 description 1
- 102000003615 TRPM2 Human genes 0.000 description 1
- 102000003620 TRPM3 Human genes 0.000 description 1
- 108060008547 TRPM3 Proteins 0.000 description 1
- 102000003618 TRPM4 Human genes 0.000 description 1
- 102000003609 TRPM5 Human genes 0.000 description 1
- 102000003611 TRPM7 Human genes 0.000 description 1
- 102000003610 TRPM8 Human genes 0.000 description 1
- 108060009332 TRPP Proteins 0.000 description 1
- 102000003563 TRPV Human genes 0.000 description 1
- 108060008564 TRPV Proteins 0.000 description 1
- 102000003570 TRPV5 Human genes 0.000 description 1
- 102000003569 TRPV6 Human genes 0.000 description 1
- 101150096736 TRPV6 gene Proteins 0.000 description 1
- 208000003664 Tarlov Cysts Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 244000145580 Thalia geniculata Species 0.000 description 1
- 235000012419 Thalia geniculata Nutrition 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 240000007313 Tilia cordata Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 235000007423 Tolu balsam tree Nutrition 0.000 description 1
- 244000007731 Tolu balsam tree Species 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
- 206010044696 Tropical spastic paresis Diseases 0.000 description 1
- 101150037542 Trpc3 gene Proteins 0.000 description 1
- 101150099990 Trpc4 gene Proteins 0.000 description 1
- 101150033973 Trpc7 gene Proteins 0.000 description 1
- 101150111302 Trpm8 gene Proteins 0.000 description 1
- 101150034091 Trpv5 gene Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047612 Vitamin B2 deficiency Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 206010047634 Vitamin K deficiency Diseases 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 208000013142 Writer cramp Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- CFMRIVODIXTERW-BHIFYINESA-N [(1r,2r,5r)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol Chemical compound COC1=CC(C(C)(C)CCCCCC)=CC(OC)=C1[C@H]1[C@H](C2(C)C)C[C@H]2C(CO)=C1 CFMRIVODIXTERW-BHIFYINESA-N 0.000 description 1
- KPQJOKRSYYJJEL-VLQRKCJKSA-K [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O KPQJOKRSYYJJEL-VLQRKCJKSA-K 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- ZAWCPGMKVKTLKI-UHFFFAOYSA-N afromodial Natural products C1CC2C(C)(C)CCCC2(C)C(CC=C(CC=O)C=O)C21CO2 ZAWCPGMKVKTLKI-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 235000016720 allyl isothiocyanate Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000007590 ariboflavinosis Diseases 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940127225 asthma medication Drugs 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229940088499 brethine Drugs 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 235000010237 calcium benzoate Nutrition 0.000 description 1
- 239000004301 calcium benzoate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MCFVRESNTICQSJ-RJNTXXOISA-L calcium sorbate Chemical compound [Ca+2].C\C=C\C=C\C([O-])=O.C\C=C\C=C\C([O-])=O MCFVRESNTICQSJ-RJNTXXOISA-L 0.000 description 1
- 235000010244 calcium sorbate Nutrition 0.000 description 1
- 239000004303 calcium sorbate Substances 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- 229950011318 cannabidiol Drugs 0.000 description 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229930007646 carveol Natural products 0.000 description 1
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Natural products CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015120 cherry juice Nutrition 0.000 description 1
- 235000020426 cherry syrup Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- 235000012698 chlorophylls and chlorophyllins Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940080423 cochineal Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 208000009854 congenital contractural arachnodactyly Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- HWDGVJUIHRPKFR-UHFFFAOYSA-I copper;trisodium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Cu+2].N1=C(C(CC([O-])=O)=C2C(C(C)C(C=C3C(=C(C=C)C(=C4)[N-]3)C)=N2)CCC([O-])=O)C(=C([O-])[O-])C(C)=C1C=C1C(CC)=C(C)C4=N1 HWDGVJUIHRPKFR-UHFFFAOYSA-I 0.000 description 1
- 239000010636 coriander oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940066901 crestor Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000007242 delphinidin Nutrition 0.000 description 1
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- 229930007024 dihydrocarveol Natural products 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- JFVXEJADITYJHK-UHFFFAOYSA-L disodium 2-(3-hydroxy-5-sulfonato-1H-indol-2-yl)-3-oxoindole-5-sulfonate Chemical compound [Na+].[Na+].Oc1c([nH]c2ccc(cc12)S([O-])(=O)=O)C1=Nc2ccc(cc2C1=O)S([O-])(=O)=O JFVXEJADITYJHK-UHFFFAOYSA-L 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 238000010292 electrical insulation Methods 0.000 description 1
- 239000001567 elettaria cardamomum seed Substances 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229940085363 evista Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 206010016208 familial periodic paralysis Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 229930182497 flavan-3-ol Natural products 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- YTAQZPGBTPDBPW-UHFFFAOYSA-N flavonoid group Chemical class O1C(C(C(=O)C2=CC=CC=C12)=O)C1=CC=CC=C1 YTAQZPGBTPDBPW-UHFFFAOYSA-N 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 229940067594 flufenamate Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 201000002865 focal hand dystonia Diseases 0.000 description 1
- 208000031477 focal task-specific dystonia Diseases 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 201000002886 generalized dystonia Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- 201000002842 hemidystonia Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000011110 idiopathic torsion dystonia Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- ZJTDDBZRNWYHKQ-UHFFFAOYSA-N incensole Natural products CC(C)C12CC=C(/C)CCC=C(/C)CCCC(O)C(C)(C1)O2 ZJTDDBZRNWYHKQ-UHFFFAOYSA-N 0.000 description 1
- HVBACKJYWZTKCA-FSSWDIPSSA-N incensole acetate Natural products CC(C)[C@]12CC[C@](C)(O1)[C@@H](CCC(C)=CCCC(C)=CC2)OC(C)=O HVBACKJYWZTKCA-FSSWDIPSSA-N 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N isomenthone Natural products CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940063711 lasix Drugs 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 208000008127 lead poisoning Diseases 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229940095570 lescol Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000009584 malvidin Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229940101576 microzide Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical class [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 210000001611 motor endplate Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000002901 multifocal dystonia Diseases 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000001673 myroxylon balsanum l. absolute Substances 0.000 description 1
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- ZYTMANIQRDEHIO-UHFFFAOYSA-N neo-Isopulegol Natural products CC1CCC(C(C)=C)C(O)C1 ZYTMANIQRDEHIO-UHFFFAOYSA-N 0.000 description 1
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 208000019382 nerve compression syndrome Diseases 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000000288 neurosarcoidosis Diseases 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 1
- BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000015206 pear juice Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- VLTOSDJJTWPWLS-UHFFFAOYSA-N pent-2-ynal Chemical compound CCC#CC=O VLTOSDJJTWPWLS-UHFFFAOYSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013997 pineapple juice Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Chemical class 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- FPGPDEPMWUWLOV-UHFFFAOYSA-N polygodial Natural products CC1(C)CCCC2(C)C(C=O)C(=CC(O)C12)C=O FPGPDEPMWUWLOV-UHFFFAOYSA-N 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229940089484 pravachol Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 229940089949 procardia Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940063566 proventil Drugs 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 235000013995 raspberry juice Nutrition 0.000 description 1
- 235000020440 raspberry syrup Nutrition 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 208000004223 riboflavin deficiency Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000008132 rose water Substances 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000002899 segmental dystonia Diseases 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical class [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000013758 sodium copper chlorophyllin Nutrition 0.000 description 1
- 229940079841 sodium copper chlorophyllin Drugs 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 229960004016 sucrose syrup Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229940000238 tasmar Drugs 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 235000008118 thearubigins Nutrition 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- 229940088660 tolu balsam Drugs 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 208000018724 torsion dystonia Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- LCYXQUJDODZYIJ-UHFFFAOYSA-N trans-Pirocalveol Natural products C1C2C(C)(C)C1CC(O)C2=C LCYXQUJDODZYIJ-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940070384 ventolin Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- HQVHOQAKMCMIIM-UHFFFAOYSA-N win 55,212-2 Chemical compound C=12N3C(C)=C(C(=O)C=4C5=CC=CC=C5C=CC=4)C2=CC=CC=1OCC3CN1CCOCC1 HQVHOQAKMCMIIM-UHFFFAOYSA-N 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000001432 zingiber officinale rosc. oleoresin Substances 0.000 description 1
- 229940072168 zocor Drugs 0.000 description 1
- NQFUSWIGRKFAHK-KEMUHUQJSA-N α-pinene-oxide Chemical compound CC12OC1C[C@H]1C(C)(C)[C@@H]2C1 NQFUSWIGRKFAHK-KEMUHUQJSA-N 0.000 description 1
- USMNOWBWPHYOEA-MRTMQBJTSA-N α-thujone Chemical compound O=C([C@@H]1C)C[C@@]2(C(C)C)[C@@H]1C2 USMNOWBWPHYOEA-MRTMQBJTSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/262—Cellulose; Derivatives thereof, e.g. ethers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to compositions of capsaicinoids, capsinoids, and related analogs or combinations thereof, and methods of preparation, formulation, and the medical use of these compositions.
- the present invention relates to compositions of capsaicinoids, capsinoids, and related analogs thereof, and methods of preparation, formulation, and the medical use of these
- Capsaicin and several related compounds belong to a class of compounds called capsaicinoids and are produced as secondary metabolites by chili peppers. Capsaicinoids are found to exert multiple pharmacological and physiological effects including analgesia and anticancer, anti-inflammation, antioxidant, and anti-obesity activities. Sweet peppers are the source of natural capsinoids, which share a similar structural scaffold with capsaicinoids.
- Capsinoids are less pungent and easily broken down under normal aqueous conditions compared to capsaicinoids. Capsinoids also possess antitumor, antioxidant, and anti-obesity properties.
- peripheral nervous system conditions e.g., peripheral neuropathy
- central nervous system conditions e.g., central nervous system conditions, muscle conditions and disorders (e.g., fibromyalgia, muscle spasms and cramps (e.g. , nocturnal cramps), painful muscle contractions (e.g., a muscle contraction of the head or neck), neuromuscular disorders (e.g., motor neuron disease) or dystonia (e.g., cervical dystonia, blepharospasm, back spasms, or leg cramps due to spinal stenosis)), connective tissue diseases (e.g., degenerative joint disease), throat conditions (e.g.
- peripheral nervous system conditions e.g., peripheral neuropathy
- muscle conditions and disorders e.g., fibromyalgia, muscle spasms and cramps (e.g. , nocturnal cramps), painful muscle contractions (e.g., a muscle contraction of the head or neck)
- neuromuscular disorders e
- compositions that include capsaicinoids and/or capsinoids and analogs thereof may be useful to treat the above-mentioned conditions.
- the present invention features a composition formulated for oral administration, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof.
- the composition comprises a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof.
- the composition further comprises a pharmaceutically acceptable excipient.
- the composition further comprises a plurality of
- the composition is formulated for modified release (e.g., delayed release, extended release, or rapid release) of said capsaicinoid, capsinoid, or related analog or combination thereof.
- said pharmaceutically acceptable excipient comprises an agent for modified release (e.g., delayed release, extended release, or rapid release) of a capsaicinoid, capsinoid, or related analog or combination thereof, such that, when orally administered to a subject, the capsaicinoid, capsinoid, or related analog or combination thereof is not substantially released in the stomach of said subject.
- the agent for modified release (e.g., delayed release, extended release, or rapid release) is selected from the group consisting of: hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, carboxymethyl cellulose, and mixtures thereof.
- said pharmaceutically acceptable excipient comprises a coating.
- said coating is selected from the group consisting of: enteric coatings, sugar coatings, and polymeric coatings.
- said capsaicinoid, capsinoid, or related analog or combination thereof is embedded in biodegradable microparticles or nanoparticles for sustained release.
- the composition further comprises a formulation base.
- the formulation base comprises an oil and a lipophilic additive.
- said oil is selected from the group consisting of: vegetable oil, mineral oil, soya oil, sunflower oil, corn oil, olive oil, nut oil, and liquid paraffin.
- said lipophilic additive is selected from the group consisting of: polyethylene glycol, fatty acid mono- , di-, or triglycerides, palmitic acid, stearic acid, behenic acid, polyethylene glycol fatty acid esters, candelilla wax, carnauba wax, polyethylene oxide wax, and petroleum wax.
- the composition further comprises a coloring agent, a dissolving agent, a flavoring agent, a sweetener, a viscosity modifier, an electrolyte, a vitamin, a mineral, an antioxidant, or a preservative.
- the capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring.
- said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate,
- said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is capsaicin. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or from about 0.001% to about 10% (v/v).
- the non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl formate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]- 2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2-dimethylpropanoate, 4-[((6E)- 8-methylnon-6-enoylamino)methyl]-2-methyoxyphen
- said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or from about 0.001% to about 10% (v/v).
- the composition is a liquid or a solid. In some embodiments, the composition is formulated as a liquid. In some embodiments, the liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, sprays, and elixirs. In some embodiments, the composition is formulated as a solid. In some embodiments, the solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, and semi-solid formulations. In some embodiments, said solid is a tablet or capsule. In some embodiments, said capsule is a hard or soft capsule.
- the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 0.01% or more of a liquid formulation, e.g., about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.075%, about 0.1%, or more. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 0.1% or more of a liquid formulation, e.g., about 0.2%, about 0.3%, about 0. 4%, about 0.5%, about 0.75%, about 1%, or more.
- the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 1% or more of a liquid formulation, e.g., about 2%, about 3%, about 4%, about 5%, about 7.5%, about 10%, or more. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises between about 0.5% and 5% of a liquid formulation. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises between about 0.5% and 2.5% of a liquid formulation.
- the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 10% or more of a liquid formulation, e.g., about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, or more.
- the composition comprises a liquid formulation (e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir) and an effective amount of the liquid formulation is at least about 1 mL, about 2 mL, about 4 mL, about 6 mL, about 8 mL, about 10 mL, about 12 mL, about 14 mL, about 16 mL, about 18 mL, about 20 mL, about 22.5 mL, about 25 mL, or more. In some embodiments, an effective amount of the liquid formulation is between about 1 mL and about 10 mL. In some embodiments, an effective amount of the liquid formulation is between about 5 mL and about 10 mL. In some embodiments, an effective amount of the liquid formulation is between about 10 mL and about 25 mL.
- a liquid formulation e.g., an emulsion, microemulsion, solution, suspension, syrup (
- the composition comprises a liquid formulation (e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir) and an effective amount of the liquid formulation is at least about 25 mL, about 30 mL, about 35 mL, about 40 mL, about 45 mL, about 50 mL, about 60 mL, about 75 mL, about 100 mL, about 150 mL, about 200 mL, about 300 mL, about 400 mL, about 500 mL, about 600 mL, about 750 mL, about 1000 mL, or more.
- a liquid formulation e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir
- an effective amount of the liquid formulation is at least about 25 mL, about 30 mL, about 35 mL, about
- an effective amount of the liquid formulation is between about 25 mL and about 100 mL. In some embodiments, an effective amount of the liquid formulation is between about 50 mL and about 500 mL. In some embodiments, an effective amount of the liquid formulation is between about 100 mL and about 1000 mL.
- the composition comprises a liquid formulation (e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir) and an effective amount of the liquid formulation is at least about 1 fluid ounce, about 2 fluid ounces, about 3 fluid ounces, about 4 fluid ounces, about 5 fluid ounces, about 6 fluid ounces, about 7 fluid ounces, about 8 fluid ounces, about 9 fluid ounces, about 10 fluid ounces, about 11 fluid ounces, about 12 fluid ounces, or more.
- a liquid formulation e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir
- an effective amount of the liquid formulation is at least about 1 fluid ounce, about 2 fluid ounces, about 3 fluid ounces, about 4 fluid ounces, about 5 fluid ounces, about 6 fluid ounce
- an effective amount of the liquid formulation is at least about 12 fluid ounces, about 16 fluid ounces, about 20 fluid ounces, about 24 fluid ounces, about 32 fluid ounces, about 40 fluid ounces, about 48 fluid ounces, about 56 fluid ounces, about 64 fluid ounces, or more.
- the composition comprises a solid formulation (e.g., a tablet, capsule, powder, crystal, paste, gel, lozenge (e.g., liquid filled lozenge), gum, candy, chew, foodstuff, dissolving strip, film, or semi-solid formulation) and an effective amount of the solid formulation is about 0.5 mg, about 1 mg, about 10 mg, about 25 mg, about 50 mg, about 100 mg, about 250 mg, about 500 mg, about 750 mg, about 1 g, about 2 g, about 5 g, about 10 g, or more. In some embodiments, an effective amount of the solid formulation is between about 0.5 mg and about 100 mg. In some embodiments, an effective amount of the solid formulation is between about 100 mg and about 500 mg. In some embodiments, an effective amount of the solid formulation is between about 500 mg and about 1000 mg.
- a solid formulation e.g., a tablet, capsule, powder, crystal, paste, gel, lozenge (e.g., liquid filled lozenge), gum, candy, chew, foodstuff, dis
- the composition is capable of reducing gastrointestinal side effects.
- the composition comprising the capsaicinoid, capsinoid, or related analog or combination thereof is formulated for use once a day. In some embodiments, the composition is formulated for use at least about 1 time per day, about 2 times per day, about 3 times per day, about 4 times per day, about 5 times per day, or more. In some embodiments, the composition is formulated for use about 1-3 times per day. In some embodiments, the composition is formulated for use for a period of about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, or more.
- the composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof, which target a TRP channel (e.g. , TRPV1).
- a TRP channel e.g. , TRPV1
- said composition comprises a TRP channel agonist (e.g. , a TRPV1 agonist).
- a TRP channel agonist e.g. , a TRPV1 agonist
- the invention features a composition formulated for oral
- said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof, and a pharmaceutically acceptable excipient, wherein said composition is a liquid or solid, and wherein said composition is formulated for delayed release of said capsaicinoid, capsinoid, or related analog or combination thereof.
- said composition comprises a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient.
- said composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof, and a plurality of pharmaceutically acceptable excipients.
- said pharmaceutically acceptable excipient comprises an agent for delayed release of a capsaicinoid, capsinoid, or related analog or combination thereof, such that, when orally administered to a subject, the capsaicinoid, capsinoid, or related analog or combination thereof is not substantially released in the stomach of said subject.
- the agent for delayed release is selected from the group consisting of:
- hydroxypropyl cellulose hydroxypropyl methyl cellulose, methyl cellulose, carboxymethyl cellulose, and mixtures thereof.
- said pharmaceutically acceptable excipient comprises a coating.
- said coating is selected from the group consisting of: enteric coatings, sugar coatings, and polymeric coatings.
- said capsaicinoid, capsinoid, or related analog or combination thereof is embedded in biodegradable microparticles or nanoparticles for sustained release.
- the composition further comprises a formulation base.
- the formulation base comprises an oil and a lipophilic additive.
- said oil is selected from the group consisting of: vegetable oil, mineral oil, soya oil, sunflower oil, corn oil, olive oil, nut oil, and liquid paraffin.
- said lipophilic additive is selected from the group consisting of: polyethylene glycol, fatty acid mono- , di-, or triglycerides, palmitic acid, stearic acid, behenic acid, polyethylene glycol fatty acid esters, candelilla wax, carnauba wax, polyethylene oxide wax, and petroleum wax.
- the composition further comprises a coloring agent, a dissolving agent, a flavoring agent, a sweetener, a viscosity modifier, an electrolyte, a vitamin, a mineral, an antioxidant, or a preservative.
- the composition is formulated as a liquid.
- the liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, and elixirs.
- the composition is formulated as a solid.
- the solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, and semisolid formulations.
- said solid is a tablet or capsule.
- said capsule is a hard or soft capsule.
- the composition comprising the capsaicinoid, capsinoid, or related analog or combination thereof is formulated for use once a day. In some embodiments, the composition is formulated for use at least about 1 time per day, about 2 times per day, about 3 times per day, about 4 times per day, about 5 times per day, or more. In some embodiments, the composition is formulated for use about 1-3 times per day. In some embodiments, the composition is formulated for use for a period of about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, or more.
- the capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring.
- said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate,
- said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is capsaicin. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or from about 0.001% to about 10% (v/v).
- the non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl formate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]- 2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2-dimethylpropanoate, 4-[((6E)- 8-methylnon-6-enoylamino)methyl]-2-methyoxyphen
- said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or from about 0.001% to about 10% (v/v).
- the composition is capable of reducing gastrointestinal side effects.
- the composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof, which target a TRP channel (e.g. , TRPV1).
- a TRP channel e.g. , TRPV1
- said composition comprises a TRP channel agonist (e.g. , a TRPV1 agonist).
- a TRP channel agonist e.g. , a TRPV1 agonist
- the invention features a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof, a formulation base, and a pharmaceutically acceptable excipient.
- said composition comprises a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof a formulation base, and a pharmaceutically acceptable excipient.
- said composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof, a formulation base, and a plurality of pharmaceutically acceptable excipients.
- the formulation base comprises an oil and a lipophilic additive.
- said oil is selected from the group consisting of: vegetable oil, mineral oil, soya oil, sunflower oil, corn oil, olive oil, nut oil, and liquid paraffin.
- said lipophilic additive is selected from the group consisting of: polyethylene glycol, fatty acid mono-, di-, or triglycerides, palmitic acid, stearic acid, behenic acid, polyethylene glycol fatty acid esters, candelilla wax, carnauba wax, polyethylene oxide wax, and petroleum wax.
- the composition further comprises a coloring agent, a dissolving agent, a flavoring agent, a sweetener, a viscosity modifier, an electrolyte, a vitamin, a mineral, an antioxidant, or a preservative.
- the composition is formulated as a liquid or a solid. In some embodiments, the composition is formulated as a liquid. In some embodiments, the liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, sprays, and elixirs. In some embodiments, the composition is formulated as a solid. In some embodiments, the solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, and semi-solid
- said solid is a tablet or capsule. In some embodiments, said capsule is a hard or soft capsule.
- the composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof is formulated for use once a day.
- the composition is formulated for use at least about 1 time per day, about 2 times per day, about 3 times per day, about 4 times per day, about 5 times per day, or more.
- the composition is formulated for use about 1-3 times per day.
- the composition is formulated for use for a period of about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, or more.
- the capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring.
- said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate,
- said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is capsaicin. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or from about 0.001% to about 10% (v/v).
- the non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4-[((6E)-8-methylnon-6- enoylamino)metliyl] -2-methyoxyphenyl formate, 4- [((6E)-8-methylnon-6-enoylamino)methyl] - 2-methyoxyphenyi acetate, 4-[((6E)-8-rnethylnon-6-enoylamino)methyl]-2-rrj.ethyoxyphenyl propanoate, 4-[((6E -8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-rn.ethoxyphenyl 2,2-dimethylpropanoate, 4-[((6E)- 8-methylnon-6
- said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or from about 0.001% to about 10% (v/v).
- the composition is capable of reducing gastrointestinal side effects.
- the composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof which target a TRP channel (e.g. , TRPV1).
- a capsaicinoid e.g. , TRPV1
- TRPV1 TRP channel
- said composition comprises a TRP channel agonist (e.g. , a TRPV1 agonist).
- a TRP channel agonist e.g. , a TRPV1 agonist
- the invention features a composition formulated for oral administration to a subject, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient, wherein upon administration, the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time of greater than about 5 seconds in the mouth of the subject.
- said composition comprises a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analog or combinations thereof and a pharmaceutically acceptable excipient.
- said composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time of greater than about 5 seconds in the mouth of a subject, e.g., greater than about 6 seconds, about 7 seconds, about 8 seconds, about 9 seconds, about 10 seconds, about 11 seconds, about 12 seconds, about 13 seconds, about 14 seconds, about 15 seconds, about 20 seconds, about 25 seconds, about 30 seconds, about 45 seconds, about 60 seconds, about 90 seconds, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, or more.
- the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time in the mouth of a subject between about 5 seconds and about 2 minutes.
- capsaicinoid, capsinoid, or related analog or combination thereof has a residence time in the mouth of a subject between about 5 seconds and about 60 seconds. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time in the mouth of a subject between about 5 seconds and about 30 seconds.
- the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time of greater than about 60 seconds in the mouth of a subject, e.g., greater than about 90 seconds, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, about 10 minutes, or more.
- the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time in the mouth of a subject between about 60 seconds and about 5 minutes.
- the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time in the mouth of a subject between about 60 seconds and about 3 minutes.
- the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time in the mouth of a subject between about 60 seconds and about 2 minutes.
- the composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof is formulated for use once a day.
- the composition is formulated for use at least about 1 time per day, about 2 times per day, about 3 times per day, about 4 times per day, about 5 times per day, or more.
- the composition is formulated for use about 1-3 times per day.
- the composition is formulated for use for a period of about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, or more.
- the composition further comprises a formulation base.
- the formulation base comprises an oil and a lipophilic additive.
- said oil is selected from the group consisting of: vegetable oil, mineral oil, soya oil, sunflower oil, corn oil, olive oil, nut oil, and liquid paraffin.
- said lipophilic additive is selected from the group consisting of: polyethylene glycol, fatty acid mono- , di-, or triglycerides, palmitic acid, stearic acid, behenic acid, polyethylene glycol fatty acid esters, candelilla wax, carnauba wax, polyethylene oxide wax, and petroleum wax.
- the composition further comprises a coloring agent, a dissolving agent, a flavoring agent, a sweetener, a viscosity modifier, an electrolyte, a vitamin, a mineral, an antioxidant, or a preservative.
- the capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring.
- said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate,
- said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is capsaicin. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present in 0.001% to 10% (w/w) or 0.001% to 10% (v/v).
- the non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl formate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]- 2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2-dimethylpropanoate, 4-[((6E)- 8-methylnon-6-enoylamino)methyl]-2-methyoxyphen
- said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present in 0.001% to 10% (w/w) or 0.001% to 10% (v/v).
- the composition is capable of reducing gastrointestinal side effects.
- the composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof which target a TRP channel (e.g. , TRPVl).
- said composition comprises a TRP channel agonist (e.g. , a TRPVl agonist).
- the composition is a liquid or a solid. In some embodiments, the composition is formulated as a liquid. In some embodiments, the liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, sprays, and elixirs. In some embodiments, the composition is formulated as a solid. In some embodiments, the solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, and semi-solid formulations. In some embodiments, said solid is a tablet or capsule. In some embodiments, said capsule is a hard or soft capsule.
- the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 0.01% or more of a liquid formulation, e.g., about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.075%, about 0.1%, or more. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 0.1% or more of a liquid formulation, e.g., about 0.2%, about 0.3%, about 0. 4%, about 0.5%, about 0.75%, about 1%, or more.
- the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 1% or more of a liquid formulation, e.g., about 2%, about 3%, about 4%, about 5%, about 7.5%, about 10%, or more. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises between about 0.5% and 5% of a liquid formulation. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises between about 0.5% and 2.5% of a liquid formulation.
- the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 10% or more of a liquid formulation, e.g., about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, or more.
- the composition comprises a liquid formulation (e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir) and an effective amount of the liquid formulation is at least about 1 mL, about 2 mL, about 4 mL, about 6 mL, about 8 mL, about 10 mL, about 12 mL, about 14 mL, about 16 mL, about 18 mL, about 20 mL, about 22.5 mL, about 25 mL, or more. In some embodiments, an effective amount of the liquid formulation is between about 1 mL and about 10 mL. In some embodiments, an effective amount of the liquid formulation is between about 5 mL and about 10 mL. In some embodiments, an effective amount of the liquid formulation is between about 10 mL and about 25 mL.
- a liquid formulation e.g., an emulsion, microemulsion, solution, suspension, syrup (
- the composition comprises a liquid formulation (e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir) and an effective amount of the liquid formulation is at least about 25 mL, about 30 mL, about 35 mL, about 40 mL, about 45 mL, about 50 mL, about 60 mL, about 75 mL, about 100 mL, about 150 mL, about 200 mL, about 300 mL, about 400 mL, about 500 mL, about 600 mL, about 750 mL, about 1000 mL, or more.
- a liquid formulation e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir
- an effective amount of the liquid formulation is at least about 25 mL, about 30 mL, about 35 mL, about
- an effective amount of the liquid formulation is between about 25 mL and about 100 mL. In some embodiments, an effective amount of the liquid formulation is between about 50 mL and about 500 mL. In some embodiments, an effective amount of the liquid formulation is between about 100 mL and about 1000 mL.
- the composition comprises a liquid formulation (e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir) and an effective amount of the liquid formulation is at least about 1 fluid ounce, about 2 fluid ounces, about 3 fluid ounces, about 4 fluid ounces, about 5 fluid ounces, about 6 fluid ounces, about 7 fluid ounces, about 8 fluid ounces, about 9 fluid ounces, about 10 fluid ounces, about 11 fluid ounces, about 12 fluid ounces, or more.
- a liquid formulation e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir
- an effective amount of the liquid formulation is at least about 1 fluid ounce, about 2 fluid ounces, about 3 fluid ounces, about 4 fluid ounces, about 5 fluid ounces, about 6 fluid ounce
- an effective amount of the liquid formulation is at least about 12 fluid ounces, about 16 fluid ounces, about 20 fluid ounces, about 24 fluid ounces, about 32 fluid ounces, about 40 fluid ounces, about 48 fluid ounces, about 56 fluid ounces, about 64 fluid ounces, or more.
- the composition comprises a solid formulation (e.g., a tablet, capsule, powder, crystal, paste, gel, lozenge, gum, candy, chew, foodstuff, dissolving strip, film, or semi-solid formulation) and an effective amount of the solid formulation is about 0.5 mg, about 1 mg, about 10 mg, about 25 mg, about 50 mg, about 100 mg, about 250 mg, about 500 mg, about 750 mg, about 1 g, about 2 g, about 5 g, about 10 g, or more. In some embodiments, an effective amount of the solid formulation is between about 0.5 mg and about 100 mg. In some embodiments, an effective amount of the solid formulation is between about 100 mg and about 500 mg. In some embodiments, an effective amount of the solid formulation is between about 500 mg and about 1000 mg.
- a solid formulation e.g., a tablet, capsule, powder, crystal, paste, gel, lozenge, gum, candy, chew, foodstuff, dissolving strip, film, or semi-solid formulation
- an effective amount of the solid formulation is about
- the capsaicinoid, a capsinoid, or related analog or combination thereof is ingested by the subject, e.g., is swallowed by the subject.
- the capsaicinoid, a capsinoid, or related analog or combination thereof is held in the mouth by the subject, e.g., is not swallowed by the subject.
- the holding in the mouth may further comprise e.g., actively swirling the ion channel activator in the mouth of the subject, or placing the against ion channel activator on the skin or surface of the mouth or tongue (e.g., sublingual delivery).
- the capsaicinoid, a capsinoid, or related analog or combination thereof is dissolved in the mouth of the subject or chewed by the subject prior to swallowing.
- the invention features a method of treating a painful muscle contraction in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- said painful muscle contraction is a muscle contraction of the head or neck. In some embodiments, said painful muscle contraction is associated with tension headache, cluster headache, or migraine headache.
- the invention features a method of treating tactile sensitivity in a subject in need thereof, said method comprising orally administering to said subject a
- said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- said tactile sensitivity is associated with autism, dyspraxia, neuralgia, anxiety disorders, venomous bites, or venomous stings.
- said anxiety disorder is selected from the group consisting of panic disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), social anxiety disorder, phobia, and generalized anxiety disorder (GAD).
- the invention features a method of treating a dystonia in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a
- said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- said dystonia is selected from the group consisting of: focal dystonia,
- blepharospasm cervical dystonia, cranial dystonia, laryngeal dystonia, back spasms, hand dystonia, or leg cramps due to spinal stenosis.
- the invention features a method of treating a peripheral nervous system (PNS) condition in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient to said subject.
- said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- said PNS condition is selected from the group consisting of: cramp fasciculation syndrome, Isaacs' Syndrome or neuromyotonia (NMT), peripheral neuropathy, carpal tunnel syndrome, and Epstein-Barr virus (EBV) infection.
- the invention features a method of treating a throat condition in a subject in need thereof, said method comprising orally administering to said subject a
- said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- said throat condition is associated with chemical injury, cancer, surgical injury, or pathogen infection.
- said throat condition is selected from the group consisting of: acid reflux, laryngospasm, dysphagia, and spasmodic dysphonias.
- the invention features a method of treating a condition associated with electrolyte imbalance or vitamin deficiency in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of
- said condition is selected from the group consisting of: hyponatremia, kidney disease, rickets, calcium deficiency, magnesium deficiency, thiamine deficiency, hypoparathyroidism, medullary cystic disease, and
- the invention features a method of treating a central nervous system (CNS) condition in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
- CNS central nervous system
- said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- said CNS condition is associated with a tumor.
- said CNS condition is selected from the group consisting of: multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, stroke, motor neuron disease, spinal injury, and stenosis.
- the invention features a method of treating a muscle condition or disorder in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- said muscle condition or disorder is associated with muscle pain, muscle spasms, muscle cramps, fasciculations, or any combination thereof.
- the muscle condition or disorder is a neuromuscular disorder (e.g., multiple sclerosis, spinal cord spasticity, spinal muscle atrophy, myasthenia gravis, spinal cord injury, traumatic brain injury, cerebral palsy, hereditary spastic paraplegia, motor neuron disease (e.g., amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, progressive spinobulbar muscular atrophy (e.g., Kennedy' s disease), or post-polio syndrome), neuralgia, fibromyalgia, Machado-Joseph disease, cramp fasciculation syndrome, carpal tunnel syndrome, acrodynia, neurofibromatosis, neuromyotonias (e.g., focal neuromyo
- said muscle condition or disorder is muscle pain, muscle spasms, muscle cramps, spasticity, or fasciculations associated with motor neuron disease (e.g., amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, progressive spinobulbar muscular atrophy (e.g., Kennedy's disease), or post-polio syndrome).
- motor neuron disease e.g., amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, progressive spinobulbar muscular atrophy (e.g., Kennedy's disease), or post-polio syndrome).
- said muscle condition or disorder is associated with treatment of said subject with dialysis, diuretics, ⁇ -blockers, statins, fibrates, p2-agonists, ACE inhibitors, ARBs, anti-psychotic medications, or any combination thereof.
- said muscle condition is associated with treatment of said subject with statins and fibrates.
- said muscle condition or disorder occurs in one or more skeletal muscles.
- said muscle condition or disorder is refractory to an approved treatment.
- said approved treatment is botox, cyclopenzaprine, orphenadrine, baclofen, or any combination thereof.
- said muscle condition or disorder is fibromyalgia.
- said muscle condition or disorder involves muscle claudication pain.
- said muscle claudication pain is associated with inactivity, restriction, economy class syndrome, paralysis, peripheral artery disease, or immobilization.
- the invention features a method of treating a respiratory condition in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- said respiratory condition comprises asthma, chronic obstructive pulmonary disease, bronchitis, emphysema, pneumonia, cystic fibrosis, influenza, or a cold.
- the invention features a method of treating a cough in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three)
- said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- said cough is associated with a respiratory condition (e.g., asthma, chronic obstructive pulmonary disease, bronchitis, emphysema, pneumonia, cystic fibrosis, influenza, or a cold), exposure to an allergen, or inflammation.
- a respiratory condition e.g., asthma, chronic obstructive pulmonary disease, bronchitis, emphysema, pneumonia, cystic fibrosis, influenza, or a cold
- the invention features a method of treating sarcoidosis in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof, and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a
- said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- the invention features a method of treating a connective tissue disease in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof, and a pharmaceutically acceptable excipient.
- said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- said connective tissue disease is selected from the group consisting of Ehlers- Danlos syndrome, epidermolysis bullosa, Marfan syndrome, osteogenesis imperfect, arthritis, scleroderma, Sjogren's syndrome, lupus, vasculitis, mixed connective tissue disease, cellulitis, polymyositis, and dermatomyositis.
- said arthritis is rheumatoid arthritis, osteoarthritis, gout, or psioratic arthritis, or wherein said vasculitis is Wegener's granulomatosis or Churg-Strauss Syndrome.
- the capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring.
- said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate, dihydrocapsiate, nordihydrocapsiate, norcapsaicin, capsiconiate, dihydrocapsiconiate and other coniferyl esters, capsiconinoid, and 3- hydroxyacetanilide.
- said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is capsaicin. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or from about 0.001% to about 10% (v/v).
- the non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl formate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]- 2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2-dimethylpropanoate, 4-[((6E)- 8-methylnon-6-enoylamino)methyl]-2-methyoxyphen
- vanillylamide-4-glycol ether 20-homovanillyl-mezerein, 20-homovanillyl-12-deoxyphorbol- 13- phenylacetate, civamide (N-[(4-hydroxy-3-methoxyphenyl)-methyl]-8-methyl-(Z)-6- nonemamide), nuvanil, capsavanil, olvanil, arvanil, and palvanil (N-palmitoyl-vanillamide).
- said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present in 0.001% to 10% (w/w) or 0.001% to 10% (v/v).
- the composition is capable of reducing gastrointestinal side effects.
- the composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof, which target a TRP channel (e.g. , TRPV1).
- a TRP channel e.g. , TRPV1
- said composition comprises a TRP channel agonist (e.g. , a TRPV1 agonist).
- a TRP channel agonist e.g. , a TRPV1 agonist
- the composition is formulated as a liquid or a solid. In some embodiments, the composition is formulated as a liquid. In some embodiments, the liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, sprays, and elixirs. In some embodiments, the composition is formulated as a solid. In some embodiments, the solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, and semi-solid
- said solid is a tablet or capsule. In some embodiments, said capsule is a hard or soft capsule.
- the invention features a method of treating a subject for unwanted or abnormal muscle contraction (e.g. , cramp, spasm, dystonia, or fasciculation) or absence of a normal muscle contraction (e.g. , gait abnormalities, e.g. , foot drop) comprising: acquiring, e.g. , directly or indirectly, knowledge of a result of a test for the efficacy of the administration of a test aliquot of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof for alleviation of test muscle contraction in said subject; and administering, e.g.
- the test comprises directly acquiring said knowledge. In some embodiments, the test comprises further performing said test.
- said muscle contraction comprises a muscle cramp. In some embodiments, said muscle contraction comprises a muscle spasm. In some embodiments, said muscle contraction comprises a dystonia. In some embodiments, said muscle contraction comprises a fasciculation. In some embodiments, said muscle contraction occurs in a skeletal muscle. In some embodiments, said muscle contraction occurs in a smooth muscle. In some embodiments, the test muscle contraction is a test muscle cramp or a test muscle spasm.
- said composition comprises a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof. In some embodiments, said composition further comprises a pharmaceutically acceptable excipient. In some embodiments,
- said composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- the capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring.
- said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate,
- said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is capsaicin. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present in 0.001% to 10% (w/w) or 0.001% to 10% (v/v).
- the non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl formate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]- 2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2-dimethylpropanoate, 4-[((6E)- 8-methylnon-6-enoylamino)methyl]-2-methyoxyphen
- said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present in 0.001% to 10% (w/w) or 0.001% to 10% (v/v).
- the composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof, which target a TRP channel (e.g. , TRPV1).
- a TRP channel e.g. , TRPV1
- said composition comprises a TRP channel agonist (e.g. , a TRPV1 agonist).
- a TRP channel agonist e.g. , a TRPV1 agonist
- the subject has a central nervous system disorder or injury, e.g. , a brain injury, stroke, or traumatic spinal cord injury.
- the subject has been diagnosed with or identified as having multiple sclerosis.
- the subject has been diagnosed with or identified as having dystonia, e.g. , cervical dystonia.
- the subject has been diagnosed with or identified as having spinal cord spasticity.
- said subject has been diagnosed with or identified as having a disorder associated with muscle cramps, e.g. , any of the disorders disclosed herein, e.g. , night cramps, multiple sclerosis, spinal cord spasticity, or dystonia.
- said muscle contraction being selected, treated, or diagnosed comprises a contraction in a muscle other than a muscle that is contracted in the test muscle contraction.
- said test muscle contraction comprises a contraction in a muscle of the foot, e.g. , the flexor hallucis brevis muscle, and the muscle cramp comprises a cramp in a muscle other than the foot, e.g. , the flexor hallucis brevis muscle.
- said muscle contraction is not induced by applied electrical stimulation.
- said muscle contraction is a night cramp. In some embodiments, said muscle contraction is associated with multiple sclerosis. In some embodiments, said muscle contraction is associated with spinal cord spasticity. In some embodiments, said muscle contraction is associated with dystonia.
- said test comprises inducing said test muscle cramp by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation. In some embodiments, said test comprises determining that a muscle contraction can be induced in a subject by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation.
- said test comprises: a) administering the test aliquot of the composition to said subject; b) inducing, e.g. , by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation, a test muscle contraction; and c) evaluating the effect of administering the test aliquot of the composition on test muscle contraction.
- step a is performed before step b. In some embodiments, step a is performed after step b.
- said test comprises: a) administering the test aliquot of the composition to said subject; b) inducing, e.g. , by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation, a test muscle contraction; and c) evaluating the effect of administering the composition on test muscle contraction, e.g. , by evaluating the electrical activity of said test muscle, e.g. , by EMG.
- electrical stimulation e.g. , percutaneous stimulation or surface stimulation
- said test comprises: a) inducing, e.g. , by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation, a first test muscle contraction; b) administering the test aliquot of the composition to said subject; c) inducing, e.g. , by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation, a second test muscle contraction; and d) evaluating the effect of administering the composition on said second test muscle contraction.
- step b is performed before step c.
- step c is performed before step b.
- the steps are performed in the order of a, b, c, and d.
- said test further comprises: e) providing a value, e.g. , a reference value, e.g. reference profile, for a muscle contraction parameter, e.g. , a value for intensity or duration of, said first test muscle contraction, e.g. , by evaluating the electrical activity of said test muscle, e.g. , by EMG; and optionally, f) providing a value, e.g. , a treatment value, e.g. , a treatment profile, for a muscle contraction parameter, e.g. , a value for intensity or duration of, said second test muscle contraction, e.g. , by evaluating the electrical activity of said test muscle, e.g. , by EMG.
- the test comprises comparing the value from step e with the value from step f to evaluate the effectiveness of a test aliquot of the composition on test muscle contraction.
- said muscle contraction parameter is the area under the curve, the peak amplitude, or the duration of the test muscle contraction.
- a decrease in the value from step f compared to the value from step e is indicative of efficacy in alleviating said test muscle cramp.
- a decrease by a preselected amount e.g. , a decrease of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35% or 50%, is indicative of efficacy in alleviating said test muscle contraction.
- said test comprises: a) inducing, e.g. , by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation, a first test muscle contraction; b) administering the test aliquot of the composition to said subject; c) inducing, e.g. , by application of electrical stimulation, e.g.
- step b is performed before step c.
- steps b and c are performed within a preselected time of one another, e.g. , they are performed sufficiently close in time that step b will modulate step c.
- said test muscle contraction comprises a contraction in a muscle of the foot, e.g. , the flexor hallucis brevis muscle.
- a decrease in the value from step f compared to the value from step e is indicative of efficacy in alleviating said test muscle contraction.
- said test comprises: a) applying a first electrical stimulus to a test muscle of the subject to induce a test muscle contraction; b) measuring the electrical activity of said test muscle to provide a reference profile, e.g. , by EMG; c) administering a test aliquot of the composition; d) applying a second electrical stimulus to the test muscle of the subject after a preselected period of time after administration of the test aliquot of the composition; e) measuring the electrical activity of said test muscle to generate a treatment profile; f) comparing the treatment profile to the reference profile to determine reduction or prevention of the test muscle contraction after administration of the test aliquot.
- the period of time between step c and step d is at least about 10 minutes, 15 minutes, 30 minutes, 1 hour, etc.
- the test further comprises: a) determining the threshold frequency for inducing a first test muscle contraction; b) administering a test aliquot of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof; c) determining the threshold frequency for inducing a second test muscle contraction; d) comparing the threshold frequency to evaluate the effectiveness of a test aliquot of the composition on test muscle contraction.
- said test aliquot of the composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof.
- said capsaicinoid, capsinoid, or related analog or combination thereof is a TRP channel agonist.
- said capsaicinoid, capsinoid, or related analog or combination thereof is a TRPV1 channel activator.
- the TRPV1 channel activated by said capsaicinoid, capsinoid, or related analog or combination thereof is present on a sensory neuron in the mouth, the esophagus and/or the stomach.
- said capsaicinoid, capsinoid, or related analog or combination thereof increases inhibitory signaling to alpha motor neurons.
- the composition is formulated as a liquid or a solid.
- the liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, sprays, and elixirs.
- the composition is formulated as a solid.
- the solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, and semisolid formulations.
- said solid is a tablet or capsule.
- said capsule is a hard or soft capsule.
- the invention features a method of evaluating a subject for abnormal or unwanted muscle contraction or absence of normal muscle contraction comprising: acquiring, e.g. , indirectly or directly, knowledge of a result of a test for the efficacy of the administration of a test aliquot of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof for alleviation of test muscle contraction in said subject; and responsive to said result, classifying said subject.
- said subject has been diagnosed or identified as having a disorder associated with muscle cramps, e.g. , any of the disorders disclosed herein, e.g. , night cramps, multiple sclerosis, spinal cord spasticity, or dystonia.
- the test comprises directly acquiring said knowledge. In some embodiments, the test further comprises performing said test. In some embodiments, said result is indicative of a preselected level of alleviation of the test muscle contraction by administration of the test aliquot. In some embodiments, said result is indicative of the alleviation of the test muscle contraction by administration of the test aliquot.
- the test comprises classifying said subject as a candidate for treatment with a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof.
- said result is indicative of the failure to provide a preselected level of alleviation of the test muscle contraction by administration of the test aliquot.
- said result is indicative of the absences of alleviation of the test muscle contraction by administration of the test aliquot.
- the test comprises classifying said subject as not being a candidate for treatment with a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof.
- said method is computer implemented.
- said composition comprises a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof. In some embodiments, said composition further comprises a pharmaceutically acceptable excipient. In some embodiments,
- said composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- the invention features a computer-implemented method of evaluating a subject for unwanted or abnormal muscle contraction, e.g. , cramp, spasm, dystonia, or fasciculation or absence of a normal muscle contraction, e.g. , gait abnormalities, e.g. , foot drop comprising: a) acquiring, e.g. , directly or indirectly, a value for a parameter related to the effect of administering a test aliquot of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof on test muscle cramping, e.g. , by evaluating the electrical activity of said test muscle, e.g.
- said composition comprises a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof. In some embodiments, said composition further comprises a pharmaceutically acceptable excipient. In some embodiments, said composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
- the invention features a system comprising a memory; and a processing unit operative to: a) evaluate the effectiveness of administering a test aliquot of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof; b) responsive to the evaluation, comprising classifying said subject as a candidate for treatment with a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof.
- the invention features a computer-readable medium comprising computer-executable instructions that, when executed on a processor of a computer, perform a method comprising acts of: a) evaluating the effectiveness of administering a test aliquot of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof; b) responsive to the evaluation, comprising classifying said subject as a candidate for treatment with a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof.
- said subject has been diagnosed or identified as having a disorder associated with muscle cramps, spasms, dystonia, or fasciculations, e.g. , any of the disorders disclosed herein, e.g. , night cramps, multiple sclerosis, spinal cord spasticity, or dystonia.
- the invention features a kit comprising a liquid tight container comprising one or more of: one or a plurality of test aliquots of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof; one or a plurality of leads for conducting current to a subject and inducing a cramp; and one or a plurality of leads for measuring electrical activity associated with a cramp.
- said kit further comprises a plurality, e.g. , at least 2, 3, 4, 5, 6, 7, 8, 9, or 10, test aliquots of the composition.
- said test aliquot of the composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof.
- said capsaicinoid, capsinoid, or related analog or combination thereof is a TRP channel agonist.
- said capsaicinoid, capsinoid, or related analog or combination thereof is a TRPVl channel activator.
- the TRPV1 channel activated by said capsaicinoid, capsinoid, or related analog or combination thereof is present on a sensory neuron in the mouth, the esophagus and/or the stomach.
- said capsaicinoid, capsinoid, or related analog or combination thereof increases inhibitory signaling to alpha motor neurons.
- the composition is formulated as a liquid or a solid.
- the liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, sprays, and elixirs.
- the composition is formulated as a solid.
- the solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, and semisolid formulations.
- said solid is a tablet or capsule.
- said capsule is a hard or soft capsule.
- the invention features a method of evaluating a composition for treating unwanted or abnormal muscle contraction, e.g. , cramp, spasm, dystonia, or fasciculation, or absence of normal muscle contraction, e.g. , gait abnormalities, comprising: a) acquiring, e.g. indirectly or directly, knowledge of a result of a test that shows that administration of a test aliquot of said composition alleviates a test muscle contraction in a test subject; and b) acquiring, e.g.
- step a comprises performing said test.
- step b comprises administering said composition to said
- step a comprises performing said test and step b comprises administering said composition to said administration subject.
- said test subject and administration subject are of the same species, e.g. , both are rodent or both are primate, e.g. , human. In some embodiments, said test subject and administration subject are the same individual. In some embodiments, said test subject and administration subject are the different individuals. In some embodiments, said test subject and administration subject are of the different species, e.g. , the test species is non-human, e.g. , rodent, and the administration subject is a primate, e.g. , a human.
- Figure 1 is a series of graphs from 6 sensory neurons isolated from the trigeminal ganglia of rats that illustrate their activation by the capsicum, cinnamon, and ginger extracts that were used in the human experiments.
- Figure 2 shows the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis (FHB) of Subject A.
- Figure 3 shows the effect of the TRP-Stim beverage on cramping of the FHB of a second subject after cramping was induced.
- Figure 4 shows the effect of the TRP-Stim beverage on cramping of the FHB of a third subject tested over longer times.
- Figure 5 shows the effect of the TRP-Stim beverage on cramping of the FHB of a fourth subject.
- Figure 6 is a graph showing the effect of the TRP-Stim beverage on cramping of the gastrocnemius (calf) muscle of a fifth subject.
- Figure 7 shows the effect of the TRP-Stim beverage on cramping of the gastrocnemius (calf) muscle of a sixth subject.
- Figure 8 is a graph showing the effect of the TRP-Stim beverage on cramping of an FHB muscle in a seventh subject who experienced spontaneous cramping induced by pointing her toe.
- peripheral nervous system conditions e.g. , peripheral neuropathy
- central nervous system conditions e.g. , central nervous system conditions
- muscle conditions and disorders e.g. , fibromyalgia, muscle spasms and cramps (e.g. , nocturnal cramps), painful muscle contractions (e.g., a muscle contraction of the head or neck), neuromuscular disorders (e.g., motor neuron disease) or dystonia (e.g., cervical dystonia, blepharospasm, back spasms, or leg cramps due to spinal stenosis)), connective tissue diseases (e.g.
- peripheral nervous system conditions e.g. , peripheral neuropathy
- muscle conditions and disorders e.g. , fibromyalgia, muscle spasms and cramps (e.g. , nocturnal cramps), painful muscle contractions (e.g., a muscle contraction of the head or neck)
- neuromuscular disorders e.g., motor neuron
- degenerative joint disease e.g., degenerative joint disease
- throat conditions e.g., dysphagia or spasmodic dysphonias
- tactile sensitivity e.g., electrolyte imbalance and/or vitamin deficiency
- respiratory conditions e.g., asthma
- cough e.g., cough, and sarcoidosis using a composition that includes a capsaicinoid, a capsinoid, or related analogs or combinations thereof.
- acidulant refers to an acidic compound (e.g. , citric acid) used to lower the pH of a composition, e.g. , the pH can be lowered in the range of 2.5-6.5 (e.g. , pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5).
- an acidic compound e.g. , citric acid
- the pH can be lowered in the range of 2.5-6.5 (e.g. , pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5).
- Acquire or “acquiring” as the terms are used herein, refer to obtaining possession of a value, e.g., a numerical value, or image, or a physical entity (e.g., a sample), by “directly acquiring” or “indirectly acquiring” the value or physical entity.
- Directly acquiring means performing a process (e.g., applying or measuring a current to or from a subject, or capturing a signal from a subject or sample or performing a synthetic or analytical method) to obtain the value or physical entity.
- Indirectly acquiring refers to receiving the value or physical entity from another party or source (e.g., a third party laboratory that directly acquired the physical entity or value).
- Directly acquiring a value or physical entity includes performing a process that includes a physical change in a physical substance or the use of a machine or device. Exemplary changes include applying a current to, or measuring a current from, the muscle of a subject. Directly acquiring a value includes performing a process that uses a machine or device, e.g. , a device to induce a cramp or a device to measure a parameter related to a cramp.
- the term "agonist,” as used herein refers to a molecule that stimulates a biological response.
- an agonist is an activator.
- the activators or agonists referred to herein activate TRP ion channels, (e.g. , TRPV1 ion channel).
- compositions and solutions are administered orally.
- compositions are used to describe a formulation that includes capsaicinoids, capsinoids, or related analogs or combinations thereof, the term refers to a comestible formulation that is suitable for oral ingestion by the subject (e.g. , the human subject).
- compositions that include capsaicinoids, capsinoids, or related analogs or combinations thereof include solid dosage forms for oral administration (e.g. , capsules, tablets, pills, dragees, crystals, pastes, gels, powders, gums, granules, chews, foodstuffs, films, and the like), liquid dosage forms for oral administration (e.g. , capsules, tablets, pills, dragees, crystals, pastes, gels, powders, gums, granules, chews, foodstuffs, films, and the like), liquid dosage forms for oral
- compositions that can be reconstituted with a liquid (e.g. , powders, granules, or tablets that may be reconstituted with water), gels, semi-solids (e.g. , ice cream, pudding, or yogurt), frozen liquids (e.g. , ice pops), lozenges or hard candies, dissolving strips (e.g. , an edible strip containing pullulan and compositions of the invention), and chewing gums.
- a liquid e.g. , powders, granules, or tablets that may be reconstituted with water
- gels e.g. , semi-solids (e.g. , ice cream, pudding, or yogurt), frozen liquids (e.g. , ice pops)
- lozenges or hard candies dissolving strips (e.g. , an edible strip containing pullulan and compositions of the invention), and chewing gums.
- dissolving strips e.g. , an edible strip containing pull
- analog or “related analogs” as used herein refer to a substance that has a similar chemical structure to another compound, but differs from it with respect to a certain component or components.
- derivative refers to a substance produced from another substance either directly or by modification or partial substitution.
- Muscle cramp as used herein is a muscle cramp which is treated with the composition described herein. In embodiments it is not induced but rather arises spontaneously either from activity or underlying disease etiology, e.g. , athletic activity or night cramp.
- the muscle cramp comprises a cramp in a muscle other than the muscle of the test muscle cramp.
- the muscle cramp can be a contraction of a skeletal muscle or the smooth muscle.
- muscle cramps occur most frequently in the muscles of the foot, calf, front of the thigh (e.g. , quadricep), back of the thigh (e.g. , hamstring), hands, arms (e.g.
- muscle cramp that occurs in the calf muscle is also commonly known as a "charley horse.” Other common muscle cramps include exercise-induced muscle cramps, menstrual cramps, "writer's cramp,” “musician' s cramp,” and night cramps (or nocturnal cramps).
- the muscle cramp is a contraction of a muscle other than a skeletal muscle, e.g. , a smooth muscle.
- Muscle spasm refers to an involuntary contraction or a muscle, or even a few fibers of a muscle. Often the magnitude or duration of a spasm is less than that of a cramp. If the spasm is forceful and sustained, it becomes a cramp.
- “Dystonia” as used herein refers to sustained muscle contractions that cause twisting and repetitive movements or abnormal postures.
- Fasciculation refers to a small, local, involuntary muscle contraction and relaxation. Fasciculations are also commonly known as a “muscle twitch”.
- an "effective amount" of a compound as used herein is that amount sufficient to effect beneficial or desired results, such as the effective treatment of peripheral nervous system conditions (e.g., peripheral neuropathy), central nervous system conditions (e.g. , amyotrophic lateral sclerosis), muscle conditions and disorder (e.g., fibromyalgia, muscle spasms and cramps, cervical dystonia, blepharospasm, back spasms, or leg cramps due to spinal stenosis), connective tissue disorders (e.g., degenerative joint disease), throat conditions (e.g., dysphagia or spasmodic dysphonias), and sarcoidosis, and, as such, an "effective amount" depends upon the context in which it is being applied.
- peripheral nervous system conditions e.g., peripheral neuropathy
- central nervous system conditions e.g. , amyotrophic lateral sclerosis
- muscle conditions and disorder e.g., fibromyalgia, muscle spasms
- an effective amount of a compound is, for example, an amount sufficient to achieve an increase in TRP channel (e.g. , TRPV1) activity as compared to the response obtained without administration of the compound (e.g. , a capsaicinoid, capsinoid, or a related analog or combination thereof).
- TRP channel e.g. , TRPV1
- the effective amount of active compound(s) used to practice the present invention can also be varied based on, for example, the age, and body weight, of the subject or the nature of the exercise.
- compositions can also include excipients that are not capsaicinoids, capsinoids, or related analogs thereof, and that are non-toxic and non-inflammatory in a subject (e.g. , in a human subject).
- the excipient(s) can provide desirable or improved physical and/or chemical properties such as stability, flow, viscosity, rate of disintegration, taste, delivery, etc.
- a disintegrant e.g. , carmellose, starch, crystalline cellulose, low- substituted hydroxypropyl cellulose, and the like
- a binder e.g.
- a surfactant e.g. , polyoxyl 40 stearate, polysorbate 80, polyoxyethylene hydrogenated castor oil, and the like
- an emulsifier e.g. , polyoxyl 40 stearate, sorbitan sesquioleate, polysorbate 80, sodium lauryl sulfate, lauromacrogol, gum arabic, cholesterol, stearic acid, povidone, glyceryl monostearate, and the like
- a plasticizer e.g.
- a lubricant e.g. , magnesium silicate, carmellose, light anhydrous silicic acid, stearic acid, calcium stearate, magnesium stearate, talc, and the like
- a sweetener e.g. , white soft sugar, honey, simple syrup, glucose, saccharin sodium, acesulfame potassium, disodium glycyrrhizinate, and the like
- a pH- adjusting agent e.g. , hydrochloric acid, citric acid, sodium hydrogen carbonate, potassium hydroxide, sodium hydroxide, sodium carbonate, and the like
- a preservative e.g.
- titanium dioxide sodium copper chlorophyllin, turmeric, gardenia, annatto dye, kaoliang dye, and the like
- an antioxidant e.g. , ascorbic acid, sodium thiosulfate, tocopherol, sodium hydrogen sulfite, and the like, or any combination thereof.
- subject refers to a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline mammal.
- the term "substantially pure” refers to a composition that includes capsaicinoids, capsinoids, or related analogs thereof in which the composition is free of organic and/or inorganic species that do not activate a TRP channel (e.g. , TRPV1) or function in the same manner as the capsaicinoids, capsinoids, or related analogs thereof, and where 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 99.5% (w/w) of the composition is a particular channel agonist compound.
- TRPV1 TRP channel
- Substantially pure compositions can be prepared and analyzed using standard methods known in the art (e.g. , chromatographic separation, extractions, and the like).
- Substantially pure compositions can include isomeric impurities (e.g. , geometric isomers) and/or salts or solvates of a capsaicinoids, capsinoids, or related analogs thereof.
- test muscle contraction is a muscle contraction, typically induced, e.g. , by the application of electrical current, in the subject. Stimulation can be applied to induce a muscle contraction that recapitulates a naturally- occurring muscle cramp, muscle spasm, dystonia, or fasciculation, e.g. , a test muscle cramp, a test muscle spasm, a test muscle dystonia, or a test muscle fasciculation.
- the test muscle cramp comprises a cramp in the flexor hallucis brevis muscle.
- efficacy in inducing a test muscle cramp in a subject is indicative of efficacy in treating muscle cramp, e.g. , with a composition described herein.
- efficacy in treating the test muscle cramp is indicative of efficacy in treating muscle cramp, spasticity, dystonias, or fasciculations.
- treat refers to administering a composition for therapeutic purposes or administering treatment to a subject already suffering from a disorder to improve the subject's condition.
- treating a condition or disorder or “ameliorating a condition or disorder” as used herein refer to the condition or disorder (e.g. , peripheral nervous system conditions (e.g., peripheral neuropathy), central nervous system conditions, muscle conditions and disorders (e.g., fibromyalgia, muscle spasms and cramps (e.g., nocturnal cramps), painful muscle contractions (e.g., a muscle contraction of the head or neck), neuromuscular disorders (e.g., motor neuron disease) or dystonia (e.g., cervical dystonia, blepharospasm, back spasms, or leg cramps due to spinal stenosis)), connective tissue diseases (e.g., degenerative joint disease), throat conditions (e.g.
- peripheral nervous system conditions e.g., peripheral neuropathy
- central nervous system conditions e.g., central nervous system conditions, muscle conditions and disorders (e.g., fibromyalgia, muscle spasms and cramps (e.
- dysphagia or spasmodic dysphonias are, e.g. , dysphagia or spasmodic dysphonias), tactile sensitivity, electrolyte imbalance and/or vitamin deficiency, respiratory conditions (e.g., asthma), cough, and sarcoidosis) and the symptoms associated with the condition or disorder are, e.g. , alleviated, reduced, cured, or placed in a state of remission.
- amelioration or degree of treatment is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%, as measured by any standard technique.
- viscosity refers to a measurement of a fluid's internal resistance to flow (e.g. , "thickness”). Viscosity is generally expressed in centipoise (cP) or pascal-seconds.
- Capsaicinoids, capsinoids, and analogs thereof are compounds that can activate TRP channels (e.g. , TRPV1 channels) and may be used in the compositions of the present invention. These compounds can be naturally occurring and non-naturally occurring compounds (e.g. , synthetic analogs and derivatives of naturally occurring compounds), including but not limited to those described below.
- Suitable capsaicinoids, capsinoids, and related analogs and derivatives and combinations thereof for use in the compositions and methods of the present invention can be naturally occurring and include: capsaicin, dihydrocapsaicm, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate,
- Capsaicinoids and related analogs and derivatives also include non-naturally occurring compounds that are derived by synthetic methods (e.g. , by combining two or more naturally occurring capsaicinoids as described above or by creating an artificial compound that does not exist in nature).
- non-naturally occurring capsaicinoids include but are not limited to: esters of capsaicinoids (e.g.
- aliphatic esters, hydrophilic esters, and the like including 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-rn.ethyoxyphenyl formate, 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylarnino)methyl]-2- methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoyIamino)methyI]-2-methyoxyphenyl butanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2- dimethylpropanoate, 4-[((6E)-8-metiiylnon-6-enoylamino)metiiyl]-2-meihyoxyphenyl
- capsinoids e.g. 8-methylnonanoic acid- substituted benzyl ester derivatives
- isobutylamides e.g.heptanoylisobutylamide
- guaiacylamides e.g. heptanoyl guaiacylamide
- halogenated capsaicin analogs e.g.
- N-(4-0-glycerol-3- methoxybenzyl)-nonamide e.g. N-nonanoyl vanillylamide-4-glyceryl ether, N-(4-0-acetic acid sodium-3-methoxybenzyl-nonamide, sodium N-nonanoyl vanillylamide-4-O-acetate, and N-(4- 0-glycol-3-methoxybenzyl)-nonamide (N-nonanoyl vanillylamide-4-glycol ether), compounds prepared by combining phorbol related diterpenes and homovanillac acid analogs via
- esterification at the exocyclic hydroxy group of the diterpene e.g. 20-homovanillyl-mezerein and 20-homovanillyl- 12-deoxyphorbol-13-phenylacetate
- civamide N-[(4-hydroxy-3- methoxyphenyl)-methyl]-8-methyl-(Z)-6-nonemamide
- nuvanil capsavanil, olvani!, arvanil, and palvanil (N-palmitoyl-vanillamide) .
- capsaicinoids and capsinoids are described by Formulas (I)-(LXI) and are exemplified by Compounds 1-300 of U.S. Provisional Application No. 61/979,423, which is hereby incorporated by reference.
- Capsaicinoids, capsinoids, and analogs and combinations thereof for use in the compositions and methods described herein can also be identified using standard methodology, as described, for example, in U.S. Patent Application Publication No. 2003/0104085, which is hereby incorporated by reference.
- Exemplary assays for identification of capsaicinoids, capsinoids, and analogs thereof include, without limitation, receptor binding assays; functional assessments of stimulation of calcium influx or membrane potential in cells expressing the TRPVl receptor; assays for the ability to induce cell death in such cells (e.g. , selective ablation of C-fiber neurons); and other assays known in the art.
- composition comprising capsaicinoids, capsinoids, and analogs thereof may further comprise an acidulant (e.g. , acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, lactic acid, or ascorbic acid) maintaining a low pH in the range of 2.5-6.5 (e.g. , pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5).
- an acidulant e.g. , acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, lactic acid, or ascorbic acid
- a low pH in the range of 2.5-6.5 e.g. , pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5.
- Capsaicinoids, capsinoids, and analogs and combinations thereof may be present in a composition of the
- capsaicinoids, capsinoids, and analogs thereof may be present in lower or higher concentrations (e.g. , less than 0.001%, e.g. , 0.0008%, 0.0005%, 0.0004%, 0.0001% (w/w) or (w/v), or more than 10%, e.g.
- Capsaicinoids, capsinoids, and analogs and combinations thereof may be present at a concentration range of about 20 mg to 500 mg per unit dosage (e.g. , 23 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 420 mg, or 450 mg).
- compositions described herein are formulations suitable for oral consumption by a subject (e.g. , by a human) and include a capsaicinoid, capsinoid, or related analog or
- the composition includes a plurality of capsaicinoid, capsinoid, or related analog or combination thereof.
- the composition includes a plurality of excipients.
- Exemplary compositions that include capsaicinoids, capsinoids, or related analogs or combinations thereof include solid dosage forms for oral administration (e.g. , capsules, tablets, pills, dragees, crystals, pastes, gels, powders, gums, granules, chews, foodstuffs, and the like), liquid dosage forms for oral administration (e.g.
- compositions that can be reconstituted with a liquid (e.g. , powders, granules, or tablets that may be reconstituted with water), gels, semi-solids (e.g. , ice cream, pudding, or yogurt), frozen liquids (e.g. , ice pops), lozenges or hard candies, dissolving strips (e.g. , an edible strip containing pullulan and compositions of the invention), and chewing gums.
- a liquid e.g. , powders, granules, or tablets that may be reconstituted with water
- gels e.g. , semi-solids (e.g. , ice cream, pudding, or yogurt), frozen liquids (e.g. , ice pops), lozenges or hard candies, dissolving strips (e.g. , an edible strip containing pullulan and compositions of the invention), and chewing gums.
- the composition is formulated for oral administration.
- TRP channels are a family of ion channels that are generally expressed on the cell surface. Members of the TRP channel family share some structural similarity and are organized in sub-families, comprising TRPA, TRPC, TRPV, TRPM, TRPML, TRMPN, and TRPP. Each of these sub-families comprise subunit genes, which include, for example, TRPVl, TRPV2, TRPV4, TRPV3, TRPV5, TRPV6, TRPAl, TRPP3, TRPP2, TRPP5, TRPC4, TRPC5, TRPC1, TRPC3, TRPC7, TRPC6, TRPM1, TRPM3, TRPM6, TRPM7, TRPM4, TRPM5, TRPM2, TRPM 8, TRPML 1, TRPML3, and TRPML2.
- the compositions described herein may comprise at least one agonist of any of the TRP channels.
- Acid-sensing ion channels are neuronal voltage-insensitive cationic channels that are activated by extracellular protons. ASIC channels are primarily expressed in the nervous system, and conduct mostly Na + . There are four ASIC channel genes, ASIC1, ASIC2, ASIC3 and ASIC4, which encode at least six ASIC channels, ASIC3, ASCI4 and splice variants of ASIC1, and ASIC2, ASICla, ASIC lb, ASIC2a, ASIC2b.
- the compositions described herein may comprise at least one agonist of any of the ASIC channels.
- the composition described herein comprises at least one TRP channel agonist. In one embodiment, two or more agonists that activate the same or different TRP channels are administered. In some embodiments, the composition described herein comprises a TRPVl agonist or a TRPAl agonist. In another embodiment, the composition described herein comprises a TRPVl agonist and a TRPAl agonist. In another embodiment, the composition described here comprises at least one ASIC channel agonist. In another
- the composition comprises a combination of at least one TRP agonist and at least one ASIC channel agonist.
- the composition described herein comprises at least one TRPVl activator and at least one TRPAl activator.
- the compositions described herein include any of the compositions described in WO 2012/015882, the contents of which are incorporated herein in its entirety.
- the composition described herein comprises a combination of capsaicin, capsaicinoids, or capsinoids; cinnamaldehyde, and gingerols.
- the composition includes each of capsaicin, cinnamaldehyde, and gingerol.
- the composition comprises 0.75% of a capsicum preparation (Clearcap Super Soluble Capsicum, Kalsec Inc.), 1% of a cinnamon volatile oil (Aquaresin Cinnamon, Kalsec Inc.), and 1.5% of a ginger oleoresin (Aquaeresin Ginger, Kalsec Inc.).
- TRPVl channel agonists Compounds that activate TRPV1 that may be used in the compositions of the present invention include, for example, capsaicin, capsaicin analogs and derivatives (e.g. , capsinoids), and any other compound that activates TRPV1, examples of which are described herein.
- TRPV1 Modulators of TRPV1 activity are known in the art (e.g. , Harteneck et al., Adv Exp Med Biol. 2011 ; 704:87- 106, and other references described herein).
- the TRPV1 channel activator is a capsaicinoid (e.g. , capsaicin (8- methyl-N-vanillyl-/ra «s , -6-nonenamide)).
- suitable TRPV1 channel agonists or activators include oleoylethanolamide, N-oleoyldopamine, 3-methyl-N-oleoyldopamine, oleamide, 1- monoacylglycerols having C18 and C20 unsaturated and C8-C12 saturated fatty acids, 2- monoacylglycerols having CI 8 and C20 unsaturated fatty acids, miogadial, miogatrial, polygodial, and other terpenoids with an alpha,beta-unsaturated 1 ,4-dialdehyde moiety, sanshools, evodiamine, acesulfame potassium, cyclamate, sulfates (e.g.
- the TRPV1 channel agonist or activator may also be an analog or derivative of any of the TRPV1 channel activators described herein.
- TRPV1 channel agonists or activators are described, for example, in U.S. Patent Nos. 8,652,497; 8,642,657; 8,420,600; 8,309,060; 7,981,460; 7,943,666; 7,632,519;
- the TRPV1 channel agonist or activator is an acidulant (e.g. , acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, or ascorbic acid) maintaining a low pH in the range of 2.5-6.5 (e.g. , pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5).
- an acidulant e.g. , acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, or ascorbic acid
- 2.5-6.5 e.g. , pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5.
- TRPV1 channel agonists or activators for use in the compositions and methods described herein can be identified using standard methodology, as described, for example, in U.S. Patent Application Publication No. 2003/0104
- Exemplary assays for identification of TRPV1 channel activators include, without limitation, receptor binding assays; functional assessments of stimulation of calcium influx or membrane potential in cells expressing the TRPV1 receptor; assays for the ability to induce cell death in such cells (e.g., selective ablation of C-fiber neurons); and other assays known in the art.
- a TRPV1 channel agonist or activator may be present in a composition of the invention at a concentration range of about 0.001 % to 10% by weight by weight based on the total volume of the composition (e.g., 0.001, 0.005, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%), though a TRPV1 channel agonist or activator may be present in lower or higher concentrations.
- TRPAl channels are activated by naturally occurring substances including, e.g., mustard oil, isothiocyanate compounds (e.g., allyl isothiocyanate), acrolein, farnesyl thiosalicylic acid, Ag-tetrahydrocannabinol (THC), eugenol, ginger, gingerol, gingerols, shogaols, nicotine, nicotine derivatives and analogs, methyl salicylate, cinnamaldehyde, cinnamon oil, wintergreen oil, clove oil, allicin, diallyl sulfide, diallyl disulfide, diallyl trisulfide, sanshools, farnesyl thiosalicylic acid, and farnesyl thioacetic acid.
- mustard oil isothiocyanate compounds (e.g., allyl isothiocyanate), acrolein, farnesyl thiosalicylic acid, Ag-tetra
- TRPAl channel agonist or activator may also be an analog or derivative of any of the TRPAl channel agonists or activators described herein, and additional TRPAl channel agonists or activators are identified in WO 2009/071631, hereby incorporated by reference. Still other modulators of TRPAl are described in, e.g., Harteneck et al., Adv Exp Med Biol. 2011, 704:87-106; Viana et al., Expert Opin. Ther. Pat. 2009,
- TRPAl channel agonists or activators are known in the art and are described, for example, in U.S. Patent No. 7,674,594.
- a TRPAl channel agonist or activator may be present in a composition of the invention at a concentration range of about 0.001% to 10% by weight by weight based on the total volume of the composition (e.g., 0.001, 0.005, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%), though a TRPAl channel agonist or activator may be present in lower or higher concentrations.
- Other TRP channel agonists e.g., 0.001, 0.005, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%
- TRP channel agonists or activators suitable for the methods and compositions described herein are known in the art.
- the TRP channel agonist may be nonselective and may activate more than one TRP channel.
- carvacrol a compound present in oregano
- icilin and menthol activate TRPAl and TRPM8.
- Naturally occurring and synthetic derivatives and analogs of carvacrol, icilin, or menthol are suitable for use in the compositions and methods of the present invention.
- Suitable agonists or activators of TRP channels for use in the compositions of the present invention or administered in accordance with the methods of the present invention are disclosed herein.
- the various agonists for the TRP channel family members listed below is not to be construed as an all-inclusive list, but is merely presented to provide examples of additional TRP agonists.
- TRPV4 agonists include, but are not limited to, 4-alpha-phorbol- 12,13 didecanoate (4CC-PDD), GSK1016790A, 5',6'-epoxyeicosatrienoic (5'6'-EET), 8',9'- epoxyeicosatrienoic (8'9'-EET), APP44- 1, R1747, arachidonic acid (AA), 12-0- tetradecanoylphorbol- 13-acetate (TP A), phorbol 12-myri.state 13-acetate (PMA),
- BAA bisandrographalide
- anandamide any of the compounds disclosed in WO
- 2006/029209 e.g. , a compound of Formula I, II, Ila, or III, N- ⁇ (lS)-l-[( ⁇ (4R)-l-[(4- chlorophenyl)sulf onyl] -3-oxohexahyd.ro- 1H- azepin-4-yl ⁇ amino)carbonyl] -3-methylbutyl ⁇ ⁇ 1 - benzothiophen-2-carboxamide, N- ⁇ ( IS)- 1 - [( ⁇ (4R)- 1 - [(4-fluorophenyl)sulfonyl] -3- oxohexahydro- lH-azepin-4-yl ⁇ amino)carbonyl]-3-methylbutyl ⁇ -l-benzothioph ⁇
- TRPC6 agonists or activators include, but are not limited to, l-oleoyl-2- acetyl-sn -glycerol (OAG), carbachol, diacyiglycerol (DAG), 1 ,2-didecanoylglycerol,
- TRPM6 agonists or activators include, but are not limited to 2- aminoethoxydiphenyl borate (2-APB).
- TRPV2 agonists or activators include, but are not limited to, diphenylborinic anhydride (DPBA), delta-9-tetrahydrocarmabinol (A 9 -THC or THC), cannabiniol (CBN), cannabidiol (CBP), 2-APB, probenecid, 0-1821, 1 1 -hydroxy- A 9 -tetrahydrocannabinol, nabilone, CP55940, HU-210, HU-21 1/dexanabinol, HU-331 , HU-308, JWH-015, WIN55, 212-2, 2- arachidonoylglycerol (2- AG), Arvil, PEA, AM404, 0- 1918, and JWH- 133.
- DPBA diphenylborinic anhydride
- a 9 -THC or THC cannabiniol
- CBP cannabidiol
- 2-APB probenecid, 0-1821, 1
- TRPV3 agonists or activators include, but are not limited to incensole, incensole acetate, a compound disclosed in WO 2008/065666 (e.g. , a compound of Formula I or Formula II, compound IA), menthol, eugenol, dihydrocarveol, carveol, thymol, vanillin, ethyl vanillin, cinnemaldehyde, 2 aminoethoxydiphenyl borate (2-APB), diphenyiamine (DPA), diphenylborinic anhydride (DPBA), camphor, (+)-borneol, (-)-isopinocampheol, (-)-fenclione, (- )-trans-pinocarveol, isoboraeol, (+)-camphorquinone, (-)-a-thujone, a-pinene oxide, 1 ,8- cineole/eucalyptol, 6-ter
- the TRP channel agonist or activator may also be an analog or derivative of any of the TRP channel activators described herein.
- a TRP channel agonist or activator may be present in a composition of the invention at a concentration range of about 0.001 % to 10% by weight by weight based on the total volume of the composition (e.g. , 0.001, 0.005, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%), though a TRP channel agonist or activator may be present in lower or higher concentrations.
- a TRP channel agonist or activator can also be identified using standard methodology.
- Exemplary assays known in the art for identification of agonists of any TRP channel in the TRP family include, without limitation, receptor binding assays; functional assessments of stimulation of calcium influx or membrane potential in cells expressing the TRPV1 receptor; assays for the ability to induce cell death in such cells (e.g. , selective ablation of C-fiber neurons); and other assays known in the art.
- ASIC Channel Activators ASIC channels are activated by low pH.
- the pH of a composition of the present invention that includes an ASIC channel activator may be in the range of 2.5-6.5 (e.g., pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5).
- the pH may be adjusted within this range by any means acceptable for compositions that are intended to be ingested by a subject.
- Exemplary acidulants are acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, lactic acid, tartaric acid, fumaric acid, and ascorbic acid.
- the acidulant may be present in a composition of the invention at a concentration range of about 0.001% to 10% by weight based on the total volume of the composition (e.g., 0.001, 0.005, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%), though the acidulant may be present in lower or higher concentrations.
- composition of the present invention may additionally include, for example, electrolytes (e.g., potassium salt or other salts), sweeteners, flavoring and coloring agents, vitamins, minerals, preservatives, viscosity modifiers, and antioxidants as described below.
- electrolytes e.g., potassium salt or other salts
- Viscosity is the ratio of shear stress to shear rate, expressed as dynes- second/cm , or poise.
- a centipoise (cP) is one one-hundredth of a poise.
- the composition of the present invention may have a viscosity greater than water (i.e., about 1.0 cP at 20°C), e.g., about 100, 200, 300, 400, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 8000, 9000 cP or more. If a consistency of corn syrup is desired, viscosities in the range of about 2500 cP are suitable. If a consistency of a soft gel or honey is desired, viscosities in the range of about 10000 cP to about 15000 cP are suitable. For puddinglike products, viscosities in the range of about 30000 cP to about 38000 cP are desirable.
- Viscosity of the compositions of the present invention may be measured with, e.g., a rheometer or viscometer, though additional methods of measuring viscosity are known in the art.
- Viscosity modifiers may be added to compositions of the present invention.
- Such viscosity modifiers include, for example, collagen, gellan gum, carbohydrate gel-forming polymers, carob bean gum, locust bean gum, carrageenan, alginates (e.g., alginic acid, sodium alginate, potassium alginate, ammonium alginate, and calcium alginate), agar, guar gum, xanthan gum, carboxymethyl cellulose, clear starch, pectin, gelatin, arrowroot, cornstarch, katakuri starch, potato starch, sago, tapioca, furcellaran, karo syrup (e.g., light karo syrup and dark karo syrup), and sodium pyrophosphate.
- alginates e.g., alginic acid, sodium alginate, potassium alginate, ammonium alginate, and calcium alginate
- agar guar gum, xanthan gum
- a viscosity modifier may be present in the composition in an amount of from about 0.01% to about 10% by weight based on the total volume of the composition (e.g. , about 0.01%, about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%), though the viscosity modifier may be present in lower or higher concentrations.
- the viscosity modifier is present in the composition from about 40% to about 60% (e.g, about 50%).
- Exemplary electrolytes include potassium salts, chloride salts, bromide salts, sodium salts, magnesium salts, calcium salts, citrate salts, acetate salts, phosphate salts, salicylates, bicarbonate salts, lactate salts, sulphate salts, tartrate salts, benzoate salts, selenite salts, molybdate salts, iodide salts, oxides, and combinations thereof.
- An electrolyte may be present in a composition of the invention at a concentration range of about 0.01% to about 10% by weight based on the total volume of the composition (e.g.
- the compositions of the present invention include high concentrations of potassium (e.g. , potassium chloride).
- concentration of potassium in the composition may be, e.g. , about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, or about 7% or more by weight based on the total volume of the composition.
- the compositions of the present invention include high concentrations of magnesium (e.g. , magnesium chloride).
- concentration of magnesium in the composition may be, e.g. , about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, or about 7% or more by weight based on the total volume of the composition.
- Sweeteners may be included in the compositions of the invention.
- Exemplary sweeteners include corn syrup (e.g., high fructose corn syrup or karo syrup), mannose, maltose, glucose polymers, sucrose (e.g. , cane sugar or beet sugar), glucose, dextrose, lactose, galactose, fructose, polysaccharides (e.g. , malodextrins), rice syrup, honey, and natural fruit juices (e.g. , orange juice, papaya juice, pineapple juice, apple juice, grape juice, apricot juice, pear juice, tomato juice, agave nectar, or cranberry juice).
- corn syrup e.g., high fructose corn syrup or karo syrup
- mannose maltose
- glucose polymers e.g. , cane sugar or beet sugar
- sucrose e.g. , cane sugar or beet sugar
- glucose dextrose
- non- or low-caloric sweeteners can be used in the compositions of the invention.
- non-caloric or low-caloric sweeteners include, but are not limited to, saccharin, cyclamates, acetosulfam, sorbitol, sucralose, xylitol, erythritol, Stevia extract, L-aspartyl-L-phenyl-alanine ester (e.g. , aspartame), L-aspartyl-D- alanine alkyl amides, L-aspartyl-L- l-hydroxymethylalkaneamide, and L-aspartyl-1- hydroxyethylalkaneamide.
- saccharin cyclamates
- acetosulfam sorbitol
- sucralose xylitol
- erythritol Stevia extract
- L-aspartyl-L-phenyl-alanine ester e.g. ,
- Sweeteners may be present in a composition of the invention at a concentration range of about 2% to about 20% by weight based on the total volume of the composition (e.g. , about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20%), though sweeteners may be present in lower or higher concentrations.
- Exemplary flavoring agents include almond oil, amaretto oil, anethole, anise oil, benzaldehyde, blackberry, black walnut oil, blueberry, caraway, caraway oil, cardamom oil, cardamom seed, cherry juice, cherry syrup, cinnamon, cinnamon oil, cinnamon water, citric acid, citric acid syrup, clove oil, cocoa, coriander oil, dextrose, eriodictyon, ethyl acetate, ethyl vanillin, fennel oil, ginger, glucose, glycerin, glycyrrhiza, grape, honey, lavender oil, lemon oil, lime, mannitol, methyl salicylate, myristica oil, orange oil, orange peel, orange syrup, peppermint, peppermint oil, peppermint water, phenylethyl alcohol, pineapple, raspberry juice, raspberry syrup, rosemary oil, rose oil, rose water, sarsaparilla syrup, sorbitol, spearmint, spearmint oil
- Coloring agents include, e.g. , beta-carotene, riboflavin dyes, FD&C dyes (e.g. , Yellow No. 5, Blue No. 1, Blue No. 2, and Red No. 40), FD&C lakes, chlorophylls and chlorophyllins, caramel coloring, annatto, cochineal, turmeric, saffron, paprika, and fruit, vegetable, and/or plant extracts (e.g., grape, black currant, aronia, carrot, beetroot, red cabbage, elderberry, and hibiscus extracts).
- the amount of coloring agent used will vary depending on the agents used in the composition and the color intensity desired in the finished product. The amount of coloring agent to be used can be readily determined by one skilled in the art.
- compositions of the present invention include, e.g., choline bitartate, niacinamide, thiamin, folic acid, d-calcium pantothenate, biotin, vitamin A, vitamin C, vitamin Bi hydrochloride, vitamin B 2 , vitamin B 3 , vitamin B 6 hydrochloride, vitamin B 12 , vitamin D, vitamin E acetate, vitamin K, and salts of calcium, potassium, magnesium, zinc, iodine, iron, and copper.
- the composition contains at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% of the U.S. recommended daily intake (RDI) for such vitamins and minerals.
- RDI U.S. recommended daily intake
- a preservative may additionally be utilized in the compositions described herein.
- Exemplary preservatives include, for example, sorbate, benzoate, and polyphosphate
- preservatives e.g., sorbic acid, benzoic acid, calcium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, and mixtures thereof.
- the preservative is included at levels from about 0.0005% to about 0.5% (e.g., about 0.0005%, about 0.001%, about 0.005%, about 0.01%, about 0.05%, about 0.1%, or about 0.5%) by weight based on the total volume of the composition, though preservatives may be present in lower or higher concentrations.
- antioxidant agent may also be included in the compositions to, for example, reduce exercise-induced oxidative stress.
- exemplary antioxidants include vitamin C and vitamin E; beta-carotene, lutein, or other carotenoids; cyanidin, delphinidin, malvidin, or other anthocyanidins; apigenin, luteolin, or other flavones; hesperitin, naringenin, or other flavonones; isorhamnetin, quercetin, kaempferol or other flavonols; and epigallocatechin-3-gallate, epicatechin, thearubigins, or other flavan-3-ols.
- the antioxidant When included in a composition of the invention, the antioxidant is included at levels from about 0.0005% to about 0.5% (e.g. , about 0.0005%, about 0.001%, about 0.005%, about 0.01%, about 0.05%, about 0.1%, or about 0.5%) by weight based on the total volume of the composition, though antioxidants may be present in lower or higher concentrations.
- compositions described herein may include amino acids (e.g. , leucine, isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), stimulants (e.g. , caffeine), emulsifying agents, carbon dioxide (e.g. , to carbonate a liquid composition), stabilizers, humectants, anticaking agents, or herbal extracts. These components may be included at levels from about 0.0005% to about 25% (e.g.
- compositions and solutions of the present invention may be formulated as ready-to- drink beverages, concentrates (e.g. , syrups), dry compositions (e.g. , powders, granules, or tablets that may be reconstituted with a liquid (e.g. , with water), gels, solids, semi-solids (e.g. , ice cream, pudding, or yogurt), frozen liquids (e.g. , ice pops), lozenges or hard candies, dissolving strips (e.g. , an edible strip containing pullulan and compositions of the invention), and chewing gum.
- a formulation base which is a substance or material mixed with or added to the capsaicinoid, capsinoid, or related analog or combination thereof and pharmaceutically acceptable excipient in order to achieve the desired form.
- compositions of the invention are mixed with a pharmaceutically-acceptable carrier, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates,
- a pharmaceutically-acceptable carrier such as sodium citrate or dicalcium phosphate
- fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid
- binders such as, for example, carboxymethylcellulose, alginates, gelatin, poly
- compositions may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- the compositions may be in the form of a dry powder, granule, tablet, or capsule that may be reconstituted in a specified amount of a liquid.
- the dried components may be mixed together and milled (e.g. , to create a homogenous powder) or mixed in aqueous solution and dried by using methods known to one of skill in the art. Dried powders or granules may be "loose" or fashioned into tablets.
- compositions of the present invention may be in the form of a gel or paste further comprising a humectant (e.g., glycerin, propylene glycol, lithium chloride, alpha hydroxy acids, diols, urea, quillaia, polyols, sugar alcohols (e.g., sorbitol, glycerol, xylitol, mannitol), glyceryl triacetate, or neoagarobiose), a gum (e.g., xanthan gum, guar gum), an abrasive (e.g., silica, (e.g., Zeodent ® )), a plasticizer, an additive (e.g., a sweetener, preservative, buffering agent, penetration agent, surfactant, coloring agent, flavoring agent, cleaning agent, and the like) or a thickener (e.g., silica (e.g., silica (
- compositions of the invention may be present in the composition of the invention from about 0.5% to about 99% (e.g. , about 0.5%, about 0.1%, about 0.5%, about 1%, about 5%, about 10%, about 20%, about 30% about 40%, about 50%, about 75%, about 90%, about 95%, or about 99%) by weight based on the total volume of the composition, though these components may be present in lower or higher concentrations.
- the gel or paste may be further packaged on or within a delivery device such as a bioadhesive strip, patch, film, or may be provided for application directly to the oral cavity (e.g., mucosal surfaces (e.g., in the mouth, nose, or throat), teeth, gums, or lips).
- a paste or gel can be packaged in a unit that contains between about 0.1 ounces to about 16 ounces of the paste or gel.
- the packaging can contain about 0.1 ounces, about 0.25 ounces, about 0.5 ounces, about 1 ounce, about 2 ounces, about 3 ounces, about 4 ounces, about 5 ounces, about 6 ounces, about 7 ounces, about 8 ounces, about 9 ounces, about 10 ounces, about 11 ounces, about 12 ounces, about 13 ounces, about 14 ounces, about 15 ounces, or about 16 ounces.
- the powdered ingredients are mixed together with a binding agent, such as acacia or tragacanth, and are then made into a plastic mass by incorporation of any liquid drugs and addition of an inert liquid.
- a binding agent such as acacia or tragacanth
- the resulting mass is then rolled into spheres and coated with talc, gelatin, or sugar.
- the capsaicinoids, capsinoids, or related analogs or combinations thereof are mixed with suitable diluents, such as dextrin, lactose, salt, starch, or synthetic substances, designed to ensure disintegration of the tablet in the body.
- suitable diluents such as dextrin, lactose, salt, starch, or synthetic substances
- a lubricant such as liquid paraffin, stearic acid, talc, or a synthetic substance is usually added.
- the tablet machines are fed with the drug mixture in a free- flowing form to ensure complete filling of the molds.
- the composition mixture is customarily granulated by mechanically forcing pellets of the mixture through a sheet of perforated-metal.
- the granulated mixture is fed into the tablet machine, which feeds the correct dose into a cavity, the mixture then being compressed by means of a punch that fits into the cavity.
- the tablet maker must choose correct diluents and lubricants, prepare suitable granules, and obtain the right degree of compression in the tablet machine. Excessive compression may mean that the tablet will not disintegrate in the body; insufficient compression results in fragile tablets that may break, causing inaccurate dosage. Coatings of various types may be applied to the tablet to protect the ingredients from deterioration, to hide the taste of certain components, to control the release of the active components from the tablet, or to produce a more attractive tablet.
- a concentrated sucrose syrup containing suspended starch, calcium or magnesium carbonate, or other suitable substance is applied, each successive layer being dried before the application of the next. After the final layer is dried, it is highly polished to give an elegant finish.
- Sugar coatings provide both protection and a sweet taste.
- Film coatings can also be used, in which a very thin transparent film, usually a cellulose derivative, is applied.
- Enteric coating is designed to resist solution in the stomach and to dissolve in the more alkaline intestinal fluid. Many substances have been used for enteric coatings, one of which is cellulose acetate phthalate (cellacephate).
- a compressed tablet is fed to a second machine where another layer is compressed around it. In this way, drugs normally incompatible may be formulated in the same tablet.
- solid dosages such as lozenges, candies, dragees, dissolving strips, or pastilles disintegrate or dissolve in the mouth, slowly releasing the active ingredient (e.g. , any of the capsaicinoids, capsinoids, or related analogs thereof described herein).
- the base usually consists of a mixture of sugar and gum or gelatin.
- Lozenges are generally manufactured by compression techniques, while pastilles are fabricated by fusion and the use of molds.
- Dry extracts are prepared by the methods for fluid extracts, followed by evaporation, usually under reduced pressure, either to a pilular consistency or to dryness. Dry extracts are usually granulated by being passed through a sieve and may be used for the preparation of tablets.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, and elixirs.
- active ingredient e.g.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol,
- Suspensions in addition to the active agent may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- compositions and solutions described herein may be bottled or packaged in, for example, glass bottles, plastic bottles and containers (e.g. , polyethylene terephthalate or foil- lined ethylene vinyl alcohol), metal cans (e.g. , coated aluminum or steel), lined cardboard containers, pouches, packs, wrappers, or any other packaging known to one of skill in the art.
- a ready-to-drink beverage can be bottled or packaged in a unit that contains between about 10- 1000 mL of the beverage.
- the packaging can contain about 10 mL, 20 mL, 50 mL, 100 mL, 200 mL, 300 mL, 400 mL, 500 mL, 600 mL, 700 mL, 800 mL, 900 mL, or 1000 mL of the beverage.
- the packaging can contain 200 mL, 250 mL, 330 mL, 350 mL, 355 mL, 375 mL, 440 mL, or 500 mL of the beverage.
- a ready-to-drink beverage can also be bottled or packaged in a unit that contains between about 1-32 fluid ounces of beverage (e.g.
- the unit may contain about 1, 2, 5, 6.75, 8, 8.3, 8.4, 8.45, 9.6, 10, 12, 15, 15.5, 16, 18.6, 20, 23, 24, or 32 fluid ounces).
- the packaging is appropriately sterilized before being filled by the pasteurized, ultra-pasteurized, or sterilized composition or solution.
- the packaging may feature multiple containers that can be mixed shortly before ingestion or that can be consumed serially.
- Formulations for oral use may also be provided as chewable tablets, or as hard gelatin capsules wherein the active ingredient (e.g. , any of the capsaicinoids, capsinoids, or related analogs or combinations thereof, described herein) is mixed with an inert solid diluent (e.g. , potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate or kaolin), or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil. Powders, granulates, and pellets may be prepared using the ingredients mentioned above under tablets and capsules in a conventional manner using, e.g. , a mixer, a fluid bed apparatus or a spray drying equipment.
- the active ingredient e.g. , any of the capsaicinoids, capsinoids, or related analogs or combinations thereof, described herein
- an inert solid diluent e.g. , potato starch, lac
- compositions of the invention can be formulated as an oil-based formulation for oral administration.
- the oil-based formulation includes a formulation base composition including an oil and a lipophilic additive, which can be solid or pasty at room temperature.
- the lipophilic additive can include waxes, fatty acid mono-, di- or triglycerides, fatty acids and polyethylene glycols and the polyethylene glycol fatty acid esters, as well as their mixtures and can be present in ranges from about 5 to 20% by weight or the composition (e.g. , about 5%, about 6%, about 10%, about 15%, about 17%, about 18%, about 19%, or about 20%),
- the waxes can be beeswax, candelilla wax, carnauba wax, polyethylene oxide wax or petroleum wax (or microcrystalline wax).
- the fatty acid mono-, di-, or triglycerides can have different degrees of esterification.
- the fatty acids can be selected from among palmitic acid, stearic acid, or behenic acid and their calcium, sodium, potassium or magnesium salts.
- the polyethylene glycols and fatty acid polyethylene glycol esters can have a molecular weight of between about 600 to 6000.
- the oil can include vegetable oils such as soya oil, sunflower oil, corn oil, olive oil or nut oil, and among the mineral oils such as liquid paraffin, as well as their mixtures,
- the oil- based formulations can be present in the form of a soft or hard capsule and can be prepared by traditional techniques known in the art.
- the lipophilic additive is incorporated into the oil which is heated at a temperature sufficiently high to melt the lipophi lic additive completely and obtain a homogeneous mixture.
- the other components such as the capsaicinoids, capsinoids, or related analogs and combinations thereof described herein are incorporated into this mixture with stirring.
- the mixture thus obtained is cooled to a temperature between 25 and 40° C, and optionally, soft or hard capsules are filled with this mixture.
- the capsaicinoids, capsinoids, or related analogs or combinations thereof can be formulated as an oil for topical administration.
- the agonists described herein at concentration ranges of about > 20% to 95% (w/w) are solubilized in a solvent capable of solubilizing the TRP channel agonist.
- Solvents that may be used include volatile solvents (e.g. , methanol, ethanol, acetone, isopropanol, n-propanol, cyclohexane and alkanes with molecular weight less than dodecane (C- 12)), semi-volatile solvents (e.g..
- volatile essential oils such as clove oil, tea tree oil, sesame oil, and cineole
- non-volatile solvents e.g. , polyethylene glycol 400, Lutrol® (polyethylene polyoxypropylene block copolymer available from BASF), glyceryl monooleate, glycerin, lanolin, low melting waxes, sesquiterpenes and alkanes, alkenes, aikanoic and alkenoic acids >C-28).
- the oils may further include a
- crystallization inhibitor for example, polyvinylpyrrolidone, Luvitol® BD 10 P (BASF), povidone and its derivatives; dextrin derivatives, polyethylene glycol, polypropylene glycol, mannitol and glycerin, and mono and diglycerides of essential oils, polyglycerin fatty acid esters, sucrose palmitic acid ester, pentaerythritol ester of wood rosin (Pentalyn A®), and Eudagrits®. Crystallization inhibitors may range from about 0.1 to 10% w/w.
- the oils of the capsaicinoids, capsinoids, or related analogs described herein may be administered orally as an oil.
- compositions that are formulated for modified release (e.g., delayed release, prolonged and/or slow release, extended release, or rapid release) of the capsaicinoids, capsinoids, or related analogs and combinations thereof to reduce gastrointestinal side-effects.
- modified release e.g., delayed release, prolonged and/or slow release, extended release, or rapid release
- Such compositions are well-known in the art and include e.g., diffusion-controlled drag delivery systems, osmotic pressure controlled dmg delivery systems, or erodible drug delivery systems.
- Exemplary delivery systems are the SQZgelTM (MacroMed, nc.), comprising a pH-sensitive polymer mixture combined with an outer coating in which the acidic environment of the stomach causes the polymer to imbibe with water and swell, entrapping the capsaicinoid, capsinoid, or related analog.
- SQZgelTM MicroMed, nc.
- the polymer Upon entering the higher pH of the intestines, the polymer slowly shrinks, or “squeezes” at a "dialed-in” rate releasing the active composition in a sustained manner); the Egalet® extrusion based technology (Egalet A/S), comprising a biodegradable coat and a matrix, including the dmg, which is surface erodible, hydrophobic, and composed of PEG-stearate); Diffucaps/Surecaps (small beads approximately 1 mm or less in diameter that can be incorporated into hard gelatin capsules, where the
- Egalet A/S the Egalet® extrusion based technology
- Diffucaps/Surecaps small beads approximately 1 mm or less in diameter that can be incorporated into hard gelatin capsules, where the
- capsaicinoid, capsinoid, or related analog release profiles are created by layering dmg onto a neutral core such as sugar spheres, crystals, or granules followed by a rate-controlling, functional membrane); and MeltDose®, which involves formulating solubilized, individual moelcules into tablets).
- a neutral core such as sugar spheres, crystals, or granules followed by a rate-controlling, functional membrane
- MeltDose® which involves formulating solubilized, individual moelcules into tablets).
- capsaicinoids, capsinoids, or related analogs and combinations thereof described herein can be formulated for pH controlled release.
- suitable formulation principles are, for example, compositions provided with an enteric coating or hydrogels of a type described in US Patent Nos, 6,537,584 and 5,484,610, which axe hereby incorporated by reference.
- Another suitable formulation includes the formulation of the capsaicinoids, capsinoids, or related analogs or combinations thereof together with vitamin E concentrate in soft or hard gelatin capsules.
- Another specific example of a suitable formulation includes formulation of the capsaicinoids, capsinoids, or related analogs or combinations thereof together with ethanol, tocopherolethylene glycol 1000 succinate (TPGS), corn oil, and wax in soft or hard gelatin capsules.
- TPGS tocopherolethylene glycol 1000 succinate
- Variations of this formulation can include efhanol, TPGS, com oil, and polyglycolized glyeerid.es ⁇ e.g., Gelucire) in soft or hard gelatin capsules, 'The resulting product can be a semisolid or solid dosage form, The release rate of this formulation is dependent on degradation due to lipases in the intestine,
- a further example of a suitable formulation is an oral pulsed dose drug delivery system.
- This dosage form can be perceived as a modified form of the Schering Repetab cablets.
- a portion of the composition of the present invention is put in the core of a tablet.
- the core can for example, be made by conventional wet granulation or continuous granulation such as extrusion followed by compaction of the granulate into tablets, '
- the core is then coated using an appropriate technology, for example, by air suspension using an enteric coating polymer such as Eudragits.
- the first releasing dose is compression coated on the core or air- suspension coated either with the enteric coat or on top of the enteric coat.
- the first releasing dose is air- suspe s on coated with the enteric coat.
- the first releasing dose is compression coated on the core, in order to avoid release of the composition according to the invention prior to the degradation of the enteric coat, such degradation typically occurring at pH values higher than those found in the gastric ventricle (i.e., the degradation of the enteric coat typically occurs after passage of the gastric ventricle),
- a suitable formulation is an oral sustained drag delivery system.
- the core can for example, be made by conventional wet granulation or continuous granulation such as extrusion followed by compaction of the granulate into tablets.
- the core is then coated using appropriate technology, for example, by airsuspension using ethyl.cellul.ose and a hydrophilic excipient such as hydroxy! propyl cellulose (HPC).
- the compositions of the inventions can include the capsaicinoids, capsinoids, or related analogs or combinations thereof in the form of micro-crystals with hydrophilic surfaces.
- the micro -crystals can be film coated directly in order to achieve a sustained release formulation.
- the compositions of the invention can also be complexed with genuine cyclodextrins and cyclodextrin-derivatives ⁇ e.g., alkyl- and hydroxyalkyl-derivatives or sulfobutyl-derivatives), The complexation is achieved by methods known in the art.
- the composition can include a pharmaceutically acceptable excipient that is an agent for delayed or controlled release of the capsaicinoids or analogs thereof and/or capsinoids or analogs thereof.
- the agent is a water-soluble polymer, including but not limited to, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose (HPMC), methyl cellulose, and carboxymethyl cellulose.
- the capsaicinoids, capsinoids, or related analogs or combinations thereof described herein can be targeted to the mucus/mucosal lining of the mouth, tongue, nose, or gastrointestinal tract (GIT) through the use of bioadhesives.
- a bioadhesive is defined as a synthetic or biological material which is capable of adhering to a biological substrate or tissue. When the biological substrate is mucus, the term “mucoadhesive" has been employed. When the biological tissue involved is the mouth or stomach, the terms “buccoadhesive” or “gastroadhesive” has been employed. Bioadhesives can remain attached to the biological substrate for an extended period of time.
- the period of time a bioadhesive is required to remain attached to a biological substrate will vary according to the target site and the condition being treated.
- Other delivery systems that can target the capsaicinoid, capsinoid, or related analogs described herein to the colon include, but are not limited to:
- capsaicinoid, capsinoid, or related analog covalent linkage of the capsaicinoid, capsinoid, or related analog with the carrier to form a prodrug that is stable in the stomach and small intestine and releases the capsaicinoid, capsinoid, or related analog in the large intestine upon enzymatic transformation by the intestinal microflora;
- prodrugs include azo-conjugates, cyclodextrin-conjugates, glycoside-conjugates, glucuronate conjugates, dextran-conjugates, polypeptide and polymeric conjugates;
- (b) approaches to deliver intact molecule to the colon such as coating with pH- sensitive polymers to release the capsaicinoid, capsinoid, or related analog at neutral to alkaline pH, or coating with biodegradable polymers which release the drug upon degradation by the bacteria in the colon;
- stomach, the capsaicinoid, capsinoid, or related analog is released after a lag time of 3-5 hrs which is equivalent to the transit time of the small intestine;
- polymers provide capsaicinoid, capsinoid, or related analog release in response to the redox potential of the colon;
- the capsaicinoids, capsinoids, or related analogs or combinations thereof-loaded nano- and micro-particles for sustained release are formulated by the nano- precipitation or the oil-in- water single emulsion solvent evaporation/extraction method.
- the capsaicinoids, capsinoids, or related analogs or combinations thereof-loaded poly(lactic-co- glycolic acid) (PLGA) nanoparticles are prepared by the nano-precipitation method.
- the volume of oil- water ratio can be adjusted (e.g., from about 1 :2 to 1 :5, e.g., about 1 :2, 1 :3, 1 :4, or 1 :5), and size of the nanoparticles can be selected (e.g.
- a modified single emulsion method can be applied with biocompatible polymers such as polylactic acid (PLLA), polyhydroxy butyrate (PHB), polyglycolic acid (PGA), PLGA, and poly-e-caprolactone (PCL).
- biocompatible polymers such as polylactic acid (PLLA), polyhydroxy butyrate (PHB), polyglycolic acid (PGA), PLGA, and poly-e-caprolactone (PCL).
- stomach specific mucoadhesive nanoparticles can be used to improve controlled delivery of the capsaicinoids, capsinoids, or related analogs or combinations thereof by continuous release of the agonist for a prolonged period to its absorption site to ensure optimal bioavailability.
- the capsaicinoids, capsinoids, or related analogs or combinations thereof with a narrow absorption window are mostly associated with improved absorption at the jejunum and ileum due to enhanced absorption properties of these sites (e.g., large surface area), or because of enhanced solubility in the stomach as opposed to the more distal parts of the gastrointestinal tract.
- Capsaicinoids, capsinoids, or related analogs or combinations thereof that may benefit from using stomach specific mucoadhesive nanoparticles includes those that act locally in the stomach, those with low solubility at high pH values, those that are primarily absorbed in the stomach, those with a narrow window of absorption, e.g. , those that are absorbed mainly from the proximal part of the small intestine, those that absorb rapidly from the gastro intestinal tract, drugs that degrade in the colon, and drugs that are unstable in intestinal fluids. Longer residence time in the stomach could be advantageous for local action especially in the upper part of the small intestine.
- a list of the micro and nano carriers for mucosal delivery applications is described in Table 1.
- compositions described herein may be administered to a subject in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art and as relating to the particular disease or condition to be treated.
- the compositions used in the methods described herein may be administered, for example, by topical, enteral, or parenteral applications.
- Topical applications include but are not limited to epicutaneous, inhalation, enema, eye drops, ear drops, and applications through mucous membranes in the body.
- Enteral applications include oral administration, rectal administration, vaginal administration, and gastric feeding tubes.
- Parenteral administration includes intravenous, intraarterial, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, intrastemal, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal, and topical modes of administration.
- Parenteral administration may be by continuous infusion over a selected period of time.
- the capsaicinoid, capsinoid, or related analog or combination thereof is administered through the oral cavity to achieve mucosal and transmucosal effects.
- exemplary applications include buccal, nasal, intradermal, inhalational, topical, subcutaneous, sublingual, sublabial, and insufflation administrations.
- Compositions of the current invention may include a penetration enhancer to increase the bioavailability of the ion channel activator within the oral cavity.
- Exemplary penetration enhances include surfactants (e.g., anionic surfactants (e.g, sodium lauryl sulfate), cationic surfactants (e.g., cetyl pyridinium chloride), and nonionic surfactants (e.g., poloxamer, Brij, Span, Myrj, Tween)), bile salts (e.g., sodium glycocholate, sodium taurodeoxycholate, sodium taurocholate), fatty acids (e.g., oleic acid, caprylic acid, lauric acid, lysophosphatidylcholine, phosphatidylcholine), cyclodextrins (e.g, -, ⁇ -, or ⁇ -cyclodextrans, methylated cyclodextrins), chelators (e.g., EDTA, citric acid, sodium salicylate, methyl salicylates), polymers (e.g., positively charged polymers (e.g
- the composition For intravenous or intrathecal delivery or direct injection, the composition must be sterile and fluid to the extent that the composition is deliverable by syringe.
- the carrier can be an isotonic buffered saline solution, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
- polyol for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like
- suitable mixtures thereof Proper fluidity can be maintained, for example, by use of coating such as lecithin, by
- isotonic agents for example, sugars, polyalcohols such as mannitol or sorbitol, and sodium chloride in the composition.
- Long-term absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.
- the choice of the route of administration will depend on whether a local or systemic effect is to be achieved.
- the composition can be formulated for topical administration and applied directly where its action is desired.
- the composition can be formulated for enteral administration and given via the digestive tract.
- the composition can be formulated for parenteral administration and given by routes other than through the digestive tract.
- parenteral depot systems from biodegradable polymers. These systems are injected or implanted into the muscle or
- Polymer- based parenteral depot systems can be classified as implants or microparticles.
- the former are cylindrical devices injected into the subcutaneous tissue whereas the latter are defined as spherical particles in the range of 10 - 100 ⁇ .
- Extrusion, compression or injection moldings are used to manufacture implants whereas for microparticles, the phase separation method, the spray-drying technique and the water-in- oil-in- water emulsion techniques are frequently employed.
- polyesters from lactic and/or glycolic acid e.g. poly(glycolic acid) and poly(L-lactic acid) (PLG/PLA microspheres).
- PLA/PLA microspheres polyesters from lactic and/or glycolic acid
- in situ forming depot systems such as thermoplastic pastes and gelling systems formed by solidification, by cooling, or due to the sol- gel transition, cross-linking systems and organogels formed by amphiphilic lipids.
- thermosensitive polymers used in the aforementioned systems include, N-isopropylacrylamide, poloxamers (ethylene oxide and propylene oxide block copolymers, such as poloxamer 188 and 407), poly(N-vinyl caprolactam), poly(siloethylene glycol), polyphosphazenes derivatives and PLGA-PEG-PLGA.
- compositions of the present invention are formulated into acceptable dosage forms by conventional methods known to those of skill in the art. Actual dosage levels of the active ingredients in the compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular subject, composition, and mode of administration, without being toxic to the subject.
- the selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of absorption of the particular agent being employed, the duration of the treatment, other drugs, substances, and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the subject being treated, and like factors well known in the medical arts.
- a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the composition required. For example, the physician or veterinarian can start doses of the substances of the invention employed in the composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
- a suitable daily dose of a composition of the invention will be that amount of the substance which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
- the effective daily dose of a therapeutic composition may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
- Preferred therapeutic dosage levels are between about 500 mg to about 1000 mg (e.g. , about 500 mg, 520 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg) of the composition per day administered orally to adults of average weight afflicted with most of the symptoms, syndromes and conditions described herein.
- Preferred prophylactic dosage levels are between about 100 mg to about 1000 mg (e.g. , about 110 mg, 140 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 460 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg).
- the dose may also be titrated (e.g. , the dose may be escalated gradually until signs of gastrointestinal toxicity appear, such as diarrhea or nausea).
- the frequency of treatment may also vary.
- the subject can be treated one or more times per day (e.g. , once, twice, three, four or more times) or every so-many hours (e.g. , about every 2, 4, 6, 8, 12, or 24 hours).
- the composition can be administered 1 or 2 times per 24 hours.
- the time course of treatment may be of varying duration, e.g. , for two, three, four, five, six, seven, eight, nine, ten, or more days, two weeks, 1 month, 2 months, 4 months, 6 months, 8 months, 10 months, or more than one year.
- the treatment can be twice a day for three days, twice a day for seven days, twice a day for ten days.
- Treatment cycles can be repeated at intervals, for example weekly, bimonthly or monthly, which are separated by periods in which no treatment is given.
- the treatment can be a single treatment or can last as long as the life span of the subject (e.g. , many years).
- the present invention also relates to the use of the composition as foodstuff, food supplement, or dietetic product (a foodstuff intended for a particular diet).
- the composition can be incorporated into foodstuffs which are industrially produced or craftsmen- prepared, such as oils, butter, margarine, bread spreads, or baked goods. It can also be presented in the form of a powder for di lution in water or food bars.
- composition of the invention can further be administered in combination with a dietary supplement to promote and/or maintain general health.
- dietary supplements include, but are not limited to, a vitamin (e.g. , Vitamin A, Vitamin B 1 ; B 2 , B 3 , B 5 , B 6 , B 7 , B9, B 12 , Vitamin C, Vitamin D, Vitamin E, and Vitamin K), a mineral (e.g. , potassium, chlorine, sodium, calcium, magnesium, phosphorus, zinc, iron, manganese, copper, iodine, selenium, and molybdenum), an herb or botanical (e.g. , St. John' s- wort, kava, Shilajit, and Chinese herbal medicines), an amino acid (e.g.
- glycine serine, methionine, cysteine, aspartic acid, glutamic acid, glutamine, tryptophan, and phenylalanine
- a concentrate constituent, extract, and/or a combination of any of the above.
- compositions of the invention may be useful for treating any of the conditions and disorders described herein.
- PNS Peripheral Nervous System
- compositions of the invention can be used to treat conditions affecting the peripheral nervous system (PNS). These conditions include: diseases, disorders, or injuries to the peripheral nervous system include but are not limited to: cramp fasciculation syndrome, Isaacs' Syndrome or neuromyotonia (NMT), peripheral neuropathy (e.g., diabetic neuropathy), carpal tunnel syndrome, or EBV infection.
- PNS peripheral nervous system
- diseases, disorders, or injuries to the peripheral nervous system include but are not limited to: cramp fasciculation syndrome, Isaacs' Syndrome or neuromyotonia (NMT), peripheral neuropathy (e.g., diabetic neuropathy), carpal tunnel syndrome, or EBV infection.
- peripheral nervous system diseases and conditions include but are not limited to: amyloid neuropathies, diabetic neuropathies, nerve compression syndromes, peripheral nervous system neoplasms, brachial plexux neuropathies, Guillain-Barre syndrome, neuralgia, polyneuropathies, complex regional pain syndromes, mononeuropathies, neuritis, acrodynia, neurofibromatosis, hand-arm vibration syndrome, pain insensitivity, and Tarlov cysts.
- compositions of the invention can be used to treat conditions affecting the central nervous system (CNS).
- CNS central nervous system
- central nervous system diseases and conditions including infections of the central nervous system such as encephalitis and poliomyelitis, early-onset neurological disorders including ADHD and autism, late-onset neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and essential tremor, autoimmune and inflammatory diseases such as multiple sclerosis and acute
- Anxiety disorders may also be characterized as a CNS condition. Anxiety disorders can be classified into:
- generalized anxiety disorder phobic disorders, panic disorders, agoraphobia, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, separation anxiety, and situational anxiety.
- compositions of the invention may be useful in treating tactile sensitivity or tactile defensiveness (TD).
- TD refers to patterns of observable behavioral and emotional responses which are aversive, negative, and out of proportion to certain types of tactile stimuli that are often found by most people to be non-painful.
- TD is a sensory integrative dysfunction in which the brain is unable to process and use information through the senses.
- Tactile sensitivity can result from conditions such as autism, dyspraxia, neuralgia, panic or anxiety disorders, or from venomous bites or stings.
- compositions of the invention may be useful in treating conditions associated with an electrolyte imbalance and/or vitamin deficiency.
- conditions associated with an electrolyte imbalance and/or vitamin deficiency include, but are not limited to: hyponatremia, hypernatremia, hyperkalemia, hypokalemia, hypercalcemia, hypocalcemia, hyperchloremia, hypochloremia, hypermagnesemia, hypomagnesemia, hyperphosphatemia, hypophosphatemia, kidney disease, rickets, scurvy, beriberi, pellagra, calcium deficiency, eating disorders, vitamin D deficiency, vitamin A deficiency, biotin deficiency, ariboflavinosis, vitamin K deficiencies, hypocobalaminemia, paraesthesia, night blindness, magnesium or thiamine deficiency, hypoparathyroidism, medullary cystic disease, and adrenocortical carcinoma.
- compositions and methods described herein include treating a subject having been diagnosed with or identified as having a muscle condition or disorder.
- exemplary disorders include night cramps, multiple sclerosis, dystonia, spinal cord spasticity, neuromuscular disorders, including muscle pain and cramping associated with a neuromuscular disorder, central nervous system disorders or injuries (e.g., spinal cord injury, brain injury, or stroke), muscle cramps, muscle spasms, and fasciculations.
- compositions of the invention are also useful for treating painful muscle contraction of the head or neck as in tension, cluster or migraine headache, back spasms, leg cramps due to spinal stenosis, skeletal muscle pain, muscle pain (e.g., fibromyalgia) and spasms (e.g., nocturnal cramps), spasms and cramps due to treatment with dialysis, diuretics, ⁇ -blockers, statins, fibrates, p2-agonists, ACE inhibitors, ARBs and anti-psychotic medications, muscle claudication pain due to inactivity or restriction as seen in "economy class syndrome", paralysis, peripheral artery disease or immobilization, and neuromuscular diseases.
- painful muscle contraction of the head or neck as in tension, cluster or migraine headache, back spasms, leg cramps due to spinal stenosis, skeletal muscle pain, muscle pain (e.g., fibromyalgia) and spasms (e.g., nocturnal cramps), spa
- Neuromuscular disease can be caused by circulatory problems, stroke, immunological and autoimmune disorders, the failure of the electrical insulation surrounding nerves myelin, genetic/hereditary disorders, such as Huntington's disease, certain rare tumors, the failure of the connections between the nerves and the muscle fibers, and exposure to pernicious environmental chemicals, poisoning (e.g. , heavy metal poisoning).
- Some neuromuscular diseases are caused either by viral infections or by attack by little-known pernicious proteins called prions.
- Diseases of the motor end plate include myasthenia gravis, a form of muscle weakness due to antibodies to the acetylcholine receptor, and its related condition Lambert-Eaton myasthenic syndrome (LEMS).
- LEMS Lambert-Eaton myasthenic syndrome
- Tetanus and botulism are bacterial infections in which bacterial toxins cause increased or decreased muscle tone, respectively.
- Myopathies are all diseases primarily resulting in muscular degeneration, rather than affecting the nerves themselves (e.g. , nemaline myopathy, centronuclear myopathy, mitochondrial myopathies, inflammatory myopathies, familial periodic paralysis, or drug-induced myopathyies).
- Muscular dystrophies including Duchenne's and Becker's, are a large group of diseases, many of them hereditary or resulting from genetic mutations, where the muscle integrity is disrupted. They lead to progressive loss of strength and decreased life span.
- Guillain-Barre syndrome and inflammatory muscle disorders, such as polymyalgia rheumatic, polymyositis, dermatomyositis, inclusion body myositis, and rhabdomyolysis.
- inflammatory muscle disorders such as polymyalgia rheumatic, polymyositis, dermatomyositis, inclusion body myositis, and rhabdomyolysis.
- Additional neuromuscular disorders include, but are not limited to, multiple sclerosis, spinal cord spasticity, spinal muscle atrophy, myasthenia gravis, spinal cord injury, traumatic brain injury, cerebral palsy, hereditary spastic paraplegia, motor neuron disease (e.g., amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, progressive spinobulbar muscular atrophy (e.g., Kennedy' s disease), or post- polio syndrome), neuralgia, fibromyalgia, Machado-Joseph disease, cramp fasciculation syndrome, carpal tunnel syndrome, acrodynia, neurofibromatosis, neuromyotonias (e.g., focal neuromyotonia, Isaacs' syndrome), peripheral neuropathy, piriformis syndrome, plexopathy (e.g. , Brachial plexopathy or Lumbosacral
- Dystonia is a neurological condition that affects a muscle or group of muscles in a specific part of the body causing involuntary muscular contractions and abnormal postures.
- Types of dystonia include: focal dystonia, multifocal dystonia, segmental dystonia, generalized dystonia (e.g. , torsion dystonia or idiopathic torsion dystonia), hemidystonia, blepharospasm, psychogenic dystonia, cervical dystonia, acute dystonic reaction, and vegetative-vascular dystonia.
- the methods and compositions described herein may be useful for cervical dystonia, cranial dystonia, laryngeal dystonia, and hand dystonia.
- Causes for the disorder include, but are not limited to, inheritance, birth-related or physical trauma, infection, poisoning (e.g. , lead poisoning), or reaction to some pharmaceutical agents, e.g. , neuroleptics. Treatment is difficult and has been limited to minimizing symptoms of the disorder, such as muscle cramping.
- the methods and compositions described herein may be useful for focal dystonia, blepharospasm, cervical dystonia, cranial dystonia, laryngeal dystonia, and hand dystonia.
- the subject has been diagnosed or identified as having multiple sclerosis.
- Multiple sclerosis is also known as disseminated sclerosis and encephalomyelitis disseminate.
- MS is an inflammatory disease in which the insulating sheaths of nerve cells in the brain and spinal cord are damaged, thereby disrupting the ability of the nervous system to communicate.
- the three main characteristics of MS are the formation of lesions in the central nervous system (also called plaques), inflammation, and the destruction of myelin sheaths of neurons. Symptoms of MS can include muscle spasms and muscle weakness.
- the subject has been diagnosed with or identified as having night cramps (also known as nocturnal cramps).
- Night cramps are spontaneous muscle contractions that occur during sleep, can be very painful, and often recur throughout the night.
- the subject has been diagnosed with or identified as having spinal cord spasticity.
- Spasticity is the uncontrolled tightening or contracting of the muscles that is common in individuals with spinal cord injuries and a variety of nervous system diseases.
- Spasticity is usually defined as a velocity-dependent increase in the tonic stretch reflex (muscle tone) with exaggerated tendon jerks, clonus, and spasms, resulting from the hyperexcitability of the stretch reflex.
- Muscle tone muscle tone
- thoracic chest
- lumbar lower back injuries.
- the subject has experienced a central nervous system injury, such as a brain injury, a stroke, or a traumatic spinal cord injury.
- the central nervous system injury is associated with unwanted or abnormal muscle contractions or spasms, or the absence of normal muscle contractions.
- the subject has been diagnosed or identified as experiencing muscle cramps, spasms, dystonias, or fasciculations (e.g., unwanted or abnormal muscle cramps, spasms, dystonias, or fasciculations). Muscle cramps, spasms, dystonias, or fasciculations can also occur as a consequence of other diseases or disorders, such as diabetes (e.g.
- diabetes e.g., diabetic neuropathy
- Addison' s disease peripheral artery disease, hypertension, alcoholism, liver cirrhosis, renal failure, hypothyroidism, neuromuscular diseases (e.g., amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, progressive spinobulbar muscular atrophy (e.g., Kennedy's disease), or post-polio syndrome), and metabolic disorders (e.g.,
- the methods described herein are also useful for treating or evaluating subjects that have been diagnosed with the other diseases or disorders associated with muscle cramps described herein.
- Muscle cramps, spasms, dystonias, or fasciculations can occur as a side effect of some drugs.
- Medications that can cause muscle cramps include: diuretics, oral contraceptives, blood pressure medications.
- the methods described herein can also be useful to treat or evaluate subjects that are prescribed or take medication that cause muscle cramps.
- medications that can induce muscle cramps include, but are not limited to: diuretics, e.g. , Lasix (furosemide), Microzide (hydrochlorothiazide); Alzheimer' s disease medication, e.g. , Aricept (donepezil); myasthenia gravis medication, e.g. , Prostigmine (neostigmine); cardiovascular medication, e.g. , Procardia (nifedipine); osteoporosis medication, e.g. , Evista (raloxifene);
- asthma medication e.g. , Brethine (terbutaline), Proventil and Ventolin (albuterol); Parkinson's disease medication, e.g. ,Tasmar (tolcapone); cholesterol medication, e.g. , statins such as Crestor (rosuvastatin), Lescol (fluvastatin), Lipitor (atorvastatin), Mevacor (lovastatin), Pravachol (pravastatin), or Zocor (simvastatin).
- statins such as Crestor (rosuvastatin), Lescol (fluvastatin), Lipitor (atorvastatin), Mevacor (lovastatin), Pravachol (pravastatin), or Zocor (simvastatin).
- compositions and methods disclosed herein are suitable for treating or evaluating a subject that has an absence of a normal muscle contraction, such as a gait abnormality.
- Gait abnormalities are deviations from normal walking or unusual and
- gait abnormalities include propulsive gait, scissors gait, spastic gait, steppage gait, and waddling gait.
- the gait abnormality is "foot drop,” in which the dropping of the forefoot happens due to muscular weakness, damage to nerves, or paralysis of muscles.
- Gait abnormalities are often associated with neuromuscular diseases or disorders. Connective Tissue Diseases
- compositions of the invention are also useful for treating connective tissue diseases.
- diseases include but are not limited to: degenerative joint disease (DJD), marfan syndrome, Ehlers-Danlos syndrome, osteogenesis imperfect, Stickler syndrome, Alport syndrome, congenital contractural arachnodactyly, psoriatic arthritis, systemic lupus
- erythematosus erythematosus, rheumatoid arthritis, scleroderma, Sjogren's syndrome, and mixed connective tissue disease.
- compositions of the invention can also treat throat disorders or throat injuries (e.g., from chemicals, cancer, surgery, or infection).
- throat disorders include, but are not limited to acid reflux, tonsillitis, pharyngitis, laryngospasm due to throat surgery, laryngitis, dysphagia, and spasmodic dysphonias.
- compositions of the invention are also useful for treating sarcoidosis.
- Sarcoidosis is a disease involving abnormal collections of inflammatory cells (granulomas) that can form as nodules in multiple organs. The granulomas are most often located in the lungs or its associated lymph nodes, but any organ can be affected.
- compositions of the invention are useful in treating various types of sarcoidosis including but not limited to: annular sarcoidosis, erythrodermic sarcoidosis, ichthyosiform sarcoidosis, hypopigmented sarcoidosis, Lofgren syndrome, lupus pernio, morpheaform sarcoidosis, mucosal sarcoidosis, neurosarcoidosis, papular sarcoid, scar sarcoid, subcutaneous sarcoidosis, systemic sarcoidosis, and ulcerative sarcoidosis.
- compositions of the invention may also useful for treating a respiratory condition or illness.
- Respiratory conditions involve the organs and/or tissues involved in respiration, including the lungs, trachea, bronchi, bronchioles, alveoli, pleura, pleural cavities.
- activation of a TRP ion channels through administration of a capsaicinoid, capsinoid, or related analog or combination thereof of the present invention may affect airway sensory nerve reactivity, thus leading to bronchodilation of airway smooth muscle.
- Exemplary respiratory conditions for which the composition of the present invention may be useful in treating include, but are not limited to, asthma, chronic obstructive pulmonary disease, bronchitis, emphysema, pneumonia, cystic fibrosis, pleural cavity diseases, influenza, or cold.
- compositions of the present invention may also be useful for treating or reducing cough in a subject.
- Cough is a reflex that is often repetitive in nature and may aid in clearing the breathing passages from particles, irritants, secretions, and the like. Coughing may be voluntary or involuntary.
- Exemplary conditions related to cough include respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease, bronchitis, emphysema, pneumonia, cystic fibrosis, pleural cavity diseases, influenza, or a cold), exposure to allergens or chemical irritants, or inflammation.
- the composition of the present invention may be a cough suppressant.
- the subject has been diagnosed with or identified as having an anxiety disorder.
- An anxiety disorder may be characterized as a condition involving the central nervous system and can cause feelings of fear, anxiety, and anguish in the subject. These conditions can result in unwanted or abnormal muscle cramps, spasms, dystonias, and fasciculations that may be treated by compositions of the disclosed invention.
- Exemplary anxiety disorders include generalized anxiety disorder, phobic disorders, panic disorders, agoraphobia, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, separation anxiety, and situational anxiety.
- the present invention provides various methods for evaluating a subject for the efficacy of a muscle cramp treatment or for treating an unwanted or abnormal muscle contraction, e.g., a muscle cramp, spasticity, dystonia, or fasciculation.
- a test muscle of a subject is electrically induced to have a test muscle cramp, and the electrical activity of the test muscle is recorded.
- a test aliquot of a composition for treating muscle cramps, spasms, dystonias, or fasciculations is administered to the subject, and a second test muscle cramp is induced. The electrical activity of the second test cramp is also recorded.
- Comparison and analysis of the recordings of the first and second test cramp can indicate the efficacy of the test aliquot on reducing, alleviating, or preventing the cramp. Comparison and analysis of the recordings can also be used to classify subjects, or identify subjects for certain treatments for muscle cramps.
- Alpha motor neurons project from the brainstem and the spinal cord and innervate the muscles. Stimulation of the alpha motor neurons results in transmittal of an electrical signal to the muscles, generated from the movement of ions across the cell membrane. The electrical stimulation from the motor neurons causes muscle movement or contraction, e.g. , a muscle cramp or spasm. When the muscles are at rest, there is minimal or no electrical signal.
- Activity of the alpha motor neurons can be modulated by signaling from primary sensory neurons, which are activated by sensory input. Stimulation of non-taste primary sensory neurons with nerve endings in the mouth, esophagus and stomach, e.g., through activation of specific ion channels, can induce cause upregulation of inhibitory signals to the alpha motor neurons. Through this mechanism of intemeuronal negative feedback, activation of primary sensory neurons inhibit or prevents alpha motor neuron firing via inhibitory signaling, and thereby inhibits muscle contractions of muscle cramps or spasms.
- Electrical stimulation can elicit a muscle contraction that recapitulates a muscle cramp, spasm, dystonia, or fasciculation.
- electrical stimulation is used to induce a test muscle cramp.
- the electrical activity of the test muscle before, during, and after the test muscle cramp is detected, measured, and recorded. Analysis of the recording of the electrical activity of a muscle experiencing an electrically induced cramp can be useful for determining the efficacy of a treatment for alleviating a muscle cramp.
- Electromyography is a technique for measuring and recording the electrical activity of a muscle during rest and movement.
- the instrument that detects and records the electric signal generated from a muscle is called an electromyograph.
- the recording of the electrical activity obtained by the electromyograph is known as an electromyogram (or myogram).
- the eletromyograph may comprise at least one recording electrode, at least one reference electrode, an amplifier unit, a device for converting the analog signals to digital signals, and a device for generating and displaying the recordings.
- the instrument may also include at least one mechanism to detect additional biofeedback, such as body or skin temperature by a skin thermistor.
- Electrodes The electrical activity of a muscle, e.g. , a test muscle, is recorded and detected by an electrode, or a lead.
- an electrode or a lead.
- the electrode used in the present invention is a surface electrode.
- a recording electrode is preferably placed over a test muscle, and a reference electrode is placed nearby, e.g. , within 2-6 inches of an active electrode.
- the reference electrode is placed on a synergistic muscle.
- a synergistic muscle is a muscle that aids or participates in movement with the test muscle but does not cramp with the test muscle when electrically induced.
- a series or an array of multiple recording electrodes is used.
- a linear array of 8 recording electrodes is applied on the test muscle, and optionally, a linear array of 4-8 recording electrodes is used on the synergistic muscle.
- a grid array of recording electrodes is applied on the target muscle, e.g. , a grid array of 6 x 5 electrodes is used.
- electrical stimulus is applied to a test muscle to induce a test muscle contraction.
- the electrical stimulus is delivered by a stimulation electrode.
- the stimulation electrode is placed preferably directly on the skin over the test muscle.
- the electrical stimulus is defined by multiple parameters, such as stimulation frequency (Hertz or Hz), current intensity (milliamps or mA), pulse frequency (pulse per second or pps), and duration of time of stimulation.
- the electrical stimulus can be delivered by percutaneous electrical stimulation or surface electrical stimulation.
- Preferred test muscles for electrically inducing a muscle cramp include the flexor hallucis brevis (FHB, or big toe flexor muscle) and gastrocnemius (calf muscle).
- Other target muscles may include the abductor hallucis (AH), the biceps brachii (biceps), the triceps surae (triceps), or the quadriceps femoris (quadriceps).
- the appropriate stimulation frequency of electrical stimulation to induce a test muscle cramp may vary depending on the size or location of the muscle or the individual.
- the electrical stimulation can be at least 1 Hz, at least 2 Hz, at least 3 Hz, at least 4 Hz, at least 5 Hz, at least 6 Hz, at least 7 Hz, at least 8 Hz, at least 9 Hz, at least 10 Hz, at least 11 Hz, at least 12 Hz, at least 13 Hz, at least 14 Hz, at least 15 Hz, at least 20 Hz, at least 25 Hz, at least 30 Hz, at least 35 Hz, at least 40 Hz, at least 50 Hz, at least 60 Hz, at least 70 Hz, at least 80 Hz, at least 90 Hz, or at least 100 Hz.
- the stimulation frequency for the FHB is 8 Hz, 10 Hz, 12 Hz, 14 Hz, or 18 Hz.
- the stimulation frequency can vary over time. For example, the stimulation frequency increases over time, e.g., from 2 Hz to 24 Hz, increasing by 2 Hz increments.
- the minimum frequency of the electrical stimulation capable of inducing a cramp has been termed the "threshold frequency.”
- the threshold frequency for cramp induction is lower in cramp-prone subjects compared with subjects with no history of cramps.
- Miller and Knight Muscle Nerve. 2009, 39:364-8; and Minetto et al., Muscle Nerve. 2009; 40:535-44.
- Miller and Knight found a threshold frequency for the flexor hallucis brevis muscle of approximately 15 Hz in subjects with a history of cramping and of approximately 25 Hz in individuals not prone to cramping.
- the amplitude, or intensity of the current, of the electrical stimulus also may vary depending on the size or location of the muscle or the individual.
- a maximal current intensity refers to the current intensity required to achieve a plateau in the M-wave peak amplitude.
- the M-wave refers to the EMG signal detected.
- the current intensity is 30% supramaximal, or greater than, the maximal current intensity.
- the maximal current intensity is determined for each individual subject prior to testing the subject. For example, the current intensity is 5 mA, 10 mA, 15 mA, 20 mA, 25 mA, 30 mA, 40 mA, 50 mA, or 60 mA.
- the electrical stimulus can be applied as a series of pulses for a duration of time.
- the stimulus may be applied as a series of at least 100 microsecond pulses, at least 120 microsecond pulses, at least 150 microsecond pulses, at least 180 microsecond pulses, at least 200 microsecond pulses, at least 300 microsecond pulses, at least 400 microsecond pulses, at least 500 microsecond pulses, or at least 600 microsecond pulses.
- the stimulus can be applied for 1 second, 2 seconds, 3 seconds, 4 seconds, 5 seconds, 6 seconds, 7 seconds, 8 seconds, 9 seconds, 10 seconds, or longer.
- the stimulus is applied as a series of 180 microsecond pulses for 7 seconds.
- the parameters of electrical stimulation to be applied to the test muscle may be adjusted to decrease or increase the magnitude of the test muscle contraction to better recapitulate a muscle cramp, spasm, dystonia, or fasciculation.
- the frequency or intensity of electrical current applied to the test muscle may vary depending on the type of test muscle contraction desired, e.g. , the frequency of stimulation is increased to induce a test muscle cramp compared to a test muscle spasm.
- the electrical activity of a target muscle is detected and recorded by a recording electrode before, during, and after an induced cramp.
- the electrical activity is recorded and displayed as a profile or electromyogram.
- the profile contains the electrical activity before, during, and after the application of electrical stimulation to induce a muscle cramp.
- the profile contains the electrical activity during the application of electrical stimulation and after the application of electrical stimulation.
- the electrical activity is converted to root mean square (RMS) values and are displayed as a function of time.
- RMS root mean square
- the profile contains the average electrical activity detected from all of the recording electrodes as a function of time.
- the pattern of the recorded electrical activity or signal can indicate the presence or absence of an induced muscle cramp.
- Indication of an induced muscle cramp includes involuntary electrical signal of the stimulated muscle after cessation of the electrical stimulation, preferably with concurrent absence of electrical signal of the synergistic muscle.
- a signal amplitude greater than 2 or 3 standard deviations above the 1 second baseline signal amplitude of either the target muscle prior to stimulation or the synergistic muscle after stimulation indicates an induced cramp.
- the induced muscle cramp can last for at least 5 seconds, at least 10 seconds, at least 15 seconds, at least 20 seconds, at least 25 seconds, at least 30 seconds, at least 35 seconds, at least 40 seconds, at least 45 seconds, at least 50 seconds, at least 55 seconds, at least 1 minute, at least 2 minutes, at least 3 minutes, at least 4 minutes, or at least 5 minutes.
- a first muscle cramp is electrically- induced in a subject prior to administration of a composition for treating a muscle cramp, and after a rest period, a second muscle cramp is electrically-induced in a subject after administration of the composition.
- the profile obtained for the first induced cramp before administration of the composition is referred to as the reference profile.
- the profile obtained for the second induced cramp after administration of the composition is referred to as the treatment profile.
- Comparison of the treatment profile and the reference profile can be used to select subjects for treatment with the composition or to identify subjects that will be responsive to the treatment with the composition. Specifically, the properties of the induced cramp in the reference and treatment profiles are compared to determine whether the composition administered reduced or prevented the second induced cramp.
- a value can be determined from the reference profile, e.g. , a reference value, and a value can be determined from the treatment profile, e.g. , a treatment value.
- the reference value and the treatment value can be compared to determine a reduction or prevention of a cramp.
- the values determined from the reference and/or treatment profile represent the parameters of muscle cramp. A decrease in the treatment value compared to the reference value indicates that that the test aliquot administered is effective at alleviating or preventing a muscle cramp.
- the parameters of a muscle cramp can be compared for determining the efficacy of a treatment for alleviating a cramp, e.g. , by a reduction of a muscle cramp parameter or prevention of a cramp.
- Parameters of muscle cramps that can be determined from the electromyogram include the area under the curve, the peak amplitude, the duration of the cramp, and a change in threshold frequency used to elicit a test muscle cramp.
- An area under the curve value can be calculated for the reference and treatment profile using standard methods known in the art. A decrease or absence of an area under the curve value in the treatment profile compared to the reference profile indicates that an electrically induced cramp has been reduced or prevented.
- the area under the curve in the treatment profile may be at least 1 %, 5%, 10%, 15,%, 20%, 25%, 30%, 35%, or 50% decreased compared to the area under the curve in the reference profile.
- the peak amplitude after cessation of the electrical stimulus can be compared between the reference and treatment profiles.
- a reduction in or absence of the peak amplitude in a treatment profile compared to a reference profile indicates that an electrically induced cramp has been reduced or prevented.
- the peak amplitude in a treatment profile may be at least 1%, 5%, 10%, 15,%, 20%, 25%, 30%, 35%, or 50% decreased compared to the peak amplitude of the reference profile.
- the duration of the test cramp can be compared between the reference and treatment profile.
- a decrease in or absence of the duration of the cramp indicates the reduction or prevention of the electrically induced cramp.
- the duration of the cramp may be at least 1%, 5%, 10%, 15,%, 20%, 25%, 30%, 35%, or 50% decreased compared to the duration of the cramp in the reference profile.
- Threshold frequency refers to the minimum frequency of electrical stimulation required to elicit a cramp.
- a change in the threshold frequency required to elicit a test muscle cramp indicates the efficacy of a treatment for alleviating a cramp.
- a change in the threshold frequency may be at least 1%, 5%, 10%, 15,%, 20%, 25%, 30%, 35%, or 50% , 100%, 200% increased compared to the threshold frequency required before treatment, e.g. , in the reference profile.
- a change in the threshold frequency may be at least 1%, 5%, 10%, 15,%, 20%, 25%, 30%, 35%, or 50% , decreased compared to the threshold frequency required before treatment, e.g. , in the reference profile.
- the rest period between the first test cramp and the second test cramp is at least 1 minute, 2 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes, 90 minutes, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 16 hours, 20 hours, or 24 hours.
- the electrical stimulation is re-applied to induce a second muscle cramp at least 1 minute, 2 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes, 90 minutes, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 16 hours, 20 hours, or 24 hours after administration of the composition for treating muscle cramps.
- the test comprises determining that a cramp can be induced in a subject by application of stimulus.
- the stimulus is percutaneous electrical stimulation or surface electrical stimulation.
- the magnitude of the parameters of the induced muscle cramp e.g., as determined from an EMG profile, identifies or classifies subjects with respect to selection of treatment regimens, or predicts the response of a subject to a specific treatment regimen.
- additional therapeutic agent(s) may be administered with compositions of the present invention for, e.g. , the treatment of peripheral nervous system conditions (e.g., peripheral neuropathy), central nervous system conditions, muscle conditions and disorders (e.g., fibromyalgia, muscle spasms and cramps (e.g. , nocturnal cramps), painful muscle contractions (e.g., a muscle contraction of the head or neck), neuromuscular disorders (e.g., motor neuron disease) or dystonia (e.g., cervical dystonia, blepharospasm, back spasms, or leg cramps due to spinal stenosis)), connective tissue diseases (e.g.
- peripheral nervous system conditions e.g., peripheral neuropathy
- central nervous system conditions e.g., central nervous system conditions, muscle conditions and disorders (e.g., fibromyalgia, muscle spasms and cramps (e.g. , nocturnal cramps), painful muscle contractions (e.g.
- the candidate therapeutic agents are agents already known in the art for use for other conditions or disorders, e.g. , neuromuscular therapeutic agents.
- the additional therapeutic agent(s) can be administered as a separate formulation or may be combined with any of the compositions described herein.
- any of the compositions described herein can be used for the treatment of nocturnal (or night) cramps.
- the compositions can be used in
- Sleep aids that can be used in combination with the compositions and methods described herein include: antihistamines (e.g. , diphenhydramine and doxylamine); benzodiazepines (e.g. , estazolam (ProSom), flurazepam (Dalmane), quazepam (Doral), temazepam (Restoril), and triazolam (Halcion)); non-benzodiazepine sedative hypnotics (e.g. , eszopiclone (Lunesta), zalepon (Sonata), and Zolpidem (Ambien)); and melatonin receptor agonist hypnotics (e.g.
- antihistamines e.g. , diphenhydramine and doxylamine
- benzodiazepines e.g. , estazolam (ProSom), flurazepam (Dalmane), quazepam (Doral), temazepam (
- Still other sleep aids that can be used in combination with the compositions and methods described herein include: chamomile, valerian root, kava kava, lemon balm, passionflower, lavender, St. John's Wort, melatonin, tryptophan (e.g. , L- tryptophan), 5-hydroxytryptophan (5-HTP), catnip, hops, rhodiola, oatstraw, lavender, GABA, L-theanine, linden, ginseng (e.g.
- any of the compositions described herein can be used for the treatment of painful muscle contraction of the head or neck as in tension, cluster or migraine headache.
- the compositions can be used with analgesics, including aspirin, ibruprofen, acetaminophen, or naproxen; with triptans including sumatriptan, rizatriptan, naratriptan; with mild sedatives including butalbital; with anti-depressants including
- compositions described herein can be also be used for the treatment of focal dystonia.
- the compositions can be used with botulinum toxin; with anticholinergic agents including trihexyphenidyl and benztropine; with GABAergic agents including benzodiazepines; and with dopaminergic agents including tetrabenazine and levodopa.
- compositions described herein can be also be used for the treatment of muscle claudication pain due to inactivity or restriction as seen in "economy class syndrome", paralysis, peripheral artery disease or immobilization.
- the compositions can be used with cilostazol or with pentoxifylline.
- the compositions described herein can be also be used for the treatment of sarcoidosis.
- compositions can be used with non-steroidal anti-inflammatory drugs (NSAIDs) including ibuprofen and aspirin; with corticosteroids, including prednisone and prednisolone; and with steroid-sparing agents, including azathioprine, methotrexate, mycophenolic acid, and
- NSAIDs non-steroidal anti-inflammatory drugs
- corticosteroids including prednisone and prednisolone
- steroid-sparing agents including azathioprine, methotrexate, mycophenolic acid
- any of the compositions described herein can also be used in combination with a treatment for pain or a disorder relating to the oral cavity, such as oral lesions, canker sores, cold sores, thrush, gingivitis, leukoplakia, halitosis, or dry mouth.
- the composition can be used with or antibacterial or antiviral agents to treat or prevent tooth decay or carries.
- any of the compositions described herein can also be used in combination with a treatment for pain or a disorder relating to the stomach or gastrointestinal tract, such as indigestion, heartburn, colitis, irritable bowel syndrome, constipation, diarrhea, lactose intolerance, gastroesophageal reflux disease, ulcers, nausea, or stomach cramps.
- compositions can be used with antacids (e.g., simethicone, magaldrate, aluminum salts, calcium salts, sodium salts, magnesium salts, alginic acid) laxatives , H 2 antagonists (e.g., ranitidine, famotidine, nizatidine, cimetidine) or proton pump inhibitors (e.g., omeprazole, lansoprazole, esomeprazole, dexlansoprazole, rabeprazole, or pentoprazole), and antidiarrheals (e.g., bismuth subsalicylate).
- antacids e.g., simethicone, magaldrate, aluminum salts, calcium salts, sodium salts, magnesium salts, alginic acid
- H 2 antagonists e.g., ranitidine, famotidine, nizatidine, cimetidine
- proton pump inhibitors e.
- any of the compositions described herein can be also be used for the treatment of disease, disorder or injury to the peripheral nervous system such as cramp fasciculation syndrome, peripheral neuropathy, carpal tunnel syndrome or EBV.
- the compositions can be used to treat cramp fasciculation syndrome with ⁇ - blockers; analgesics including ibuprofen and acetaminophen; magnesium; or carbamazepine.
- the compositions can be used to treat peripheral neuropathy with tricyclic antidepressants, including amitriptyline; with antiepileptic therapies including gabapentin and sodium valproate; with synthetic cannabinoids including nabilone; with pregabalin; or with serotonin-norepinephrine reuptake inhibitors (SNRIs), including duloxetine.
- the compositions can be used to treat carpal tunnel syndrome with corticosteroids.
- TRP-Stim The solution (“TRP-Stim”) administered to the volunteers contains: a base of a 1: 1 mixture of water and light karo syrup (for increased viscosity); 0.075% of a capsicum
- the active stimulation electrode is a 1.25" circular mesh -backed silver patch electrode (Bio-Flex manufactured by Lead-Lok) and is placed so as to produce contraction of the FHB with minimal stimulation amplitude.
- the stimulation reference electrode is a 2" square patch electrode (Bio-Flex manufactured by Lead-Lok) is placed on the opposite side of the foot, e.g., under the lateral malleous.
- Cramping of the FHB is induced as described by Minetto et al. (ibid.) using a battery-powered electrical muscle stimulator (EMS-7500, Current Solutions LLC) to deliver pulses.
- EMS-7500 battery-powered electrical muscle stimulator
- a series of 180 microsecond biphasic square pulses of voltages is applied at various frequencies to stimulate the muscle.
- the amplitude is adjusted to -30% more than the threshold amplitude for eliciting strong contraction of the muscle.
- the muscle is then stimulated by a train of 180 microsecond pulses of this amplitude delivered for 7 seconds at various frequencies.
- the stimulation delivered by the stimulator includes "ramp up” and "ramp down” periods of 1 second preceding and following the main 7- second stimulation period during which the amplitude of the pulses is ramped up or down to and from the final value.
- Cramping is quantified by making EMG recordings from the belly of the FHB.
- Two external EMG recording electrodes (Vermed SilveRest) are placed along the belly of the FHB.
- the differential voltage relative to a third ground electrode placed at the ankle is amplified, digitized, and saved to computer using a 1-330-C2+ EMG unit with PhysioLab software (J&J Engineering, Poulsbo, WA).
- the raw wide -band EMG signal (10-400 Hz) is processed by being rectified and integrated to provide the area under the curve (RMS).
- the duration of cramp is quantified by the time required for the RMS EMG to return to an amplitude of 3 standard deviations above the baseline value. This will correlate well with duration of the cramp as observed by the return to the toe to resting position.
- capsicum extract used in the TRP-Stim beverage are applied to the neurons after dilution in balanced salt solution (in mM: 145 NaCl, 5 KC1, 2 CaCl 2 , 1 MgCl 2 , 10 HEPES, and 10 glucose) for perfusion of the neurons.
- Caspicum extract is applied at a dilution of 1/800,000, cinnamon extract at a dilution of 1/5,000, and ginger extract at a dilution of 1/12,000.
- the calcium ionophore ionomycin is added following the tests with extracts to produce a large entry of calcium as an index of the maximal possible signal, illustrating the strength of activation by the heavily diluted extracts.
- Figure 1 shows graphs from six sensory neurons isolated from the trigeminal ganglia of rats, illustrating their activation by the capsicum, cinnamon, and ginger extracts that are used in the human experiments. Activation is quantified as an increase in intracellular free calcium, monitored by a fluorescent calcium indicator. Extracts are diluted into normal extracellular saline (Tyrode's solution) and are tested at lower concentrations than used in the beverage, taking account that concentrations present at nerve endings in mouth, esophagus, or stomach are expected to be lower than the beverage as a result of dilution into mucosa and interstitial fluid. All three extracts are capable of activating individual neurons when applied at concentrations 50- fold to 15,000-fold lower than used in the beverage.
- Each trace shows a record from a different neuron, illustrating that some neurons could be activated by each of the extracts and that the strength of activation by each extract varied among particular neurons.
- These records illustrate that each agent is capable of acting alone to activate some neurons and that a combination of agents can produce stronger activation of a larger fraction of neurons. Further, the bottom two records show that there can be strongly synergistic activation of neurons by the capsicum extract and the ginger extract when applied in combination.
- Example 1 The in vitro data of Example 1 show that each individual component of the TRP-Stim solution by itself is capable of activating sensory neurons. Consistent with this, human experiments show the efficacy of a beverage with capsicum alone (ClearCap capsicum at 1/2000 dilution) to inhibit cramping, achieved within 5 minutes.
- Figures 2-8 are graphs of EMG recordings of muscle contractions in seven human volunteers (four females and three males) that show the efficacy in preventing and treating cramps of ingesting 50 mL of a solution designed to stimulate TRP VI and TRPA1 receptors in the mouth, esophagus, and stomach. Muscle cramps are induced by brief stimulation of toe or calf muscles ( Figures 2-7) or occurred spontaneously ( Figure 8). After recording cramping in control, subjects drink 50 mL of the TRP-Stim solution containing capsaicin and capsaicinoids (TRPV1 agonists), cinnamaldehyde (TRPA1 agonist), and gingerols (TRPA1 and TRPVl agonists). After ingestion of the solution, subjects are tested for muscle cramping using the same procedures as in control at times ranging from 4 minutes to 11 hours after ingestion.
- TRPV1 agonists capsaicin and capsaicinoids
- TRPA1 agonist cinnamalde
- Figure 2 is a graph showing the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis of Subject A.
- cramping is reliably induced by stimulating the muscle using an electrical muscle stimulator (EMS-7500, Current Solutions LLC) placed with external electrodes for FHB stimulation. Muscle activity is recorded using external electrodes placed over the belly of the muscle attached to an EMG amplifier (J&J Engineering I- 330C2+).
- EMG amplifier J&J Engineering I- 330C2+.
- stimulation using 180 microsecond biphasic pulses delivered at 18 Hz for 5 seconds reliably and reproducibly produce cramping of the muscle, which is evident by EMG activity continuing after the cessation of stimulation.
- cramping is very brief after 11 minutes and essentially absent at tests at 20 minutes and 2 1 ⁇ 2 hours after ingestion.
- Figure 3 is a graph showing the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis of a second subject.
- cramping is induced by stimulation at 10 Hz for 5 seconds (180 microsecond pulses, amplitude set to -30% higher than threshold for muscle contraction), and a longer cramp is induced by increasing the frequency to 12 Hz.
- stimulation at 10 Hz or 12 Hz produced essentially no cramping, and increasing the frequency of stimulation to 14 Hz also did not induce cramping. The dramatic reduction in cramping was still present 4 hours later in this subject.
- Figure 4 is a graph showing the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis of a third subject tested over longer times.
- a cramp lasting 58 seconds is induced by stimulation at 18 Hz for 5 seconds (180 microsecond pulses, amplitude set to -30% higher than threshold for muscle contraction).
- the duration of the cramp is reduced to 27 seconds after 8 minutes and to 8 seconds after 15 minutes.
- Cramping is abolished after 20 minutes and in a test after 2 hours. In tests 11 hours after ingestion, reliable cramping returns.
- the subject again drinks 50 mL of the TRP-Stim beverage, cramping is completely abolished in tests beginning after 10 minutes.
- Figure 5 is a graph showing the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis of a fourth subject.
- This subject engages in strenuous exercise (triathlon) four hours earlier and experiences muscle twitchiness.
- This subject has an unusually low frequency threshold (8 Hz) for induction of cramping in the FHB muscle, and the resulting cramps are unusually long (172 seconds after 8 Hz stimulation and 222 seconds after 10 Hz stimulation).
- Cramping is completely gone in tests starting 13 minutes after ingestion of the TRP-Stim beverage, even when increasing the stimulation frequency to 12 Hz. Cramping is still abolished 3 hours later.
- cramping returns with an increased frequency threshold (10 Hz) and shorter cramps than in control.
- the subject again drinks 50 mL of the TRP- Stim beverage, cramping is again completely abolished.
- Figure 6 is a graph showing the effect of the TRP-Stim beverage on cramping of the gastrocnemius (calf) muscle of a fifth subject.
- the muscle is stimulated by a protocol ramping the frequency of stimulation from 2 Hz to 28 Hz (180 microsecond pulses, amplitude set to -30% higher than threshold for muscle contraction). After cessation of stimulation, the muscle went into a prolonged cramp lasting 59 seconds. In a test 3 minutes after ingestion of 50 mL of TRP-Stim, cramping is abolished.
- Figure 7 is a graph showing the effect of the TRP-Stim beverage on cramping of the gastrocnemius (calf) muscle of a sixth subject.
- the muscle is stimulated by a protocol ramping the frequency of stimulation from 2 Hz to 24 Hz (180 microsecond pulses, amplitude set to -30% higher than threshold for muscle contraction). After cessation of stimulation, the muscle went into a prolonged cramp lasting 96 seconds. In a test 4 minutes after ingestion of 50 mL of TRP- Stim, cramping is abolished. Cramping is still abolished in a test conducted 40 minutes later.
- Figure 8 is a graph showing the effect of the TRP-Stim beverage on cramping of an FHB muscle in a seventh subject, who experiences spontaneous cramping induced by pointing her toe.
- voluntary toe flexes lasting ⁇ 5 seconds reliably producedscramping of the FHB lasting 5-8 seconds in different trials.
- the methods described in this example can be used to evaluate subjects with disorders associated with muscle cramps, for example, subjects that experience night cramps or have been diagnosed or identified as having a neuromuscular disease, e.g. , multiple sclerosis, spinal cord spasticity, or dystonias.
- the methods described in this example can be used to assess the efficacy of any of the compositions described herein for alleviation of an electrically- induced muscle cramp in a subject diagnosed or identified as having a disorder associated with muscle cramps.
- the methods described in this example can also be used to evaluating and classifying a subject diagnosed or having a disorder associated with muscle cramps.
Abstract
The present invention relates to compositions of capsaicinoids, capsinoids, or related analogs or combinations thereof, and methods of preparation, formulation, and the medical use of these compositions. In one aspect, the present invention features a composition formulated for oral administration, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof.
Description
METHODS AND FORMULATIONS OF CAPSAICINOIDS AND CAPSINOIDS
CLAIM OF PRIORITY
This application claims priority to U.S. Provisional Application No. 61/979,405, filed April 14, 2014, U.S. Provisional Application No. 62/073, 129, filed October 31, 2014, and U.S. Provisional Application No. 62/073,258, filed October 31, 2014, the entire contents of each of which is incorporated herein by reference.
FIELD OF THE INVENTION
The invention relates to compositions of capsaicinoids, capsinoids, and related analogs or combinations thereof, and methods of preparation, formulation, and the medical use of these compositions.
BACKGROUND
The present invention relates to compositions of capsaicinoids, capsinoids, and related analogs thereof, and methods of preparation, formulation, and the medical use of these
compositions.
Capsaicin and several related compounds belong to a class of compounds called capsaicinoids and are produced as secondary metabolites by chili peppers. Capsaicinoids are found to exert multiple pharmacological and physiological effects including analgesia and anticancer, anti-inflammation, antioxidant, and anti-obesity activities. Sweet peppers are the source of natural capsinoids, which share a similar structural scaffold with capsaicinoids.
Capsinoids are less pungent and easily broken down under normal aqueous conditions compared to capsaicinoids. Capsinoids also possess antitumor, antioxidant, and anti-obesity properties.
There exists a need in the art for improved methods and compositions for treating peripheral nervous system conditions (e.g., peripheral neuropathy), central nervous system conditions, muscle conditions and disorders (e.g., fibromyalgia, muscle spasms and cramps (e.g. , nocturnal cramps), painful muscle contractions (e.g., a muscle contraction of the head or neck), neuromuscular disorders (e.g., motor neuron disease) or dystonia (e.g., cervical dystonia, blepharospasm, back spasms, or leg cramps due to spinal stenosis)), connective tissue diseases (e.g., degenerative joint disease), throat conditions (e.g. , dysphagia or spasmodic dysphonias), tactile sensitivity, electrolyte
imbalance and/or vitamin deficiency, respiratory conditions (e.g., asthma), cough, and sarcoidosis. As shown herein, compositions that include capsaicinoids and/or capsinoids and analogs thereof may be useful to treat the above-mentioned conditions.
SUMMARY OF THE INVENTION
In one aspect, the present invention features a composition formulated for oral administration, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof. In some embodiments, the composition comprises a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof. In some embodiments, the composition further comprises a pharmaceutically acceptable excipient. In some embodiments, the composition further comprises a plurality of
pharmaceutically acceptable excipients.
In some embodiments, the composition is formulated for modified release (e.g., delayed release, extended release, or rapid release) of said capsaicinoid, capsinoid, or related analog or combination thereof. In some embodiments, said pharmaceutically acceptable excipient comprises an agent for modified release (e.g., delayed release, extended release, or rapid release) of a capsaicinoid, capsinoid, or related analog or combination thereof, such that, when orally administered to a subject, the capsaicinoid, capsinoid, or related analog or combination thereof is not substantially released in the stomach of said subject. In some embodiments, the agent for modified release (e.g., delayed release, extended release, or rapid release) is selected from the group consisting of: hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, carboxymethyl cellulose, and mixtures thereof.
In some embodiments, said pharmaceutically acceptable excipient comprises a coating. In some embodiments, said coating is selected from the group consisting of: enteric coatings, sugar coatings, and polymeric coatings. In some embodiments, said capsaicinoid, capsinoid, or related analog or combination thereof is embedded in biodegradable microparticles or nanoparticles for sustained release.
In some embodiments, the composition further comprises a formulation base. In some embodiments, the formulation base comprises an oil and a lipophilic additive. In some
embodiments, said oil is selected from the group consisting of: vegetable oil, mineral oil, soya oil, sunflower oil, corn oil, olive oil, nut oil, and liquid paraffin. In some embodiments, said lipophilic additive is selected from the group consisting of: polyethylene glycol, fatty acid mono- , di-, or triglycerides, palmitic acid, stearic acid, behenic acid, polyethylene glycol fatty acid esters, candelilla wax, carnauba wax, polyethylene oxide wax, and petroleum wax. In some embodiments, the composition further comprises a coloring agent, a dissolving agent, a flavoring agent, a sweetener, a viscosity modifier, an electrolyte, a vitamin, a mineral, an antioxidant, or a preservative.
In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate,
dihydrocapsiate, nordihydrocapsiate, norcapsaicin, capsiconiate, dihydrocapsiconiate and other coniferyl esters, capsiconinoid, and 3-hydroxyacetanilide. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is capsaicin. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or from about 0.001% to about 10% (v/v).
In some embodiments, the non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl formate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]- 2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2-dimethylpropanoate, 4-[((6E)- 8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl octadecanoate, 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl{4-[((6E)-8-methylnon-6-enoylamino)methyl]-2- methoxyphenoxy} formate, homovanillyl 8-methylnonanoate, 3-(3-methoxy-4- hydroxyphenyl)propyl 8-methylnonanoate, 8-methylnonyl homovanillate, 8-methylnonanoic acid- substituted benzyl ester derivative, heptanoyl isobutylamide, heptanoyl guaiacylamide, 7- phenylhept-6-yne-acid-4-hydroxy-3-methoxybenzylamide, dohevanil, denatonium capsaicinate,
N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4-chlorophenyl)ethyl]thiourea, N-[4-(2- aminoethoxy) - 3 -methoxybenzyl] -N'- [2- (4-fluorophenyl)ethyl] thiourea, N- [4- (2- aminoethoxy) -3 - methoxybenzyl]-N'-[2-(2,4-dichlorophenyl)ethyl]thiourea,N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-benzyloxyphenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-(n-octyloxy)phenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[4-n-octyloxybenzyl]thiourea, N-phenylmethylalkynamide capsaicin derivatives, N-(4-0-glycerol-3-methoxybenzyl)-nonamide, N-nonanoyl vanillylamide-4-glyceryl ether, N-(4-0-acetic acid sodium-3-methoxybenzyl-nonamide), sodium N-nonanoyl
vanillylamide-4-O-acetate, N-(4-0-glycol-3-methoxybenzyl)-nonamide (N-nonanoyl
vanillylamide-4-glycol ether), 20-homovanillyl-mezerein, 20-homovanillyl-12-deoxyphorbol- 13- phenylacetate, civamide (N-[(4-hydroxy-3-methoxyphenyl)-methyl]-8-methyl-(Z)-6- nonemamide), nuvanil, capsavanil, olvanil, arvanil, and palvanil (N-palmitoyl-vanillamide). In some embodiments, said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or from about 0.001% to about 10% (v/v).
In some embodiments, the composition is a liquid or a solid. In some embodiments, the composition is formulated as a liquid. In some embodiments, the liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, sprays, and elixirs. In some embodiments, the composition is formulated as a solid. In some embodiments, the solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, and semi-solid formulations. In some embodiments, said solid is a tablet or capsule. In some embodiments, said capsule is a hard or soft capsule.
In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 0.01% or more of a liquid formulation, e.g., about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.075%, about 0.1%, or more. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 0.1% or more of a liquid formulation, e.g., about 0.2%, about 0.3%, about 0. 4%, about 0.5%, about 0.75%, about 1%, or more. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 1% or more of a liquid formulation, e.g., about 2%, about
3%, about 4%, about 5%, about 7.5%, about 10%, or more. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises between about 0.5% and 5% of a liquid formulation. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises between about 0.5% and 2.5% of a liquid formulation. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 10% or more of a liquid formulation, e.g., about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, or more.
In some embodiments, the composition comprises a liquid formulation (e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir) and an effective amount of the liquid formulation is at least about 1 mL, about 2 mL, about 4 mL, about 6 mL, about 8 mL, about 10 mL, about 12 mL, about 14 mL, about 16 mL, about 18 mL, about 20 mL, about 22.5 mL, about 25 mL, or more. In some embodiments, an effective amount of the liquid formulation is between about 1 mL and about 10 mL. In some embodiments, an effective amount of the liquid formulation is between about 5 mL and about 10 mL. In some embodiments, an effective amount of the liquid formulation is between about 10 mL and about 25 mL.
In some embodiments, the composition comprises a liquid formulation (e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir) and an effective amount of the liquid formulation is at least about 25 mL, about 30 mL, about 35 mL, about 40 mL, about 45 mL, about 50 mL, about 60 mL, about 75 mL, about 100 mL, about 150 mL, about 200 mL, about 300 mL, about 400 mL, about 500 mL, about 600 mL, about 750 mL, about 1000 mL, or more. In some embodiments, an effective amount of the liquid formulation is between about 25 mL and about 100 mL. In some embodiments, an effective amount of the liquid formulation is between about 50 mL and about 500 mL. In some embodiments, an effective amount of the liquid formulation is between about 100 mL and about 1000 mL.
In some embodiments, the composition comprises a liquid formulation (e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir) and an effective amount of the liquid formulation is at least about 1 fluid ounce, about 2 fluid ounces, about 3 fluid ounces, about 4 fluid ounces, about 5 fluid ounces, about 6 fluid ounces, about 7 fluid ounces, about 8 fluid ounces, about 9 fluid ounces, about 10 fluid ounces, about 11 fluid ounces, about 12 fluid ounces, or more. In some embodiments, an effective amount of the liquid
formulation is at least about 12 fluid ounces, about 16 fluid ounces, about 20 fluid ounces, about 24 fluid ounces, about 32 fluid ounces, about 40 fluid ounces, about 48 fluid ounces, about 56 fluid ounces, about 64 fluid ounces, or more.
In some embodiments, the composition comprises a solid formulation (e.g., a tablet, capsule, powder, crystal, paste, gel, lozenge (e.g., liquid filled lozenge), gum, candy, chew, foodstuff, dissolving strip, film, or semi-solid formulation) and an effective amount of the solid formulation is about 0.5 mg, about 1 mg, about 10 mg, about 25 mg, about 50 mg, about 100 mg, about 250 mg, about 500 mg, about 750 mg, about 1 g, about 2 g, about 5 g, about 10 g, or more. In some embodiments, an effective amount of the solid formulation is between about 0.5 mg and about 100 mg. In some embodiments, an effective amount of the solid formulation is between about 100 mg and about 500 mg. In some embodiments, an effective amount of the solid formulation is between about 500 mg and about 1000 mg.
In some embodiments, the composition is capable of reducing gastrointestinal side effects.
In some embodiments, the composition comprising the capsaicinoid, capsinoid, or related analog or combination thereof is formulated for use once a day. In some embodiments, the composition is formulated for use at least about 1 time per day, about 2 times per day, about 3 times per day, about 4 times per day, about 5 times per day, or more. In some embodiments, the composition is formulated for use about 1-3 times per day. In some embodiments, the composition is formulated for use for a period of about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, or more.
In some embodiments, the composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof, which target a TRP channel (e.g. , TRPV1). In some
embodiments, said composition comprises a TRP channel agonist (e.g. , a TRPV1 agonist).
In another aspect, the invention features a composition formulated for oral
administration, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof, and a pharmaceutically acceptable excipient, wherein said composition is a liquid or solid, and wherein said composition is formulated for delayed release
of said capsaicinoid, capsinoid, or related analog or combination thereof. In some embodiments, said composition comprises a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient. In another embodiment, said composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof, and a plurality of pharmaceutically acceptable excipients.
In some embodiments, said pharmaceutically acceptable excipient comprises an agent for delayed release of a capsaicinoid, capsinoid, or related analog or combination thereof, such that, when orally administered to a subject, the capsaicinoid, capsinoid, or related analog or combination thereof is not substantially released in the stomach of said subject. In some embodiments, the agent for delayed release is selected from the group consisting of:
hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, carboxymethyl cellulose, and mixtures thereof.
In some embodiments, said pharmaceutically acceptable excipient comprises a coating. In some embodiments, said coating is selected from the group consisting of: enteric coatings, sugar coatings, and polymeric coatings. In some embodiments, said capsaicinoid, capsinoid, or related analog or combination thereof is embedded in biodegradable microparticles or nanoparticles for sustained release.
In some embodiments, the composition further comprises a formulation base. In some embodiments, the formulation base comprises an oil and a lipophilic additive. In some embodiments, said oil is selected from the group consisting of: vegetable oil, mineral oil, soya oil, sunflower oil, corn oil, olive oil, nut oil, and liquid paraffin. In some embodiments, said lipophilic additive is selected from the group consisting of: polyethylene glycol, fatty acid mono- , di-, or triglycerides, palmitic acid, stearic acid, behenic acid, polyethylene glycol fatty acid esters, candelilla wax, carnauba wax, polyethylene oxide wax, and petroleum wax. In some embodiments, the composition further comprises a coloring agent, a dissolving agent, a flavoring agent, a sweetener, a viscosity modifier, an electrolyte, a vitamin, a mineral, an antioxidant, or a preservative.
In some embodiments, the composition is formulated as a liquid. In some embodiments, the liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, and elixirs. In some
embodiments, the composition is formulated as a solid. In some embodiments, the solid is
selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, and semisolid formulations. In some embodiments, said solid is a tablet or capsule. In some
embodiments, said capsule is a hard or soft capsule.
In some embodiments, the composition comprising the capsaicinoid, capsinoid, or related analog or combination thereof is formulated for use once a day. In some embodiments, the composition is formulated for use at least about 1 time per day, about 2 times per day, about 3 times per day, about 4 times per day, about 5 times per day, or more. In some embodiments, the composition is formulated for use about 1-3 times per day. In some embodiments, the composition is formulated for use for a period of about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, or more.
In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate,
dihydrocapsiate, nordihydrocapsiate, norcapsaicin, capsiconiate, dihydrocapsiconiate and other coniferyl esters, capsiconinoid, and 3-hydroxyacetanilide. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is capsaicin. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or from about 0.001% to about 10% (v/v).
In some embodiments, the non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl formate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]- 2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2-dimethylpropanoate, 4-[((6E)- 8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl octadecanoate, 4-[((6E)-8-methylnon-6-
enoylamino)methyl]-2-methyoxyphenyl{4-[((6E)-8-methylnon-6-enoylamino)methyl]-2- methoxyphenoxy} formate, homovanillyl 8-methylnonanoate, 3-(3-methoxy-4- hydroxyphenyl)propyl 8-methylnonanoate, 8-methylnonyl homovanillate, 8-methylnonanoic acid- substituted benzyl ester derivative, heptanoyl isobutylamide, heptanoyl guaiacylamide, 7- phenylhept-6-yne-acid-4-hydroxy-3-methoxybenzylamide, dohevanil, denatonium capsaicinate, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4-chlorophenyl)ethyl]thiourea, N-[4-(2- aminoethoxy) - 3 -methoxybenzyl] -N'- [2- (4-fluorophenyl)ethyl] thiourea, N- [4- (2- aminoethoxy) -3 - methoxybenzyl]-N'-[2-(2,4-dichlorophenyl)ethyl]thiourea,N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-benzyloxyphenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-(n-octyloxy)phenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[4-n-octyloxybenzyl]thiourea, N-phenylmethylalkynamide capsaicin derivatives, N-(4-0-glycerol-3-methoxybenzyl)-nonamide, N-nonanoyl vanillylamide-4-glyceryl ether, N-(4-0-acetic acid sodium-3-methoxybenzyl-nonamide), sodium N-nonanoyl
vanillylamide-4-O-acetate, N-(4-0-glycol-3-methoxybenzyl)-nonamide (N-nonanoyl
vanillylamide-4-glycol ether), 20-homovanillyl-mezerein, 20-homovanillyl-12-deoxyphorbol- 13- phenylacetate, civamide (N-[(4-hydroxy-3-methoxyphenyl)-methyl]-8-methyl-(Z)-6- nonemamide), nuvanil, capsavanil, olvanil, arvanil, and palvanil (N-palmitoyl-vanillamide). In some embodiments, said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or from about 0.001% to about 10% (v/v).
In some embodiments, the composition is capable of reducing gastrointestinal side effects.
In some embodiments, the composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof, which target a TRP channel (e.g. , TRPV1). In some
embodiments, said composition comprises a TRP channel agonist (e.g. , a TRPV1 agonist).
In another aspect, the invention features a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof, a formulation base, and a pharmaceutically acceptable excipient. In some embodiments, said composition comprises a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof a formulation base, and a pharmaceutically acceptable excipient. In some embodiments,
said composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof, a formulation base, and a plurality of pharmaceutically acceptable excipients.
In some embodiments, the formulation base comprises an oil and a lipophilic additive. In some embodiments, said oil is selected from the group consisting of: vegetable oil, mineral oil, soya oil, sunflower oil, corn oil, olive oil, nut oil, and liquid paraffin. In some embodiments, said lipophilic additive is selected from the group consisting of: polyethylene glycol, fatty acid mono-, di-, or triglycerides, palmitic acid, stearic acid, behenic acid, polyethylene glycol fatty acid esters, candelilla wax, carnauba wax, polyethylene oxide wax, and petroleum wax. In some embodiments, the composition further comprises a coloring agent, a dissolving agent, a flavoring agent, a sweetener, a viscosity modifier, an electrolyte, a vitamin, a mineral, an antioxidant, or a preservative.
In some embodiments, the composition is formulated as a liquid or a solid. In some embodiments, the composition is formulated as a liquid. In some embodiments, the liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, sprays, and elixirs. In some embodiments, the composition is formulated as a solid. In some embodiments, the solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, and semi-solid
formulations. In some embodiments, said solid is a tablet or capsule. In some embodiments, said capsule is a hard or soft capsule.
In some embodiments, the composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof is formulated for use once a day. In some embodiments, the composition is formulated for use at least about 1 time per day, about 2 times per day, about 3 times per day, about 4 times per day, about 5 times per day, or more. In some embodiments, the composition is formulated for use about 1-3 times per day. In some embodiments, the composition is formulated for use for a period of about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, or more.
In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring. In some embodiments, said naturally
occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate,
dihydrocapsiate, nordihydrocapsiate, norcapsaicin, capsiconiate, dihydrocapsiconiate and other coniferyl esters, capsiconinoid, and 3-hydroxyacetanilide. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is capsaicin. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or from about 0.001% to about 10% (v/v).
In some embodiments, the non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4-[((6E)-8-methylnon-6- enoylamino)metliyl] -2-methyoxyphenyl formate, 4- [((6E)-8-methylnon-6-enoylamino)methyl] - 2-methyoxyphenyi acetate, 4-[((6E)-8-rnethylnon-6-enoylamino)methyl]-2-rrj.ethyoxyphenyl propanoate, 4-[((6E -8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-rn.ethoxyphenyl 2,2-dimethylpropanoate, 4-[((6E)- 8-methylnon-6-enoylarnino)rnethyl]-2-methyoxyphenyl octadecanoate, 4-[((6E)-8-methylnon-6- enoylamino)m.ethyl]-2-methyoxyphenyl{4-[((6E)-8-me1hylnon-6-enoylam.ino)methyl]-2- methoxyphenoxy}formate, homovanillyl 8-methylnonanoate, 3-(3-methoxy-4- hydroxyphenyl)propyl 8-methylnonanoate, 8-methylnonyl homovanillate, 8-methylnonanoic acid- substituted benzyl ester derivative, heptanoyl isobutylamide, heptanoyl guaiacylamide, 7- phenylhept-6-yne-acid-4-hydroxy-3-methoxybenzylamide, dohevanil, denatonium capsaicinate, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4-chlorophenyl)ethyl]thiourea, N-[4-(2- aminoethoxy) - 3 -methoxybenzyl] -N'- [2- (4-fluorophenyl)ethyl] thiourea, N- [4- (2- aminoethoxy) -3 - methoxybenzyl]-N'-[2-(2,4-dichlorophenyl)ethyl]thiourea,N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-benzyloxyphenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-(n-octyloxy)phenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[4-n-octyloxybenzyl]thiourea, N-phenylmethylalkynamide capsaicin derivatives, N-(4-0-glycerol-3-methoxybenzyl)-nonamide, N-nonanoyl vanillylamide-4-glyceryl ether, N-(4-0-acetic acid sodium-3-methoxybenzyl-nonamide), sodium N-nonanoyl
vanillylamide-4-O-acetate, N-(4-0-glycol-3-methoxybenzyl)-nonamide (N-nonanoyl
vanillylamide-4-glycol ether), 20-homovanillyl-mezerein, 20-homovanillyl-12-deoxyphorbol-13-
phenylacetate, civamide (N-[(4-hydroxy-3-methoxyphenyl)-methyl]-8-methyl-(Z)-6- nonemamide), nuvanil, capsavanil, olvanil, arvanil, and paly anil (N-palmitoyl-vanillarnide). In some embodiments, said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or from about 0.001% to about 10% (v/v).
In some embodiments, the composition is capable of reducing gastrointestinal side effects.
In some embodiments, the composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof which target a TRP channel (e.g. , TRPV1). In some
embodiments, said composition comprises a TRP channel agonist (e.g. , a TRPV1 agonist).
In another aspect, the invention features a composition formulated for oral administration to a subject, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient, wherein upon administration, the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time of greater than about 5 seconds in the mouth of the subject. In some
embodiments, said composition comprises a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analog or combinations thereof and a pharmaceutically acceptable excipient. In some embodiments, said composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time of greater than about 5 seconds in the mouth of a subject, e.g., greater than about 6 seconds, about 7 seconds, about 8 seconds, about 9 seconds, about 10 seconds, about 11 seconds, about 12 seconds, about 13 seconds, about 14 seconds, about 15 seconds, about 20 seconds, about 25 seconds, about 30 seconds, about 45 seconds, about 60 seconds, about 90 seconds, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, or more. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time in the mouth of a subject between about 5 seconds and about 2 minutes. In some embodiments, capsaicinoid, capsinoid, or related analog or combination thereof has a residence time in the mouth of a subject between about 5 seconds and about 60 seconds. In
some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time in the mouth of a subject between about 5 seconds and about 30 seconds.
In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time of greater than about 60 seconds in the mouth of a subject, e.g., greater than about 90 seconds, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, about 10 minutes, or more. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time in the mouth of a subject between about 60 seconds and about 5 minutes. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time in the mouth of a subject between about 60 seconds and about 3 minutes. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof has a residence time in the mouth of a subject between about 60 seconds and about 2 minutes.
In some embodiments, the composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof is formulated for use once a day. In some embodiments, the composition is formulated for use at least about 1 time per day, about 2 times per day, about 3 times per day, about 4 times per day, about 5 times per day, or more. In some embodiments, the composition is formulated for use about 1-3 times per day. In some embodiments, the composition is formulated for use for a period of about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, or more.
In some embodiments, the composition further comprises a formulation base. In some embodiments, the formulation base comprises an oil and a lipophilic additive. In some embodiments, said oil is selected from the group consisting of: vegetable oil, mineral oil, soya oil, sunflower oil, corn oil, olive oil, nut oil, and liquid paraffin. In some embodiments, said lipophilic additive is selected from the group consisting of: polyethylene glycol, fatty acid mono- , di-, or triglycerides, palmitic acid, stearic acid, behenic acid, polyethylene glycol fatty acid esters, candelilla wax, carnauba wax, polyethylene oxide wax, and petroleum wax. In some embodiments, the composition further comprises a coloring agent, a dissolving agent, a flavoring
agent, a sweetener, a viscosity modifier, an electrolyte, a vitamin, a mineral, an antioxidant, or a preservative.
In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate,
dihydrocapsiate, nordihydrocapsiate, norcapsaicin, capsiconiate, dihydrocapsiconiate and other coniferyl esters, capsiconinoid, and 3-hydroxyacetanilide. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is capsaicin. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present in 0.001% to 10% (w/w) or 0.001% to 10% (v/v).
In some embodiments, the non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl formate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]- 2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2-dimethylpropanoate, 4-[((6E)- 8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl octadecanoate, 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl{4-[((6E)-8-methylnon-6-enoylamino)methyl]-2- methoxyphenoxy} formate, homovanillyl 8-methylnonanoate, 3-(3-methoxy-4- hydroxyphenyl)propyl 8-methylnonanoate, 8-methylnonyl homovanillate, 8-methylnonanoic acid- substituted benzyl ester derivative, heptanoyl isobutylamide, heptanoyl guaiacylamide, 7- phenylhept-6-yne-acid-4-hydroxy-3-methoxybenzylamide, dohevanil, denatonium capsaicinate, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4-chlorophenyl)ethyl]thiourea, N-[4-(2- aminoethoxy) - 3 -methoxybenzyl] -N'- [2- (4-fluorophenyl)ethyl] thiourea, N- [4- (2- aminoethoxy) -3 - methoxybenzyl]-N'-[2-(2,4-dichlorophenyl)ethyl]thiourea,N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-benzyloxyphenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-(n-octyloxy)phenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[4-n-octyloxybenzyl]thiourea, N-phenylmethylalkynamide capsaicin derivatives, N-(4-0-glycerol-3-methoxybenzyl)-nonamide, N-nonanoyl vanillylamide-4-glyceryl
ether, N-(4-0-acetic acid sodium-3-methoxybenzyl-nonamide), sodium N-nonanoyl vanillylamide-4-O-acetate, N-(4-0-glycol-3-methoxybenzyl)-nonamide (N-nonanoyl
vanillylamide-4-glycol ether), 20-homovanillyl-mezerein, 20-homovanillyl-12-deoxyphorbol- 13- phenylacetate, civamide (N-[(4-hydroxy-3-methoxyphenyl)-methyl]-8-methyl-(Z)-6- nonemamide), nuvanil, capsavanil, olvanil, arvanil, and palvanil (N-palmitoyl-vanillamide). In some embodiments, said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present in 0.001% to 10% (w/w) or 0.001% to 10% (v/v).
In some embodiments, the composition is capable of reducing gastrointestinal side effects.
In some embodiments, the composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof which target a TRP channel (e.g. , TRPVl). In some embodiments, said composition comprises a TRP channel agonist (e.g. , a TRPVl agonist).
In some embodiments, the composition is a liquid or a solid. In some embodiments, the composition is formulated as a liquid. In some embodiments, the liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, sprays, and elixirs. In some embodiments, the composition is formulated as a solid. In some embodiments, the solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, and semi-solid formulations. In some embodiments, said solid is a tablet or capsule. In some embodiments, said capsule is a hard or soft capsule.
In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 0.01% or more of a liquid formulation, e.g., about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.075%, about 0.1%, or more. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 0.1% or more of a liquid formulation, e.g., about 0.2%, about 0.3%, about 0. 4%, about 0.5%, about 0.75%, about 1%, or more. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 1% or more of a liquid formulation, e.g., about 2%, about 3%, about 4%, about 5%, about 7.5%, about 10%, or more. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises between about 0.5% and 5% of a liquid formulation. In some embodiments, the capsaicinoid, capsinoid, or related
analog or combination thereof comprises between about 0.5% and 2.5% of a liquid formulation. In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof comprises about 10% or more of a liquid formulation, e.g., about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, or more.
In some embodiments, the composition comprises a liquid formulation (e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir) and an effective amount of the liquid formulation is at least about 1 mL, about 2 mL, about 4 mL, about 6 mL, about 8 mL, about 10 mL, about 12 mL, about 14 mL, about 16 mL, about 18 mL, about 20 mL, about 22.5 mL, about 25 mL, or more. In some embodiments, an effective amount of the liquid formulation is between about 1 mL and about 10 mL. In some embodiments, an effective amount of the liquid formulation is between about 5 mL and about 10 mL. In some embodiments, an effective amount of the liquid formulation is between about 10 mL and about 25 mL.
In some embodiments, the composition comprises a liquid formulation (e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir) and an effective amount of the liquid formulation is at least about 25 mL, about 30 mL, about 35 mL, about 40 mL, about 45 mL, about 50 mL, about 60 mL, about 75 mL, about 100 mL, about 150 mL, about 200 mL, about 300 mL, about 400 mL, about 500 mL, about 600 mL, about 750 mL, about 1000 mL, or more. In some embodiments, an effective amount of the liquid formulation is between about 25 mL and about 100 mL. In some embodiments, an effective amount of the liquid formulation is between about 50 mL and about 500 mL. In some embodiments, an effective amount of the liquid formulation is between about 100 mL and about 1000 mL.
In some embodiments, the composition comprises a liquid formulation (e.g., an emulsion, microemulsion, solution, suspension, syrup (e.g., syrup concentrate), linctus, drop, or elixir) and an effective amount of the liquid formulation is at least about 1 fluid ounce, about 2 fluid ounces, about 3 fluid ounces, about 4 fluid ounces, about 5 fluid ounces, about 6 fluid ounces, about 7 fluid ounces, about 8 fluid ounces, about 9 fluid ounces, about 10 fluid ounces, about 11 fluid ounces, about 12 fluid ounces, or more. In some embodiments, an effective amount of the liquid formulation is at least about 12 fluid ounces, about 16 fluid ounces, about 20 fluid ounces, about 24 fluid ounces, about 32 fluid ounces, about 40 fluid ounces, about 48 fluid ounces, about 56 fluid ounces, about 64 fluid ounces, or more.
In some embodiments, the composition comprises a solid formulation (e.g., a tablet, capsule, powder, crystal, paste, gel, lozenge, gum, candy, chew, foodstuff, dissolving strip, film, or semi-solid formulation) and an effective amount of the solid formulation is about 0.5 mg, about 1 mg, about 10 mg, about 25 mg, about 50 mg, about 100 mg, about 250 mg, about 500 mg, about 750 mg, about 1 g, about 2 g, about 5 g, about 10 g, or more. In some embodiments, an effective amount of the solid formulation is between about 0.5 mg and about 100 mg. In some embodiments, an effective amount of the solid formulation is between about 100 mg and about 500 mg. In some embodiments, an effective amount of the solid formulation is between about 500 mg and about 1000 mg.
In some embodiments, the capsaicinoid, a capsinoid, or related analog or combination thereof is ingested by the subject, e.g., is swallowed by the subject. In some embodiments, the capsaicinoid, a capsinoid, or related analog or combination thereof is held in the mouth by the subject, e.g., is not swallowed by the subject. In some embodiments, the holding in the mouth may further comprise e.g., actively swirling the ion channel activator in the mouth of the subject, or placing the against ion channel activator on the skin or surface of the mouth or tongue (e.g., sublingual delivery). In some embodiments, the capsaicinoid, a capsinoid, or related analog or combination thereof is dissolved in the mouth of the subject or chewed by the subject prior to swallowing.
In another aspect, the invention features a method of treating a painful muscle contraction in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients. In some embodiments, said painful muscle contraction is a muscle contraction of the head or neck. In some embodiments, said painful muscle contraction is associated with tension headache, cluster headache, or migraine headache.
In another aspect, the invention features a method of treating tactile sensitivity in a subject in need thereof, said method comprising orally administering to said subject a
composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients. In some embodiments, said tactile sensitivity is associated with autism, dyspraxia, neuralgia, anxiety disorders, venomous bites, or venomous stings. In some embodiments, said anxiety disorder is selected from the group consisting of panic disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), social anxiety disorder, phobia, and generalized anxiety disorder (GAD).
In another aspect, the invention features a method of treating a dystonia in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a
pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients. In some embodiments, said dystonia is selected from the group consisting of: focal dystonia,
blepharospasm, cervical dystonia, cranial dystonia, laryngeal dystonia, back spasms, hand dystonia, or leg cramps due to spinal stenosis.
In another aspect, the invention features a method of treating a peripheral nervous system (PNS) condition in a subject in need thereof, said method comprising orally administering to said
subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient to said subject. In some embodiments, said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients. In some embodiments, said PNS condition is selected from the group consisting of: cramp fasciculation syndrome, Isaacs' Syndrome or neuromyotonia (NMT), peripheral neuropathy, carpal tunnel syndrome, and Epstein-Barr virus (EBV) infection.
In another aspect, the invention features a method of treating a throat condition in a subject in need thereof, said method comprising orally administering to said subject a
composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients. In some embodiments, said throat condition is associated with chemical injury, cancer, surgical injury, or pathogen infection. In some embodiments, said throat condition is selected from the group consisting of: acid reflux, laryngospasm, dysphagia, and spasmodic dysphonias.
In another aspect, the invention features a method of treating a condition associated with electrolyte imbalance or vitamin deficiency in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient. In some
embodiments, said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of
pharmaceutically acceptable excipients. In some embodiments, said condition is selected from the group consisting of: hyponatremia, kidney disease, rickets, calcium deficiency, magnesium deficiency, thiamine deficiency, hypoparathyroidism, medullary cystic disease, and
adrenocortical carcinoma.
In another aspect, the invention features a method of treating a central nervous system (CNS) condition in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient. In some
embodiments, said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients. In some embodiments, said CNS condition is associated with a tumor. In some embodiments, said CNS condition is selected from the group consisting of: multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, stroke, motor neuron disease, spinal injury, and stenosis.
In another aspect, the invention features a method of treating a muscle condition or disorder in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients. In some embodiments, said muscle condition or disorder is associated with muscle pain, muscle spasms,
muscle cramps, fasciculations, or any combination thereof. In some embodiments, the muscle condition or disorder is a neuromuscular disorder (e.g., multiple sclerosis, spinal cord spasticity, spinal muscle atrophy, myasthenia gravis, spinal cord injury, traumatic brain injury, cerebral palsy, hereditary spastic paraplegia, motor neuron disease (e.g., amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, progressive spinobulbar muscular atrophy (e.g., Kennedy' s disease), or post-polio syndrome), neuralgia, fibromyalgia, Machado-Joseph disease, cramp fasciculation syndrome, carpal tunnel syndrome, acrodynia, neurofibromatosis, neuromyotonias (e.g., focal neuromyotonia, Isaacs' syndrome), peripheral neuropathy, piriformis syndrome, plexopathy (e.g. , Brachial plexopathy or Lumbosacral plexobathy), radiculopathy (e.g., lower lumbar radiculopathy), and encephalitis).
In some embodiments, said muscle condition or disorder is muscle pain, muscle spasms, muscle cramps, spasticity, or fasciculations associated with motor neuron disease (e.g., amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, progressive spinobulbar muscular atrophy (e.g., Kennedy's disease), or post-polio syndrome).
In some embodiments, said muscle condition or disorder is associated with treatment of said subject with dialysis, diuretics, β-blockers, statins, fibrates, p2-agonists, ACE inhibitors, ARBs, anti-psychotic medications, or any combination thereof. In some embodiments, said muscle condition is associated with treatment of said subject with statins and fibrates. In some embodiments, said muscle condition or disorder occurs in one or more skeletal muscles. In some embodiments, said muscle condition or disorder is refractory to an approved treatment. In some embodiments, said approved treatment is botox, cyclopenzaprine, orphenadrine, baclofen, or any combination thereof. In some embodiments, said muscle condition or disorder is fibromyalgia. In some embodiments, said muscle condition or disorder involves muscle claudication pain. In some embodiments, said muscle claudication pain is associated with inactivity, restriction, economy class syndrome, paralysis, peripheral artery disease, or immobilization.
In another aspect, the invention features a method of treating a respiratory condition in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or
combination thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients. In some embodiments, said respiratory condition comprises asthma, chronic obstructive pulmonary disease, bronchitis, emphysema, pneumonia, cystic fibrosis, influenza, or a cold.
In another aspect, the invention features a method of treating a cough in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three)
capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients. In some embodiments, said cough is associated with a respiratory condition (e.g., asthma, chronic obstructive pulmonary disease, bronchitis, emphysema, pneumonia, cystic fibrosis, influenza, or a cold), exposure to an allergen, or inflammation.
In another aspect, the invention features a method of treating sarcoidosis in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof, and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a
pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
In another aspect, the invention features a method of treating a connective tissue disease in a subject in need thereof, said method comprising orally administering to said subject a composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof, and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient. In some embodiments, said method comprises orally administering to a subject a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients. In some embodiments, said connective tissue disease is selected from the group consisting of Ehlers- Danlos syndrome, epidermolysis bullosa, Marfan syndrome, osteogenesis imperfect, arthritis, scleroderma, Sjogren's syndrome, lupus, vasculitis, mixed connective tissue disease, cellulitis, polymyositis, and dermatomyositis. In some embodiments, said arthritis is rheumatoid arthritis, osteoarthritis, gout, or psioratic arthritis, or wherein said vasculitis is Wegener's granulomatosis or Churg-Strauss Syndrome.
In any of the aspects described above, in some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate, dihydrocapsiate, nordihydrocapsiate, norcapsaicin, capsiconiate, dihydrocapsiconiate and other coniferyl esters, capsiconinoid, and 3- hydroxyacetanilide. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is capsaicin. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or from about 0.001% to about 10% (v/v).
In some embodiments, the non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl formate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-
2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2-dimethylpropanoate, 4-[((6E)- 8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl octadecanoate, 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl{4-[((6E)-8-methylnon-6-enoylarnino)methyl]-2- methoxyphenoxy} formate, homovanillyl 8-methylnonanoate, 3-(3-methoxy-4- hydroxyphenyl)propyl 8-methylnonanoate, 8-methylnonyl homovanillate, 8-methylnonanoic acid- substituted benzyl ester derivative, heptanoyl isobutylamide, heptanoyl guaiacylamide, 7- phenylhept-6-yne-acid-4-hydroxy-3-methoxybenzylamide, dohevanil, denatonium capsaicinate, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4-chlorophenyl)ethyl]thiourea, N-[4-(2- aminoethoxy) - 3 -methoxybenzyl] -N'- [2- (4-fluorophenyl)ethyl] thiourea, N- [4- (2- aminoethoxy) -3 - methoxybenzyl]-N'-[2-(2,4-dichlorophenyl)ethyl]thiourea,N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-benzyloxyphenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-(n-octyloxy)phenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[4-n-octyloxybenzyl]thiourea, N-phenylmethylalkynamide capsaicin derivatives, N-(4-0-glycerol-3-methoxybenzyl)-nonamide, N-nonanoyl vanillylamide-4-glyceryl ether, N-(4-0-acetic acid sodium-3-methoxybenzyl-nonamide), sodium N-nonanoyl
vanillylamide-4-O-acetate, N-(4-0-glycol-3-methoxybenzyl)-nonamide (N-nonanoyl
vanillylamide-4-glycol ether), 20-homovanillyl-mezerein, 20-homovanillyl-12-deoxyphorbol- 13- phenylacetate, civamide (N-[(4-hydroxy-3-methoxyphenyl)-methyl]-8-methyl-(Z)-6- nonemamide), nuvanil, capsavanil, olvanil, arvanil, and palvanil (N-palmitoyl-vanillamide). In some embodiments, said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present in 0.001% to 10% (w/w) or 0.001% to 10% (v/v).In some embodiments, the composition is capable of reducing gastrointestinal side effects.
In some embodiments, the composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof, which target a TRP channel (e.g. , TRPV1). In some
embodiments, said composition comprises a TRP channel agonist (e.g. , a TRPV1 agonist).
In some embodiments, the composition is formulated as a liquid or a solid. In some embodiments, the composition is formulated as a liquid. In some embodiments, the liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, sprays, and elixirs. In some embodiments, the
composition is formulated as a solid. In some embodiments, the solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, and semi-solid
formulations. In some embodiments, said solid is a tablet or capsule. In some embodiments, said capsule is a hard or soft capsule.
In another aspect, the invention features a method of treating a subject for unwanted or abnormal muscle contraction (e.g. , cramp, spasm, dystonia, or fasciculation) or absence of a normal muscle contraction (e.g. , gait abnormalities, e.g. , foot drop) comprising: acquiring, e.g. , directly or indirectly, knowledge of a result of a test for the efficacy of the administration of a test aliquot of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof for alleviation of test muscle contraction in said subject; and administering, e.g. , in response to said result, an amount of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof sufficient to alleviate unwanted or abnormal muscle contraction or absence of normal muscle contraction to said subject. In some embodiments, the test comprises directly acquiring said knowledge. In some embodiments, the test comprises further performing said test.
In some embodiments, said muscle contraction comprises a muscle cramp. In some embodiments, said muscle contraction comprises a muscle spasm. In some embodiments, said muscle contraction comprises a dystonia. In some embodiments, said muscle contraction comprises a fasciculation. In some embodiments, said muscle contraction occurs in a skeletal muscle. In some embodiments, said muscle contraction occurs in a smooth muscle. In some embodiments, the test muscle contraction is a test muscle cramp or a test muscle spasm.
In some embodiments, said composition comprises a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof. In some embodiments, said composition further comprises a pharmaceutically acceptable excipient. In some
embodiments, said composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
In some embodiments, the capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the
group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate,
dihydrocapsiate, nordihydrocapsiate, norcapsaicin, capsiconiate, dihydrocapsiconiate and other coniferyl esters, capsiconinoid, and 3-hydroxyacetanilide. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is capsaicin. In some embodiments, said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present in 0.001% to 10% (w/w) or 0.001% to 10% (v/v).
In some embodiments, the non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl formate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]- 2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2-dimethylpropanoate, 4-[((6E)- 8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl octadecanoate, 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl{4-[((6E)-8-methylnon-6-enoylamino)methyl]-2- methoxyphenoxy} formate, homovanillyl 8-methylnonanoate, 3-(3-methoxy-4- hydroxyphenyl)propyl 8-methylnonanoate, 8-methylnonyl homovanillate, 8-methylnonanoic acid- substituted benzyl ester derivative, heptanoyl isobutylamide, heptanoyl guaiacylamide, 7- phenylhept-6-yne-acid-4-hydroxy-3-methoxybenzylamide, dohevanil, denatonium capsaicinate, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4-chlorophenyl)ethyl]thiourea, N-[4-(2- aminoethoxy) - 3 -methoxybenzyl] -N'- [2- (4-fluorophenyl)ethyl] thiourea, N- [4- (2- aminoethoxy) -3 - methoxybenzyl]-N'-[2-(2,4-dichlorophenyl)ethyl]thiourea,N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-benzyloxyphenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-(n-octyloxy)phenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[4-n-octyloxybenzyl]thiourea, N-phenylmethylalkynamide capsaicin derivatives, N-(4-0-glycerol-3-methoxybenzyl)-nonamide, N-nonanoyl vanillylamide-4-glyceryl ether, N-(4-0-acetic acid sodium-3-methoxybenzyl-nonamide), sodium N-nonanoyl
vanillylamide-4-O-acetate, N-(4-0-glycol-3-methoxybenzyl)-nonamide (N-nonanoyl
vanillylamide-4-glycol ether), 20-homovanillyl-mezerein, 20-homovanillyl-12-deoxyphorbol-13- phenylacetate, civamide (N-[(4-hydroxy-3-methoxyphenyl)-methyl]-8-methyl-(Z)-6- nonemamide), nuvanil, capsavanil, olvanil, arvanil, and palvanil (N-palmitoyl-vanillamide). In
some embodiments, said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present in 0.001% to 10% (w/w) or 0.001% to 10% (v/v).
In some embodiments, the composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof, which target a TRP channel (e.g. , TRPV1). In some
embodiments, said composition comprises a TRP channel agonist (e.g. , a TRPV1 agonist).
In some embodiments, the subject has a central nervous system disorder or injury, e.g. , a brain injury, stroke, or traumatic spinal cord injury. In some embodiments, the subject has been diagnosed with or identified as having multiple sclerosis. In some embodiments, the subject has been diagnosed with or identified as having dystonia, e.g. , cervical dystonia. In some
embodiments, the subject has been diagnosed with or identified as having spinal cord spasticity. In some embodiments, said subject has been diagnosed with or identified as having a disorder associated with muscle cramps, e.g. , any of the disorders disclosed herein, e.g. , night cramps, multiple sclerosis, spinal cord spasticity, or dystonia.
In some embodiments, said muscle contraction being selected, treated, or diagnosed, comprises a contraction in a muscle other than a muscle that is contracted in the test muscle contraction. In some embodiments, said test muscle contraction comprises a contraction in a muscle of the foot, e.g. , the flexor hallucis brevis muscle, and the muscle cramp comprises a cramp in a muscle other than the foot, e.g. , the flexor hallucis brevis muscle. In some embodiments, said muscle contraction is not induced by applied electrical stimulation.
In some embodiments, said muscle contraction is a night cramp. In some embodiments, said muscle contraction is associated with multiple sclerosis. In some embodiments, said muscle contraction is associated with spinal cord spasticity. In some embodiments, said muscle contraction is associated with dystonia.
In some embodiments, said test comprises inducing said test muscle cramp by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation. In some embodiments, said test comprises determining that a muscle contraction can be induced in a subject by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation.
In some embodiments, said test comprises: a) administering the test aliquot of the composition to said subject; b) inducing, e.g. , by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation, a test muscle contraction; and c) evaluating the
effect of administering the test aliquot of the composition on test muscle contraction. In some embodiments, step a is performed before step b. In some embodiments, step a is performed after step b.
In some embodiments, said test comprises: a) administering the test aliquot of the composition to said subject; b) inducing, e.g. , by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation, a test muscle contraction; and c) evaluating the effect of administering the composition on test muscle contraction, e.g. , by evaluating the electrical activity of said test muscle, e.g. , by EMG.
In some embodiments, said test comprises: a) inducing, e.g. , by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation, a first test muscle contraction; b) administering the test aliquot of the composition to said subject; c) inducing, e.g. , by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation, a second test muscle contraction; and d) evaluating the effect of administering the composition on said second test muscle contraction. In some embodiments, step b is performed before step c. In some embodiments, step c is performed before step b. In some embodiments, the steps are performed in the order of a, b, c, and d.
In some embodiments, said test further comprises: e) providing a value, e.g. , a reference value, e.g. reference profile, for a muscle contraction parameter, e.g. , a value for intensity or duration of, said first test muscle contraction, e.g. , by evaluating the electrical activity of said test muscle, e.g. , by EMG; and optionally, f) providing a value, e.g. , a treatment value, e.g. , a treatment profile, for a muscle contraction parameter, e.g. , a value for intensity or duration of, said second test muscle contraction, e.g. , by evaluating the electrical activity of said test muscle, e.g. , by EMG. In some embodiments, the test comprises comparing the value from step e with the value from step f to evaluate the effectiveness of a test aliquot of the composition on test muscle contraction. In some embodiments, said muscle contraction parameter is the area under the curve, the peak amplitude, or the duration of the test muscle contraction. In some
embodiments, a decrease in the value from step f compared to the value from step e is indicative of efficacy in alleviating said test muscle cramp. In some embodiments, a decrease by a preselected amount, e.g. , a decrease of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35% or 50%, is indicative of efficacy in alleviating said test muscle contraction.
In some embodiments, said test comprises: a) inducing, e.g. , by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation, a first test muscle contraction; b) administering the test aliquot of the composition to said subject; c) inducing, e.g. , by application of electrical stimulation, e.g. , percutaneous stimulation or surface stimulation, a second test muscle contraction; d) evaluating the effect of administering the composition on test contraction cramping; e) providing a value for a muscle contraction parameter, e.g. , a value for intensity or duration of, said first test muscle contraction, e.g. , by evaluating the electrical activity of said test muscle, e.g. , by EMG; and f) providing a value for a muscle contraction parameter, e.g. , a value for intensity or duration of, said second test muscle contraction, e.g. , by evaluating the electrical activity of said test muscle, e.g. , by EMG. In some embodiments, step b is performed before step c. In some embodiments, steps b and c are performed within a preselected time of one another, e.g. , they are performed sufficiently close in time that step b will modulate step c. In some embodiments, said test muscle contraction comprises a contraction in a muscle of the foot, e.g. , the flexor hallucis brevis muscle. In some embodiments, a decrease in the value from step f compared to the value from step e is indicative of efficacy in alleviating said test muscle contraction.
In some embodiments, said test comprises: a) applying a first electrical stimulus to a test muscle of the subject to induce a test muscle contraction; b) measuring the electrical activity of said test muscle to provide a reference profile, e.g. , by EMG; c) administering a test aliquot of the composition; d) applying a second electrical stimulus to the test muscle of the subject after a preselected period of time after administration of the test aliquot of the composition; e) measuring the electrical activity of said test muscle to generate a treatment profile; f) comparing the treatment profile to the reference profile to determine reduction or prevention of the test muscle contraction after administration of the test aliquot. In some embodiments, the period of time between step c and step d is at least about 10 minutes, 15 minutes, 30 minutes, 1 hour, etc. In some embodiments, comprising determining the area under the curve from the reference profile and the treatment profile, wherein when the area under the curve from the treatment profile is decreased compared to the reference profile, the test muscle contraction is reduced or prevented.
In some embodiments, the test further comprises: a) determining the threshold frequency for inducing a first test muscle contraction; b) administering a test aliquot of a composition
comprising a capsaicinoid, capsinoid, or related analog or combination thereof; c) determining the threshold frequency for inducing a second test muscle contraction; d) comparing the threshold frequency to evaluate the effectiveness of a test aliquot of the composition on test muscle contraction.
In some embodiments, said test aliquot of the composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof. In some embodiments, said capsaicinoid, capsinoid, or related analog or combination thereof is a TRP channel agonist. In some embodiments, said capsaicinoid, capsinoid, or related analog or combination thereof is a TRPV1 channel activator. In some embodiments, the TRPV1 channel activated by said capsaicinoid, capsinoid, or related analog or combination thereof is present on a sensory neuron in the mouth, the esophagus and/or the stomach. In some embodiments, said capsaicinoid, capsinoid, or related analog or combination thereof increases inhibitory signaling to alpha motor neurons.
In some embodiments, the composition is formulated as a liquid or a solid. In some embodiments, the liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, sprays, and elixirs. In some embodiments, the composition is formulated as a solid. In some embodiments, the solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, and semisolid formulations. In some embodiments, said solid is a tablet or capsule. In some
embodiments, said capsule is a hard or soft capsule.
In another aspect, the invention features a method of evaluating a subject for abnormal or unwanted muscle contraction or absence of normal muscle contraction comprising: acquiring, e.g. , indirectly or directly, knowledge of a result of a test for the efficacy of the administration of a test aliquot of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof for alleviation of test muscle contraction in said subject; and responsive to said result, classifying said subject. In some embodiments, said subject has been diagnosed or identified as having a disorder associated with muscle cramps, e.g. , any of the disorders disclosed herein, e.g. , night cramps, multiple sclerosis, spinal cord spasticity, or dystonia. In some embodiments, the test comprises directly acquiring said knowledge. In some embodiments, the test further comprises performing said test.
In some embodiments, said result is indicative of a preselected level of alleviation of the test muscle contraction by administration of the test aliquot. In some embodiments, said result is indicative of the alleviation of the test muscle contraction by administration of the test aliquot.
In some embodiments, the test comprises classifying said subject as a candidate for treatment with a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof. In some embodiments, said result is indicative of the failure to provide a preselected level of alleviation of the test muscle contraction by administration of the test aliquot. In some embodiments, said result is indicative of the absences of alleviation of the test muscle contraction by administration of the test aliquot. In some embodiments, the test comprises classifying said subject as not being a candidate for treatment with a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof. In some embodiments, said method is computer implemented.
In some embodiments, said composition comprises a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof. In some embodiments, said composition further comprises a pharmaceutically acceptable excipient. In some
embodiments, said composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
In another aspect, the invention features a computer-implemented method of evaluating a subject for unwanted or abnormal muscle contraction, e.g. , cramp, spasm, dystonia, or fasciculation or absence of a normal muscle contraction, e.g. , gait abnormalities, e.g. , foot drop comprising: a) acquiring, e.g. , directly or indirectly, a value for a parameter related to the effect of administering a test aliquot of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof on test muscle cramping, e.g. , by evaluating the electrical activity of said test muscle, e.g. , by EMG; b) evaluating the effectiveness of administering the test aliquot on a computer, e.g. , by comparing a test value or profile with a treatment value or profile; c) responsive to the evaluation, comprising classifying said subject as a candidate for treatment with a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof.
In some embodiments, said composition comprises a plurality of (e.g., two or three) capsaicinoids, capsinoids, or related analogs or combinations thereof. In some embodiments,
said composition further comprises a pharmaceutically acceptable excipient. In some embodiments, said composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of pharmaceutically acceptable excipients.
In another aspect, the invention features a system comprising a memory; and a processing unit operative to: a) evaluate the effectiveness of administering a test aliquot of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof; b) responsive to the evaluation, comprising classifying said subject as a candidate for treatment with a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof.
In another aspect, the invention features a computer-readable medium comprising computer-executable instructions that, when executed on a processor of a computer, perform a method comprising acts of: a) evaluating the effectiveness of administering a test aliquot of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof; b) responsive to the evaluation, comprising classifying said subject as a candidate for treatment with a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof.
In some embodiments, said subject has been diagnosed or identified as having a disorder associated with muscle cramps, spasms, dystonia, or fasciculations, e.g. , any of the disorders disclosed herein, e.g. , night cramps, multiple sclerosis, spinal cord spasticity, or dystonia.
In another aspect, the invention features a kit comprising a liquid tight container comprising one or more of: one or a plurality of test aliquots of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof; one or a plurality of leads for conducting current to a subject and inducing a cramp; and one or a plurality of leads for measuring electrical activity associated with a cramp. In some embodiments, said kit further comprises a plurality, e.g. , at least 2, 3, 4, 5, 6, 7, 8, 9, or 10, test aliquots of the composition.
In some embodiments, said test aliquot of the composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof. In some embodiments, said capsaicinoid, capsinoid, or related analog or combination thereof is a TRP channel agonist. In some embodiments, said capsaicinoid, capsinoid, or related analog or combination thereof is a TRPVl
channel activator. In some embodiments, the TRPV1 channel activated by said capsaicinoid, capsinoid, or related analog or combination thereof is present on a sensory neuron in the mouth, the esophagus and/or the stomach. In some embodiments, said capsaicinoid, capsinoid, or related analog or combination thereof increases inhibitory signaling to alpha motor neurons.
In some embodiments, the composition is formulated as a liquid or a solid. In some embodiments, the liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, sprays, and elixirs. In some embodiments, the composition is formulated as a solid. In some embodiments, the solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, and semisolid formulations. In some embodiments, said solid is a tablet or capsule. In some
embodiments, said capsule is a hard or soft capsule.
In another aspect, the invention features a method of evaluating a composition for treating unwanted or abnormal muscle contraction, e.g. , cramp, spasm, dystonia, or fasciculation, or absence of normal muscle contraction, e.g. , gait abnormalities, comprising: a) acquiring, e.g. indirectly or directly, knowledge of a result of a test that shows that administration of a test aliquot of said composition alleviates a test muscle contraction in a test subject; and b) acquiring, e.g. indirectly or directly acquiring, knowledge of the effectiveness of the administration said composition to an administration subject in the treatment of unwanted or abnormal muscle contraction or absence of normal muscle contraction; wherein effectiveness in treating muscle cramp in one or both of step a and step b is indicative of usefulness of the composition for treating muscle cramp. In some embodiments, administration of the test aliquot alleviates the test muscle contraction. In some embodiments, step b is performed only if the composition alleviates the test muscle contraction in step a. In some embodiments, step a comprises performing said test. In some embodiments, step b comprises administering said composition to said
administration subject. In some embodiments, step a comprises performing said test and step b comprises administering said composition to said administration subject.
In some embodiments, said test subject and administration subject are of the same species, e.g. , both are rodent or both are primate, e.g. , human. In some embodiments, said test subject and administration subject are the same individual. In some embodiments, said test
subject and administration subject are the different individuals. In some embodiments, said test subject and administration subject are of the different species, e.g. , the test species is non-human, e.g. , rodent, and the administration subject is a primate, e.g. , a human.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a series of graphs from 6 sensory neurons isolated from the trigeminal ganglia of rats that illustrate their activation by the capsicum, cinnamon, and ginger extracts that were used in the human experiments.
Figure 2 shows the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis (FHB) of Subject A.
Figure 3 shows the effect of the TRP-Stim beverage on cramping of the FHB of a second subject after cramping was induced.
Figure 4 shows the effect of the TRP-Stim beverage on cramping of the FHB of a third subject tested over longer times.
Figure 5 shows the effect of the TRP-Stim beverage on cramping of the FHB of a fourth subject.
Figure 6 is a graph showing the effect of the TRP-Stim beverage on cramping of the gastrocnemius (calf) muscle of a fifth subject.
Figure 7 shows the effect of the TRP-Stim beverage on cramping of the gastrocnemius (calf) muscle of a sixth subject.
Figure 8 is a graph showing the effect of the TRP-Stim beverage on cramping of an FHB muscle in a seventh subject who experienced spontaneous cramping induced by pointing her toe.
DETAILED DESCRIPTION OF THE INVENTION
The methods and compositions of the present invention are directed to the treatment of peripheral nervous system conditions (e.g. , peripheral neuropathy), central nervous system conditions, muscle conditions and disorders (e.g. , fibromyalgia, muscle spasms and cramps (e.g. , nocturnal cramps), painful muscle contractions (e.g., a muscle contraction of the head or neck), neuromuscular disorders (e.g., motor neuron disease) or dystonia (e.g., cervical dystonia,
blepharospasm, back spasms, or leg cramps due to spinal stenosis)), connective tissue diseases (e.g. , degenerative joint disease), throat conditions (e.g., dysphagia or spasmodic dysphonias), tactile sensitivity, electrolyte imbalance and/or vitamin deficiency, respiratory conditions (e.g., asthma), cough, and sarcoidosis using a composition that includes a capsaicinoid, a capsinoid, or related analogs or combinations thereof.
Definitions
The term "acidulant" as used herein refers to an acidic compound (e.g. , citric acid) used to lower the pH of a composition, e.g. , the pH can be lowered in the range of 2.5-6.5 (e.g. , pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5).
"Acquire" or "acquiring" as the terms are used herein, refer to obtaining possession of a value, e.g., a numerical value, or image, or a physical entity (e.g., a sample), by "directly acquiring" or "indirectly acquiring" the value or physical entity. "Directly acquiring" means performing a process (e.g., applying or measuring a current to or from a subject, or capturing a signal from a subject or sample or performing a synthetic or analytical method) to obtain the value or physical entity. "Indirectly acquiring" refers to receiving the value or physical entity from another party or source (e.g., a third party laboratory that directly acquired the physical entity or value). Directly acquiring a value or physical entity includes performing a process that includes a physical change in a physical substance or the use of a machine or device. Exemplary changes include applying a current to, or measuring a current from, the muscle of a subject. Directly acquiring a value includes performing a process that uses a machine or device, e.g. , a device to induce a cramp or a device to measure a parameter related to a cramp. The term "agonist," as used herein refers to a molecule that stimulates a biological response. In some embodiments, an agonist is an activator. For example, the activators or agonists referred to herein activate TRP ion channels, (e.g. , TRPV1 ion channel).
The use of the words "a" or "an" when used in conjunction with the term "comprising" herein may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one."
The term "administering" and "administration" refers to a mode of delivery. A daily dosage can be divided into one, two, three or more doses in a suitable form to be administered one, two, three or more times throughout a time period. In preferred embodiments of the present
invention, compositions and solutions are administered orally. Where the term "composition" is used to describe a formulation that includes capsaicinoids, capsinoids, or related analogs or combinations thereof, the term refers to a comestible formulation that is suitable for oral ingestion by the subject (e.g. , the human subject). Exemplary compositions that include capsaicinoids, capsinoids, or related analogs or combinations thereof include solid dosage forms for oral administration (e.g. , capsules, tablets, pills, dragees, crystals, pastes, gels, powders, gums, granules, chews, foodstuffs, films, and the like), liquid dosage forms for oral
administration (e.g. , emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, and elixirs), ready-to-drink beverages, dry compositions that can be reconstituted with a liquid (e.g. , powders, granules, or tablets that may be reconstituted with water), gels, semi-solids (e.g. , ice cream, pudding, or yogurt), frozen liquids (e.g. , ice pops), lozenges or hard candies, dissolving strips (e.g. , an edible strip containing pullulan and compositions of the invention), and chewing gums. Other compositions are described herein.
The terms "analog" or "related analogs" as used herein refer to a substance that has a similar chemical structure to another compound, but differs from it with respect to a certain component or components.
The term "derivative" as used herein refers to a substance produced from another substance either directly or by modification or partial substitution.
"Muscle cramp" as used herein is a muscle cramp which is treated with the composition described herein. In embodiments it is not induced but rather arises spontaneously either from activity or underlying disease etiology, e.g. , athletic activity or night cramp. In an embodiment, the muscle cramp comprises a cramp in a muscle other than the muscle of the test muscle cramp. The muscle cramp can be a contraction of a skeletal muscle or the smooth muscle. In an embodiment, muscle cramps occur most frequently in the muscles of the foot, calf, front of the thigh (e.g. , quadricep), back of the thigh (e.g. , hamstring), hands, arms (e.g. , bicep or tricep), abdomen, and muscles along the rib cage. A muscle cramp that occurs in the calf muscle is also commonly known as a "charley horse." Other common muscle cramps include exercise-induced muscle cramps, menstrual cramps, "writer's cramp," "musician' s cramp," and night cramps (or nocturnal cramps). In an embodiment, the muscle cramp is a contraction of a muscle other than a skeletal muscle, e.g. , a smooth muscle.
"Muscle spasm" as used herein refers to an involuntary contraction or a muscle, or even a few fibers of a muscle. Often the magnitude or duration of a spasm is less than that of a cramp. If the spasm is forceful and sustained, it becomes a cramp.
"Dystonia" as used herein refers to sustained muscle contractions that cause twisting and repetitive movements or abnormal postures.
"Fasciculation" as used herein refers to a small, local, involuntary muscle contraction and relaxation. Fasciculations are also commonly known as a "muscle twitch".
The term an "effective amount" of a compound as used herein, is that amount sufficient to effect beneficial or desired results, such as the effective treatment of peripheral nervous system conditions (e.g., peripheral neuropathy), central nervous system conditions (e.g. , amyotrophic lateral sclerosis), muscle conditions and disorder (e.g., fibromyalgia, muscle spasms and cramps, cervical dystonia, blepharospasm, back spasms, or leg cramps due to spinal stenosis), connective tissue disorders (e.g., degenerative joint disease), throat conditions (e.g., dysphagia or spasmodic dysphonias), and sarcoidosis, and, as such, an "effective amount" depends upon the context in which it is being applied. For example, in the context of administering capsaicinoids, capsinoids, or related analogs or combinations thereof, an effective amount of a compound (e.g. , a capsaicinoid, capsinoid, or related analogs thereof) is, for example, an amount sufficient to achieve an increase in TRP channel (e.g. , TRPV1) activity as compared to the response obtained without administration of the compound (e.g. , a capsaicinoid, capsinoid, or a related analog or combination thereof). The effective amount of active compound(s) used to practice the present invention can also be varied based on, for example, the age, and body weight, of the subject or the nature of the exercise.
The compositions can also include excipients that are not capsaicinoids, capsinoids, or related analogs thereof, and that are non-toxic and non-inflammatory in a subject (e.g. , in a human subject). In some embodiments, the excipient(s) can provide desirable or improved physical and/or chemical properties such as stability, flow, viscosity, rate of disintegration, taste, delivery, etc. Exemplary, non-limiting excipients that can be selected from: a disintegrant (e.g. , carmellose, starch, crystalline cellulose, low- substituted hydroxypropyl cellulose, and the like), a binder (e.g. , gum acacia, carmellose, gelatin, crystalline cellulose, simple syrup, honey, hydroxypropyl cellulose, povidone, methylcellulose, and the like), a surfactant (e.g. , polyoxyl 40 stearate, polysorbate 80, polyoxyethylene hydrogenated castor oil, and the like), an emulsifier
(e.g. , polyoxyl 40 stearate, sorbitan sesquioleate, polysorbate 80, sodium lauryl sulfate, lauromacrogol, gum arabic, cholesterol, stearic acid, povidone, glyceryl monostearate, and the like), a plasticizer (e.g. , glycerin, propylene glycol, macrogol, and the like), a lubricant (e.g. , magnesium silicate, carmellose, light anhydrous silicic acid, stearic acid, calcium stearate, magnesium stearate, talc, and the like), a sweetener (e.g. , white soft sugar, honey, simple syrup, glucose, saccharin sodium, acesulfame potassium, disodium glycyrrhizinate, and the like), a pH- adjusting agent (e.g. , hydrochloric acid, citric acid, sodium hydrogen carbonate, potassium hydroxide, sodium hydroxide, sodium carbonate, and the like), a preservative (e.g. , benzoic acid, benzalkonium chloride, ethyl parahydroxybenzoate, butyl parahydroxybenzoate, propyl parahydroxybenzoate, methyl parahydroxybenzoate, and the like), a flavor (e.g. , fennel oil, orange oil, cinnamon oil, thymol, orange peel tincture, dl-menthol, 1 -menthol, eucalyptus oil, and the like), or a coloring agent (e.g. , Food Red No. 2, No. 3, No. 40, No. 102, No. 104, No. 105 or No. 106, Food Yellow No. 4 or No. 5, Food Green No. 3, Food Blue No. 1 or No. 2, titanium dioxide, sodium copper chlorophyllin, turmeric, gardenia, annatto dye, kaoliang dye, and the like), or an antioxidant (e.g. , ascorbic acid, sodium thiosulfate, tocopherol, sodium hydrogen sulfite, and the like), or any combination thereof.
The term "subject" as used herein refers to a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline mammal.
As used herein, and when used in reference to capsaicinoids, capsinoids, or related analogs thereof, the term "substantially pure" refers to a composition that includes capsaicinoids, capsinoids, or related analogs thereof in which the composition is free of organic and/or inorganic species that do not activate a TRP channel (e.g. , TRPV1) or function in the same manner as the capsaicinoids, capsinoids, or related analogs thereof, and where 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 99.5% (w/w) of the composition is a particular channel agonist compound. Substantially pure compositions can be prepared and analyzed using standard methods known in the art (e.g. , chromatographic separation, extractions, and the like). Substantially pure compositions can include isomeric impurities (e.g. , geometric isomers) and/or salts or solvates of a capsaicinoids, capsinoids, or related analogs thereof.
A "test muscle contraction" as used herein is a muscle contraction, typically induced, e.g. , by the application of electrical current, in the subject. Stimulation can be applied to induce a muscle contraction that recapitulates a naturally- occurring muscle cramp, muscle spasm,
dystonia, or fasciculation, e.g. , a test muscle cramp, a test muscle spasm, a test muscle dystonia, or a test muscle fasciculation. In embodiments, the test muscle cramp comprises a cramp in the flexor hallucis brevis muscle. In some embodiments, efficacy in inducing a test muscle cramp in a subject is indicative of efficacy in treating muscle cramp, e.g. , with a composition described herein. In other embodiments, efficacy in treating the test muscle cramp is indicative of efficacy in treating muscle cramp, spasticity, dystonias, or fasciculations.
The terms "treat," "treating," or "ameliorating" as used herein refer to administering a composition for therapeutic purposes or administering treatment to a subject already suffering from a disorder to improve the subject's condition.
The terms "treating a condition or disorder" or "ameliorating a condition or disorder" as used herein refer to the condition or disorder (e.g. , peripheral nervous system conditions (e.g., peripheral neuropathy), central nervous system conditions, muscle conditions and disorders (e.g., fibromyalgia, muscle spasms and cramps (e.g., nocturnal cramps), painful muscle contractions (e.g., a muscle contraction of the head or neck), neuromuscular disorders (e.g., motor neuron disease) or dystonia (e.g., cervical dystonia, blepharospasm, back spasms, or leg cramps due to spinal stenosis)), connective tissue diseases (e.g., degenerative joint disease), throat conditions (e.g. , dysphagia or spasmodic dysphonias), tactile sensitivity, electrolyte imbalance and/or vitamin deficiency, respiratory conditions (e.g., asthma), cough, and sarcoidosis) and the symptoms associated with the condition or disorder are, e.g. , alleviated, reduced, cured, or placed in a state of remission. As compared with an equivalent untreated control, such amelioration or degree of treatment is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%, as measured by any standard technique.
The term "viscosity" as used herein refers to a measurement of a fluid's internal resistance to flow (e.g. , "thickness"). Viscosity is generally expressed in centipoise (cP) or pascal-seconds.
Other features and advantages of the invention will be apparent from the detailed description and from the claims.
Capsaicinoids and analogs thereof, capsinoids and analogs thereof
Capsaicinoids, capsinoids, and analogs thereof are compounds that can activate TRP channels (e.g. , TRPV1 channels) and may be used in the compositions of the present invention.
These compounds can be naturally occurring and non-naturally occurring compounds (e.g. , synthetic analogs and derivatives of naturally occurring compounds), including but not limited to those described below.
Suitable capsaicinoids, capsinoids, and related analogs and derivatives and combinations thereof for use in the compositions and methods of the present invention can be naturally occurring and include: capsaicin, dihydrocapsaicm, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate,
dihydrocapsiate, nordihydrocapsiate, norcapsaicin, capsiconiate, dihydrocapsiconiate and other coniferyl esters, capsiconinoid, and 3-hydroxyacetanilide.
Capsaicinoids and related analogs and derivatives also include non-naturally occurring compounds that are derived by synthetic methods (e.g. , by combining two or more naturally occurring capsaicinoids as described above or by creating an artificial compound that does not exist in nature). Examples of non-naturally occurring capsaicinoids include but are not limited to: esters of capsaicinoids (e.g. , aliphatic esters, hydrophilic esters, and the like including 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-rn.ethyoxyphenyl formate, 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylarnino)methyl]-2- methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoyIamino)methyI]-2-methyoxyphenyl butanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2- dimethylpropanoate, 4-[((6E)-8-metiiylnon-6-enoylamino)metiiyl]-2-meihyoxyphenyl octadecanoate, and 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl{4-[((6E)-8- methylnon-6-enoylamino)methyl]-2-metlioxyphenoxy}formate, ester derivatives of capsinoids, (e.g. homovanillyl 8-methylnonanoate), 3-3-methoxy-4-hydroxyphenyl)propyl 8- methylnonanoate, 8-methylnonyl homovanillate, substituted benzyl ester derivatives of capsinoids (e.g. 8-methylnonanoic acid- substituted benzyl ester derivatives), isobutylamides (e.g.heptanoylisobutylamide), guaiacylamides (e.g. heptanoyl guaiacylamide), halogenated capsaicin analogs, phenylcapsaicins (e.g. 7-phenyIhept-6-yne-acid-4-hydroxy-3- methoxybenzylamide), N-vanillyl fatty acid amides (e.g. dohevanil), denatonium capsaicinate, capsaicin derivatives (e.g. N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4- chlorophenyl)ethyl] thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4- fluorophenyl)ethyl] thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(2,4- dichlorophenyl)ethyl]thiourea,N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4-
benzyloxyphenyl)ethyl] thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4-(N- octyloxy)phenyl)ethyl] thiourea, and N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[4-N- octyloxybenzyl] thiourea), N-phenylmethylalkynamide capsaicin derivatives, ether linked and relatively nonpungent analogs of N-nonanoyl vanillylamide (e.g. N-(4-0-glycerol-3- methoxybenzyl)-nonamide (e.g. N-nonanoyl vanillylamide-4-glyceryl ether, N-(4-0-acetic acid sodium-3-methoxybenzyl-nonamide, sodium N-nonanoyl vanillylamide-4-O-acetate, and N-(4- 0-glycol-3-methoxybenzyl)-nonamide (N-nonanoyl vanillylamide-4-glycol ether), compounds prepared by combining phorbol related diterpenes and homovanillac acid analogs via
esterification at the exocyclic hydroxy group of the diterpene (e.g. 20-homovanillyl-mezerein and 20-homovanillyl- 12-deoxyphorbol-13-phenylacetate), civamide (N-[(4-hydroxy-3- methoxyphenyl)-methyl]-8-methyl-(Z)-6-nonemamide), nuvanil, capsavanil, olvani!, arvanil, and palvanil (N-palmitoyl-vanillamide) .
Additional capsaicinoids are described, for example, in U.S. Patent Nos. 8,652,497; 8,642,657; 8,420,600; 8,309,060; 8,212,068; 7,981,460; 7,943,666; 7,446,226; 7,034,058;
6,333,421 ; 5,891,919; 5,403,868; 5,290,816; 5,221,692; 5,021,450; 4,812,446; 4,493,848;
4,564,633; and 4,313,958.
Additional capsaicinoids and capsinoids are described by Formulas (I)-(LXI) and are exemplified by Compounds 1-300 of U.S. Provisional Application No. 61/979,423, which is hereby incorporated by reference.
Capsaicinoids, capsinoids, and analogs and combinations thereof for use in the compositions and methods described herein can also be identified using standard methodology, as described, for example, in U.S. Patent Application Publication No. 2003/0104085, which is hereby incorporated by reference. Exemplary assays for identification of capsaicinoids, capsinoids, and analogs thereof include, without limitation, receptor binding assays; functional assessments of stimulation of calcium influx or membrane potential in cells expressing the TRPVl receptor; assays for the ability to induce cell death in such cells (e.g. , selective ablation of C-fiber neurons); and other assays known in the art.
In addition, the composition comprising capsaicinoids, capsinoids, and analogs thereof may further comprise an acidulant (e.g. , acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, lactic acid, or ascorbic acid) maintaining a low pH in the range of 2.5-6.5 (e.g. , pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5).
Capsaicinoids, capsinoids, and analogs and combinations thereof may be present in a composition of the invention at a concentration range of about 0.001 to 10% by weight by weight (w/w) based on the total weight of the composition (e.g. , 0.001, 0.005, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%) or at a concentration range of about 0.001% to 10% by weight by volume (w/v) based on the total volume of the composition (e.g. , 0.001, 0.005, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%), though capsaicinoids, capsinoids, and analogs thereof may be present in lower or higher concentrations (e.g. , less than 0.001%, e.g. , 0.0008%, 0.0005%, 0.0004%, 0.0001% (w/w) or (w/v), or more than 10%, e.g. , 12%, 15%, 20%, 30%, 35%, 40%, 50% (w/w) or (w/v)). Capsaicinoids, capsinoids, and analogs and combinations thereof may be present at a concentration range of about 20 mg to 500 mg per unit dosage (e.g. , 23 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 420 mg, or 450 mg).
TRP Channels and ASIC Channels
The compositions described herein are formulations suitable for oral consumption by a subject (e.g. , by a human) and include a capsaicinoid, capsinoid, or related analog or
combination thereof, as well as an excipient as described herein. In some embodiments, the composition includes a plurality of capsaicinoid, capsinoid, or related analog or combination thereof. In an embodiment, the composition includes a plurality of excipients. Exemplary compositions that include capsaicinoids, capsinoids, or related analogs or combinations thereof include solid dosage forms for oral administration (e.g. , capsules, tablets, pills, dragees, crystals, pastes, gels, powders, gums, granules, chews, foodstuffs, and the like), liquid dosage forms for oral administration (e.g. , emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, and elixirs), ready-to-drink beverages, dry compositions that can be reconstituted with a liquid (e.g. , powders, granules, or tablets that may be reconstituted with water), gels, semi-solids (e.g. , ice cream, pudding, or yogurt), frozen liquids (e.g. , ice pops), lozenges or hard candies, dissolving strips (e.g. , an edible strip containing pullulan and compositions of the invention), and chewing gums. In an embodiment, the composition is formulated for oral administration.
Transient Receptor Protein (TRP) channels are a family of ion channels that are generally expressed on the cell surface. Members of the TRP channel family share some structural
similarity and are organized in sub-families, comprising TRPA, TRPC, TRPV, TRPM, TRPML, TRMPN, and TRPP. Each of these sub-families comprise subunit genes, which include, for example, TRPVl, TRPV2, TRPV4, TRPV3, TRPV5, TRPV6, TRPAl, TRPP3, TRPP2, TRPP5, TRPC4, TRPC5, TRPC1, TRPC3, TRPC7, TRPC6, TRPM1, TRPM3, TRPM6, TRPM7, TRPM4, TRPM5, TRPM2, TRPM 8, TRPML 1, TRPML3, and TRPML2. The compositions described herein may comprise at least one agonist of any of the TRP channels.
Acid-sensing ion channels (ASIC) are neuronal voltage-insensitive cationic channels that are activated by extracellular protons. ASIC channels are primarily expressed in the nervous system, and conduct mostly Na+. There are four ASIC channel genes, ASIC1, ASIC2, ASIC3 and ASIC4, which encode at least six ASIC channels, ASIC3, ASCI4 and splice variants of ASIC1, and ASIC2, ASICla, ASIC lb, ASIC2a, ASIC2b. The compositions described herein may comprise at least one agonist of any of the ASIC channels.
In some embodiments, the composition described herein comprises at least one TRP channel agonist. In one embodiment, two or more agonists that activate the same or different TRP channels are administered. In some embodiments, the composition described herein comprises a TRPVl agonist or a TRPAl agonist. In another embodiment, the composition described herein comprises a TRPVl agonist and a TRPAl agonist. In another embodiment, the composition described here comprises at least one ASIC channel agonist. In another
embodiment, the composition comprises a combination of at least one TRP agonist and at least one ASIC channel agonist. For example, the composition described herein comprises at least one TRPVl activator and at least one TRPAl activator. The compositions described herein include any of the compositions described in WO 2012/015882, the contents of which are incorporated herein in its entirety.
In one embodiment, the composition described herein comprises a combination of capsaicin, capsaicinoids, or capsinoids; cinnamaldehyde, and gingerols. In an embodiment, the composition includes each of capsaicin, cinnamaldehyde, and gingerol. In another embodiment, the composition comprises 0.75% of a capsicum preparation (Clearcap Super Soluble Capsicum, Kalsec Inc.), 1% of a cinnamon volatile oil (Aquaresin Cinnamon, Kalsec Inc.), and 1.5% of a ginger oleoresin (Aquaeresin Ginger, Kalsec Inc.).
TRPVl channel agonists
Compounds that activate TRPV1 that may be used in the compositions of the present invention include, for example, capsaicin, capsaicin analogs and derivatives (e.g. , capsinoids), and any other compound that activates TRPV1, examples of which are described herein.
Modulators of TRPV1 activity are known in the art (e.g. , Harteneck et al., Adv Exp Med Biol. 2011 ; 704:87- 106, and other references described herein).
In one embodiment, the TRPV1 channel activator is a capsaicinoid (e.g. , capsaicin (8- methyl-N-vanillyl-/ra«s,-6-nonenamide)). Other suitable TRPV1 channel agonists or activators include oleoylethanolamide, N-oleoyldopamine, 3-methyl-N-oleoyldopamine, oleamide, 1- monoacylglycerols having C18 and C20 unsaturated and C8-C12 saturated fatty acids, 2- monoacylglycerols having CI 8 and C20 unsaturated fatty acids, miogadial, miogatrial, polygodial, and other terpenoids with an alpha,beta-unsaturated 1 ,4-dialdehyde moiety, sanshools, evodiamine, acesulfame potassium, cyclamate, sulfates (e.g. , CuS04, ZnS04, and FeS04), arvanil, anandamide, N-arachidonoyl-dopamine, flufenamic acid, dopamide and other dopamine amides of fenamic acids, 4-hydroxynonenal, SA13353 (e.g., l-[2-(l-adamantyl)ethyl]- l-pentyl-3-[3-(4-pyridyl)propyl]urea), or salts of magnesium.
The TRPV1 channel agonist or activator may also be an analog or derivative of any of the TRPV1 channel activators described herein.
Additional TRPV1 channel agonists or activators are described, for example, in U.S. Patent Nos. 8,652,497; 8,642,657; 8,420,600; 8,309,060; 7,981,460; 7,943,666; 7,632,519;
7,446,226; 7,429,673; 7,407,950; 7,034,058; 6,333,421 ; 6,022,718; 5,962,532; 5,891,919;
5,762,963; 5,403,868; 5,290,816; 5,221,692; 4,812,446; 4,599,342; 4,564,633; 4,544,669;
4,544,668; 4,532,139; 4,493,848; 4,424,205; 4,313,958; in U.S. Patent Application Publication Nos. 2007/0293703; 2007/0167524; 2006/0240097; and 2005/0085652; and in WO 00/50387, each of which is incorporated by reference. Additional capsaicinoids and capsinoids are additionally exemplified by U.S. Provisional Application No. 61/979,405, which is hereby incorporated by reference.
In some embodiments, the TRPV1 channel agonist or activator is an acidulant (e.g. , acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, or ascorbic acid) maintaining a low pH in the range of 2.5-6.5 (e.g. , pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5).
TRPV1 channel agonists or activators for use in the compositions and methods described herein can be identified using standard methodology, as described, for example, in U.S. Patent Application Publication No. 2003/0104085, which is hereby incorporated by reference.
Exemplary assays for identification of TRPV1 channel activators include, without limitation, receptor binding assays; functional assessments of stimulation of calcium influx or membrane potential in cells expressing the TRPV1 receptor; assays for the ability to induce cell death in such cells (e.g., selective ablation of C-fiber neurons); and other assays known in the art.
A TRPV1 channel agonist or activator may be present in a composition of the invention at a concentration range of about 0.001 % to 10% by weight by weight based on the total volume of the composition (e.g., 0.001, 0.005, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%), though a TRPV1 channel agonist or activator may be present in lower or higher concentrations.
TRPAl channel agonists
TRPAl channels are activated by naturally occurring substances including, e.g., mustard oil, isothiocyanate compounds (e.g., allyl isothiocyanate), acrolein, farnesyl thiosalicylic acid, Ag-tetrahydrocannabinol (THC), eugenol, ginger, gingerol, gingerols, shogaols, nicotine, nicotine derivatives and analogs, methyl salicylate, cinnamaldehyde, cinnamon oil, wintergreen oil, clove oil, allicin, diallyl sulfide, diallyl disulfide, diallyl trisulfide, sanshools, farnesyl thiosalicylic acid, and farnesyl thioacetic acid. The TRPAl channel agonist or activator may also be an analog or derivative of any of the TRPAl channel agonists or activators described herein, and additional TRPAl channel agonists or activators are identified in WO 2009/071631, hereby incorporated by reference. Still other modulators of TRPAl are described in, e.g., Harteneck et al., Adv Exp Med Biol. 2011, 704:87-106; Viana et al., Expert Opin. Ther. Pat. 2009,
19(12): 1787-99).
Methods for identifying TRPAl channel agonists or activators are known in the art and are described, for example, in U.S. Patent No. 7,674,594.
A TRPAl channel agonist or activator may be present in a composition of the invention at a concentration range of about 0.001% to 10% by weight by weight based on the total volume of the composition (e.g., 0.001, 0.005, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%), though a TRPAl channel agonist or activator may be present in lower or higher concentrations.
Other TRP channel agonists
Other TRP channel agonists or activators suitable for the methods and compositions described herein are known in the art. In one embodiment, the TRP channel agonist may be nonselective and may activate more than one TRP channel. For example, carvacrol, a compound present in oregano, activates both TRPAl and TRPV3. For example, icilin and menthol activate TRPAl and TRPM8. Naturally occurring and synthetic derivatives and analogs of carvacrol, icilin, or menthol are suitable for use in the compositions and methods of the present invention. Suitable agonists or activators of TRP channels for use in the compositions of the present invention or administered in accordance with the methods of the present invention are disclosed herein. The various agonists for the TRP channel family members listed below is not to be construed as an all-inclusive list, but is merely presented to provide examples of additional TRP agonists.
Examples of TRPV4 agonists include, but are not limited to, 4-alpha-phorbol- 12,13 didecanoate (4CC-PDD), GSK1016790A, 5',6'-epoxyeicosatrienoic (5'6'-EET), 8',9'- epoxyeicosatrienoic (8'9'-EET), APP44- 1, R1747, arachidonic acid (AA), 12-0- tetradecanoylphorbol- 13-acetate (TP A), phorbol 12-myri.state 13-acetate (PMA),
bisandrographalide (BAA), anandamide, and any of the compounds disclosed in WO
2006/029209 (e.g. , a compound of Formula I, II, Ila, or III, N-{ (lS)-l-[({ (4R)-l-[(4- chlorophenyl)sulf onyl] -3-oxohexahyd.ro- 1H- azepin-4-yl } amino)carbonyl] -3-methylbutyl }■■ 1 - benzothiophen-2-carboxamide, N- { ( IS)- 1 - [( { (4R)- 1 - [(4-fluorophenyl)sulfonyl] -3- oxohexahydro- lH-azepin-4-yl } amino)carbonyl]-3-methylbutyl } -l-benzothioph^
carboxamide, N- { ( 1 S)- 1 - [( { (4R)- 1 - [(2-cyanophenyl)sulfonyl] - 3-oxohexahydro-lH-azepin-4- y! ] amino)carbonyl]-3-methylbutyl}-l -methyl- lH-indole-2-carboxamide, N-{ (lS)- l -[( { (4R)- 1- [(2-cyanophenyl)sulfonyl]hexahydro- lH-azepin-4-yl } amino)carbonyl] -3-methylbutyl } - 1 - methyl-IH-indole-2-carboxam.ide), or N-(4-hydroxyphenyl)-5Z,8Z,llZ, .14Z-eicosatetraenamide (AM404).
Examples of TRPC6 agonists or activators include, but are not limited to, l-oleoyl-2- acetyl-sn -glycerol (OAG), carbachol, diacyiglycerol (DAG), 1 ,2-didecanoylglycerol,
flufenamate/flufenamic acid, niflumate/niflumic acid, liyperforin, and the compounds disclosed in WO 2010/015965 (e.g. , a compound of Formula IV, compound IX, compound X, compound XI, compounds XII).
Examples of TRPM6 agonists or activators include, but are not limited to 2- aminoethoxydiphenyl borate (2-APB).
Examples of TRPV2 agonists or activators include, but are not limited to, diphenylborinic anhydride (DPBA), delta-9-tetrahydrocarmabinol (A9-THC or THC), cannabiniol (CBN), cannabidiol (CBP), 2-APB, probenecid, 0-1821, 1 1 -hydroxy- A9-tetrahydrocannabinol, nabilone, CP55940, HU-210, HU-21 1/dexanabinol, HU-331 , HU-308, JWH-015, WIN55, 212-2, 2- arachidonoylglycerol (2- AG), Arvil, PEA, AM404, 0- 1918, and JWH- 133.
Examples of TRPV3 agonists or activators include, but are not limited to incensole, incensole acetate, a compound disclosed in WO 2008/065666 (e.g. , a compound of Formula I or Formula II, compound IA), menthol, eugenol, dihydrocarveol, carveol, thymol, vanillin, ethyl vanillin, cinnemaldehyde, 2 aminoethoxydiphenyl borate (2-APB), diphenyiamine (DPA), diphenylborinic anhydride (DPBA), camphor, (+)-borneol, (-)-isopinocampheol, (-)-fenclione, (- )-trans-pinocarveol, isoboraeol, (+)-camphorquinone, (-)-a-thujone, a-pinene oxide, 1 ,8- cineole/eucalyptol, 6-tert-butyl-m-cresol, carvacrol, p-xylenol, cresol, propofol, p-cymene, (-)- isopulegol, (-)-carvone, (+)-dihydrocarvone, (-)-menthone, (+)-linalool, geranlol, farnesyl pyrophosphate, farnesyl diphosphate, isopentenyl pyrophosphate, and l-isopropyl-4- methyl - bicyclo[3.1 ,0]hexan-4-oI,
The TRP channel agonist or activator may also be an analog or derivative of any of the TRP channel activators described herein.
A TRP channel agonist or activator may be present in a composition of the invention at a concentration range of about 0.001 % to 10% by weight by weight based on the total volume of the composition (e.g. , 0.001, 0.005, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%), though a TRP channel agonist or activator may be present in lower or higher concentrations.
A TRP channel agonist or activator can also be identified using standard methodology. Exemplary assays known in the art for identification of agonists of any TRP channel in the TRP family include, without limitation, receptor binding assays; functional assessments of stimulation of calcium influx or membrane potential in cells expressing the TRPV1 receptor; assays for the ability to induce cell death in such cells (e.g. , selective ablation of C-fiber neurons); and other assays known in the art.
ASIC Channel Activators
ASIC channels are activated by low pH. The pH of a composition of the present invention that includes an ASIC channel activator may be in the range of 2.5-6.5 (e.g., pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5). The pH may be adjusted within this range by any means acceptable for compositions that are intended to be ingested by a subject. Exemplary acidulants are acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, lactic acid, tartaric acid, fumaric acid, and ascorbic acid. The acidulant may be present in a composition of the invention at a concentration range of about 0.001% to 10% by weight based on the total volume of the composition (e.g., 0.001, 0.005, 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%), though the acidulant may be present in lower or higher concentrations.
Additional Components of the Composition
The composition of the present invention may additionally include, for example, electrolytes (e.g., potassium salt or other salts), sweeteners, flavoring and coloring agents, vitamins, minerals, preservatives, viscosity modifiers, and antioxidants as described below. Other exemplary excipients are described in Handbook of Pharmaceutical Excipients, 6th Edition, Rowe et al., Eds., Pharmaceutical Press (2009).
Viscosity and Viscosity Modifiers
Viscosity is the ratio of shear stress to shear rate, expressed as dynes- second/cm , or poise. A centipoise (cP) is one one-hundredth of a poise.
The composition of the present invention may have a viscosity greater than water (i.e., about 1.0 cP at 20°C), e.g., about 100, 200, 300, 400, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 8000, 9000 cP or more. If a consistency of corn syrup is desired, viscosities in the range of about 2500 cP are suitable. If a consistency of a soft gel or honey is desired, viscosities in the range of about 10000 cP to about 15000 cP are suitable. For puddinglike products, viscosities in the range of about 30000 cP to about 38000 cP are desirable.
Viscosity of the compositions of the present invention may be measured with, e.g., a rheometer or viscometer, though additional methods of measuring viscosity are known in the art.
Viscosity modifiers may be added to compositions of the present invention. Such viscosity modifiers include, for example, collagen, gellan gum, carbohydrate gel-forming polymers, carob bean gum, locust bean gum, carrageenan, alginates (e.g., alginic acid, sodium
alginate, potassium alginate, ammonium alginate, and calcium alginate), agar, guar gum, xanthan gum, carboxymethyl cellulose, clear starch, pectin, gelatin, arrowroot, cornstarch, katakuri starch, potato starch, sago, tapioca, furcellaran, karo syrup (e.g., light karo syrup and dark karo syrup), and sodium pyrophosphate. A viscosity modifier may be present in the composition in an amount of from about 0.01% to about 10% by weight based on the total volume of the composition (e.g. , about 0.01%, about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%), though the viscosity modifier may be present in lower or higher concentrations. In some embodiments, the viscosity modifier is present in the composition from about 40% to about 60% (e.g, about 50%).
Electrolytes
Exemplary electrolytes include potassium salts, chloride salts, bromide salts, sodium salts, magnesium salts, calcium salts, citrate salts, acetate salts, phosphate salts, salicylates, bicarbonate salts, lactate salts, sulphate salts, tartrate salts, benzoate salts, selenite salts, molybdate salts, iodide salts, oxides, and combinations thereof. An electrolyte may be present in a composition of the invention at a concentration range of about 0.01% to about 10% by weight based on the total volume of the composition (e.g. , about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%), though an electrolyte may be present in lower or higher concentrations.
In certain embodiments, the compositions of the present invention include high concentrations of potassium (e.g. , potassium chloride). The concentration of potassium in the composition may be, e.g. , about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, or about 7% or more by weight based on the total volume of the composition.
In certain embodiments, the compositions of the present invention include high concentrations of magnesium (e.g. , magnesium chloride). The concentration of magnesium in the composition may be, e.g. , about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, or about 7% or more by weight based on the total volume of the composition.
Sweeteners
Sweeteners may be included in the compositions of the invention. Exemplary sweeteners include corn syrup (e.g., high fructose corn syrup or karo syrup), mannose, maltose, glucose polymers, sucrose (e.g. , cane sugar or beet sugar), glucose, dextrose, lactose, galactose, fructose, polysaccharides (e.g. , malodextrins), rice syrup, honey, and natural fruit juices (e.g. , orange juice, papaya juice, pineapple juice, apple juice, grape juice, apricot juice, pear juice, tomato juice, agave nectar, or cranberry juice). Additionally, non- or low-caloric sweeteners can be used in the compositions of the invention. Examples of such non-caloric or low-caloric sweeteners include, but are not limited to, saccharin, cyclamates, acetosulfam, sorbitol, sucralose, xylitol, erythritol, Stevia extract, L-aspartyl-L-phenyl-alanine ester (e.g. , aspartame), L-aspartyl-D- alanine alkyl amides, L-aspartyl-L- l-hydroxymethylalkaneamide, and L-aspartyl-1- hydroxyethylalkaneamide. Sweeteners may be present in a composition of the invention at a concentration range of about 2% to about 20% by weight based on the total volume of the composition (e.g. , about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20%), though sweeteners may be present in lower or higher concentrations.
Flavoring and Coloring Agents
Exemplary flavoring agents include almond oil, amaretto oil, anethole, anise oil, benzaldehyde, blackberry, black walnut oil, blueberry, caraway, caraway oil, cardamom oil, cardamom seed, cherry juice, cherry syrup, cinnamon, cinnamon oil, cinnamon water, citric acid, citric acid syrup, clove oil, cocoa, coriander oil, dextrose, eriodictyon, ethyl acetate, ethyl vanillin, fennel oil, ginger, glucose, glycerin, glycyrrhiza, grape, honey, lavender oil, lemon oil, lime, mannitol, methyl salicylate, myristica oil, orange oil, orange peel, orange syrup, peppermint, peppermint oil, peppermint water, phenylethyl alcohol, pineapple, raspberry juice, raspberry syrup, rosemary oil, rose oil, rose water, sarsaparilla syrup, sorbitol, spearmint, spearmint oil, strawberry, sucrose, thyme oil, tolu balsam, vanilla, vanillin, and wild cherry syrup. Additional flavoring agents may be found in Food Chemicals Codex and Fenaroli's Handbook of Flavor Ingredients.
Small amounts of a coloring agent may be utilized in the compositions of the present invention. Coloring agents include, e.g. , beta-carotene, riboflavin dyes, FD&C dyes (e.g. ,
Yellow No. 5, Blue No. 1, Blue No. 2, and Red No. 40), FD&C lakes, chlorophylls and chlorophyllins, caramel coloring, annatto, cochineal, turmeric, saffron, paprika, and fruit, vegetable, and/or plant extracts (e.g., grape, black currant, aronia, carrot, beetroot, red cabbage, elderberry, and hibiscus extracts). The amount of coloring agent used will vary depending on the agents used in the composition and the color intensity desired in the finished product. The amount of coloring agent to be used can be readily determined by one skilled in the art.
Vitamins and Minerals
Non-limiting examples of vitamins and minerals that may be included in the
compositions of the present invention include, e.g., choline bitartate, niacinamide, thiamin, folic acid, d-calcium pantothenate, biotin, vitamin A, vitamin C, vitamin Bi hydrochloride, vitamin B2, vitamin B3, vitamin B6 hydrochloride, vitamin B12, vitamin D, vitamin E acetate, vitamin K, and salts of calcium, potassium, magnesium, zinc, iodine, iron, and copper. When included in a composition of the invention, the composition contains at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% of the U.S. recommended daily intake (RDI) for such vitamins and minerals.
Preservatives
A preservative may additionally be utilized in the compositions described herein.
Exemplary preservatives include, for example, sorbate, benzoate, and polyphosphate
preservatives (e.g., sorbic acid, benzoic acid, calcium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, and mixtures thereof). When included in a composition of the invention, the preservative is included at levels from about 0.0005% to about 0.5% (e.g., about 0.0005%, about 0.001%, about 0.005%, about 0.01%, about 0.05%, about 0.1%, or about 0.5%) by weight based on the total volume of the composition, though preservatives may be present in lower or higher concentrations.
Antioxidants
An antioxidant agent may also be included in the compositions to, for example, reduce exercise-induced oxidative stress. Exemplary antioxidants include vitamin C and vitamin E; beta-carotene, lutein, or other carotenoids; cyanidin, delphinidin, malvidin, or other
anthocyanidins; apigenin, luteolin, or other flavones; hesperitin, naringenin, or other flavonones; isorhamnetin, quercetin, kaempferol or other flavonols; and epigallocatechin-3-gallate, epicatechin, thearubigins, or other flavan-3-ols. When included in a composition of the invention, the antioxidant is included at levels from about 0.0005% to about 0.5% (e.g. , about 0.0005%, about 0.001%, about 0.005%, about 0.01%, about 0.05%, about 0.1%, or about 0.5%) by weight based on the total volume of the composition, though antioxidants may be present in lower or higher concentrations.
Additional components of the compositions described herein may include amino acids (e.g. , leucine, isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), stimulants (e.g. , caffeine), emulsifying agents, carbon dioxide (e.g. , to carbonate a liquid composition), stabilizers, humectants, anticaking agents, or herbal extracts. These components may be included at levels from about 0.0005% to about 25% (e.g. , about 0.0005%, about 0.001%, about 0.005%, about 0.01%, about 0.05%, about 0.1%, about 0.5%, about 1%, about 5%, about 10%, about 15%, about 20%, or about 25%) by weight based on the total volume of the composition, though an additional component may be present in lower or higher
concentrations.
Formulations and Methods of Preparing Compositions
The compositions and solutions of the present invention may be formulated as ready-to- drink beverages, concentrates (e.g. , syrups), dry compositions (e.g. , powders, granules, or tablets that may be reconstituted with a liquid (e.g. , with water), gels, solids, semi-solids (e.g. , ice cream, pudding, or yogurt), frozen liquids (e.g. , ice pops), lozenges or hard candies, dissolving strips (e.g. , an edible strip containing pullulan and compositions of the invention), and chewing gum. Formulation of these compositions may require the use of a formulation base, which is a substance or material mixed with or added to the capsaicinoid, capsinoid, or related analog or combination thereof and pharmaceutically acceptable excipient in order to achieve the desired form.
In solid dosage forms for oral administration (e.g., tablets, capsules, powders, crystals, pastes, gels, lozenges (e.g., liquid filled lozenges), gums, candies, chews, foodstuffs, dissolving strips, films, semi-solid formulations, dragees, and the like), the compositions of the invention are mixed with a pharmaceutically-acceptable carrier, such as sodium citrate or dicalcium
phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid
polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
In some embodiments, the compositions may be in the form of a dry powder, granule, tablet, or capsule that may be reconstituted in a specified amount of a liquid. The dried components may be mixed together and milled (e.g. , to create a homogenous powder) or mixed in aqueous solution and dried by using methods known to one of skill in the art. Dried powders or granules may be "loose" or fashioned into tablets.
In other embodiments, the compositions of the present invention may be in the form of a gel or paste further comprising a humectant (e.g., glycerin, propylene glycol, lithium chloride, alpha hydroxy acids, diols, urea, quillaia, polyols, sugar alcohols (e.g., sorbitol, glycerol, xylitol, mannitol), glyceryl triacetate, or neoagarobiose), a gum (e.g., xanthan gum, guar gum), an abrasive (e.g., silica, (e.g., Zeodent®)), a plasticizer, an additive (e.g., a sweetener, preservative, buffering agent, penetration agent, surfactant, coloring agent, flavoring agent, cleaning agent, and the like) or a thickener (e.g., silica (e.g., Zeodent®)). These additional components may be present in the composition of the invention from about 0.5% to about 99% (e.g. , about 0.5%, about 0.1%, about 0.5%, about 1%, about 5%, about 10%, about 20%, about 30% about 40%, about 50%, about 75%, about 90%, about 95%, or about 99%) by weight based on the total volume of the composition, though these components may be present in lower or higher concentrations.
The gel or paste may be further packaged on or within a delivery device such as a bioadhesive strip, patch, film, or may be provided for application directly to the oral cavity (e.g., mucosal surfaces (e.g., in the mouth, nose, or throat), teeth, gums, or lips). For example, a paste or gel can be packaged in a unit that contains between about 0.1 ounces to about 16 ounces of the paste or gel. For example, the packaging can contain about 0.1 ounces, about 0.25 ounces, about 0.5 ounces, about 1 ounce, about 2 ounces, about 3 ounces, about 4 ounces, about 5 ounces, about 6 ounces, about 7 ounces, about 8 ounces, about 9 ounces, about 10 ounces, about 11 ounces, about 12 ounces, about 13 ounces, about 14 ounces, about 15 ounces, or about 16 ounces.
To make pills containing the composition of the invention, the powdered ingredients are mixed together with a binding agent, such as acacia or tragacanth, and are then made into a plastic mass by incorporation of any liquid drugs and addition of an inert liquid. The resulting mass, known as a pill mass, is then rolled into spheres and coated with talc, gelatin, or sugar.
To make tablets, the capsaicinoids, capsinoids, or related analogs or combinations thereof are mixed with suitable diluents, such as dextrin, lactose, salt, starch, or synthetic substances, designed to ensure disintegration of the tablet in the body. To prevent sticking in the machine, a lubricant such as liquid paraffin, stearic acid, talc, or a synthetic substance is usually added. Furthermore, it is essential that the tablet machines are fed with the drug mixture in a free- flowing form to ensure complete filling of the molds. To achieve this, the composition mixture is customarily granulated by mechanically forcing pellets of the mixture through a sheet of perforated-metal. The granulated mixture is fed into the tablet machine, which feeds the correct dose into a cavity, the mixture then being compressed by means of a punch that fits into the cavity. To be successful, the tablet maker must choose correct diluents and lubricants, prepare suitable granules, and obtain the right degree of compression in the tablet machine. Excessive compression may mean that the tablet will not disintegrate in the body; insufficient compression results in fragile tablets that may break, causing inaccurate dosage. Coatings of various types may be applied to the tablet to protect the ingredients from deterioration, to hide the taste of certain components, to control the release of the active components from the tablet, or to produce a more attractive tablet. For sugar coatings, a concentrated sucrose syrup containing suspended starch, calcium or magnesium carbonate, or other suitable substance is applied, each successive layer being dried before the application of the next. After the final layer is dried, it is highly
polished to give an elegant finish. Sugar coatings provide both protection and a sweet taste. Film coatings can also be used, in which a very thin transparent film, usually a cellulose derivative, is applied. Enteric coating is designed to resist solution in the stomach and to dissolve in the more alkaline intestinal fluid. Many substances have been used for enteric coatings, one of which is cellulose acetate phthalate (cellacephate). In the manufacture of layered tablets, incorporating two or more drugs, a compressed tablet is fed to a second machine where another layer is compressed around it. In this way, drugs normally incompatible may be formulated in the same tablet.
Other solid dosages such as lozenges, candies, dragees, dissolving strips, or pastilles disintegrate or dissolve in the mouth, slowly releasing the active ingredient (e.g. , any of the capsaicinoids, capsinoids, or related analogs thereof described herein). The base usually consists of a mixture of sugar and gum or gelatin. Lozenges are generally manufactured by compression techniques, while pastilles are fabricated by fusion and the use of molds. Dry extracts are prepared by the methods for fluid extracts, followed by evaporation, usually under reduced pressure, either to a pilular consistency or to dryness. Dry extracts are usually granulated by being passed through a sieve and may be used for the preparation of tablets.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups (e.g., syrup concentrates), linctuses, drops, and elixirs. In addition to the active ingredient (e.g. , any of the capsaicinoids, capsinoids, or related analogs or combinations thereof described herein), the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Suspensions, in addition to the active agent may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
The compositions and solutions described herein may be bottled or packaged in, for example, glass bottles, plastic bottles and containers (e.g. , polyethylene terephthalate or foil-
lined ethylene vinyl alcohol), metal cans (e.g. , coated aluminum or steel), lined cardboard containers, pouches, packs, wrappers, or any other packaging known to one of skill in the art. For example, a ready-to-drink beverage can be bottled or packaged in a unit that contains between about 10- 1000 mL of the beverage. For example, the packaging can contain about 10 mL, 20 mL, 50 mL, 100 mL, 200 mL, 300 mL, 400 mL, 500 mL, 600 mL, 700 mL, 800 mL, 900 mL, or 1000 mL of the beverage. Alternatively, the packaging can contain 200 mL, 250 mL, 330 mL, 350 mL, 355 mL, 375 mL, 440 mL, or 500 mL of the beverage. A ready-to-drink beverage can also be bottled or packaged in a unit that contains between about 1-32 fluid ounces of beverage (e.g. , the unit may contain about 1, 2, 5, 6.75, 8, 8.3, 8.4, 8.45, 9.6, 10, 12, 15, 15.5, 16, 18.6, 20, 23, 24, or 32 fluid ounces). Where a shelf-stable composition or solution is desired, the packaging is appropriately sterilized before being filled by the pasteurized, ultra-pasteurized, or sterilized composition or solution. Where required for mutual stability of two or more components (for example if a component is unstable at low pH), the packaging may feature multiple containers that can be mixed shortly before ingestion or that can be consumed serially.
Formulations for oral use may also be provided as chewable tablets, or as hard gelatin capsules wherein the active ingredient (e.g. , any of the capsaicinoids, capsinoids, or related analogs or combinations thereof, described herein) is mixed with an inert solid diluent (e.g. , potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate or kaolin), or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil. Powders, granulates, and pellets may be prepared using the ingredients mentioned above under tablets and capsules in a conventional manner using, e.g. , a mixer, a fluid bed apparatus or a spray drying equipment.
Oil-based Formulations
The compositions of the invention can be formulated as an oil-based formulation for oral administration.
In one embodiment, the oil-based formulation includes a formulation base composition including an oil and a lipophilic additive, which can be solid or pasty at room temperature. The lipophilic additive can include waxes, fatty acid mono-, di- or triglycerides, fatty acids and polyethylene glycols and the polyethylene glycol fatty acid esters, as well as their mixtures and can be present in ranges from about 5 to 20% by weight or the composition (e.g. , about 5%,
about 6%, about 10%, about 15%, about 17%, about 18%, about 19%, or about 20%), The waxes can be beeswax, candelilla wax, carnauba wax, polyethylene oxide wax or petroleum wax (or microcrystalline wax). The fatty acid mono-, di-, or triglycerides can have different degrees of esterification. The fatty acids can be selected from among palmitic acid, stearic acid, or behenic acid and their calcium, sodium, potassium or magnesium salts. The polyethylene glycols and fatty acid polyethylene glycol esters can have a molecular weight of between about 600 to 6000. The oil can include vegetable oils such as soya oil, sunflower oil, corn oil, olive oil or nut oil, and among the mineral oils such as liquid paraffin, as well as their mixtures, The oil- based formulations can be present in the form of a soft or hard capsule and can be prepared by traditional techniques known in the art. In one such technique, the lipophilic additive is incorporated into the oil which is heated at a temperature sufficiently high to melt the lipophi lic additive completely and obtain a homogeneous mixture. After cooling to approximately 50° C, the other components such as the capsaicinoids, capsinoids, or related analogs and combinations thereof described herein are incorporated into this mixture with stirring. The mixture thus obtained is cooled to a temperature between 25 and 40° C, and optionally, soft or hard capsules are filled with this mixture. For a detailed discussion of lipids and lipid-based formulations see, for example, Porter et al., Nat Rev Drug Discov. 2007, 6(3):231-248.
In another embodiment, the capsaicinoids, capsinoids, or related analogs or combinations thereof can be formulated as an oil for topical administration. Generally, the agonists described herein at concentration ranges of about > 20% to 95% (w/w) are solubilized in a solvent capable of solubilizing the TRP channel agonist. Solvents that may be used include volatile solvents (e.g. , methanol, ethanol, acetone, isopropanol, n-propanol, cyclohexane and alkanes with molecular weight less than dodecane (C- 12)), semi-volatile solvents (e.g.. volatile essential oils such as clove oil, tea tree oil, sesame oil, and cineole), and non-volatile solvents (e.g. , polyethylene glycol 400, Lutrol® (polyethylene polyoxypropylene block copolymer available from BASF), glyceryl monooleate, glycerin, lanolin, low melting waxes, sesquiterpenes and alkanes, alkenes, aikanoic and alkenoic acids >C-28). The oils may further include a
crystallization inhibitor, for example, polyvinylpyrrolidone, Luvitol® BD 10 P (BASF), povidone and its derivatives; dextrin derivatives, polyethylene glycol, polypropylene glycol, mannitol and glycerin, and mono and diglycerides of essential oils, polyglycerin fatty acid esters, sucrose palmitic acid ester, pentaerythritol ester of wood rosin (Pentalyn A®), and Eudagrits®.
Crystallization inhibitors may range from about 0.1 to 10% w/w. The oils of the capsaicinoids, capsinoids, or related analogs described herein may be administered orally as an oil.
Controlled Release Formulations
It is also within the scope of the invention to provide compositions that are formulated for modified release (e.g., delayed release, prolonged and/or slow release, extended release, or rapid release) of the capsaicinoids, capsinoids, or related analogs and combinations thereof to reduce gastrointestinal side-effects. Such compositions are well-known in the art and include e.g., diffusion-controlled drag delivery systems, osmotic pressure controlled dmg delivery systems, or erodible drug delivery systems. Exemplary delivery systems are the SQZgel™ (MacroMed, nc.), comprising a pH-sensitive polymer mixture combined with an outer coating in which the acidic environment of the stomach causes the polymer to imbibe with water and swell, entrapping the capsaicinoid, capsinoid, or related analog. Upon entering the higher pH of the intestines, the polymer slowly shrinks, or "squeezes" at a "dialed-in" rate releasing the active composition in a sustained manner); the Egalet® extrusion based technology (Egalet A/S), comprising a biodegradable coat and a matrix, including the dmg, which is surface erodible, hydrophobic, and composed of PEG-stearate); Diffucaps/Surecaps (small beads approximately 1 mm or less in diameter that can be incorporated into hard gelatin capsules, where the
capsaicinoid, capsinoid, or related analog release profiles are created by layering dmg onto a neutral core such as sugar spheres, crystals, or granules followed by a rate-controlling, functional membrane); and MeltDose®, which involves formulating solubilized, individual moelcules into tablets).
The capsaicinoids, capsinoids, or related analogs and combinations thereof described herein can be formulated for pH controlled release. Examples of suitable formulation principles are, for example, compositions provided with an enteric coating or hydrogels of a type described in US Patent Nos, 6,537,584 and 5,484,610, which axe hereby incorporated by reference.
Another suitable formulation includes the formulation of the capsaicinoids, capsinoids, or related analogs or combinations thereof together with vitamin E concentrate in soft or hard gelatin capsules. Another specific example of a suitable formulation includes formulation of the capsaicinoids, capsinoids, or related analogs or combinations thereof together with ethanol, tocopherolethylene glycol 1000 succinate (TPGS), corn oil, and wax in soft or hard gelatin
capsules. Variations of this formulation can include efhanol, TPGS, com oil, and polyglycolized glyeerid.es {e.g., Gelucire) in soft or hard gelatin capsules, 'The resulting product can be a semisolid or solid dosage form, The release rate of this formulation is dependent on degradation due to lipases in the intestine,
A further example of a suitable formulation is an oral pulsed dose drug delivery system. This dosage form can be perceived as a modified form of the Schering Repetab cablets. A portion of the composition of the present invention is put in the core of a tablet. The core can for example, be made by conventional wet granulation or continuous granulation such as extrusion followed by compaction of the granulate into tablets, 'The core is then coated using an appropriate technology, for example, by air suspension using an enteric coating polymer such as Eudragits. The first releasing dose is compression coated on the core or air- suspension coated either with the enteric coat or on top of the enteric coat. In an embodiment of the invention, the first releasing dose is air- suspe s on coated with the enteric coat. In a further embodiment of the invention, the first releasing dose is compression coated on the core, in order to avoid release of the composition according to the invention prior to the degradation of the enteric coat, such degradation typically occurring at pH values higher than those found in the gastric ventricle (i.e., the degradation of the enteric coat typically occurs after passage of the gastric ventricle), Another example of a suitable formulation is an oral sustained drag delivery system. In this delivery system, the core can for example, be made by conventional wet granulation or continuous granulation such as extrusion followed by compaction of the granulate into tablets. The core is then coated using appropriate technology, for example, by airsuspension using ethyl.cellul.ose and a hydrophilic excipient such as hydroxy! propyl cellulose (HPC).
In some embodiments, the compositions of the inventions can include the capsaicinoids, capsinoids, or related analogs or combinations thereof in the form of micro-crystals with hydrophilic surfaces. The micro -crystals can be film coated directly in order to achieve a sustained release formulation. The compositions of the invention can also be complexed with genuine cyclodextrins and cyclodextrin-derivatives {e.g., alkyl- and hydroxyalkyl-derivatives or sulfobutyl-derivatives), The complexation is achieved by methods known in the art.
Complexation can lead to a higher solubility and a higher dissolution rate and higher
bioavailability.
In other embodiments, the composition can include a pharmaceutically acceptable excipient that is an agent for delayed or controlled release of the capsaicinoids or analogs thereof and/or capsinoids or analogs thereof. In some aspects, the agent is a water-soluble polymer, including but not limited to, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose (HPMC), methyl cellulose, and carboxymethyl cellulose.
The capsaicinoids, capsinoids, or related analogs or combinations thereof described herein can be targeted to the mucus/mucosal lining of the mouth, tongue, nose, or gastrointestinal tract (GIT) through the use of bioadhesives. A bioadhesive is defined as a synthetic or biological material which is capable of adhering to a biological substrate or tissue. When the biological substrate is mucus, the term "mucoadhesive" has been employed. When the biological tissue involved is the mouth or stomach, the terms "buccoadhesive" or "gastroadhesive" has been employed. Bioadhesives can remain attached to the biological substrate for an extended period of time. The period of time a bioadhesive is required to remain attached to a biological substrate will vary according to the target site and the condition being treated. Other delivery systems that can target the capsaicinoid, capsinoid, or related analogs described herein to the colon include, but are not limited to:
(a) covalent linkage of the capsaicinoid, capsinoid, or related analog with the carrier to form a prodrug that is stable in the stomach and small intestine and releases the capsaicinoid, capsinoid, or related analog in the large intestine upon enzymatic transformation by the intestinal microflora; examples of these prodrugs include azo-conjugates, cyclodextrin-conjugates, glycoside-conjugates, glucuronate conjugates, dextran-conjugates, polypeptide and polymeric conjugates;
(b) approaches to deliver intact molecule to the colon, such as coating with pH- sensitive polymers to release the capsaicinoid, capsinoid, or related analog at neutral to alkaline pH, or coating with biodegradable polymers which release the drug upon degradation by the bacteria in the colon;
(c) embedding the capsaicinoid, capsinoid, or related analog in biodegradable
matrices and hydrogels which release the drug in response to the pH or biodegradation;
(d) time released systems where once the multicoated formulation passes the
stomach, the capsaicinoid, capsinoid, or related analog is released after a lag time of 3-5 hrs which is equivalent to the transit time of the small intestine;
(e) using redox- sensitive polymers where a combination of azo and disulfide
polymers, provide capsaicinoid, capsinoid, or related analog release in response to the redox potential of the colon;
(f) osmotic controlled capsaicinoid, capsinoid, or related analog delivery where the capsaicinoid, capsinoid, or related analog is released through semi-permeable membrane due to osmotic pressure.
Micro and Nanoparticle Formulations
In one embodiment, the capsaicinoids, capsinoids, or related analogs or combinations thereof-loaded nano- and micro-particles for sustained release are formulated by the nano- precipitation or the oil-in- water single emulsion solvent evaporation/extraction method. First, the capsaicinoids, capsinoids, or related analogs or combinations thereof-loaded poly(lactic-co- glycolic acid) (PLGA) nanoparticles are prepared by the nano-precipitation method. The volume of oil- water ratio can be adjusted (e.g., from about 1 :2 to 1 :5, e.g., about 1 :2, 1 :3, 1 :4, or 1 :5), and size of the nanoparticles can be selected (e.g. , from about 162 +/- 3 nm to 153 +/- 3 nm, e.g. , about 154, 155, 156, 157, 158, 159, 160, 161, or 162) to increase drug loading efficiency and drug release period. To get a more sustained release, a modified single emulsion method can be applied with biocompatible polymers such as polylactic acid (PLLA), polyhydroxy butyrate (PHB), polyglycolic acid (PGA), PLGA, and poly-e-caprolactone (PCL).
In another embodiment, stomach specific mucoadhesive nanoparticles (SSMN) can be used to improve controlled delivery of the capsaicinoids, capsinoids, or related analogs or combinations thereof by continuous release of the agonist for a prolonged period to its absorption site to ensure optimal bioavailability. The capsaicinoids, capsinoids, or related analogs or combinations thereof with a narrow absorption window are mostly associated with improved absorption at the jejunum and ileum due to enhanced absorption properties of these sites (e.g., large surface area), or because of enhanced solubility in the stomach as opposed to the more distal parts of the gastrointestinal tract. Capsaicinoids, capsinoids, or related analogs or combinations thereof that may benefit from using stomach specific mucoadhesive nanoparticles
includes those that act locally in the stomach, those with low solubility at high pH values, those that are primarily absorbed in the stomach, those with a narrow window of absorption, e.g. , those that are absorbed mainly from the proximal part of the small intestine, those that absorb rapidly from the gastro intestinal tract, drugs that degrade in the colon, and drugs that are unstable in intestinal fluids. Longer residence time in the stomach could be advantageous for local action especially in the upper part of the small intestine. A list of the micro and nano carriers for mucosal delivery applications is described in Table 1.
Table 1. Micro and nano carriers for mucosal delivery
Carrier Size (μιτϊ) Zeta potential Loading
fmV) method
Chitosan 0.215 20.7 Encapsulation
Chitosan Encapsulation
Chitosan/HPMCPa 0.255 30.1 Encapsulation
Chitosan/dextran sulfate 0.479-1 .612 21.5 to 3.2 Encapsulation
Chiiosan/dextran sulfate 0.527, 1.577 20.6, 1 1.5 Encapsulation
Chfiosan/eudragit L1Q0-55 0.196 29.51 Encapsulation
Chitosan/lecithin 0.121-0.347 7.5-32.7 Encapsulation
Chitosan/aiginate 0.779.1.858 Encapsulation
Chitosan/aiginate 0.748 5.6 Encapsulation
Laury! succinyl chitosan 0.315-1.090 Encapsulation
TMCO-60%b Encapsulation
N-trimethyi chitosan-cysteine 0.102-0.168 12.3-18.8 Self assembly
Poiyfiaetic acid)-chitosan 0.065 5 Encapsulation
MePEG-PLA-CSc 0.094 13 Encapsulation
DEAPA-PVA-g-PLLAd 0.200-0.400 15-35 Seif assembly
PLGAe 0.216-1.145 Encapsulation
PLGAe 0.15 Encapsulation
WGA modified PLGAf 0.232-0.240 -4.2 to -2.6 Encapsulation
Poiy aery lie acid/sperm ine 0.191-0.228 -29.3 to -7.3 Encapsulation
Po!yacrylic acid/MgCI2 0.278-23.4 Encapsulation
Lipid nanopartie!es 0.2 -50.3 Encapsulation
Lipid nanopartie!es/PEG 0.207-0.226 -36.6 to -34.8 Encapsulation
Lipid nanopartic!es chitosan 0.538 29.2 Encapsulation
Solid lipid nanopariicies 0.050-0.064 -46.3 to -38 Encapsulation
WGA-N-giut-PEmodified SLNsp 0.058-0.075 57.7-75.3 Encapsulation
Routes of Administration
The compositions described herein may be administered to a subject in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art and as relating to the particular disease or condition to be treated. The compositions used in
the methods described herein may be administered, for example, by topical, enteral, or parenteral applications. Topical applications include but are not limited to epicutaneous, inhalation, enema, eye drops, ear drops, and applications through mucous membranes in the body. Enteral applications include oral administration, rectal administration, vaginal administration, and gastric feeding tubes. Parenteral administration includes intravenous, intraarterial, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, intrastemal, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal, and topical modes of administration. Parenteral administration may be by continuous infusion over a selected period of time.
In some embodiments of the current invention, the capsaicinoid, capsinoid, or related analog or combination thereof is administered through the oral cavity to achieve mucosal and transmucosal effects. Exemplary applications include buccal, nasal, intradermal, inhalational, topical, subcutaneous, sublingual, sublabial, and insufflation administrations. Compositions of the current invention may include a penetration enhancer to increase the bioavailability of the ion channel activator within the oral cavity. Exemplary penetration enhances include surfactants (e.g., anionic surfactants (e.g, sodium lauryl sulfate), cationic surfactants (e.g., cetyl pyridinium chloride), and nonionic surfactants (e.g., poloxamer, Brij, Span, Myrj, Tween)), bile salts (e.g., sodium glycocholate, sodium taurodeoxycholate, sodium taurocholate), fatty acids (e.g., oleic acid, caprylic acid, lauric acid, lysophosphatidylcholine, phosphatidylcholine), cyclodextrins (e.g, -, β-, or γ-cyclodextrans, methylated cyclodextrins), chelators (e.g., EDTA, citric acid, sodium salicylate, methyl salicylates), polymers (e.g., positively charged polymers (e.g., chitosan, trimethyl chitosan)), and cationic compounds (e.g., poly L-arginine, L-lysine).
For intravenous or intrathecal delivery or direct injection, the composition must be sterile and fluid to the extent that the composition is deliverable by syringe. In addition to water, the carrier can be an isotonic buffered saline solution, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by use of coating such as lecithin, by
maintenance of required particle size in the case of dispersion and by use of surfactants. In many cases, it is preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol or sorbitol, and sodium chloride in the composition. Long-term absorption of the
injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.
The choice of the route of administration will depend on whether a local or systemic effect is to be achieved. For example, for local effects, the composition can be formulated for topical administration and applied directly where its action is desired. For systemic, long term effects, the composition can be formulated for enteral administration and given via the digestive tract. For systemic, immediate and/or short term effects, the composition can be formulated for parenteral administration and given by routes other than through the digestive tract.
Within the scope of the present invention are also parenteral depot systems from biodegradable polymers. These systems are injected or implanted into the muscle or
subcutaneous tissue and release the incorporated drug over extended periods of time, ranging from several days to several months. Both the characteristics of the polymer and the structure of the device can control the release kinetics which can be either continuous or pulsatile. Polymer- based parenteral depot systems can be classified as implants or microparticles. The former are cylindrical devices injected into the subcutaneous tissue whereas the latter are defined as spherical particles in the range of 10 - 100 μιη. Extrusion, compression or injection moldings are used to manufacture implants whereas for microparticles, the phase separation method, the spray-drying technique and the water-in- oil-in- water emulsion techniques are frequently employed. The most commonly used biodegradable polymers to form microparticles are polyesters from lactic and/or glycolic acid, e.g. poly(glycolic acid) and poly(L-lactic acid) (PLG/PLA microspheres). Of particular interest are in situ forming depot systems, such as thermoplastic pastes and gelling systems formed by solidification, by cooling, or due to the sol- gel transition, cross-linking systems and organogels formed by amphiphilic lipids. Examples of thermosensitive polymers used in the aforementioned systems include, N-isopropylacrylamide, poloxamers (ethylene oxide and propylene oxide block copolymers, such as poloxamer 188 and 407), poly(N-vinyl caprolactam), poly(siloethylene glycol), polyphosphazenes derivatives and PLGA-PEG-PLGA.
Dosage
The compositions of the present invention are formulated into acceptable dosage forms by conventional methods known to those of skill in the art. Actual dosage levels of the active
ingredients in the compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular subject, composition, and mode of administration, without being toxic to the subject. The selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of absorption of the particular agent being employed, the duration of the treatment, other drugs, substances, and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the subject being treated, and like factors well known in the medical arts. A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the composition required. For example, the physician or veterinarian can start doses of the substances of the invention employed in the composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. In general, a suitable daily dose of a composition of the invention will be that amount of the substance which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Preferably, the effective daily dose of a therapeutic composition may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
Preferred therapeutic dosage levels are between about 500 mg to about 1000 mg (e.g. , about 500 mg, 520 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg) of the composition per day administered orally to adults of average weight afflicted with most of the symptoms, syndromes and conditions described herein. Preferred prophylactic dosage levels are between about 100 mg to about 1000 mg (e.g. , about 110 mg, 140 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 460 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg). The dose may also be titrated (e.g. , the dose may be escalated gradually until signs of gastrointestinal toxicity appear, such as diarrhea or nausea).
The frequency of treatment may also vary. The subject can be treated one or more times per day (e.g. , once, twice, three, four or more times) or every so-many hours (e.g. , about every 2, 4, 6, 8, 12, or 24 hours). The composition can be administered 1 or 2 times per 24 hours. The time course of treatment may be of varying duration, e.g. , for two, three, four, five, six, seven,
eight, nine, ten, or more days, two weeks, 1 month, 2 months, 4 months, 6 months, 8 months, 10 months, or more than one year. For example, the treatment can be twice a day for three days, twice a day for seven days, twice a day for ten days. Treatment cycles can be repeated at intervals, for example weekly, bimonthly or monthly, which are separated by periods in which no treatment is given. The treatment can be a single treatment or can last as long as the life span of the subject (e.g. , many years).
Foodstuff and Food Supplements
The present invention also relates to the use of the composition as foodstuff, food supplement, or dietetic product (a foodstuff intended for a particular diet). In particular, the composition can be incorporated into foodstuffs which are industrially produced or craftsmen- prepared, such as oils, butter, margarine, bread spreads, or baked goods. It can also be presented in the form of a powder for di lution in water or food bars.
The composition of the invention can further be administered in combination with a dietary supplement to promote and/or maintain general health. Examples of dietary supplements include, but are not limited to, a vitamin (e.g. , Vitamin A, Vitamin B1 ; B2, B3, B5, B6, B7, B9, B12, Vitamin C, Vitamin D, Vitamin E, and Vitamin K), a mineral (e.g. , potassium, chlorine, sodium, calcium, magnesium, phosphorus, zinc, iron, manganese, copper, iodine, selenium, and molybdenum), an herb or botanical (e.g. , St. John' s- wort, kava, Shilajit, and Chinese herbal medicines), an amino acid (e.g. , glycine, serine, methionine, cysteine, aspartic acid, glutamic acid, glutamine, tryptophan, and phenylalanine), and a concentrate, constituent, extract, and/or a combination of any of the above.
Conditions and Disorders
The compositions of the invention may be useful for treating any of the conditions and disorders described herein.
Peripheral Nervous System (PNS) conditions
Compositions of the invention can be used to treat conditions affecting the peripheral nervous system (PNS). These conditions include: diseases, disorders, or injuries to the peripheral nervous system include but are not limited to: cramp fasciculation syndrome, Isaacs'
Syndrome or neuromyotonia (NMT), peripheral neuropathy (e.g., diabetic neuropathy), carpal tunnel syndrome, or EBV infection. Other peripheral nervous system diseases and conditions include but are not limited to: amyloid neuropathies, diabetic neuropathies, nerve compression syndromes, peripheral nervous system neoplasms, brachial plexux neuropathies, Guillain-Barre syndrome, neuralgia, polyneuropathies, complex regional pain syndromes, mononeuropathies, neuritis, acrodynia, neurofibromatosis, hand-arm vibration syndrome, pain insensitivity, and Tarlov cysts.
Central Nervous System (CNS) conditions
The compositions of the invention can be used to treat conditions affecting the central nervous system (CNS). These conditions include: diseases, disorders, and injuries to the central nervous system due to tumor, multiple sclerosis, spasticity due to cerebral palsy, stroke, motor neuron disease or spinal injury or stenosis. There are many other central nervous system diseases and conditions, including infections of the central nervous system such as encephalitis and poliomyelitis, early-onset neurological disorders including ADHD and autism, late-onset neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and essential tremor, autoimmune and inflammatory diseases such as multiple sclerosis and acute
disseminated encephalomyelitis, genetic disorders such as Krabbe's disease and Huntington's disease, as well as amyotrophic lateral sclerosis and adrenoleukodystrophy. Other diseases of the CNS include but are not limited to: catalepsy, epilepsy, meningitis, migraine, tropical spastic paraparesis, arachnoid cysts, locked- in syndrome, and Tourette's syndrome. Anxiety disorders may also be characterized as a CNS condition. Anxiety disorders can be classified into:
generalized anxiety disorder, phobic disorders, panic disorders, agoraphobia, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, separation anxiety, and situational anxiety.
Tactile Sensitivity
The compositions of the invention may be useful in treating tactile sensitivity or tactile defensiveness (TD). TD refers to patterns of observable behavioral and emotional responses which are aversive, negative, and out of proportion to certain types of tactile stimuli that are often found by most people to be non-painful. TD is a sensory integrative dysfunction in which
the brain is unable to process and use information through the senses. Tactile sensitivity can result from conditions such as autism, dyspraxia, neuralgia, panic or anxiety disorders, or from venomous bites or stings.
Electrolyte Imbalance and/or Vitamin Deficiency
The compositions of the invention may be useful in treating conditions associated with an electrolyte imbalance and/or vitamin deficiency. Examples of such condition include, but are not limited to: hyponatremia, hypernatremia, hyperkalemia, hypokalemia, hypercalcemia, hypocalcemia, hyperchloremia, hypochloremia, hypermagnesemia, hypomagnesemia, hyperphosphatemia, hypophosphatemia, kidney disease, rickets, scurvy, beriberi, pellagra, calcium deficiency, eating disorders, vitamin D deficiency, vitamin A deficiency, biotin deficiency, ariboflavinosis, vitamin K deficiencies, hypocobalaminemia, paraesthesia, night blindness, magnesium or thiamine deficiency, hypoparathyroidism, medullary cystic disease, and adrenocortical carcinoma.
Muscle Conditions and Disorders
The compositions and methods described herein include treating a subject having been diagnosed with or identified as having a muscle condition or disorder. Exemplary disorders include night cramps, multiple sclerosis, dystonia, spinal cord spasticity, neuromuscular disorders, including muscle pain and cramping associated with a neuromuscular disorder, central nervous system disorders or injuries (e.g., spinal cord injury, brain injury, or stroke), muscle cramps, muscle spasms, and fasciculations.
In some embodiments, the compositions of the invention are also useful for treating painful muscle contraction of the head or neck as in tension, cluster or migraine headache, back spasms, leg cramps due to spinal stenosis, skeletal muscle pain, muscle pain (e.g., fibromyalgia) and spasms (e.g., nocturnal cramps), spasms and cramps due to treatment with dialysis, diuretics, β-blockers, statins, fibrates, p2-agonists, ACE inhibitors, ARBs and anti-psychotic medications, muscle claudication pain due to inactivity or restriction as seen in "economy class syndrome", paralysis, peripheral artery disease or immobilization, and neuromuscular diseases.
Neuromuscular disease can be caused by circulatory problems, stroke, immunological and autoimmune disorders, the failure of the electrical insulation surrounding nerves myelin,
genetic/hereditary disorders, such as Huntington's disease, certain rare tumors, the failure of the connections between the nerves and the muscle fibers, and exposure to pernicious environmental chemicals, poisoning (e.g. , heavy metal poisoning). Some neuromuscular diseases are caused either by viral infections or by attack by little-known pernicious proteins called prions. Diseases of the motor end plate include myasthenia gravis, a form of muscle weakness due to antibodies to the acetylcholine receptor, and its related condition Lambert-Eaton myasthenic syndrome (LEMS). Tetanus and botulism are bacterial infections in which bacterial toxins cause increased or decreased muscle tone, respectively. Myopathies are all diseases primarily resulting in muscular degeneration, rather than affecting the nerves themselves (e.g. , nemaline myopathy, centronuclear myopathy, mitochondrial myopathies, inflammatory myopathies, familial periodic paralysis, or drug-induced myopathyies). Muscular dystrophies, including Duchenne's and Becker's, are a large group of diseases, many of them hereditary or resulting from genetic mutations, where the muscle integrity is disrupted. They lead to progressive loss of strength and decreased life span. Also within the scope of the invention is treatment of Guillain-Barre syndrome and inflammatory muscle disorders, such as polymyalgia rheumatic, polymyositis, dermatomyositis, inclusion body myositis, and rhabdomyolysis. Additional neuromuscular disorders include, but are not limited to, multiple sclerosis, spinal cord spasticity, spinal muscle atrophy, myasthenia gravis, spinal cord injury, traumatic brain injury, cerebral palsy, hereditary spastic paraplegia, motor neuron disease (e.g., amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, progressive spinobulbar muscular atrophy (e.g., Kennedy' s disease), or post- polio syndrome), neuralgia, fibromyalgia, Machado-Joseph disease, cramp fasciculation syndrome, carpal tunnel syndrome, acrodynia, neurofibromatosis, neuromyotonias (e.g., focal neuromyotonia, Isaacs' syndrome), peripheral neuropathy, piriformis syndrome, plexopathy (e.g. , Brachial plexopathy or Lumbosacral plexobathy), radiculopathy (e.g., lower lumbar radiculopathy), and encephalitis.
Dystonia is a neurological condition that affects a muscle or group of muscles in a specific part of the body causing involuntary muscular contractions and abnormal postures. Types of dystonia include: focal dystonia, multifocal dystonia, segmental dystonia, generalized dystonia (e.g. , torsion dystonia or idiopathic torsion dystonia), hemidystonia, blepharospasm, psychogenic dystonia, cervical dystonia, acute dystonic reaction, and vegetative-vascular
dystonia. The methods and compositions described herein may be useful for cervical dystonia, cranial dystonia, laryngeal dystonia, and hand dystonia. Causes for the disorder include, but are not limited to, inheritance, birth-related or physical trauma, infection, poisoning (e.g. , lead poisoning), or reaction to some pharmaceutical agents, e.g. , neuroleptics. Treatment is difficult and has been limited to minimizing symptoms of the disorder, such as muscle cramping. The methods and compositions described herein may be useful for focal dystonia, blepharospasm, cervical dystonia, cranial dystonia, laryngeal dystonia, and hand dystonia.
In one embodiment, the subject has been diagnosed or identified as having multiple sclerosis. Multiple sclerosis (MS) is also known as disseminated sclerosis and encephalomyelitis disseminate. MS is an inflammatory disease in which the insulating sheaths of nerve cells in the brain and spinal cord are damaged, thereby disrupting the ability of the nervous system to communicate. The three main characteristics of MS are the formation of lesions in the central nervous system (also called plaques), inflammation, and the destruction of myelin sheaths of neurons. Symptoms of MS can include muscle spasms and muscle weakness.
In some embodiments, the subject has been diagnosed with or identified as having night cramps (also known as nocturnal cramps). Night cramps are spontaneous muscle contractions that occur during sleep, can be very painful, and often recur throughout the night. Elderly people, e.g., over 50 years of age, are at higher risk for experiencing night cramps.
In one embodiment, the subject has been diagnosed with or identified as having spinal cord spasticity. Spasticity is the uncontrolled tightening or contracting of the muscles that is common in individuals with spinal cord injuries and a variety of nervous system diseases.
Spasticity is usually defined as a velocity-dependent increase in the tonic stretch reflex (muscle tone) with exaggerated tendon jerks, clonus, and spasms, resulting from the hyperexcitability of the stretch reflex. About 65 -78 of the spinal cord injury population have some amount of spasticity, and it is more common in cervical (neck) than thoracic (chest) and lumbar (lower back) injuries. In one embodiment, the subject has experienced a central nervous system injury, such as a brain injury, a stroke, or a traumatic spinal cord injury. For example, the central nervous system injury is associated with unwanted or abnormal muscle contractions or spasms, or the absence of normal muscle contractions.
In some embodiments, the subject has been diagnosed or identified as experiencing muscle cramps, spasms, dystonias, or fasciculations (e.g., unwanted or abnormal muscle cramps,
spasms, dystonias, or fasciculations). Muscle cramps, spasms, dystonias, or fasciculations can also occur as a consequence of other diseases or disorders, such as diabetes (e.g. , diabetic neuropathy), Addison' s disease, peripheral artery disease, hypertension, alcoholism, liver cirrhosis, renal failure, hypothyroidism, neuromuscular diseases (e.g., amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, progressive spinobulbar muscular atrophy (e.g., Kennedy's disease), or post-polio syndrome), and metabolic disorders (e.g.,
adrenoleukodystrophy, phenylketonuria, or Krabbe disease). Accordingly, the methods described herein are also useful for treating or evaluating subjects that have been diagnosed with the other diseases or disorders associated with muscle cramps described herein.
Muscle cramps, spasms, dystonias, or fasciculations can occur as a side effect of some drugs. Medications that can cause muscle cramps include: diuretics, oral contraceptives, blood pressure medications. The methods described herein can also be useful to treat or evaluate subjects that are prescribed or take medication that cause muscle cramps. Exemplary
medications that can induce muscle cramps include, but are not limited to: diuretics, e.g. , Lasix (furosemide), Microzide (hydrochlorothiazide); Alzheimer' s disease medication, e.g. , Aricept (donepezil); myasthenia gravis medication, e.g. , Prostigmine (neostigmine); cardiovascular medication, e.g. , Procardia (nifedipine); osteoporosis medication, e.g. , Evista (raloxifene);
asthma medication, e.g. , Brethine (terbutaline), Proventil and Ventolin (albuterol); Parkinson's disease medication, e.g. ,Tasmar (tolcapone); cholesterol medication, e.g. , statins such as Crestor (rosuvastatin), Lescol (fluvastatin), Lipitor (atorvastatin), Mevacor (lovastatin), Pravachol (pravastatin), or Zocor (simvastatin).
In an embodiment, the compositions and methods disclosed herein are suitable for treating or evaluating a subject that has an absence of a normal muscle contraction, such as a gait abnormality. Gait abnormalities are deviations from normal walking or unusual and
uncontrollable walking patterns. Examples of gait abnormalities include propulsive gait, scissors gait, spastic gait, steppage gait, and waddling gait. For example, the gait abnormality is "foot drop," in which the dropping of the forefoot happens due to muscular weakness, damage to nerves, or paralysis of muscles. Gait abnormalities are often associated with neuromuscular diseases or disorders.
Connective Tissue Diseases
The compositions of the invention are also useful for treating connective tissue diseases. Examples of diseases include but are not limited to: degenerative joint disease (DJD), marfan syndrome, Ehlers-Danlos syndrome, osteogenesis imperfect, Stickler syndrome, Alport syndrome, congenital contractural arachnodactyly, psoriatic arthritis, systemic lupus
erythematosus, rheumatoid arthritis, scleroderma, Sjogren's syndrome, and mixed connective tissue disease.
Throat Conditions
The compositions of the invention can also treat throat disorders or throat injuries (e.g., from chemicals, cancer, surgery, or infection). Examples of throat disorders include, but are not limited to acid reflux, tonsillitis, pharyngitis, laryngospasm due to throat surgery, laryngitis, dysphagia, and spasmodic dysphonias.
Sarcoidosis
The compositions of the invention are also useful for treating sarcoidosis. Sarcoidosis is a disease involving abnormal collections of inflammatory cells (granulomas) that can form as nodules in multiple organs. The granulomas are most often located in the lungs or its associated lymph nodes, but any organ can be affected. The compositions of the invention are useful in treating various types of sarcoidosis including but not limited to: annular sarcoidosis, erythrodermic sarcoidosis, ichthyosiform sarcoidosis, hypopigmented sarcoidosis, Lofgren syndrome, lupus pernio, morpheaform sarcoidosis, mucosal sarcoidosis, neurosarcoidosis, papular sarcoid, scar sarcoid, subcutaneous sarcoidosis, systemic sarcoidosis, and ulcerative sarcoidosis.
Respiratory Conditions
The compositions of the invention may also useful for treating a respiratory condition or illness. Respiratory conditions involve the organs and/or tissues involved in respiration, including the lungs, trachea, bronchi, bronchioles, alveoli, pleura, pleural cavities. Without wishing to be bound by theory, activation of a TRP ion channels through administration of a capsaicinoid, capsinoid, or related analog or combination thereof of the present invention may
affect airway sensory nerve reactivity, thus leading to bronchodilation of airway smooth muscle. Exemplary respiratory conditions for which the composition of the present invention may be useful in treating include, but are not limited to, asthma, chronic obstructive pulmonary disease, bronchitis, emphysema, pneumonia, cystic fibrosis, pleural cavity diseases, influenza, or cold.
Cough
The compositions of the present invention may also be useful for treating or reducing cough in a subject. Cough is a reflex that is often repetitive in nature and may aid in clearing the breathing passages from particles, irritants, secretions, and the like. Coughing may be voluntary or involuntary. Exemplary conditions related to cough include respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease, bronchitis, emphysema, pneumonia, cystic fibrosis, pleural cavity diseases, influenza, or a cold), exposure to allergens or chemical irritants, or inflammation. In some embodiments, the composition of the present invention may be a cough suppressant.
Anxiety Disorders
In some embodiments, the subject has been diagnosed with or identified as having an anxiety disorder. An anxiety disorder may be characterized as a condition involving the central nervous system and can cause feelings of fear, anxiety, and anguish in the subject. These conditions can result in unwanted or abnormal muscle cramps, spasms, dystonias, and fasciculations that may be treated by compositions of the disclosed invention. Exemplary anxiety disorders include generalized anxiety disorder, phobic disorders, panic disorders, agoraphobia, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, separation anxiety, and situational anxiety.
Methods of evaluating a subject
The present invention provides various methods for evaluating a subject for the efficacy of a muscle cramp treatment or for treating an unwanted or abnormal muscle contraction, e.g., a muscle cramp, spasticity, dystonia, or fasciculation. In the methods described herein, a test muscle of a subject is electrically induced to have a test muscle cramp, and the electrical activity of the test muscle is recorded. In some embodiments, a test aliquot of a composition for treating
muscle cramps, spasms, dystonias, or fasciculations is administered to the subject, and a second test muscle cramp is induced. The electrical activity of the second test cramp is also recorded. Comparison and analysis of the recordings of the first and second test cramp can indicate the efficacy of the test aliquot on reducing, alleviating, or preventing the cramp. Comparison and analysis of the recordings can also be used to classify subjects, or identify subjects for certain treatments for muscle cramps.
Alpha motor neurons project from the brainstem and the spinal cord and innervate the muscles. Stimulation of the alpha motor neurons results in transmittal of an electrical signal to the muscles, generated from the movement of ions across the cell membrane. The electrical stimulation from the motor neurons causes muscle movement or contraction, e.g. , a muscle cramp or spasm. When the muscles are at rest, there is minimal or no electrical signal. Activity of the alpha motor neurons can be modulated by signaling from primary sensory neurons, which are activated by sensory input. Stimulation of non-taste primary sensory neurons with nerve endings in the mouth, esophagus and stomach, e.g., through activation of specific ion channels, can induce cause upregulation of inhibitory signals to the alpha motor neurons. Through this mechanism of intemeuronal negative feedback, activation of primary sensory neurons inhibit or prevents alpha motor neuron firing via inhibitory signaling, and thereby inhibits muscle contractions of muscle cramps or spasms.
Electrical stimulation can elicit a muscle contraction that recapitulates a muscle cramp, spasm, dystonia, or fasciculation. In the methods described herein, electrical stimulation is used to induce a test muscle cramp. The electrical activity of the test muscle before, during, and after the test muscle cramp is detected, measured, and recorded. Analysis of the recording of the electrical activity of a muscle experiencing an electrically induced cramp can be useful for determining the efficacy of a treatment for alleviating a muscle cramp.
Electromyography is a technique for measuring and recording the electrical activity of a muscle during rest and movement. The instrument that detects and records the electric signal generated from a muscle is called an electromyograph. The recording of the electrical activity obtained by the electromyograph is known as an electromyogram (or myogram). The eletromyograph may comprise at least one recording electrode, at least one reference electrode, an amplifier unit, a device for converting the analog signals to digital signals, and a device for generating and displaying the recordings. Optionally, the instrument may also include at least
one mechanism to detect additional biofeedback, such as body or skin temperature by a skin thermistor.
The electrical activity of a muscle, e.g. , a test muscle, is recorded and detected by an electrode, or a lead. There are two main types of electrodes: surface electrodes and inserted electrodes. Surface electrodes are non-invasive and are placed on the skin. Inserted electrodes include needle and fine wire electrodes, and are inserted directly into the muscle tissue. In a preferred embodiment, the electrode used in the present invention is a surface electrode.
A recording electrode is preferably placed over a test muscle, and a reference electrode is placed nearby, e.g. , within 2-6 inches of an active electrode. Preferably, the reference electrode is placed on a synergistic muscle. A synergistic muscle is a muscle that aids or participates in movement with the test muscle but does not cramp with the test muscle when electrically induced. In some preferred embodiments, a series or an array of multiple recording electrodes is used. For example, a linear array of 8 recording electrodes is applied on the test muscle, and optionally, a linear array of 4-8 recording electrodes is used on the synergistic muscle. In other embodiments, a grid array of recording electrodes is applied on the target muscle, e.g. , a grid array of 6 x 5 electrodes is used.
In the methods described herein, electrical stimulus is applied to a test muscle to induce a test muscle contraction. The electrical stimulus is delivered by a stimulation electrode. The stimulation electrode is placed preferably directly on the skin over the test muscle. The electrical stimulus is defined by multiple parameters, such as stimulation frequency (Hertz or Hz), current intensity (milliamps or mA), pulse frequency (pulse per second or pps), and duration of time of stimulation. The electrical stimulus can be delivered by percutaneous electrical stimulation or surface electrical stimulation.
Preferred test muscles for electrically inducing a muscle cramp include the flexor hallucis brevis (FHB, or big toe flexor muscle) and gastrocnemius (calf muscle). Other target muscles may include the abductor hallucis (AH), the biceps brachii (biceps), the triceps surae (triceps), or the quadriceps femoris (quadriceps).
The appropriate stimulation frequency of electrical stimulation to induce a test muscle cramp may vary depending on the size or location of the muscle or the individual. For example, the electrical stimulation can be at least 1 Hz, at least 2 Hz, at least 3 Hz, at least 4 Hz, at least 5 Hz, at least 6 Hz, at least 7 Hz, at least 8 Hz, at least 9 Hz, at least 10 Hz, at least 11 Hz, at least
12 Hz, at least 13 Hz, at least 14 Hz, at least 15 Hz, at least 20 Hz, at least 25 Hz, at least 30 Hz, at least 35 Hz, at least 40 Hz, at least 50 Hz, at least 60 Hz, at least 70 Hz, at least 80 Hz, at least 90 Hz, or at least 100 Hz. In some preferred embodiments, the stimulation frequency for the FHB is 8 Hz, 10 Hz, 12 Hz, 14 Hz, or 18 Hz. In some embodiments, the stimulation frequency can vary over time. For example, the stimulation frequency increases over time, e.g., from 2 Hz to 24 Hz, increasing by 2 Hz increments.
The minimum frequency of the electrical stimulation capable of inducing a cramp has been termed the "threshold frequency." Studies have shown that the threshold frequency for cramp induction is lower in cramp-prone subjects compared with subjects with no history of cramps. (Bertolasi et al., Ann. Neurol. 1993, 133:303-6; Miller and Knight, Muscle Nerve. 2009, 39:364-8; and Minetto et al., Muscle Nerve. 2009; 40:535-44). For example, Miller and Knight (Muscle Nerve. 2009; 39:364-8) found a threshold frequency for the flexor hallucis brevis muscle of approximately 15 Hz in subjects with a history of cramping and of approximately 25 Hz in individuals not prone to cramping.
The amplitude, or intensity of the current, of the electrical stimulus also may vary depending on the size or location of the muscle or the individual. A maximal current intensity refers to the current intensity required to achieve a plateau in the M-wave peak amplitude. The M-wave refers to the EMG signal detected. In a preferred embodiment, the current intensity is 30% supramaximal, or greater than, the maximal current intensity. In some embodiments, the maximal current intensity is determined for each individual subject prior to testing the subject. For example, the current intensity is 5 mA, 10 mA, 15 mA, 20 mA, 25 mA, 30 mA, 40 mA, 50 mA, or 60 mA.
The electrical stimulus can be applied as a series of pulses for a duration of time. For example, the stimulus may be applied as a series of at least 100 microsecond pulses, at least 120 microsecond pulses, at least 150 microsecond pulses, at least 180 microsecond pulses, at least 200 microsecond pulses, at least 300 microsecond pulses, at least 400 microsecond pulses, at least 500 microsecond pulses, or at least 600 microsecond pulses. The stimulus can be applied for 1 second, 2 seconds, 3 seconds, 4 seconds, 5 seconds, 6 seconds, 7 seconds, 8 seconds, 9 seconds, 10 seconds, or longer. Preferably for inducing cramps in the FHB, the stimulus is applied as a series of 180 microsecond pulses for 7 seconds.
In some embodiments, the parameters of electrical stimulation to be applied to the test muscle may be adjusted to decrease or increase the magnitude of the test muscle contraction to better recapitulate a muscle cramp, spasm, dystonia, or fasciculation. For example, the frequency or intensity of electrical current applied to the test muscle may vary depending on the type of test muscle contraction desired, e.g. , the frequency of stimulation is increased to induce a test muscle cramp compared to a test muscle spasm.
In the methods described herein, the electrical activity of a target muscle is detected and recorded by a recording electrode before, during, and after an induced cramp. The electrical activity is recorded and displayed as a profile or electromyogram. Preferably, the profile contains the electrical activity before, during, and after the application of electrical stimulation to induce a muscle cramp. In some embodiments, the profile contains the electrical activity during the application of electrical stimulation and after the application of electrical stimulation. In some embodiments, the electrical activity is converted to root mean square (RMS) values and are displayed as a function of time. In the case where more than one recording electrode is utilized to measure the electrical activity of the target muscle, the profile contains the average electrical activity detected from all of the recording electrodes as a function of time.
The pattern of the recorded electrical activity or signal can indicate the presence or absence of an induced muscle cramp. Indication of an induced muscle cramp includes involuntary electrical signal of the stimulated muscle after cessation of the electrical stimulation, preferably with concurrent absence of electrical signal of the synergistic muscle. Alternatively, a signal amplitude greater than 2 or 3 standard deviations above the 1 second baseline signal amplitude of either the target muscle prior to stimulation or the synergistic muscle after stimulation indicates an induced cramp. The induced muscle cramp can last for at least 5 seconds, at least 10 seconds, at least 15 seconds, at least 20 seconds, at least 25 seconds, at least 30 seconds, at least 35 seconds, at least 40 seconds, at least 45 seconds, at least 50 seconds, at least 55 seconds, at least 1 minute, at least 2 minutes, at least 3 minutes, at least 4 minutes, or at least 5 minutes.
In some embodiments, a first muscle cramp is electrically- induced in a subject prior to administration of a composition for treating a muscle cramp, and after a rest period, a second muscle cramp is electrically-induced in a subject after administration of the composition. The profile obtained for the first induced cramp before administration of the composition is referred
to as the reference profile. The profile obtained for the second induced cramp after administration of the composition is referred to as the treatment profile. Comparison of the treatment profile and the reference profile can be used to select subjects for treatment with the composition or to identify subjects that will be responsive to the treatment with the composition. Specifically, the properties of the induced cramp in the reference and treatment profiles are compared to determine whether the composition administered reduced or prevented the second induced cramp.
Alternatively, a value can be determined from the reference profile, e.g. , a reference value, and a value can be determined from the treatment profile, e.g. , a treatment value. The reference value and the treatment value can be compared to determine a reduction or prevention of a cramp. In one embodiment, the values determined from the reference and/or treatment profile represent the parameters of muscle cramp. A decrease in the treatment value compared to the reference value indicates that that the test aliquot administered is effective at alleviating or preventing a muscle cramp.
The parameters of a muscle cramp can be compared for determining the efficacy of a treatment for alleviating a cramp, e.g. , by a reduction of a muscle cramp parameter or prevention of a cramp. Parameters of muscle cramps that can be determined from the electromyogram include the area under the curve, the peak amplitude, the duration of the cramp, and a change in threshold frequency used to elicit a test muscle cramp.
An area under the curve value can be calculated for the reference and treatment profile using standard methods known in the art. A decrease or absence of an area under the curve value in the treatment profile compared to the reference profile indicates that an electrically induced cramp has been reduced or prevented. For example, the area under the curve in the treatment profile may be at least 1 %, 5%, 10%, 15,%, 20%, 25%, 30%, 35%, or 50% decreased compared to the area under the curve in the reference profile.
The peak amplitude after cessation of the electrical stimulus can be compared between the reference and treatment profiles. A reduction in or absence of the peak amplitude in a treatment profile compared to a reference profile indicates that an electrically induced cramp has been reduced or prevented. For example, the peak amplitude in a treatment profile may be at least 1%, 5%, 10%, 15,%, 20%, 25%, 30%, 35%, or 50% decreased compared to the peak amplitude of the reference profile.
The duration of the test cramp can be compared between the reference and treatment profile. A decrease in or absence of the duration of the cramp indicates the reduction or prevention of the electrically induced cramp. For example, the duration of the cramp may be at least 1%, 5%, 10%, 15,%, 20%, 25%, 30%, 35%, or 50% decreased compared to the duration of the cramp in the reference profile.
Threshold frequency refers to the minimum frequency of electrical stimulation required to elicit a cramp. In an embodiment, a change in the threshold frequency required to elicit a test muscle cramp indicates the efficacy of a treatment for alleviating a cramp. For example, a change in the threshold frequency may be at least 1%, 5%, 10%, 15,%, 20%, 25%, 30%, 35%, or 50% , 100%, 200% increased compared to the threshold frequency required before treatment, e.g. , in the reference profile. For example, a change in the threshold frequency may be at least 1%, 5%, 10%, 15,%, 20%, 25%, 30%, 35%, or 50% , decreased compared to the threshold frequency required before treatment, e.g. , in the reference profile.
In certain embodiments, the rest period between the first test cramp and the second test cramp is at least 1 minute, 2 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes, 90 minutes, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 16 hours, 20 hours, or 24 hours. In certain embodiments, the electrical stimulation is re-applied to induce a second muscle cramp at least 1 minute, 2 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes, 90 minutes, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 16 hours, 20 hours, or 24 hours after administration of the composition for treating muscle cramps.
In one embodiment, the test comprises determining that a cramp can be induced in a subject by application of stimulus. For example, the stimulus is percutaneous electrical stimulation or surface electrical stimulation. In some embodiments, the magnitude of the parameters of the induced muscle cramp, e.g., as determined from an EMG profile, identifies or classifies subjects with respect to selection of treatment regimens, or predicts the response of a subject to a specific treatment regimen.
Combination Therapies
In certain embodiments, additional therapeutic agent(s) may be administered with compositions of the present invention for, e.g. , the treatment of peripheral nervous system conditions (e.g., peripheral neuropathy), central nervous system conditions, muscle conditions and disorders (e.g., fibromyalgia, muscle spasms and cramps (e.g. , nocturnal cramps), painful muscle contractions (e.g., a muscle contraction of the head or neck), neuromuscular disorders (e.g., motor neuron disease) or dystonia (e.g., cervical dystonia, blepharospasm, back spasms, or leg cramps due to spinal stenosis)), connective tissue diseases (e.g. , degenerative joint disease), throat conditions (e.g., dysphagia or spasmodic dysphonias), tactile sensitivity, electrolyte imbalance and/or vitamin deficiency, respiratory conditions (e.g., asthma), cough, and sarcoidosis. In one embodiment, the candidate therapeutic agents are agents already known in the art for use for other conditions or disorders, e.g. , neuromuscular therapeutic agents. When combination therapy is employed, the additional therapeutic agent(s) can be administered as a separate formulation or may be combined with any of the compositions described herein.
For example, any of the compositions described herein can be used for the treatment of nocturnal (or night) cramps. In some embodiments, the compositions can be used in
combination with a sleep aid. Sleep aids that can be used in combination with the compositions and methods described herein include: antihistamines (e.g. , diphenhydramine and doxylamine); benzodiazepines (e.g. , estazolam (ProSom), flurazepam (Dalmane), quazepam (Doral), temazepam (Restoril), and triazolam (Halcion)); non-benzodiazepine sedative hypnotics (e.g. , eszopiclone (Lunesta), zalepon (Sonata), and Zolpidem (Ambien)); and melatonin receptor agonist hypnotics (e.g. , ramelteon (Rozerem). Still other sleep aids that can be used in combination with the compositions and methods described herein include: chamomile, valerian root, kava kava, lemon balm, passionflower, lavender, St. John's Wort, melatonin, tryptophan (e.g. , L- tryptophan), 5-hydroxytryptophan (5-HTP), catnip, hops, rhodiola, oatstraw, lavender, GABA, L-theanine, linden, ginseng (e.g. , Siberian ginseng), honey, nutmeg, mugwort, butterbur, rauwolfia, taumelloolch, American hellebore, quassia, tulip tree, brewer's yeast, inositol, skullcap, phosphatidylserine, calcium, magnesium, vitamin B6, vitamin B 12, and pantothenic acid (B5).
In another embodiment, any of the compositions described herein can be used for the treatment of painful muscle contraction of the head or neck as in tension, cluster or migraine headache. In some embodiments, the compositions can be used with analgesics, including
aspirin, ibruprofen, acetaminophen, or naproxen; with triptans including sumatriptan, rizatriptan, naratriptan; with mild sedatives including butalbital; with anti-depressants including
amitriptyline; with dihydroergotamine mesylate; or with ketorolac.
Any of the compositions described herein can be also be used for the treatment of focal dystonia. In some embodiments, the compositions can be used with botulinum toxin; with anticholinergic agents including trihexyphenidyl and benztropine; with GABAergic agents including benzodiazepines; and with dopaminergic agents including tetrabenazine and levodopa.
In further embodiments, the compositions described herein can be also be used for the treatment of muscle claudication pain due to inactivity or restriction as seen in "economy class syndrome", paralysis, peripheral artery disease or immobilization. In some embodiments, the compositions can be used with cilostazol or with pentoxifylline. The compositions described herein can be also be used for the treatment of sarcoidosis. In some embodiments, the compositions can be used with non-steroidal anti-inflammatory drugs (NSAIDs) including ibuprofen and aspirin; with corticosteroids, including prednisone and prednisolone; and with steroid-sparing agents, including azathioprine, methotrexate, mycophenolic acid, and
leflunomide.
In other embodiments, any of the compositions described herein can also be used in combination with a treatment for pain or a disorder relating to the oral cavity, such as oral lesions, canker sores, cold sores, thrush, gingivitis, leukoplakia, halitosis, or dry mouth. In some embodiments, the composition can be used with or antibacterial or antiviral agents to treat or prevent tooth decay or carries.
In other embodiments, any of the compositions described herein can also be used in combination with a treatment for pain or a disorder relating to the stomach or gastrointestinal tract, such as indigestion, heartburn, colitis, irritable bowel syndrome, constipation, diarrhea, lactose intolerance, gastroesophageal reflux disease, ulcers, nausea, or stomach cramps. In some embodiments, the compositions can be used with antacids (e.g., simethicone, magaldrate, aluminum salts, calcium salts, sodium salts, magnesium salts, alginic acid) laxatives , H2 antagonists (e.g., ranitidine, famotidine, nizatidine, cimetidine) or proton pump inhibitors (e.g., omeprazole, lansoprazole, esomeprazole, dexlansoprazole, rabeprazole, or pentoprazole), and antidiarrheals (e.g., bismuth subsalicylate).
In other embodiments, any of the compositions described herein can be also be used for the treatment of disease, disorder or injury to the peripheral nervous system such as cramp fasciculation syndrome, peripheral neuropathy, carpal tunnel syndrome or EBV. In some embodiments, the compositions can be used to treat cramp fasciculation syndrome with β- blockers; analgesics including ibuprofen and acetaminophen; magnesium; or carbamazepine. In some embodiments, the compositions can be used to treat peripheral neuropathy with tricyclic antidepressants, including amitriptyline; with antiepileptic therapies including gabapentin and sodium valproate; with synthetic cannabinoids including nabilone; with pregabalin; or with serotonin-norepinephrine reuptake inhibitors (SNRIs), including duloxetine. In some embodiments, the compositions can be used to treat carpal tunnel syndrome with corticosteroids.
EXAMPLES
General Procedures
TRP-Stim Solution
The solution ("TRP-Stim") administered to the volunteers contains: a base of a 1: 1 mixture of water and light karo syrup (for increased viscosity); 0.075% of a capsicum
preparation intended for human use (Clearcap Super Soluble Caspsicum, alsec Inc.); 1% of a cinnamon volatile oil intended for human consumption (Aquaresin Cinnamon, Kalsec Inc); and 1.5% of a ginger oleoresin intended for human use (Aquaeresin Ginger, Kalsec Inc).
Electromyography (EMG) Measurements of Cramps
Methods for placing stimulating electrodes on the flexor hallucis brevis (FHB) or gastrocnemius muscles followed the procedures described by Minetto et al., Muscle Nerve, 40: 535-544, 2009, the contents of which are incorporated herein by reference in its entirety. The active stimulation electrode (cathode) is a 1.25" circular mesh -backed silver patch electrode (Bio-Flex manufactured by Lead-Lok) and is placed so as to produce contraction of the FHB with minimal stimulation amplitude. The stimulation reference electrode is a 2" square patch electrode (Bio-Flex manufactured by Lead-Lok) is placed on the opposite side of the foot, e.g., under the lateral malleous. Cramping of the FHB is induced as described by Minetto et al. (ibid.) using a battery-powered electrical muscle stimulator (EMS-7500, Current Solutions LLC) to
deliver pulses. A series of 180 microsecond biphasic square pulses of voltages is applied at various frequencies to stimulate the muscle. First, using slow (2 Hz) stimulation, the amplitude is adjusted to -30% more than the threshold amplitude for eliciting strong contraction of the muscle. The muscle is then stimulated by a train of 180 microsecond pulses of this amplitude delivered for 7 seconds at various frequencies. The stimulation delivered by the stimulator includes "ramp up" and "ramp down" periods of 1 second preceding and following the main 7- second stimulation period during which the amplitude of the pulses is ramped up or down to and from the final value.
It has been previously shown that susceptibility to cramping of the FHB using similar electrical stimulation protocols is highly reproducible within each subject (Minetto et al., Muscle Nerve 2008, 37:90-100, 2008) and is correlated with susceptibility to "ordinary muscle cramps" (Miller et al., Muscle Nerve 2009, 39:364-368).
Cramping is quantified by making EMG recordings from the belly of the FHB. Two external EMG recording electrodes (Vermed SilveRest) are placed along the belly of the FHB. The differential voltage relative to a third ground electrode placed at the ankle is amplified, digitized, and saved to computer using a 1-330-C2+ EMG unit with PhysioLab software (J&J Engineering, Poulsbo, WA). The raw wide -band EMG signal (10-400 Hz) is processed by being rectified and integrated to provide the area under the curve (RMS). The duration of cramp is quantified by the time required for the RMS EMG to return to an amplitude of 3 standard deviations above the baseline value. This will correlate well with duration of the cramp as observed by the return to the toe to resting position.
Recordings of cramps in calf muscles (medial gastrocnemius) are made using similar procedures, with placement of stimulation and recording electrodes following that by Minetto et al., Muscle Nerve 2009,40:535-544). The amplitude of stimulation by a single 180 microsecond biphasic square pulses is adjusted to be -30% of the amplitude required for maximal contraction of the muscle. After a short period of slow stimulation (2 Hz), the frequency of stimulation is ramped up to 22-24 Hz over - 5 seconds and is held at this frequency for an additional 5 seconds before terminating the stimulation. This protocol reliably induces cramping of 30-90 seconds.
Assay of Activation of Rat Sensory Neurons
Methods to monitor activation of primary sensory neurons isolated from the trigeminal ganglion of rats follow those published by Park et al. (J Biol Chem. 2006, 281: 17304-17311). Cells isolated from rat trigeminal ganglia are loaded with the fluorescent calcium indicator Fura- 2AM (Fura-2-acetoxymethyl ester), and increases in intracellular calcium reflecting activation of the neurons are measured as an increase in Fura-2 fluorescence as measured by digital video micro-fluorometry with an intensified CCD camera. The same capsicum extract, cinnamon extract, and ginger extract used in the TRP-Stim beverage are applied to the neurons after dilution in balanced salt solution (in mM: 145 NaCl, 5 KC1, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose) for perfusion of the neurons. Caspicum extract is applied at a dilution of 1/800,000, cinnamon extract at a dilution of 1/5,000, and ginger extract at a dilution of 1/12,000. In some experiments the calcium ionophore ionomycin is added following the tests with extracts to produce a large entry of calcium as an index of the maximal possible signal, illustrating the strength of activation by the heavily diluted extracts.
Example 1: Activation of Rat Sensory Neurons by Capsicum, Cinnamon, and Ginger Extracts
Figure 1 shows graphs from six sensory neurons isolated from the trigeminal ganglia of rats, illustrating their activation by the capsicum, cinnamon, and ginger extracts that are used in the human experiments. Activation is quantified as an increase in intracellular free calcium, monitored by a fluorescent calcium indicator. Extracts are diluted into normal extracellular saline (Tyrode's solution) and are tested at lower concentrations than used in the beverage, taking account that concentrations present at nerve endings in mouth, esophagus, or stomach are expected to be lower than the beverage as a result of dilution into mucosa and interstitial fluid. All three extracts are capable of activating individual neurons when applied at concentrations 50- fold to 15,000-fold lower than used in the beverage. Each trace shows a record from a different neuron, illustrating that some neurons could be activated by each of the extracts and that the strength of activation by each extract varied among particular neurons. These records illustrate that each agent is capable of acting alone to activate some neurons and that a combination of agents can produce stronger activation of a larger fraction of neurons. Further, the bottom two records show that there can be strongly synergistic activation of neurons by the capsicum extract and the ginger extract when applied in combination.
Example 2: Effect of TRP-Stim Administration to Human Subjects
The in vitro data of Example 1 show that each individual component of the TRP-Stim solution by itself is capable of activating sensory neurons. Consistent with this, human experiments show the efficacy of a beverage with capsicum alone (ClearCap capsicum at 1/2000 dilution) to inhibit cramping, achieved within 5 minutes.
The following experiments, illustrated by Figures 2-8, show cramp relief by the administration of a uniform beverage composition designed for maximal TRP stimulation containing capsicum, cinnamon extract, and ginger extract, and where the physiological effects were monitored by EMG recording. These experiments demonstrate the utility of evaluating subjects using EMG for determining the efficacy of a composition for alleviating an electrically induced cramp. The methods demonstrated in this example can also be used in subjects that have been diagnosed or identified with a disorder associated with muscle cramps, e.g. , a disorder disclosed herein, such as night cramps or a neuromuscular disorder, e.g. , multiple sclerosis, spinal cord spasticity, and dystonia.
Figures 2-8 are graphs of EMG recordings of muscle contractions in seven human volunteers (four females and three males) that show the efficacy in preventing and treating cramps of ingesting 50 mL of a solution designed to stimulate TRP VI and TRPA1 receptors in the mouth, esophagus, and stomach. Muscle cramps are induced by brief stimulation of toe or calf muscles (Figures 2-7) or occurred spontaneously (Figure 8). After recording cramping in control, subjects drink 50 mL of the TRP-Stim solution containing capsaicin and capsaicinoids (TRPV1 agonists), cinnamaldehyde (TRPA1 agonist), and gingerols (TRPA1 and TRPVl agonists). After ingestion of the solution, subjects are tested for muscle cramping using the same procedures as in control at times ranging from 4 minutes to 11 hours after ingestion.
Eight human volunteers are tested using the TRP-Stim beverage. Seven of the eight show an abolition or dramatic reduction in cramping following ingestion of the beverage (Figures 2-8). The effect is typically complete within 4-15 minutes and lasted for 2 ½ to 4 hours in different subjects. An eighth subject showed cramping of the FHB that is not dramatically affected by the TRP-Stim beverage. The cramping in this subject is of much lower EMG amplitude that the other subjects and appeared to involve repetitive contraction of only a few motor units.
Figure 2 is a graph showing the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis of Subject A. Under control conditions, cramping is reliably induced by stimulating the muscle using an electrical muscle stimulator (EMS-7500, Current Solutions LLC) placed with external electrodes for FHB stimulation. Muscle activity is recorded using external electrodes placed over the belly of the muscle attached to an EMG amplifier (J&J Engineering I- 330C2+). In control, stimulation using 180 microsecond biphasic pulses delivered at 18 Hz for 5 seconds reliably and reproducibly produce cramping of the muscle, which is evident by EMG activity continuing after the cessation of stimulation. After ingestion of the TRP-Stim beverage, cramping is very brief after 11 minutes and essentially absent at tests at 20 minutes and 2 ½ hours after ingestion.
Figure 3 is a graph showing the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis of a second subject. Under control conditions, cramping is induced by stimulation at 10 Hz for 5 seconds (180 microsecond pulses, amplitude set to -30% higher than threshold for muscle contraction), and a longer cramp is induced by increasing the frequency to 12 Hz. In recordings beginning 12 minutes after ingestion of the TRP-Stim beverage, stimulation at 10 Hz or 12 Hz produced essentially no cramping, and increasing the frequency of stimulation to 14 Hz also did not induce cramping. The dramatic reduction in cramping was still present 4 hours later in this subject.
Figure 4 is a graph showing the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis of a third subject tested over longer times. Under control conditions, a cramp lasting 58 seconds is induced by stimulation at 18 Hz for 5 seconds (180 microsecond pulses, amplitude set to -30% higher than threshold for muscle contraction). After ingestion of the TRP-Stim beverage, the duration of the cramp is reduced to 27 seconds after 8 minutes and to 8 seconds after 15 minutes. Cramping is abolished after 20 minutes and in a test after 2 hours. In tests 11 hours after ingestion, reliable cramping returns. After the subject again drinks 50 mL of the TRP-Stim beverage, cramping is completely abolished in tests beginning after 10 minutes.
Figure 5 is a graph showing the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis of a fourth subject. This subject engages in strenuous exercise (triathlon) four hours earlier and experiences muscle twitchiness. This subject has an unusually low frequency threshold (8 Hz) for induction of cramping in the FHB muscle, and the resulting cramps are unusually long (172 seconds after 8 Hz stimulation and 222 seconds after 10 Hz
stimulation). Cramping is completely gone in tests starting 13 minutes after ingestion of the TRP-Stim beverage, even when increasing the stimulation frequency to 12 Hz. Cramping is still abolished 3 hours later. After 4 hours, cramping returns with an increased frequency threshold (10 Hz) and shorter cramps than in control. After the subject again drinks 50 mL of the TRP- Stim beverage, cramping is again completely abolished.
Figure 6 is a graph showing the effect of the TRP-Stim beverage on cramping of the gastrocnemius (calf) muscle of a fifth subject. The muscle is stimulated by a protocol ramping the frequency of stimulation from 2 Hz to 28 Hz (180 microsecond pulses, amplitude set to -30% higher than threshold for muscle contraction). After cessation of stimulation, the muscle went into a prolonged cramp lasting 59 seconds. In a test 3 minutes after ingestion of 50 mL of TRP-Stim, cramping is abolished.
Figure 7 is a graph showing the effect of the TRP-Stim beverage on cramping of the gastrocnemius (calf) muscle of a sixth subject. The muscle is stimulated by a protocol ramping the frequency of stimulation from 2 Hz to 24 Hz (180 microsecond pulses, amplitude set to -30% higher than threshold for muscle contraction). After cessation of stimulation, the muscle went into a prolonged cramp lasting 96 seconds. In a test 4 minutes after ingestion of 50 mL of TRP- Stim, cramping is abolished. Cramping is still abolished in a test conducted 40 minutes later.
Figure 8 is a graph showing the effect of the TRP-Stim beverage on cramping of an FHB muscle in a seventh subject, who experiences spontaneous cramping induced by pointing her toe. In control conditions, voluntary toe flexes lasting ~5 seconds reliably producedscramping of the FHB lasting 5-8 seconds in different trials. Ten minutes after the subject ingests 50 mL of the TRP-Stim beverage, cramping is abolished.
The methods described in this example can be used to evaluate subjects with disorders associated with muscle cramps, for example, subjects that experience night cramps or have been diagnosed or identified as having a neuromuscular disease, e.g. , multiple sclerosis, spinal cord spasticity, or dystonias. For example, the methods described in this example can be used to assess the efficacy of any of the compositions described herein for alleviation of an electrically- induced muscle cramp in a subject diagnosed or identified as having a disorder associated with muscle cramps. Also, the methods described in this example can also be used to evaluating and classifying a subject diagnosed or having a disorder associated with muscle cramps.
Other Embodiments
From the foregoing description, it is apparent that variations and modifications may be made to the invention described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.
All publications, patent applications, and patents mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication, patent application, or patent was specifically and individually indicated to be incorporated by reference.
Claims
1. A composition formulated for oral administration, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof, and a pharmaceutically acceptable excipient, wherein said composition is a liquid or solid, and wherein said composition is formulated for delayed release of said capsaicinoid, capsinoid, or related analog or combination thereof.
2. The composition of claim 1, wherein said composition comprises a plurality of capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient.
3. The composition of claims 1 and 2, wherein said composition comprises two
capsaicinoids, capsinoids, or related analogs or combinations thereof and a pharmaceutically acceptable excipient.
4. The composition of any one of claims 1-3, wherein said composition comprises a capsaicinoid, capsinoid, or related analog or combination thereof and a plurality of
pharmaceutically acceptable excipients.
5. The composition of any one of claims 1-4, wherein said pharmaceutically acceptable excipient comprises an agent for delayed release of a capsaicinoid, capsinoid, or related analog or combination thereof, such that, when orally administered to a subject, the capsaicinoid, capsinoid, or related analog or combination thereof is not substantially released in the stomach of said subject.
6. The composition of claim 5, wherein the agent for delayed release is selected from the group consisting of: hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, carboxymethyl cellulose, and mixtures thereof.
7. The composition of any one of claims 1-6, wherein said pharmaceutically acceptable excipient comprises a coating.
8. The composition of claim 7, wherein said coating is selected from the group consisting of: enteric coatings, sugar coatings, and polymeric coatings.
9. The composition of any one of claims 1-8, wherein said capsaicinoid, capsinoid, or related analog or combination thereof is embedded in biodegradable microparticles or nanoparticles for sustained release.
10. The composition of any one of claims 1-9, wherein said composition further comprises a formulation base.
11. The composition of claim 10, wherein said formulation base comprises an oil and a lipophilic additive.
12. The composition of claim 11, wherein said oil is selected from the group consisting of: vegetable oil, mineral oil, soya oil, sunflower oil, corn oil, olive oil, nut oil, and liquid paraffin.
13. The composition of claim 11, wherein said lipophilic additive is selected from the group consisting of: polyethylene glycol, fatty acid mono-, di-, or triglycerides, palmitic acid, stearic acid, behenic acid, polyethylene glycol fatty acid esters, candelilla wax, carnauba wax, polyethylene oxide wax, and petroleum wax.
14. The composition of any one of claims 1-13, wherein the composition further comprises a coloring agent, a dissolving agent, a flavoring agent, a sweetener, a viscosity modifier, an electrolyte, a vitamin, a mineral, an antioxidant, or a preservative.
15. The composition of any one of claims 1-14, wherein said composition is formulated as a liquid.
16. The composition of claim 15, wherein said liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups, linctuses, drops, sprays, and elixirs.
17. The composition of any one of claims 1-14, wherein said composition is formulated as a solid.
18. The composition of claim 17, wherein said solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges, gums, candies, chews, foodstuffs, dissolving strips, films, and semi-solid formulations.
19. The composition of claim 18, wherein said capsule is a hard or soft capsule.
20. The composition of any one of claims 1-19, wherein said capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring.
21. The composition of claim 20, wherein said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate, dihydrocapsiate, nordihydrocapsiate, norcapsaicin, capsiconiate, dihydrocapsiconiate and other coniferyl esters, capsiconinoid, and 3- hydroxyacetanilide .
22. The composition of claim 21, wherein said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or about 0.001% to about 10% (v/v).
23. The composition of 20, wherein said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4-[((6E)-8- methylnon-6-enoyl.aiTiino)methyl.]-2-methyoxyphenyl formate, 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2- methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoyIamino)methyI]-2-methyoxyphenyl
butanoate, 4-[((6F -8-raethylnon-6-enoylamino)rnethyl]-2-meth.oxyphenyl 2,2- dimethylpropanoate, 4-[((6E)-8-methylnon-6-enoylaiiiino)methyl]-2-methyoxyphenyl octadecanoate, 4-[((6E)-8-metiiylnon-6-enoylamino)metiiyl]-2-methyoxyphenyl{4-[((6E)-8- methylnon-6-enoylamino)methyl]-2-methoxyphenoxy}forrnate, homovanillyl 8- methylnonanoate, 3-(3-methoxy-4-hydroxyphenyl)propyl 8-methylnonanoate, 8-methylnonyl homovanillate), 8-methylnonanoic acid- substituted benzyl ester derivative),
heptanoylisobutylamide, heptanoyl guaiacylamide, 7-phenylhept-6-yne-acid-4-hydroxy-3- methoxybenzy] amide, dohevanil, denatonium capsaicinate, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-chlorophenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-fluorophenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]- N'- [2- (2,4-dichlorophenyl)ethyl] thiourea,N- [4- (2-aminoethoxy)-3-methoxybenzyl] -N'- [2- (4- benzyloxyphenyl)ethyl] thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4-(N- octyloxy)phenyl)ethyl] thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[4-N- octyloxybenzyl] thiourea, N-phenylmethylalkynamide capsaicin derivatives, N-(4-0-glycerol-3- methoxybenzyl)-nonamide, N-nonanoyl vanillylamide-4-glyceryl ether, N-(4-0-acetic acid sodium-3-methoxybenzyl-nonamide, sodium N-nonanoyl vanillylamide-4-O-acetate, N-(4-0- glycol-3-methoxybenzyl)-nonamide (N-nonanoyl vanillylamide-4-glycol ether), 20- homovanillyl-mezerein, 20-homovanillyl- 12-deoxyphorbol- 13-phenylacetate), civamide (N-[(4- hydroxy-3-methoxyphenyl)-methyl]-8-methyl-(Z)-6-nonemamide), nuvanil, capsavanil, olvanil, arvanil, and palvanil (N-palmitoyl-vaniUamide).
24. The composition of claim 23, wherein said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or about 0.001% to about 10% (v/v).
25. The composition of any one of claims 1-24, wherein said composition is capable of reducing gastrointestinal side effects.
26. The composition of any one of claims 1-25, wherein said composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof which target a TRP channel.
27. The composition of claim 26, wherein said composition comprises a TRP channel activator.
28. A composition formulated for oral administration to a subject, said composition comprising an effective amount of a capsaicinoid, a capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient, wherein upon administration, the capsaicinoid, a capsinoid, or related analog or combination thereof has a residence time of greater than about 5 seconds in the mouth of the subject.
29. The composition of claim 28, wherein said composition comprises a plurality of capsaicinoids, capsinoids, or related analogs or combinations thereof.
30. The composition of any one of claims 28-29, wherein said composition comprises two capsaicinoids, capsinoids, or related analogs or combinations thereof
31. The composition of any one of claims 28-30, wherein said composition comprises a plurality of pharmaceutically acceptable excipients.
32. The composition of any one of claims 28-31, wherein said capsaicinoid, capsinoid, or related analog or combination thereof has a residence time of greater than about 60 seconds in the mouth of a subject.
33. The composition of any one of claims 28-32, wherein said composition further comprises a formulation base.
34. The composition of claim 33, wherein said formulation base comprises an oil and a lipophilic additive.
35. The composition of claim 34, wherein said oil is selected from the group consisting of: vegetable oil, mineral oil, soya oil, sunflower oil, corn oil, olive oil, nut oil, and liquid paraffin.
36. The composition of claim 34, wherein said lipophilic additive is selected from the group consisting of: polyethylene glycol, fatty acid mono-, di-, or triglycerides, palmitic acid, stearic acid, behenic acid, polyethylene glycol fatty acid esters, candelilla wax, carnauba wax, polyethylene oxide wax, and petroleum wax.
37. The composition of any one of claims 28-36, wherein the composition further comprises a coloring agent, a dissolving agent, a flavoring agent, a sweetener, a viscosity modifier, an electrolyte, a vitamin, a mineral, an antioxidant, or a preservative.
38. The composition of any one of claims 28-37, wherein said composition is formulated as a liquid.
39. The composition of claim 38, wherein said liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups, linctuses, drops, sprays, and elixirs.
40. The composition of any one of claims 28-37, wherein said composition is formulated as a solid.
41. The composition of claim 40, wherein said solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges, gums, candies, chews, foodstuffs, dissolving strips, films, and semi-solid formulations.
42. The composition of claim 41, wherein said capsule is a hard or soft capsule.
43. The composition of any one of claims 28-42, wherein said capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring.
44. The composition of claim 43, wherein said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate, dihydrocapsiate, nordihydrocapsiate,
norcapsaicin, capsiconiate, dihydrocapsiconiate and other coniferyl esters, capsiconinoid, and 3- hydroxyacetanilide .
45. The composition of claim 44, wherein said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or about 0.001% to about 10% (v/v).
46. The composition of claim 43, wherein said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl formate, 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2- methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2- dimethylpropanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl octadecanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl{4-[((6E)-8- methylnon-6-enoylamino)methyl]-2-methoxyphenoxy}formate, homovanillyl 8- methylnonanoate, 3-(3-methoxy-4-hydroxyphenyl)propyl 8-methylnonanoate, 8-methylnonyl homovanillate), 8-methylnonanoic acid- substituted benzyl ester derivative),
heptanoylisobutylamide, heptanoyl guaiacylamide, 7-phenylhept-6-yne-acid-4-hydroxy-3- methoxybenzylamide, dohevanil, denatonium capsaicinate, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-chlorophenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-fluorophenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]- N'- [2- (2,4-dichlorophenyl)ethyl] thiourea,N- [4- (2-aminoethoxy)-3-methoxybenzyl] -N'- [2- (4- benzyloxyphenyl)ethyl] thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4-(N- octyloxy)phenyl)ethyl] thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[4-N- octyloxybenzyl] thiourea, N-phenylmethylalkynamide capsaicin derivatives, N-(4-0-glycerol-3- methoxybenzyl)-nonamide, N-nonanoyl vanillylamide-4-glyceryl ether, N-(4-0-acetic acid sodium-3-methoxybenzyl-nonamide, sodium N-nonanoyl vanillylamide-4-O-acetate, N-(4-0- glycol-3-methoxybenzyl)-nonamide (N-nonanoyl vanillylamide-4-glycol ether), 20- homovanillyl-mezerein, 20-homovanillyl-12-deoxyphorbol-13-phenylacetate), civamide (N-[(4-
hydroxy-3-methoxyphenyl)-methyl]-8-methyl-(Z)-6-nonemamide), nuvanil, capsavanil, olvanil, arvanil, and palvanil (N-palmitoyl-vanillamide).
47. The composition of claim 46, wherein said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or about 0.001% to about 10% (v/v).
48. The composition of any one of claims 28-47, wherein said composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof which target a TRP channel.
49. The composition of claim 48, wherein said composition comprises a TRP channel activator.
50. The composition of any one of claims 28-49, wherein said capsaicinoid, capsinoid, or related analog or combination thereof is ingested by the subject.
51. The composition of any one of claims 28-50, wherein said capsaicinoid, capsinoid, or related analog or combination thereof is held in the mouth by the subject.
52. The composition of any one of claims 28-51, wherein said capsaicinoid, capsinoid, or related analog or combination thereof is dissolved in the mouth of the subject or chewed by the subject prior to swallowing.
53. A composition for use in a method for treating a painful muscle contraction in a subject in need thereof, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
54. The composition of claim 53, wherein said painful muscle contraction is a muscle contraction of the head or neck.
55. The composition of any one of claims 53-54, wherein said painful muscle contraction is associated with tension headache, cluster headache, or migraine headache.
56. A composition for use in a method for treating tactile sensitivity in a subject in need thereof, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
57. The composition of claim 56, wherein said tactile sensitivity is associated with autism, dyspraxia, neuralgia, anxiety disorders, venomous bites, or venomous stings.
58. The composition of claim 57, wherein said anxiety disorder is selected from the group consisting of panic disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), social anxiety disorder, phobia, and generalized anxiety disorder (GAD).
59. A composition for use in a method for treating a dystonia in a subject in need thereof, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
60. The composition of claim 59, wherein said dystonia is selected from the group consisting of: focal dystonia, blepharospasm, cervical dystonia, cranial dystonia, laryngeal dystonia, and hand dystonia.
61. A composition for use in a method for treating a peripheral nervous system (PNS) condition in a subject in need thereof, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient to said subject.
62. The composition of claim 61, wherein said PNS condition is selected from the group consisting of: cramp fasciculation syndrome, Isaacs' Syndrome or neuromyotonia, peripheral neuropathy, carpal tunnel syndrome, and Epstein-Barr virus infection.
63. A composition for use in a method for treating a throat condition in a subject in need thereof, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
64. The composition of claim 63, wherein said throat condition is associated with chemical injury, cancer, surgical injury, or pathogen infection.
65. The composition of any one of claims 63-64, wherein said throat condition is selected from the group consisting of: acid reflux, laryngospasm, dysphagia, and spasmodic dysphonias.
66. A composition for use in a method for treating a condition associated with an electrolyte imbalance or vitamin deficiency in a subject in need thereof, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
67. The composition of claim 66, wherein said condition is selected from the group consisting of: hyponatremia, hypocalcemia, hypomagnesemia, kidney disease, rickets, calcium or magnesium deficiency, thiamine deficiency, hypoparathyroidism, medullary cystic disease, and adrenocortical carcinoma.
68. A composition for use in a method for treating a central nervous system (CNS) condition in a subject in need thereof, said composition comprising an effective amount a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
69. The composition of claim 68, wherein said CNS condition is associated with a tumor.
70. The composition of any one of claims 68-69, wherein said CNS condition is selected from the group consisting of: multiple sclerosis, cerebral palsy, stroke, motor neuron disease, spinal injury, and stenosis.
71. A composition for use in a method for treating a muscle condition or disorder in a subject in need thereof, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
72. The composition of claim 71, wherein said muscle condition or disorder is associated with muscle pain, muscle spasms, muscle cramps, fasciculations, or any combination thereof.
73. The composition of any one of claims 71-72, wherein said muscle condition or disorder is a neuromuscular disorder.
74. The composition of any one of claims 71-73, wherein said muscle condition or disorder is muscle pain, muscle spasms, spasticity, or fasciculations associated with motor neuron disease.
75. The composition of claim 74, wherein said motor neuron disease is selected from the group consisting of amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, progressive spinobulbar muscular atrophy, and post-polio syndrome.
76. The composition of any one of claims 71-75, wherein said muscle condition or disorder is associated with treatment of said subject with dialysis, diuretics, β-blockers, statins, fibrates, β2- agonists, ACE inhibitors, ARBs, anti-psychotic medications, or any combination thereof.
77. The composition of claim 76, wherein said muscle condition or disorder is associated with treatment of said subject with statins and fibrates.
78. The composition of any one of claims 71-77, wherein said muscle condition or disorder occurs in one or more skeletal muscles.
79. The composition of any one of claims 71-78, wherein said muscle condition or disorder is refractory to an approved treatment.
80. The composition of claim 79, wherein said approved treatment is botox, cyclopenzaprine, orphenadrine, baclofen, or any combination thereof.
81. The composition of any one of claims 71-80, wherein said muscle condition or disorder involves muscle claudication pain.
82. The composition of claim 81, wherein said muscle claudication pain is associated with inactivity, restriction, economy class syndrome, paralysis, peripheral artery disease, or immobilization.
83. A composition for use in a method for treating a respiratory condition in a subject in need thereof, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
84. The composition of claim 83, wherein said respiratory condition comprises asthma, chronic obstructive pulmonary disease, bronchitis, emphysema, pneumonia, cystic fibrosis, pleural cavity diseases, influenza, or cold.
85. A composition for use in a method for treating cough in a subject in need thereof, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
86. The method of claim 85, wherein said cough is caused by a respiratory condition, exposure to allergens or chemical irritants, or inflammation.
87. A composition for use in a method for treating sarcoidosis in a subject in need thereof, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
88. A composition for use in a method for treating a connective tissue disease in a subject in need thereof, said composition comprising an effective amount of a capsaicinoid, capsinoid, or related analog or combination thereof and a pharmaceutically acceptable excipient.
89. The composition of claim 88, wherein said connective tissue disease is selected from the group consisting of Ehlers-Danlos syndrome, epidermolysis bullosa, Marfan syndrome, osteogenesis imperfect, arthritis, scleroderma, Sjogren's syndrome, lupus, vasculitis, mixed connective tissue disease, cellulitis, polymyositis, and dermatomyositis.
90. The composition of claim 89, wherein said arthritis is rheumatoid arthritis, osteoarthritis, gout, or psioratic arthritis, or wherein said vasculitis is Wegener's granulomatosis or Churg- Strauss Syndrome.
91. The composition of any one of claims 53-90, wherein said capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring.
92. The composition of claim 91, wherein said capsaicinoids, capsinoids, or related analogs or combinations thereof are naturally occurring and selected from the group consisting of:
capsaicin, diliydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide, pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate, dihydrocapsiate,
nordihydrocapsiate, norcapsaicin, capsiconiate, dihydrocapsiconiate and other coniferyl esters, capsiconinoid, and 3-hydroxyacetanilide.
93. The composition of claim 92, wherein said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or about 0.001% to about 10% (v/v).
94. The composition of claim 91, wherein said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4- [((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl formate, 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-
methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2- dimethylpropanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl octadecanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl{4-[((6E)-8- methylnon-6-enoylamino)methyl]-2-methoxyphenoxy}formate, homovanillyl 8- methylnonanoate, 3-(3-methoxy-4-hydroxyphenyl)propyl 8-methylnonanoate, 8-methylnonyl homovanillate), 8-methylnonanoic acid- substituted benzyl ester derivative),
heptanoylisobutylamide, heptanoyl guaiacylamide, 7-phenylhept-6-yne-acid-4-hydroxy-3- methoxybenzylamide, dohevanil, denatonium capsaicinate, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-chlorophenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-fluorophenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]- N'- [2- (2,4-dichlorophenyl)ethyl] thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4- benzyloxyphenyl)ethyl] thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4-(N- octyloxy)phenyl)ethyl] thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[4-N- octyloxybenzyl] thiourea, N-phenylmethylalkynamide capsaicin derivatives, N-(4-0-glycerol-3- methoxybenzyl)-nonamide, N-nonanoyl vanillylamide-4-glyceryl ether, N-(4-0-acetic acid sodium-3-methoxybenzyl-nonamide, sodium N-nonanoyl vanillylamide-4-O-acetate, N-(4-0- glycol-3-methoxybenzyl)-nonamide (N-nonanoyl vanillylamide-4-glycol ether), 20- homovanillyl-mezerein, 20-homovanillyl-12-deoxyphorbol-13-phenylacetate), civamide (N-[(4- hydroxy-3-methoxyphenyl)-methyl]-8-methyl-(Z)-6-nonemamide), nuvanil, capsavanil, olvanil, arvanil, and palvanil (N-palmitoyl-vanillamide).
95. The composition of claim 94, wherein said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or about 0.001% to about 10% (v/v).
96. The composition of any one of claims 53-95, wherein said composition is formulated as a liquid.
97. The composition of claim 96, wherein said liquid is selected from the group consisting of emulsions, microemulsions, solutions, suspensions, syrups, linctuses, drops, sprays, and elixirs.
98 The composition of any one of claims 53-95, wherein said composition is formulated as a solid.
99. The composition of claim 98, wherein said solid is selected from the group consisting of tablets, capsules, powders, crystals, pastes, gels, lozenges, gums, candies, chews, foodstuffs, dissolving strips, films, and semi-solid formulations.
100. The composition of claim 99, wherein said capsule is a hard or soft capsule.
101. A composition for use in a method for treating a subject for unwanted or abnormal muscle contraction or absence of a normal muscle contraction comprising:
acquiring knowledge of a result of a test for the efficacy of the administration of a test aliquot of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof for alleviation of test muscle contraction in said subject;
administering an amount of a composition comprising a capsaicinoid, capsinoid, or related analog or combination thereof sufficient to alleviate unwanted or abnormal muscle contraction or absence of a normal muscle contraction to said subject.
102. The method of claim 101, wherein said muscle contraction comprises a muscle cramp, muscle spasm, dystonia, or fasciculation.
103. The method of any one of claims 101-102, wherein said muscle contraction occurs in a skeletal muscle or smooth muscle.
104. The method of claim 101, wherein the test muscle contraction is a test muscle cramp or a test muscle spasm.
105. The composition of claim 101, wherein the subject has a central nervous system disorder or injury.
106. The composition of claim 101, wherein the subject has been diagnosed with or identified as having multiple sclerosis.
107. The composition of claim 101, wherein the subject has been diagnosed with or identified as having dystonia.
108. The composition of claim 101, wherein the subject has been diagnosed with or identified as having spinal cord spasticity.
109. The composition of claim 101, wherein said subject has been diagnosed with or identified as having a disorder associated with muscle cramps, muscle pain, muscle spasms, spasticity, or fasciculations.
110. The composition of claim 101, comprising directly acquiring said knowledge.
111. The composition of claim 101, further comprising performing said test.
112. The composition of claim 101, wherein said muscle contraction being selected, treated, or diagnosed comprises a contraction in a muscle other than a muscle that is contracted in the test muscle contraction.
113. The composition of claim 101, wherein said test muscle contraction comprises a contraction in a muscle of the foot and the muscle cramp comprises a cramp in a muscle other than the foot.
114. The composition of claim 101, wherein said muscle contraction is not induced by applied electrical stimulation.
115. The composition of claim 101, wherein said muscle contraction is a night cramp.
116. The composition of claim 101, wherein said muscle contraction is associated with multiple sclerosis.
117. The composition of claim 101, wherein said muscle contraction is associated with spinal cord spasticity.
118. The composition of claim 101, wherein said muscle contraction is associated with dystonia.
119. The composition of claim 101, wherein said test comprises inducing said test muscle cramp by application of electrical stimulation.
120. The composition of claim 101, wherein said test comprises determining that a muscle contraction can be induced in a subject by application of electrical stimulation.
121. The composition of claim 101, wherein said test comprises:
a) administering the test aliquot of the composition to said subject; b) inducing a test muscle contraction; and
c) evaluating the effect of administering the test aliquot of the composition on test muscle contraction.
122. The composition of claim 121, wherein step a is performed before step b.
123. The composition of claim 121, wherein step a is performed after step b.
124. The method of any one of claims 101-123, wherein said capsaicinoid, capsinoid, or related analog or combination thereof is naturally occurring or non-naturally occurring.
125. The method of claim 124, wherein said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin, nonivamide,
pseudocapsaicin, resiniferatoxin, tinyatoxin, capsiate, dihydrocapsiate, nordihydrocapsiate, norcapsaicin, capsiconiate, dihydrocapsiconiate and other coniferyl esters, capsiconinoid, and 3- hydroxyacetanilide .
126. The method of claim 125, wherein said naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or about 0.001% to about 10% (v/v).
127. The method of 124, wherein said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is selected from the group consisting of: 4-[((6E)-8- methylnon-6-enoylamino)methyl]-2-methyoxyphenyl formate, 4-[((6E)-8-methylnon-6- enoylamino)methyl]-2-methyoxyphenyl acetate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2- methyoxyphenyl propanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl butanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methoxyphenyl 2,2- dimethylpropanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl octadecanoate, 4-[((6E)-8-methylnon-6-enoylamino)methyl]-2-methyoxyphenyl{4-[((6E)-8- methylnon-6-enoylamino)methyl]-2-methoxyphenoxy}formate, homovanillyl 8- methylnonanoate, 3-(3-methoxy-4-hydroxyphenyl)propyl 8-methylnonanoate, 8-methylnonyl homovanillate), 8-methylnonanoic acid- substituted benzyl ester derivative),
heptanoylisobutylamide, heptanoyl guaiacylamide, 7-phenylhept-6-yne-acid-4-hydroxy-3- methoxybenzylamide, dohevanil, denatonium capsaicinate, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-chlorophenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3- methoxybenzyl]-N'-[2-(4-fluorophenyl)ethyl]thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]- N'- [2- (2,4-dichlorophenyl)ethyl] thiourea,N- [4- (2-aminoethoxy)-3-methoxybenzyl] -N'- [2- (4- benzyloxyphenyl)ethyl] thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[2-(4-(N- octyloxy)phenyl)ethyl] thiourea, N-[4-(2-aminoethoxy)-3-methoxybenzyl]-N'-[4-N- octyloxybenzyl] thiourea, N-phenylmethylalkynamide capsaicin derivatives, N-(4-0-glycerol-3- methoxybenzyl)-nonamide, N-nonanoyl vanillylamide-4-glyceryl ether, N-(4-0-acetic acid sodium-3-methoxybenzyl-nonamide, sodium N-nonanoyl vanillylamide-4-O-acetate, N-(4-0- glycol-3-methoxybenzyl)-nonamide (N-nonanoyl vanillylamide-4-glycol ether), 20- homovanillyl-mezerein, 20-homovanillyl-12-deoxyphorbol-13-phenylacetate), civamide (N-[(4-
hydroxy-3-methoxyphenyl)-methyl]-8-methyl-(Z)-6-nonemamide), nuvanil, capsavanil, olvanil, arvanil, and palvanil (N-palmitoyl-vanillamide).
128. The method of claim 127, wherein said non-naturally occurring capsaicinoid, capsinoid, or related analog or combination thereof is present from about 0.001% to about 10% (w/w) or about 0.001% to about 10% (v/v).
129. The method of any one of claims 101-128, wherein said composition comprises a capsaicinoid, a capsinoid, or related analog or combination thereof, which target a TRP channel.
130. The method of claim 129, wherein said composition comprises a TRP channel activator.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461979405P | 2014-04-14 | 2014-04-14 | |
US61/979,405 | 2014-04-14 | ||
US201462073129P | 2014-10-31 | 2014-10-31 | |
US201462073258P | 2014-10-31 | 2014-10-31 | |
US62/073,258 | 2014-10-31 | ||
US62/073,129 | 2014-10-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015160842A1 true WO2015160842A1 (en) | 2015-10-22 |
WO2015160842A8 WO2015160842A8 (en) | 2016-03-17 |
Family
ID=54324507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/025810 WO2015160842A1 (en) | 2014-04-14 | 2015-04-14 | Methods and formulatiions of capsaicinoids and capsinoids |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015160842A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017120473A1 (en) * | 2016-01-07 | 2017-07-13 | Conagen Inc. | Methods of making capsinoids by biosynthetic processes |
WO2017160156A1 (en) * | 2016-03-18 | 2017-09-21 | Axichem Ab | Synthetic capasaicin analogs as trpv1 agonists |
WO2017160687A1 (en) * | 2016-03-15 | 2017-09-21 | Vitality Biopharma, Inc. | Methods and compositions for the treatment of demyelinating disorders |
WO2018136943A1 (en) * | 2017-01-23 | 2018-07-26 | Flex Pharma, Inc. | Compositions and methods affecting exercise performance |
WO2018148523A1 (en) * | 2017-02-09 | 2018-08-16 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the treatment of peripheral artery disease |
EP3401307A1 (en) * | 2017-05-11 | 2018-11-14 | Antalgenics, S.L. | Trpv1 modulator compounds |
CN110035740A (en) * | 2016-11-02 | 2019-07-19 | 中枢疗法公司 | Stable aqueous capsaicine injectable formulation and its medical usage |
WO2018090022A3 (en) * | 2016-11-14 | 2019-09-06 | Farm To Farma, Inc. | Cannabinoid formulations and method of making the same |
CN112194592A (en) * | 2020-11-11 | 2021-01-08 | 刘晓珍 | Capsaicin salt and preparation method thereof |
US11000050B2 (en) | 2015-10-09 | 2021-05-11 | Axichem Ab | Bird feed and in particular poultry feed, comprising synthetic capsaicinoid derivatives and such feed for prophylactic use or treatment of Salmonella infection |
US20210169787A1 (en) * | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Oral composition and method of manufacture |
WO2022006200A1 (en) * | 2020-07-01 | 2022-01-06 | Capsugel Belgium Nv | Dietary composition and method |
US11459591B2 (en) | 2016-07-19 | 2022-10-04 | Conagen Inc. | Method for the microbial production of specific natural capsaicinoids |
NO346587B1 (en) * | 2021-06-02 | 2022-10-17 | Axichem Ab | Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis |
US11471429B2 (en) * | 2017-10-20 | 2022-10-18 | Axichem Ab | Synthetic capsaicin analogues as bioenhancers |
CN115282134A (en) * | 2022-07-20 | 2022-11-04 | 天津中医药大学 | Application of capsaicin in preparation of medicine for treating fragile X syndrome |
CN115636767A (en) * | 2021-07-20 | 2023-01-24 | 中国石油天然气股份有限公司 | Biosurfactant for oil displacement and fracturing and preparation method thereof |
US11793230B2 (en) | 2019-12-09 | 2023-10-24 | Nicoventures Trading Limited | Oral products with improved binding of active ingredients |
US11826462B2 (en) | 2019-12-09 | 2023-11-28 | Nicoventures Trading Limited | Oral product with sustained flavor release |
US11872231B2 (en) | 2019-12-09 | 2024-01-16 | Nicoventures Trading Limited | Moist oral product comprising an active ingredient |
US11969502B2 (en) | 2021-02-24 | 2024-04-30 | Nicoventures Trading Limited | Oral products |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020016354A1 (en) * | 1998-12-04 | 2002-02-07 | Jensen Bo Skaaning | Use of isatin derivatives as ion channel activating agents |
US20060034894A1 (en) * | 2004-08-11 | 2006-02-16 | Cadbury Adams Usa Llc. | Warming compositions and delivery systems therefor |
US20120027693A1 (en) * | 2010-07-27 | 2012-02-02 | Bean Bruce P | Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise |
US20120128762A1 (en) * | 2005-07-20 | 2012-05-24 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Sphingomyelin Liposomes for the Treatment of Hyperactive Bladder Disorders |
US20130197094A1 (en) * | 2012-02-01 | 2013-08-01 | Warsaw Orthopedic, Inc. | Trpv1 compounds in a biodegradable polymer carrier |
-
2015
- 2015-04-14 WO PCT/US2015/025810 patent/WO2015160842A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020016354A1 (en) * | 1998-12-04 | 2002-02-07 | Jensen Bo Skaaning | Use of isatin derivatives as ion channel activating agents |
US20060034894A1 (en) * | 2004-08-11 | 2006-02-16 | Cadbury Adams Usa Llc. | Warming compositions and delivery systems therefor |
US20120128762A1 (en) * | 2005-07-20 | 2012-05-24 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Sphingomyelin Liposomes for the Treatment of Hyperactive Bladder Disorders |
US20120027693A1 (en) * | 2010-07-27 | 2012-02-02 | Bean Bruce P | Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise |
US20130197094A1 (en) * | 2012-02-01 | 2013-08-01 | Warsaw Orthopedic, Inc. | Trpv1 compounds in a biodegradable polymer carrier |
Non-Patent Citations (1)
Title |
---|
LUO ET AL.: "Targeting Pain-evoking Transient Receptor Potential Channels for the Treatment of Pain.", CURRENT NEUROPHARMACOLOGY, vol. 11, 2013, pages 652 - 663, XP055230606, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849790> [retrieved on 20150605] * |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11000050B2 (en) | 2015-10-09 | 2021-05-11 | Axichem Ab | Bird feed and in particular poultry feed, comprising synthetic capsaicinoid derivatives and such feed for prophylactic use or treatment of Salmonella infection |
US10655150B2 (en) | 2016-01-07 | 2020-05-19 | Conagen Inc. | Methods of making capsinoids by biosynthetic processes |
WO2017120473A1 (en) * | 2016-01-07 | 2017-07-13 | Conagen Inc. | Methods of making capsinoids by biosynthetic processes |
WO2017160687A1 (en) * | 2016-03-15 | 2017-09-21 | Vitality Biopharma, Inc. | Methods and compositions for the treatment of demyelinating disorders |
WO2017160156A1 (en) * | 2016-03-18 | 2017-09-21 | Axichem Ab | Synthetic capasaicin analogs as trpv1 agonists |
US11459591B2 (en) | 2016-07-19 | 2022-10-04 | Conagen Inc. | Method for the microbial production of specific natural capsaicinoids |
US11946083B2 (en) | 2016-07-19 | 2024-04-02 | Conagen Inc. | Method for the microbial production of specific natural capsaicinoids |
CN110035740B (en) * | 2016-11-02 | 2023-08-04 | 中枢疗法公司 | Stable aqueous capsaicin injectable formulations and medical uses thereof |
US11344516B2 (en) | 2016-11-02 | 2022-05-31 | Centrexion Therapeutics Corporation | Stable aqueous capsaicin injectable formulations and medical uses thereof |
CN110035740A (en) * | 2016-11-02 | 2019-07-19 | 中枢疗法公司 | Stable aqueous capsaicine injectable formulation and its medical usage |
US11000490B2 (en) * | 2016-11-02 | 2021-05-11 | Centrexion Therapeutics Corporation | Stable aqueous capsaicin injectable formulations and medical uses thereof |
WO2018090022A3 (en) * | 2016-11-14 | 2019-09-06 | Farm To Farma, Inc. | Cannabinoid formulations and method of making the same |
US10525093B2 (en) | 2016-11-14 | 2020-01-07 | Farm To Farma, Inc. | Cannabinoid formulations and method of making the same |
US11253493B2 (en) | 2017-01-23 | 2022-02-22 | Cliff-Cartwright Corporation | Compositions and methods affecting exercise performance |
WO2018136943A1 (en) * | 2017-01-23 | 2018-07-26 | Flex Pharma, Inc. | Compositions and methods affecting exercise performance |
EP3570861A4 (en) * | 2017-01-23 | 2020-11-18 | Flex Pharma, Inc. | Compositions and methods affecting exercise performance |
WO2018148523A1 (en) * | 2017-02-09 | 2018-08-16 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the treatment of peripheral artery disease |
CN110392569A (en) * | 2017-02-09 | 2019-10-29 | 内布拉斯加大学董事会 | For treating the composition and method of peripheral arterial disease |
US11274073B2 (en) | 2017-05-11 | 2022-03-15 | Antalgenics, S.L. | TRPV1 modulator compounds |
CN110621654A (en) * | 2017-05-11 | 2019-12-27 | 安塔尔遗传学公司 | TRPV1 modulator compounds |
WO2018206742A1 (en) * | 2017-05-11 | 2018-11-15 | Antalgenics, S.L. | Trpv1 modulator compounds |
JP2020519636A (en) * | 2017-05-11 | 2020-07-02 | アンタルゲニクス, エセ.エレ.Antalgenics, S.L. | TRPV1 modulator compound |
KR20200007804A (en) * | 2017-05-11 | 2020-01-22 | 안탈헤닉스, 에스.엘. | TRPV1 Modulator Compound |
EP3401307A1 (en) * | 2017-05-11 | 2018-11-14 | Antalgenics, S.L. | Trpv1 modulator compounds |
AU2018265460B2 (en) * | 2017-05-11 | 2022-08-18 | Antalgenics, S.L. | TRPV1 modulator compounds |
JP7245404B2 (en) | 2017-05-11 | 2023-03-24 | アンタルゲニクス,エセ.エレ. | TRPV1 modulator compounds |
TWI780150B (en) * | 2017-05-11 | 2022-10-11 | 西班牙商安托基因有限公司 | Trpv1 modulator compounds |
KR102649310B1 (en) | 2017-05-11 | 2024-03-19 | 안탈헤닉스, 에스.엘. | TRPV1 modulator compounds |
US11471429B2 (en) * | 2017-10-20 | 2022-10-18 | Axichem Ab | Synthetic capsaicin analogues as bioenhancers |
US11883527B2 (en) * | 2019-12-09 | 2024-01-30 | Nicoventures Trading Limited | Oral composition and method of manufacture |
US11872231B2 (en) | 2019-12-09 | 2024-01-16 | Nicoventures Trading Limited | Moist oral product comprising an active ingredient |
US20210169787A1 (en) * | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Oral composition and method of manufacture |
US11826462B2 (en) | 2019-12-09 | 2023-11-28 | Nicoventures Trading Limited | Oral product with sustained flavor release |
US11793230B2 (en) | 2019-12-09 | 2023-10-24 | Nicoventures Trading Limited | Oral products with improved binding of active ingredients |
WO2022006200A1 (en) * | 2020-07-01 | 2022-01-06 | Capsugel Belgium Nv | Dietary composition and method |
CN112194592A (en) * | 2020-11-11 | 2021-01-08 | 刘晓珍 | Capsaicin salt and preparation method thereof |
US11969502B2 (en) | 2021-02-24 | 2024-04-30 | Nicoventures Trading Limited | Oral products |
NO346587B1 (en) * | 2021-06-02 | 2022-10-17 | Axichem Ab | Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis |
CN115636767A (en) * | 2021-07-20 | 2023-01-24 | 中国石油天然气股份有限公司 | Biosurfactant for oil displacement and fracturing and preparation method thereof |
CN115282134A (en) * | 2022-07-20 | 2022-11-04 | 天津中医药大学 | Application of capsaicin in preparation of medicine for treating fragile X syndrome |
Also Published As
Publication number | Publication date |
---|---|
WO2015160842A8 (en) | 2016-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190038573A1 (en) | Ion channel activators and methods of use | |
WO2015160842A1 (en) | Methods and formulatiions of capsaicinoids and capsinoids | |
US20220387539A1 (en) | Methods of treating muscle cramping and related compositions | |
JP6263699B2 (en) | Aqueous drug delivery system with an unpleasant taste masking agent | |
US20180116976A1 (en) | Methods and compositions for unwanted or abnormal muscle contractions | |
KR20030094272A (en) | Tablets quickly disintegrating in oral cavity | |
Tehseen et al. | Design and characterization of twice daily mini-tablets formulation of pregabalin | |
WO2018129315A1 (en) | Methods and compositions for the treatment of disease | |
EP2642980A2 (en) | Pediatric formulation | |
US20230086660A1 (en) | Oral formulations of metronidazole and methods of treating an infection using same | |
Ghanchi et al. | Taste masking technologies of pharmaceuticals | |
Gade | A Review article on Oral Jellies for Pediatrics | |
JP5329866B2 (en) | Pharmaceutical composition and preventive and therapeutic agent for joint disorders | |
CN110115766B (en) | Compound preparation containing flurbiprofen axetil and preparation method thereof | |
Gangadhar | Design and Evaluation of Fluoxetine Orodispersible Tablets. | |
JP2010100550A (en) | Medicinal composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15780337 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15780337 Country of ref document: EP Kind code of ref document: A1 |